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Abstract
Molecular processes involved in the development of malignancy have a role to play in the 
establishment of the multidrug resistant (MDR) phenotype. Analysis of oncogene expression, 
at the mRNA level using RT-PCR, in resistant variants of the human squamous lung cell 
line, DLKP, and the human ovarian carcinoma cell line, OAW42, was carried out in this 
study. Analysis of gene expression, by RT-PCR and in situ hybridisation, on tumours from 
breast cancer patients was also carried out on fresh and formalin-fixed paraffin-embedded 
tissue.
Altered expression of c-erbB-2, c-Ha-rov, c-myc and c-fos and the bcl-2 family members, bcl- 
xL and bax, were seen in resistant variants of the DLKP cell line developed by continuous 
exposure to adriamycin, carboplatin and VP-16. Ribozyme technology was used to down- 
regulate the expression of the c-fos gene in the adriamycin-selected variant, DLKP-A, and the 
effect on adriamycin toxicity was analysed.
Drug-resistant cell lines developed by continuous exposure to drug for prolonged periods are 
frequently resistant to drug concentrations above those achieved in the clinic. As patients can 
develop drug resistance after only a few courses of chemotherapy, a more clinicallly relevant 
in vitro model of drug resistance was developed in this thesis by pulse exposure of clonal 
populations of DLKP, DLKP-SQ and DLKP-I, to clinically attainable levels of adriamycin 
for a short period of time. The resulting resistant variants, DLKP-SQ/A25010p and DLKP- 
I/A25010p, exhibited a classical MDR phenotype in that increased resistance to adriamycin, 
vincristine and VP-16 was demonstrated. However, no alteration in 5-fluorouracil sensitivity 
was seen. The cell lines were found to over-express the mdrJ gene and decreased adriamycin 
accumulation was observed in the resistant variants.
Characterisation of the resistant variant of DLKP-SQ revealed increased expression, using 
RT-PCR, of the bcl-xL, bax, c-erbB-2 and c-fos genes relative to the sensitive parental line. 
To counter-act the effect of bcl-xL over-expression in the DLKP-SQ/A25010p, the 
antagonistic bcl-xs gene was introduced into the resistant cell line, which resulted in increased 
sensitivity to adriamycin, VP-16 and vincristine but not to 5-fluorouracil.
Attempts were made throughout the course of this thesis to determine the initialising events 
in the establishment of the MDR phenotype in the pulse-selected model. Results found 
indicate that bcl-xL and c-fos may be important initialising events in this process. Molecular 
studies of gene expression pattern in the pulse-selected variant of DLKP-SQ suggested that 
this may be a novel system amenable to the search for inhibitors of resistance development. 
Initial studies have been carried out in this thesis to determine if known 
inhibitors/circumventors of the MDR phenotype or oncogene signalling cascades affected the 
development of resistance using the DLKP-SQ model.
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Introduction
1.1 Introduction
In cellular systems the balance of life and death is paramount, with control o f cell number 
under tight genetic regulation; any alteration to this control can have catastrophic effects 
for the organism as a whole. The control of cell number involves mechanisms for 
regulating cell proliferation and cell death. Malignancy is seen as a loss of normal control 
of cell growth whereby accumulation of multiple events leads to the propagation of a mass 
of cells that ignore any normal inhibitory messages and have the propensity to grow 
indefinitely if left undetected or untreated. Cancer, therefore, is fundamentally a result of 
inappropriate cell proliferation.
Studies of malignant cells have identified molecular mechanisms whereby an appropriately 
regulated cell is transformed into a potentially immortal cell that has the ability to ignore 
cellular control. The mechanism which regulates this transformational process is governed 
by oncogenes, dominant mutated forms of normal cellular gene products which encode 
proteins that are involved in basic cellular signal transduction cascades. These signal 
cascades transduce growth-regulatory messages from outside the cell to the cell’s 
replication workshop in the nucleus; any alteration to these stringently controlled pathways 
can result in the development of neoplasia (for review see Bishop, 1991). To date over 
100 oncogenes have been identified.
1.2 Treatment of Cancer
Currently, cancer is treated either by surgery, radiotherapy, immunotherapy, hormone 
treatment or chemotherapy. The aim of any o f these regimens is to achieve optimal kill of 
malignant cells while sparing their normal neighbours. Chemotherapy is most useful 
against tumours with a high proportion of proliferating cells, such as leukaemia and 
lymphoma. The more common solid tumours (colorectal, lung, breast) have a low 
proportion of dividing cells and are largely refractory to chemotherapeutic drug treatment. 
Some normal tissues, such as bone marrow and cells lining the gastrointestinal tract, also 
have a high proportion of proliferating cells and therefore are also targetted by 
chemotherapeutic drugs. Clinical doses of chemotherapeutic drugs administered in vivo are 
limited by these facts.
The original strategy employed in the design o f chemotherapeutic drugs which are used to
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treat cancer, involved the development of agents which prevented malignant cells from 
dividing. The commonly used chemotherapeutic drugs include the anthracyclines, vinca 
alkaloids, epipodophyllotoxins, antipyrimidines and the platinum analogues. These drugs 
act at many sites to interfere with cell growth and division (Figure 1.2.1)
Figure 1.2.1 Sites of action of Cytotoxic Drugs
Purine synthesis Pyrimidine synthesis
\  /
Ribonucleotides
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Deoxyribonucleotides
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^  (^ a n ti-p y r im id in e s^ )
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1.2.1 The Anthracyclines
The anthracyclines are a class of anti-tumour antibiotics derived from the Streptomyces 
species (Tannock and Hill, 1992). Included in this family are adriamycin (also called 
doxorubicin), daunorubicin, epirubicin and an ever-increasing number of semi-synthetic 
variants. Adriamycin is one of the most important agents used in the treatment of human 
cancer (Tritton and Yee, 1982). Clinical effectiveness is seen in the treatment of acute 
myelogenous leukaemia, acute lymphoblastic leukaemia, carcinomas of the bladder, 
breast, ovaries, lung, bronchi and thyroid, Ewing’s sarcoma, non-Hodgkin’s lymphoma, 
Hodgkin’s disease, neuroblastoma and many others (Carter et al., 1987). Adriamycin 
exhibits a tri-phasic plasma decay curve with half-lives of 12 minutes, 3.3 hours and 30 
hours (Pratt and Ruddon, 1979). The standard dosage of adriamycin is 30-60mg/m2 
intravenously to a total cumulative dosage of 550mg/m2 (Carter et al., 1987).
Adriamycin treatment is not without its faults, however, as serious side-effects are seen
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with use of this drug. The drug is carcinogenic and mutagenic and causes 
immunosuppression. Damage to heart muscle is a major side-effect and incidence 
increases with increasing cumulative dose of drug (Tannock and Hill, 1992).
The primary mechanism of action of adriamycin in the cell is due to the drug’s ability to 
bind DNA and RNA. Intercalation between adjacent pairs in the double helix results in the 
inhibition of replication, transcription and translation. The drug stabilises topoisomerase 
II-DNA complexes (Chan et al., 1993a) and exerts free radical mediated cytotoxicity 
(Pasada et al., 1989) which may be responsible for the cardiotoxicity of adriamycin (Pratt 
etal, 1994).
1.2.2 The Epipodophyllotoxins
The plant Podophyllum peltatum synthesises a compound known as podophyllotoxin which 
is a mitotic inhibitor that acts by binding to tubulin (Pratt and Ruddon, 1979) thereby 
preventing the formation of microtubules by blocking polymerisation of tubulin (Long, 
1991). Semi-synthetic derivatives of podophyllotoxin, namely etoposide (VP-16) and 
teniposide (VM-26), have shown efficacy in the treatment o f some human cancers, 
including testicular and small cell lung cancer (Carter et al., 1987; Van Maanen et al., 
1988). Administration is by intravenous injection or orally (Smyth et al., 1985). The 
plasma decay of etoposide is bi-phasic (Carter et al., 1987) with a terminal half life of 4 - 
9 hours. Haematologic toxicity is usually dose-limiting in the treatment of cancer patients 
with epipodophyllotoxins and gastrointestinal side-effects are frequently seen.
Originally it was believed that V P-16 exerted its effect on proliferation by inhibiting 
microtubule function. It has since been shown that the main target of this 
epipodophyllotoxin is the topoisomerase II protein, an enzyme that facilitates DNA 
unwinding (Van Maanen et al, 1988).
1.2.3 Microtubule Inhibitors
The Vinca alkaloids are derived from the periwinkle plant Catharanthus rosea. The two 
drugs in common clinical use are vincristine and vinblastine. Vincristine exhibits a 
relatively low toxicity for normal bone marrow cells and is used to treat acute leukaemia, 
Hodgkin’s lymphoma, aggressive non-Hodgkin’s lymphoma, small cell lung cancer, 
W ihn’s tumour, neuroblastoma, rhabdomyosarcoma and Ewing’s sarcoma (Pratt et al.,
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1994). This drug, administered as a bolus intravenous injection, exhibits tri-phasic decay 
kinetics. The dose-limiting toxicity of vincristine is pre-dominantly peripheral neuropathy. 
Vincristine arrests cells in the mitotic phase of the cell cycle by disrupting the mitotic 
spindle by interrupting microtubule polymerisation (Pratt et al., 1994).
Another microtubule inhibitor is taxol. Taxol was first isolated from the bark of the slow- 
growing yew tree, Taxus brevifola, and now synthetic derivatives are on the market. The 
importance of microtubules as a target for taxol was suggested by its ability to induce cell 
cycle arrest at G2/M with minimal effect on RNA, DNA or protein synthesis. Taxol 
treatment stabilises cytoplasmic microtubules and the formation o f abnormal bundles of 
microtubules. Taxol is administered either as short (1-6 hour) or long (24 hour) infusions, 
at doses of 200-300mg/m2. The drug appears to have bi-phasic kinetics with a terminal 
half-life o f about 5 hours. Clinical effectiveness is seen in the treatment o f refractory 
ovarian cancer and metastatic breast cancer. Dose-limiting side-effects include bone 
marrow depression, hypersensitivity reaction, peripheral neuropathies and cardiac 
arrhythmias (Pratt et al., 1994).
1.2.4 The Antimetabolites
The antimetabolites are drugs that are chemically related to naturally occurring compounds 
and interfere with cellular metabolic pathways, especially those involved in the synthesis 
of DNA. This group of cytotoxic drugs is divided into folate antagonists, pyrimidine 
analogues and purine analogues (for review see Skovsgaard et al., 1994).
Methotrexate, an analogue of folic acid, is the most important anti-folate and since its 
introduction in the clinic in 1948 is the best understood antineoplastic compound to date. 
Methotrexate exerts its cytotoxic effect by competitive inhibition o f the cytosolic enzyme 
dihydrofolate reductase (DHFR) (Waltham et al., 1988) which is the key enzyme in the 
biosynthesis of pyrimidines and purines. Methotrexate is used in the treatment of acute 
lymphocytic leukaemia of children, osteosarcomas, head and neck cancers, and is also 
used effectively in combination for the treatment o f breast cancer (Pratt et al., 1994). The 
two major sites of methotrexate toxicity are the bone marrow and the endothelium of the 
oropharynx and gastrointestinal tract. Methotrexate is administered by oral, intravenous, 
intraarterial or intrathecal routes. The plasma disappearance curve of methotrexate has 
been characterised as tri-phasic with half-lives of 0.75, 3.5 and 27 hours.
5-Fluorouracil, an anti-pyrimidine, is one of the most widely used agents in the treatment
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of human cancer and is effective in the treatment of the most commonly occurring solid 
tumours, including colorectal, breast, head and neck, gastric and pancreatic cancers (Pratt 
et al., 1994). Other anti-pyrimidines include cytosine arabinoside which is widely used in 
antileukaemic therapies. 5-Fluorouracil is usually administered parenterally as a 
continuous infusion. 5-Fluorouracil is more toxic to proliferating than non-proliferating 
cells leading to toxic side-effects in tissues of the gastrointestinal tract and bone marrow. 
5-Fluorouracil represents one of the few examples o f antineoplastic drugs synthesised on a 
rational basis. 5-Fluorouracil is a simple derivative of uracil where the hydrogen at 
position 5 is replaced by a fluorine atom. The rationale used in the design of this drug was 
that rat hepatomas utilised more uracil than non-malignant tissues. 5-Fluorouracil is a 
direct inhibitor of thymidylate synthase, a key enzyme in the production of thymidine 
nucleotides; the drug can also be incorporated into RNA and DNA and consequently 
inhibits transcription, translation and the intracellular distribution of mRNA (Pratt et al., 
1994).
1.2.5 Covalent DNA-Binding Drugs
The first successful systemic application of cancer chemotherapy was demonstrated in 
1942 when Gilman, Goodman, Lidskog and Dougherty used nitrogen mustard to treat a 
patient suffering from lymphosarcoma (Pratt et al ,  1994). Since then many alkylating 
agents have been tested for their usefulness as anti-cancer agents. DNA-binding drugs 
have proven effective in a variety of different tumours and many are used commonly in 
modern chemotherapeutic regimens. Cyclophosphamide, another nitrogen mustard, is the 
most commonly used alkylating agent. The drug is used in combination to treat a wide 
variety of cancers, including lymhoid tumours, myeloma, osteogenic disease, 
neurobastoma, retinoblastoma and carcinomas o f the breast, lung, ovary and 
endometrium. It is administered either orally or intravenously. Dose-limiting toxicities 
include immunosuppression, bone marrow suppression and long-term treatment can be 
followed by the development o f bladder cancer (Pratt et al, 1994). The alkylating agents 
are capable of cross-linking an alkyl group with cellular constituents such as DNA. 
Alkylation of the DNA decreases its ability to act as a template for DNA synthesis and 
results in DNA damage and potential cell kill.
The platinum complexes were first discovered by Rosenberg and co-workers and were 
shown to cross-link DNA in a manner distinct from alkylation. The platinum compunds
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exert their toxicity by binding to base pairs of DNA, resulting in the formation of intra­
strand cross-links and adducts, and ultimately leads to the disruption and unwinding of the 
DNA double helix. Cisplatin is currently one of the most effective anticancer agents, used 
in the treatment of ovarian, testicular, head and neck, non-small cell lung and brain 
tumours (Rosenberg, 1985). Dose-limiting toxicity is nephrotoxicity which may ultimately 
lead to renal failure. Other side effects include gastrointestinal toxicities, 
myelosuppression, tinnitus and loss of hearing. To avoid these side-effects other platinum 
compounds, including carboplatin, have been designed. Carboplatin produces considerably 
less nephrotoxicity than cisplatin and is often used in preference to cisplatin for the 
treatment of ovarian and lung carcinomas (Gore et al., 1989; Raghaven et al., 1994). The 
platinum compounds are usually injected intravenously and following administration are 
rapidly and tightly bound to proteins. The clearance o f total drug (free and bound) has 
been described as tri-phasic with a prolonged terminal half-life of 58 to 73 hours.
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1.3 Chemotherapy and Cell Death
The metabolic processes targeted by chemotherapeutic drugs are thought to be more 
critical for the viability of rapidly dividing tumour cells than their normal counterparts, 
However, non-cycling tumour cells, such as the ones that accumulate in chronic 
lymphocytic leukaemia, are also targeted effectively by the same agents (Orrenius, 1995). 
Recently it has been shown that chemotherapeutic drugs act not only to prevent 
proliferation by targetting cellular DNA or inhibiting cell division but also succeed in their 
task by promoting an active form of cell death, namely apoptosis (Skladanowski and 
Konopa, 1993). Why chemotherapeutic agents are more toxic to cancer cells than normal 
cells is unknown but a clue may lie in the mechanisms whereby drugs with different 
cellular targets, result in a common cell death pathway.
1.3.1 Apoptosis
Apoptosis is a mechanism of cell death whereby a cell actively participates in its own 
destruction. “Apoptosis” was a term used by Kerr et al. (1972) to describe a series of 
morphological changes shared by dying cells in various biological systems. These 
morphological changes include cell shrinkage, membrane blebbing, chromatin 
condensation and endonucleolytic cleavage of DNA into nucleosomal-length fragments, 
and finally the production of budding “apoptotic bodies” . The process does not induce an 
inflammatory response.
Figure 1.3.1.1 The Apoptotic Pathway
Apoptotic Stimulus Molecular Cascade cell death
Since those initial findings, a tightly controlled molecular pathway has emerged which 
ultimately leads to the demise of the cell. M ost of the early research on apoptosis was
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carried out on the nematode, Caenorhabditis elegans. This organism has a defined cell 
lineage of 1090 somatic cells, 131 of which are programmed to die during the 
development of the organism making it an ideal system to study programmed cell death. 
Three cell death abnormal iced) genes (ced3, ced4 and ced9) were identified as playing a 
role in the regulation o f cell death in the nematode (for review see Uren and Vaux, 1996). 
Two of these genes, ced3 and ced4, are required for all programmed cell deaths in C. 
elegans. The ced3 amino acid sequence shows significant homology to a mammalian 
cysteine protease, interleukin-ip converting enzyme (ICE), with novel specificity for 
aspartic acid; no mammalian homologues for ced4 have been identified. The observation 
of homology between the amino acid sequence of ced3 and ICE was followed by the 
demonstration that over-expression of ICE in cells triggered apoptosis (Miura et al„
1993). Ced-9 was found to have an antagonistic activity to ced-3 and ced-4. Ced-9 loss of 
function mutations result in excess cell death. Loss of either ced-3 or ced-4 genes appears 
to compensate for the loss of the ced-9 function. The mammalian inhibitor of cell death, 
bcl-2, was found to be highly homologous to the C. elegans ced-9 gene (Hengartner and 
Horvitz, 1994). The role of bcl-2 family members in the regulation of apoptosis will be 
addressed later (Section 1.7.1). The other seven ced genes so far identified appear to 
encode proteins involved in disposal of the dead cell’s corpse. Another cell death effector 
gene, nuc-1, encodes an endonuclease involved in digestion o f the dead cell’s DNA. Other 
players in the apoptotic pathway include p53, c-myc and other oncogenes are discussed in 
more detail in Section 1.7.
The importance of apoptosis in development, tissue homeostasis, defence against viral 
infection and oncogenesis is becoming increasingly evident. Developmental cell death 
shapes the digits in foetal hands by the deletion o f interdigital cells and removes the 
superfluous neurons seen in the foetus as compared to the adult. Apoptosis of virus- 
infected cells interrupts viral replication, thus preventing the spread of infection to other 
cells in the organism. Apoptosis is used by the immune system to remove potentially 
autoreactive lymphocytes or those that fail to form a functional antigen receptor. DNA- 
damaged cells are also known to undergo apoptosis induced by p53, thus preventing the 
establishment of a mutated cell in the population. Apoptosis is also physiologically 
involved in the hormone-response of many tissues such as involution o f the mammary 
glands in late lactation. The anti-tumour cytokines, tumour necrosis factor -a and -p, 
mediate their effect by inducing apoptosis; a molecule essential in the regulation of
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apoptosis is the cell surface receptor CD95 (Fas/APO-1), a member of the tumour 
necrosis factor receptor family (Nagata and Golstein, 1995). M ore than 100 different 
stimuli, including many chemotherapeutic drugs and toxins, have been shown to induce 
apoptosis in experimental systems.
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1.3.2 Apoptosis and Chemotherapeutic Drugs
Several chemotherapeutic agents commonly used in the treatment of both solid and 
haematological tumours have been shown to induce apoptosis in a number of cell lines in 
vitro. These include adriamycin (Ling et al., 1993; Skladanowski and Konopa, 1993), 
cisplatin (Demarcq et al., 1994), the epipodophyllotoxins (Holm et al., 1994), 
macromolecular synthesis inhibitors (Gorczya et al., 1993; Okamoto et al., 1996), DNA 
alkylating agents (O’Connor et al., 1991; Gorczya et al., 1993), and topoisomerase 
inhibitors (Solary et al., 1994; Dubrez et al., 1995). One hypothesis used to explain the 
apoptotic response of chemotherapeutic drugs is that of a non-specific defense response to 
a perceived threat (Vaux and Haecker, 1995), thus explaining why so many agents of 
differing pharmacological action provoke the same response. Chemotherapeutic drugs act 
primarily by causing DNA damage, which in turn stimulates the p53 protein. Stimulation 
of p53 leads to cell cycle arrest in Gi or G2 (Figure 1.3.2.1) and results either in the repair 
of DNA damage and cell recovery or in the induction of apoptosis. p53 has been shown to 
affect apoptosis directly by down-regulating expression of the Bcl-2 protein and up- 
regulating Bax and Bcl-xL expression (Miyashita et al., 1994; Miyashita and Reed, 1995; 
Merchant et al., 1996). Recently it has been shown that chemotherapeutic drugs mediate 
an apoptotic pathway by inducing the expression of the CD95 (Fas/APO-1) and its ligand 
(Micheau et al., 1997). The up-regulation of CD95 expression may be at the “crossroad” 
of DNA damage, p53 accumulation, and the apoptosis response pathway (Debatin, 1997).
Figure 1.3.2.1 Cell Cycle
Growth Phase
out of 
cycle
Mitosis M DNASynthesis
Cell Pauses as it Prepares to Divide
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1.4 Multi drug resistance (MDR)
Failure to cure cancer by chemotherapy is caused primarily by the clinical development of 
chemotherapeutic drug resistance whereby tumours continue to proliferate in the presence 
of a cytotoxic agent designed to prevent proliferation; resistance can be either intrinsic (to 
the untreated tumour) or acquired (by an initially sensitive tumour after exposure to a 
chemotherapeutic agent). Although resistance of a tumour to one chemotherapeutic drug 
prevents the recovery of the patient, combination chemotherapy approaches could, in 
theory, alleviate this problem. The ultimate failure of cancer chemotherapy is seen in the 
development o f Multidrug Resistance (MDR) - a phenomenon whereby a particular 
tumour is resistant not only to one drug but rather a variety o f structurally unrelated and 
mechanistically varied natural product chemotherapeutic drugs such as the anthracyclines, 
the vinca alkaloids, epipodophyllotoxins, colchicine, actinomycin D and Taxol. The 
sensitivity of the tumour to alkylating agents, antimetabolites or platinum compounds 
appears unaltered (Clynes, 1993). Tumour types vary in their response to anti-cancer 
drugs - many tumours are inherently resistant to chemotherapy, such as colon carcinoma; 
others are sensitive to chemotherapy, such as non-Hodgkin’s lymphomas, W ilm ’s tumour; 
but other tumour types, such as breast and ovarian cancers, which are initially responsive 
to chemotherapy, relapse and present with drug-resistant tumours (Spiers, 1994).
The underlying cause of progressive drug resistance is spontaneous genetic mutations 
which occur in all living cells. In any given cell population mutants that are resistant to a 
given drug occur at a frequency of somewhere between 1 in 105 and 1 in 108 cells. In a 
tumour of detectable size (1cm) there is at least 108 cells, some of which may be resistant, 
and by treatment with a drug, these potentially lethal cells are selected from a mostly 
drug-sensitive population (Kartner and Ling, 1989). The first insight into the MDR- 
phenotype was revealed in the 1960s when cross-resistance to completely unrelated drugs 
was found in tumours. The cause of this phenomenon in vivo is quite complex, however, 
and properties such as tumour size, vascularisation and specific cellular mechanisms such 
as increased drug efflux from cells, increased drug detoxification, DNA repair and others, 
may all be involved in the survival of a resistant tumour when under attack from a 
chemotherapeutic regimen.
The M DR phenomenon was first described in vitro in 1970 by Biedler and Riehm in 
studies of Chinese hamster lung cells and P388 leukaemia cells and since then much
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research has been carried out on cellular models of multidrug resistance which act as 
“magnifiers” of the cellular response to commonly used chemotherapeutic agents. These 
studies have identified the main players involved in in vitro drug resistance and include 
efflux pumps such as P-glycoprotein, M RP and LRP. Topoisomerases have also been 
found to be involved in MDR.
1.4.1 P-glycoprotein and its role in Multidrug Resistance
Several genes have been found to be over-expressed in multidrug resistant human cancer 
cell lines and the product of the mdrl gene, P-glycoprotein, has been extensively studied 
in many in vitro model systems. This protein acts as an energy-dependent efflux pump 
located in the plasma membrane.
P-glycoprotein is present at high levels in normal human kidney and adrenal glands; at 
intermediate levels in lung, liver and colon; and at low levels in most other tissues 
(Tannock and Hill, 1992). Those organs which constitutively express P-glycoprotein often 
give rise to tumours that are innately drug resistant; other tumours, such as breast, which 
are initially responsive to chemotherapy (and express mdrl infrequently) often relapse and 
present with P-glycoprotein positive tumours (Nooter and Herweijer, 1991).
The results of a series o f experiments raise the possibility that expression o f the mdrl gene 
is regulated by the genes that drive tumour progression (Chin et al., 1992). It was found 
that the mdrl gene promoter is a potential target of ras and p53 and that the mdrl gene 
was turned on as a result of activation of ras genes (Section 1.6.2) and inactivation of the 
p53 tumour suppressor gene, common events which occur during tumourigenesis. A study 
by Cornwell and Smith (1993) revealed that stimulation o f signal transduction through the 
c-Raf kinase pathway (Section 1.6.2.2) also increased the activity of the mdrl promoter.
1.4.2 Other Mechanisms involved in Drug Resistance
The Multidrug Resistance-associated Protein, M RP, is another cellular pump which 
effluxes drug from resistant cell lines. The gene has been identified in non-P-glycoprotein 
multidrug cell lines derived from small cell lung, leukaemias, fibrosarcomas, breast and 
other carcinomas. Its expression appears to precede that of P-glycoprotein as a series of 
drug-resistant cell lines were found to over-express MRP in low-level resistant cells, 
followed by P-glycoprotein over-expression in the same cells at higher levels of resistance,
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and, may for this reason be a more clinically relevant marker of resistance (Loe et al. , 
1996).
A lung-resistance related protein (LRP), identified originally in a non-P-glycoprotein 
MDR lung cell line (Scheper et al., 1993), is also believed to play a role in low-level 
M DR cells. Studies in different cancers are underway to determine if LRP expression in 
tumours is predictive of response to chemotherapy and prognosis (Izquierdo et al., 1996). 
Topoisomerases, proteins that facilitate the unwinding of DNA during DNA replication 
and transcription, have also been shown to be important in multidrug resistant cell lines 
(Beck, 1989). Many chemotherapeutic agents e.g. adriamycin, etoposide and others, act 
by targeting  the topoisomerase enzymes, binding to the complex formed with DNA and 
preventing rejoining of the DNA strands (Chan et al., 1993a). Low level Topoisomerase 
activity has been observed in many drug-resistant cell lines and resulted in relative 
insensitivity to Topoisomerase II targetting drugs (Long et al., 1991). Topoisomerase Ha 
expression has been found co-amplified with c-erbB-2 (a poor prognostic marker in breast 
cancer, Section 1.6.1.3) and those patients that over-expressed c-erbB-2 were found to be 
sensitive to Topoisomerase II inhibitors (Isaacs et al., 1995).
Resistance to cisplatin and other platinum compounds is usually associated with DNA 
repair activity. Cisplatin reacts readily with compounds containing a thiol group and 
resistance in some cases has been found to correlate with glutathione content (Pratt et al.,
1994). Another thiol-containing modifier of drug response is the metal-binding protein 
metallothionein. The metallothionein is a small 6-7kDa protein, 30% of which comprises 
of cysteine residues. High levels of metallothioneins are often seen in cisplatin-resistant 
cell lines (Kelley et al., 1988).
The enzyme dihydrofolate reductase (DHFR) is responsible for the conversion of folate to 
a variety o f coenzymes that are required for the synthesis of thymidylate, purines, 
methionine and glycine. Methotrexate blocks this process and in so doing results in 
inhibition of DNA, RNA and protein synthesis. Methotrexate resistant cells, therefore, 
frequently over-express the DHFR enzyme although other mechanisms of resistance are 
also known (Pratt et al., 1994). Normal conversion of dUMP to dTMP is mediated by the 
thymidylate synthase (TS) enzyme and is inhibited by the fluoropyrimidines. Over­
expression of TS is, therefore, seen in 5-fluorouracil resistant cell lines.
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As control of cell number is intrinsic to normal cellular growth, and apoptosis has such an 
important role to play in normal cellular regulation, disturbance of these tightly controlled 
pathways could have alarming consequences. It has been shown that a disordered apoptotic 
pathway is responsible for many pathogenic diseases involving a hyper-active (virus- 
induced lymphocyte depletion (AIDS), Alzheimer’s disease, Parkinson’s disease, aplastic 
anaemia, myelodysplastic syndrome (reviewed by Thompson, 1995)) or a hypo-active 
(neoplasia and some autoimmune diseases such as systemic lupus erythematosis (for 
review see Uren and Vaux, 1996)) death response. The interest for a role of apoptosis in 
cancer is two-fold. Deficient apoptosis promotes tumorigenesis by allowing the 
accumulation of dividing cells and by not removing damaged variants with enhanced 
malignant potential. Secondly, awareness of the apoptotic pathway is vital in 
understanding the treatment of cancer by chemotherapy. Cells which are given a survival 
advantage due to the over-expression of anti-apoptotic or proliferation genes or down- 
regulation of pro-apoptotic genes are less likely to die when exposed to an apoptotic 
stimulus such as chemotherapeutic drugs (Figure 1.3.1). Clinical evidence supports this 
theory as it has been shown that the common solid tumours that frequently develop 
resistance to chemotherapeutic drugs have a low apoptotic index (Staunton and Gaffney,
1995). These cells survive attack of an apoptotic agent and subsequently develop 
“resistance” to that agent.
Figure 1.3.1 Emergence of drug resistant cells when treated with chemotherapeutic drug
1.4.3 Control of Cell Death and Proliferation as a means of Multidrug Resistance
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chemotherapeutic drug
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The inherent problem with drug resistant cells is that they proliferate when they ought not,
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the fundamental basis of the malignant process. The emergence of M DR is frequently, but 
not always, associated with tumour progression (Kellen, 1994) which is the result of 
oncogene activation. Over-expression of almost all classes of oncogenes has been shown to 
affect the cell’s response to attack from chemotherapeutic agents. The epidermal growth 
factor receptor and its homologue, c-erbB-2, increase the resistance profile of some cell 
lines (Shin et al, 1991; Meyers et al, 1993; Muss et al., 1994; Sabbatini et al., 1994); 
signal transducers such as the Ras and Raf proteins which play a fundamental role in 
cellular proliferation affect resistance levels in in vitro systems as well (Isonishi et al., 
1991; Sabbatini et al, 1994). Over-expression of nuclear oncogenes which act as 
transcription factors has increased resistance in cell lines (Scanlon et al, 1991; Funato et 
al., 1992; Zhao et al, 1995); the role of the bcl-2 family in drug resistance is well 
documented (Kitada et al, 1994; Teixeira et al, 1995; W agener et al., 1996) as are other 
apoptosis effecting genes such as p53 (reviewed in Kellen, 1994) and c-myc (Kashani- 
Sabet et al., 1990; Sklar and Prochownik, 1991; Mizutani et al., 1994). The anti-apoptotic 
oncogene Bcr-abl has been definitively shown to block cell death in neutrophils caused by 
anticancer drugs and other cellular stresses (McGahon et al., 1994). Treatment of cells 
with drug has also demonstrated an inductive effect of certain oncogenes (Kashani-Sabet et 
al., 1990; Kim and Beck; 1994; Sinha et al, 1995; Tu et al, 1996). The common factor 
uniting all of these genes in the regulation of drug resistance is the fact that they all 
promote cellular proliferation, suggesting that the M DR phenotype is fundamentally a 
result of inappropriate proliferation.
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1.5 Oncogenes in the Study of Multidrug Resistance
Oncogenes are dominant mutated forms o f normal cellular proteins involved in signal 
transduction cascades, expression of which results in inappropriate proliferation. There are 
three main methods whereby the normal cellular protein (proto-oncogene) is mutated to its 
oncogenic counterpart. The methods involved include
(a) deletion or point mutation in coding sequence of gene resulting in a hyperactive protein 
made in normal amounts;
(b) gene amplification leading to the over-production of a normal protein;
(c) chromosomal rearrangement whereby a gene is under transcriptional regulation of an 
actively transcribed gene. (Alberts et al., 1994).
As the fundamental theory of chemotherapy demonstrates, chemotherapeutic drugs are 
more toxic to malignant cells than normal cells suggesting a role for the transformation 
from normal to cancerous cells in determining the response of a cell to the drug. A 
causative role for oncogenes in drug-resistance has received much attention in the last few 
years. This is not surprising as most chemotherapeutic drugs act by inducing apoptosis 
which is controlled by many signal transduction pathways involving oncogenes 
(Skladanowski and Konopa, 1993; Hickman, 1996). Drug-resistant cells proliferate in the 
presence of anti-proliferative drugs, therefore a mechanism is present which results in the 
dominant proliferation and survival of cells in the presence o f a chemotherapeutic drug. A 
number o f oncogenes are currently under investigation in the broad discipline of 
chemotherapy, such as targetting oncogene-expressing cells with antibody-linked 
chemotherapeutic drug (Suzuki et al., 1995), and especially in the area o f drug resistance. 
When treated with chemotherapeutic drugs, increased expression o f genes which promote 
proliferation, either by increasing cell division or blocking cell death, would be expected 
to give cells a survival advantage and therefore result in the emergence of clinical drug 
resistance.
It is possible to group oncogenes into two main categories - those that increase the rate of 
cell division and those that influence cell death (both groups often overlap); this latter 
group can be sub-divided into genes that suppress or induce apoptosis. The balance of 
these genes in the cell determines the cells ability to survive an attack, for example, by a 
chemotherapeutic agent and emerge as a resistant population. Therefore, the consequence 
of inhibiting cells from undergoing apoptosis is another method whereby cells can develop 
resistance to chemotherapy.
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1.6 Oncogenes and their role in Cell Proliferation
Oncogenes were discovered due to their characteristic capacity of increasing cellular 
proliferation, thereby resulting in the growth of a tumour. Oncogenes fall into many 
cellular categories, including growth factor receptors, cytosolic proteins and transcription 
factors, and are part of a cascade of proteins leading from the plasma membrane through 
the cytoplasm and into the nucleus (for review see Bishop, 1991). Molecular co-operation 
between different classes of these oncoproteins results in the development of a 
proliferating mass of undisciplined cells.
Even though over one hundred oncogenes have been identified to date only three 
biochemical mechanisms are known whereby the genes exert their transforming capacities; 
these mechanisms involve (a) phosphorylation of proteins on serine, threonine or tyrosine 
residues, (b) transmission of signals by GTPases, or (c) transcription from DNA (Bishop, 
1991). Protein phosphorylation, regulated by protein kinases and phosphatases, controls a 
wide range of cellular events, such as cell division, cell signalling, differentiation and 
metabolism. Intrinsic to the transforming ability of oncogenes is a phosphorylation 
cascade whereby phosphorylation of a membrane-associated protein transduces a signal 
through the cytosol to the nucleus.
1.6.1 Oncogenesis at the Plasma Membrane
A number o f oncogenes encode mutant forms of cell surface growth factor receptors 
whereby the mutated form gives rise to a cell with enhanced propensity for growth despite 
the presence of normal regulatory messages. Many of these oncogenes are derived from 
receptor protein-tyrosine kinase genes which encode either receptors for known growth 
factors (e.g. EGF receptor, PDGF receptor, IGF receptor) or receptor-like proteins with 
unknown ligands (e.g. neu / c-erbB-2). Other non-receptor tyrosine kinase proteins exist 
which include the cytoplasmic Src family, of which Lck is a member, and the nuclear Abl 
protein. Normal cells rarely phosphorylate tyrosine residues unless stimulated by growth 
factors.
Receptor protein tyrosine kinases have an extracellular ligand-binding domain, a single 
transmembrane domain and a cytosolic domain. When activated by ligand binding, the 
cytosolic domains of receptor dimers cross-phosphorylate each other on tyrosine residues 
which causes a conformational change that enhances the kinase activity of the receptor
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towards other substrates. Oncogenic variants of normal receptors include deletion of large 
portions of the extracellular domain, single amino acid substitutions in the trans­
membrane domain or mutations in the cytosolic domain (for review see Cantley et al., 
1991). The effect of these mutations is the activation of the receptor without the need for 
ligand binding.
The prototype of the cytosolic non-receptor protein tyrosine kinase is the c-Src protein. 
All protein-tyrosine kinases show sequence homology over a stretch of 300 amino acids 
known to encode the kinase domain. The Src subfamily has additional regions of 
homology not found in the receptor family which includes a short amino-terminal 
sequence required for the addition of myristic acid (necessary for membrane localisation) 
and two additional domains named Src homology 2 and 3 (SH-2 and SH-3), required for 
protein interactions (Cantley et al., 1991). Most members of the src family are highly 
regulated and exhibit little activity in normal cells in the absence o f an activating 
sequence. This tight regulation is mediated via tyrosine phosphorylation in the carboxy- 
terminal tail which results in a conformational change which blocks the interaction of 
effector proteins with the SH-2 and SH-3 domains and also inactivates the enzymatic 
ability of the kinase (Cooper and Howell, 1993). Inhibiting the phosphorylation of the 
carboxy domain will therefore remove the inhibition of the Src protein and maintain the 
kinase in an active form capable of interacting with other proteins. Stimulation of Src 
occurs via interaction with the receptor tyrosine kinases (reviewed by Parsons and 
Parsons, 1997).
Studies have shown that up-regulation of the epidermal growth factor receptor confers a 
poor prognosis and increased invasive ability on tumour cells (Holting et al., 1995; Jones 
et al., 1996; Nagane et al., 1996). Previous studies have suggested a role for the up- 
regulation o f the EGF receptor in multidrug resistant cell lines (Meyers et al., 1993 and 
Shin et al., 1991), although Reeve and co-workers (1990) demonstrated a reduced 
expression of the EGF receptor in a human large cell lung cancer M DR cell line. M ore 
recently, evidence in the literature suggests that the homologous c-erbB-2 protein affects 
chemosensitivity levels of tumour cells in vivo and in vitro (see Table 1.6.1.2.1). c-erbB-2 
is well established as a marker of poor prognosis in many tumours, especially breast 
(DePotter and Schelfhout, 1995).
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1.6.1.1 The c-erbB-2 Oncogene
EGFR (c-erbB 1) and c-erbB-2 / neu belong to the transmembrane type I receptor tyrosine 
kinase (RTK) family and the expression of these genes is associated with an 
invasive/metastatic phenotype and relative insensitivity to conventional treatments (Eccles 
et al., 1995). Evidence is gathering that these family members may co-operate with each 
other in their transforming capacity (Bacus et al., 1994). The c-erbB-2 gene, localised on 
the long arm of chromosome 17, encodes a protein of 185 kDa and is identified either as 
c-erbB-2, neu or HER-2. Transfection experiments whereby the gene was introduced into 
NIH 3T3 cells led to a malignant phenotype with an increased growth potential (DePotter 
and Schelfhout, 1995). An interesting observation was noted by Imyanitov and co-workers
(1993) where amplification of erbB-2 was combined with 17p deletions (chromosomal 
location of p53, the tumour suppressor). The promoter region o f the c-erbB-2 gene 
contains sequences that respond to several environmental signals including EGF, TPA, 
cAMP and retinoic acid (Hudson et al., 1990). EGF stimulates phosphorylation o f c-erbB- 
2 and its effect on promoter activity provides a second mechanism whereby EGF may 
increase c-erbB-2 activity. A specific transcription factor, OB2.1, has been found in breast 
cancer cell lines that over-express the c-erbB-2 gene (Hollywood and Hurst, 1993).
The close similarity of c-erbB-2 to EGFR has suggested a role for this protein as a growth 
factor receptor, although evidence exists that its ligand may be a “non-classical” growth 
factor as expression of c-erbB-2 has been found in non-proliferating cells (Bargmann, 
1988). The ligand for this receptor kinase remains elusive, although some molecules have 
been identified which specifically induce phosphorylation of the c-erbB-2 protein e.g. 
Heregulin (the human homologue of NDF (neu differentiation factor) (DePotter and 
Schelfhout, 1995). Activation of c-erbB-2 by Heregulin is cell type-specific (Wallasch et 
al., 1995) It appears that the interaction o f c-erbB-2 with NDF involves 
heterodimerization of the former with another member of the EGFR family e.g. HER3 
(Bacus et al., 1994; Wallasach et al., 1995). Disruption o f the tightly co-ordinated 
interplay between members of the type I RTKs may have severe consequences on the cell, 
a fact borne out by the frequent involvement of such genes in human cancers. NDF 
induces morphologic changes in cells overexpressing c-erbB-2 and correlates with up- 
regulation of intracellular adhesion molecule 1 (ICAM-1) which plays a role in 
inflammation and cancer in mammary cells.
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Other than its role as a stimulator of mitogenesis in cells, c-erbB-2 has also been reported 
to play a role in the process of active cell death and is believed to act in a manner similar 
to that of the “dual role” of c-myc (see Section 1.7.1.2) (Harris et al., 1995). Harris et al. 
(1995) reported that over-expression of c-erbB-2 (by transfecting with a mutated neu gene) 
resulted in a marked apoptotic response when serum levels were reduced. This was the 
first report whereby a link was made between receptor tyrosine kinases and apoptosis in 
epithelial cells. The relevance of this is yet to be fully realised but its importance in breast 
tissue is noted as apoptosis naturally occurs during involution of the lactating rodent 
mammary gland following weaning and in the human breast epithelium during the 
menstrual cycle but no specific mechanisms that induce or inhibit apoptosis in the normal 
mammary gland have yet been identified.
To add to this “dual ro le” hypothesis, Dolnikov et al. (1995) found that v-erbB (the viral 
counter-part of the human homologue c-erbB-2) expression prevents programmed cell 
death. Increased resistance to chemotherapeutic drugs due to the over-expression of c- 
erbB-2 may be associated with this gene’s role in apoptosis.
1.6.1.2 c-erbB-2 in Human Tumours and Effect on Response to Chemotherapy
Alteration to c-erbB-2 expression has been seen in a wide variety of human tumours. The 
neu gene was first isolated from a rat neuroblastoma and since then the human homologue 
has been associated with cancers of the breast (Slamon et al., 1987; van de Vijver et al., 
1988; DePotter et al, 1995; Keshgegian et al., 1995; Scorilas et al, 1995; Slamon et al, 
1989; Qu6nel et al., 1995), ovaries (Slamon et al., 1989; Katsaros et al., 1995; Simpson 
etal., 1995; Wong et al., 1995), stomach (Orita et al., 1997), lung (Tateishi et al., 1991; 
Rachwal et al., 1995; Diez et al, 1997), bladder and many other adenocarcinomas 
(Bargmann, 1988). Amplification o f c-erbB-2 takes place in a different set of tumours to 
that of the EGF receptor (Bargmann, 1988).
Expression of the protein in many of these tumours correlates with increased metastatic 
capacity and poor prognosis (Eccles et al, 1995; Tan et al, 1997). Liver metastases and 
haematogenous metastases are frequently found in c-erftB-2-overexpressing patients 
(DePotter and Schelfhout, 1995). Adding further to the role of c-erbB-2 as a poor 
prognostic marker is the fact that over-expression of c-erbB-2 in some human tumours 
affects resistance to chemotherapy treatment. In vitro studies also propose a role for c- 
erbB-2 in drug resistance in tumour cell lines (results of these studies are summarised in
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Table 1.6.1.2.1 and discussed in more detail in Section 4.1.1).
Table 1.6.1.2.1 Effect of c-erbB-2 expression on Chemoresistance
Tissue Type Drug Reference
breastT CMF Bacus et al., 1994
breastT CMF BitraneiaZ., 1996
breast0 cisplatin/5-fluorouracil Dickson etal., 1990
breastT adriamycin Muss etal., 1994
breast0 adriamycin Sabbatini et al., 1994
breast0 taxol Yu etal., 1996
non-small cell lung0 cisplatin/doxorubicin/etoposide Zhang and Hung, 1996
c in vitro studies on human cell lines; T in vivo studies on human tumour specimens; CMF = 
cyclophosphamide:methotrexate:5-fluorouracil.
1.6.1.3 c-erbB-2 and its Predictive Role in the Outcome of Breast Cancer
Size of primary tumour, stage of disease at diagnosis, hormonal receptor status and 
number of axillary lymph nodes involved in the disease are all important prognostic 
factors in the prognosis of breast cancer. In previous studies it was found that c-erbB-2 
was a useful prognostic marker coming second to the classical indicators such as number 
of invaded axillary lymph nodes, receptor status etc. (DePotter and Schelfhout, 1995) and 
correlated well with many of these classical disease parameters (Slamon et al., 1987). 
Hormones have been shown to play a role in c-erbB-2 regulation in breast cancer as it has 
been found that oestrogen receptor positive tumours are well differentiated and less 
invasive whereas c-erbB-2 positive tumours are less differentiated and more aggressive 
(DePotter and Schelfhout, 1995). Antoniotti et al. (1994) demonstrated that oestrogen 
represses the transcription of the c-erbB-2 gene and also decreases the level o f protein 
present in the cell. Over-expression of c-erbB-2 tyrosine kinase receptor is a common 
feature of human breast cancer and appears to be an early event in progression of the 
disease and follows through to metastatic spread. Amplification and overexpression of the 
c-erbB-2 gene occurs in approximately 30% of breast cancers and correlation with earlier 
relapses and shorter overall survival times has suggested its use as a prognostic marker in 
breast cancer patients.
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1.6.2 Transmission of Membrane Signals
Molecular signals at the plasma membrane are transmitted through to the nucleus via 
kinases in the cytoplasm as part of a signal transduction cascade. The primary cascade 
involved in signal transduction initiates signalling through the family of small nucleotide 
binding proteins, namely small G-proteins, to effector proteins that eventually transmit the 
signal to the nucleus. The initiating protein in this event is the ras protein whose 
importance was high-lighted when it was discovered that the first transforming genes of 
human cancers to be isolated were activated cellular counterparts of the normal cellular 
homologues of viral ras oncogenes (Lacal Tronick, 1988).
1.6.2.1 G-proteins
There are two main families of G-proteins, namely the heterotrimeric proteins and the 
monomeric proteins. Trimeric G-proteins were discovered in the late 1970s as crucial 
mediaries in signal transduction (Linder and Gilman, 1992). The proteins belong to a 
large superfamily of proteins that are regulated by Guanine nucleotides and are in their 
inactive state when bound to GDP but are quickly activated if cellular signals result in the 
replacement of the GDP molecule with GTP. These proteins are arranged on the 
cytoplasmic side of the plasma membrane and receive a signalling message from a specific 
receptor in the plasma membrane and transduce this message to an effector molecule such 
as adenylyl cyclase which in turn releases a second messenger (e.g. cyclic AMP (c-AMP)) 
resulting in the biochemical effect expected of the initial signalling message. The G- 
protein consists of three subunits, namely a , p and y with the guanine nucleotides binding 
to the a-subunit. After activation by binding of GTP to the a-subunit, the a-subunit 
dissociates from the rest of the molecule and diffuses along the plasma membrane and 
binds to an effector molecule which is then activated. The GTP is then hydrolysed to GDP 
and the a-subunit reassociates with the rest of the G-protein complex.
The ras family belong to the group of monomeric G-proteins, otherwise known as small 
G-proteins (also included in this group are the rho and rab families). The small G-proteins 
are most homologous to the a-subunit (Lacal Tronick, 1988) of the heterotrimeric proteins 
being active when bound with GTP and inactive when bound with GDP with the capacity 
to hydrolyse GTP to GDP. The molecular weight of all family members is 21-25kDa.
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The ras oncogenes were first reported in 1964 as the Harvey sarcoma virus (H-ras) and 
since then other members have been discovered including Ki-ras and N-ras. In the case of 
these 21kDa proteins it has been shown that point mutations quite readily convert normal 
genes to proliferative oncogenes and these point mutations act by either reducing the 
inherent GTPase activity of the protein or decrease the affinity of the protein for GDP - 
both result in the continual activation of the protein by increasing the time the protein is 
bound to GTP. Many proteins have been identified which interact with the small G- 
proteins including GAP (GTPase Activating Protein), GIP (GTPase Inhibiting Protein) and 
GDI (GDP Inhibition Protein), among others (Lacal and M cCormick, 1993). The normal 
function of ras in cells is believed to be in the regulation of growth and differentiation.
1.6.2.2 Transduction of Cellular Signal from Ras
The activation of Ras is stimulated via growth factor, such as platelet-derived growth 
factor or epidermal growth factor, binding to its receptor in the plasma membrane. This 
results in a conformational change, via phosphorylation, in the growth factor receptor and 
subsequent activation o f the ras protein. Transfer of message from the growth factor 
receptor to the small G-protein is mediated via adaptor molecules (see Figure 1.6.2.2.1) 
(for review see Krontiris, 1995). Recruitment of Grb-2 (the growth factor receptor binding 
protein 2), an adaptor molecule, from the cytosol to the receptor following ligand binding, 
enlists the assistance of the Sos (son of sevenless) protein. Sos is a nucleotide exchange 
factor that engages the Ras-GDP protein and helps it exchange GDP for the active GTP- 
bound protein (reviewed by Krontiris, 1995). Ras GTPase activating protein (GAP) 
controls the lifetime of signalling by the ras protein by increasing the GTPase activity 
inherent in ras (it has been suggested that this GAP protein is the neurofibromatosis 
tumour suppressor gene (NF-1) (Xu et al., 1990)). Other G-protein regulatory proteins 
have also been identified which down-regulate the activity o f the protein, for review see 
Koelle (1997). As many oncogenes are truncated versions of growth factor receptors 
which no longer need a stimulus to become active and inhibitors of ras activation are 
absent in some tumours (e.g. NF-1), hyper-activity of ras is expected in many tumour 
cells.
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Figure 1.6.2.2.1 Stimulation of Ras activity by Growth Factor Binding to Receptor
Activation of the tyrosine kinase receptor by ligand binding recruits the cytoplasmic proteins Grb-2 
and Sos to the plasma membrane where they induce the Ras protein to exchange its bound GDP for 
GTP. GAP exerts its GTPase activity and converts the active GTP-bound Ras to its inactive GDP- 
bound form.
Growth factor stimulated Ras proteins interact on the cytosolic side of the plasma 
membrane yet it is in the nucleus that growth factors induce alterations in gene expression. 
To forward cell membrane messages, Ras begins a cytoplasmic signalling to the 
serine/threonine kinase protein, Raf. Three distinct members o f the Raf family exists, 
namely, c-Raf-1, A-Raf and B-Raf which share three highly conserved regions (CR1-3) 
(Daum et al., 1994). The role of Ras in the activation of c-Raf-1 is in the translocation of 
c-Raf-1 from the cytosol to the plasma membrane (Leevers, 1994). Translocation to the 
plasma membrane is not sufficient to activate c-Raf-1 and it has been found that 
phosphorylation on tyrosine residues is essential in this process. This phosphorylation can 
be carried out by the Src protein, among others (for review see de Vries et al., 1996 and 
Morrison and Cutler, 1997). Recruitment o f c-Raf-1 to the plasma membrane activates a 
number of kinases that eventually activate the transcription of a number of genes and 
phosphorylation of many proteins involved in cell proliferation. The substrate of the 
activated c-Raf-1 protein is the threonine/tyrosine protein kinase M APK/ERK Kinase 1/2 
(MEK1/2) that is activated by serine phosphorylation due to the kinase activity o f c-Raf-1 
(MEK kinase (MEKK)). MEK1 in turn activates the cytosolic serine/threonine Mitogen 
Activated Protein Kinases (MAPKs) by phosphorylation on threonine and tyrosine 
residues. De-phosphorylation of MAPKs is carried out by dual-specificity phosphatases
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(DSPs) (reviewed in Neel and Tonks, 1997), such as MKP-1 (MAPK phosphatase 1). 
Mitogen activated protein kinases are constitutively activated in ras-transformed cell lines 
(Woodgett, 1992). MAPKs phosphorylate multiple proteins, including Sos and c-Raf-1, 
suggesting the existence o f a negative feed-back loop (Cherniack et al, 1994; Davis,
1993). Sustained activation of MAPKs induces translocation o f the cytosolic kinases to the 
nucleus (Marshall, 1995) where nuclear transcription target proteins such as c-Myc, c-Jun, 
c-Fos and p53 reside (see Figure 1.6.2.2.2).
Cross-talk between the MAPK pathway and other signalling pathways occurs with 
integration occuring at many levels. A likely benefit of this cross-talk is an increase in the 
number of targets for positive and negative regulation o f many cellular signals. The 
oncogenic pathway leading from ras therefore floods the cell with growth stimulatory 
signals and induces proliferation.
Figure 1.6.2.2.2 Signalling Cascade of Ras Protein
A ctivation  Signal
MAPK = Mitogen Activated Protein Kinase; P =  Phosphorylation; MEK = MAPK/ERK Kinase
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1.6.2.3 The Role of Ras in Survival Signalling and Proliferation
Wyllie et al. (1987) suggested a role for c-H-ras in survival signalling when the first 
studies of the effects of oncogenes on apoptosis were carried out; in these experiments it 
was surmised that spontaneous apoptosis was suppressed by the expression o f c-H-ras. 
More recent evidence supporting a role for ras in survival signalling comes from 
experimental evidence by Kinoshita et al. (1995) which showed that ras rapidly up- 
regulates the survival factors bcl-xL and bcl-2 (see Section 1.7.1) but not the antagonistic 
homologue bax in haematopoietic cells exposed to interleukin-3 and GM-CSF. Chen and 
Faller (1995) found that activated Ras was a potent inducer of apoptosis when combined 
with down-regulation of protein kinase C (conflicting role in apoptosis process (Lucas and 
Stachez-M argalet, 1995)) activity but could be abolished by co-expression of bcl-2.
Ras activity is also thought to be necessary in cell cycle progression, including G0 to Gi 
and G2 to M transitions possibly via c-Myc activation. Another interesting observation in 
the path leading to oncogenesis is the recent finding (G.Breier, pers.comm.) where v-H- 
ras was found to increase the expression of the YEGF (vascular endothelial growth factor) 
gene thereby showing v-H-ras not only to have a direct effect on proliferation but also to 
play an indirect role by stimulating tumour angiogenesis as a result o f up-regulation of 
VEGF mRNA.
1.6.2.4 Ras Expression in Human Tumours and Effect on Prognosis
Ras has demanded much attention as it has been found expressed in 30% of all human 
tumours. It is believed to be important in the initial steps leading to carcinogenesis (often 
detected in benign disease e.g. colon, thyroid and prostate (Bushman et al., 1995) and 
results in malignancy when co-expressed with other oncogenes such as c-myc (Hunter, 
1991). Mutations in K-ras are seen in 40% of colon tumours while H-ras mutations are 
associated with poor prognosis in cervical cancer. Elevated ras expression is associated 
with the pre-malignant “polyp” stage of colon cancer. Increased ras expression has also 
been seen in the progression of stomach, lung (K-ras mutations may be associated with the 
appearance of the malignant phenotype) (Sugio et al., 1994) and breast cancer and 
correlates with disease recurrence in the latter (Field and Spandidos, 1990). 
Overexpression of members of the ras family occurs frequently (59%) in squamous cell 
carcinoma of the head and neck and McDonald et al. (1994) found this expression to play
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an important part in the latter stages of tumourigenesis.
The role of Ras family members in clinical drug resistance has not been addressed. A 
number o f in vitro studies have been carried out on H-ras and drug resistance in cancer 
cell lines, however (see Table 1.6.2.4.1; results are discussed in Section 4.1.2).
Table 1.6.2.4.1 Effect of H-ras Expression on Chemoreststance
Cell Type Drug Reference
rat liver adriamycin/vinblastme Burt etal., 1988
NIH3T3 fibroblasts cisplatin Isonishi et al., 1991
NIH3T3 fibroblasts alkylating agents Niimi etal., 1991
human breast adriamycin Sabbatini et al., 1994
N1H3T3 fibroblasts cisplatin Sklar, 1988
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1.6.3 Orchestration of Cellular Signals at the Nucleus
To change the growth rate of cells, stable changes in cellular gene expression must occur 
and, therefore, gene transcription can be considered an ultimate target of oncogene 
activity. Those genes that control the expression o f genes involved in proliferation bind 
DNA and are likely to function as transcription factors. Many oncogenic transcription 
factors appear to be constitutively activated forms of their normal cellular counterparts 
(Hunter, 1991).
The transcription factor AP-1 (HeLa cell activator protein 1) binds to a short sequence of 
DNA (namely TGACTCA) found in many human gene promoters to activate (or 
sometimes repress) expression of these genes. AP-1 is a known target of M AP kinase 
signalling pathways (reviewed by Whitmarsh and Davis, 1996). The complex consists of a 
variety of polypeptides including the Fos, Jun and activating transcription factor 2 (ATF2) 
proteins. The complex can act either as Jun (v-Jun, c-Jun, JunB, JunD) or ATF (ATF3, B- 
ATF) homo-dimers or Jun/ATF/Fos (v-Fos, c-Fos, FosB, F ra l, Fra2) heterodimers but 
not as Fos homo-dimers. These genes are “B-Zip” proteins containing a basic DNA- 
binding region and a leucine Zipper region that allows both proteins to interact with each 
other. Both genes are known as “immediate early genes” and are induced by a wide 
variety of mitogens in different cell types. Much interest in the AP-1 complex and its 
relevance to drug resistance comes from the realisation that the hall-mark protein of drug 
resistance, P-glycoprotein, contains an AP-1 transcription site in its gene promoter (Teeter 
etal., 1991).
1.6.3.1 c-Fos as Proliferation Inducer
c-Fos was originally recognised as a viral oncogene (Finkel-Biskis-Jinkins murine 
osteosaroma virus; FBJ-MuSV) that induced osteogenic sarcoma in vivo and transformed 
fibroblasts in vitro. The cellular homologue of FBJ-MuSV was identified in human cells 
and the human c-fos gene was found to encode a protein of 380 amino acids (van Straaten 
etal., 1983).
The basal level of c-fos expression is very low in most cells, however, treatment with a 
variety of agents, including serum and chemotherapeutic drugs, leads to dramatic, but 
transient, induction of the gene as it acts to convert short-term signals occurring within a 
few minutes o f the primary stimulus to long-term cellular responses that occur over hours
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and days (Curran, 1988). In the search to find a common function for c-Fos a number of 
roles have been proposed for the gene in cell-cycle regulation, cellular proliferation and 
differentiation (Curran, 1988). Greenberg and Ziff (1984) found that stimulation of 
BALB/c-3T3 cells with serum, PDGF or TPA resulted in a transient increase in the 
transcription o f c-fos during the transition from G0 to Gi; a 15-fold increase was noted 
very soon after stimulation with a return to basal levels within 30min; increased 
transcripts are apparent as early as five minutes after serum addition, peak after ten 
minutes and begin to decrease by fifteen minutes. The authors concluded that continuous 
expression of c-fos might prevent a cell from ever entering a quiescent state resulting in a 
population of continually dividing cells. Anti-sense studies revealed that a reduction in c- 
fos mRNA levels resulted in an increase in doubling time of 3T3 cells and that the c-fos 
gene product appeared to have a required role in normal cell division (Holt et al., 1986). 
Balsalobre and Jolicoeur (1995) found that c-Fos proteins can act as negative regulators of 
cell growth in some cell types, however, independently of the c-fos transforming pathway. 
It has been found that c-Fos is expressed immediately prior to apoptosis (and together with 
c-Jun may represent an important early event in the activation of the genetic cascade 
leading to cell death) (Colotta et al., 1992) and induces apoptosis when continuously 
expressed (Smeyne et al., 1993). It is for this reason that c-fos has been granted the title 
“harbinger of death” . Continuous expression of Fos begins hours or days before cell death 
and is a hallmark of terminal differentiation and death in skin, hair follicle and bone. The 
part Fos has to play in cell death is as yet hypothetical but (i) it may have a primary role 
in the process of cell death; (ii) it may be necessary for apoptosis in only some 
circumstances; or (iii) it may be that a signal leading to cell death co-incidentally induces 
c -fos.
1.6.3.2 The c-Jun Oncogene
The v-jun oncogene was isolated from avian sarcoma virus 17 (ASV-17) which induces 
fibrosarcomas in chickens and can transform chick embryo fibroblasts. Analysis revealed 
the C-terminus to be similar to the DNA-binding domain of yeast transcriptional activator 
GCN4. The half life of the jun mRNA is very short (perhaps explaining the absence of 
introns in this gene) thus a signal leading to increased jun transcription can result in an 
increase in AP-1 activity rapidly and the low stability of the mRNA could be responsible 
for the correct termination of such a signal (Hattori et al., 1988). c-Jun is also an
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“immediate early gene” that responds to many cellular stimuli and therefore has an 
important role to play in mitogenesis. The induction of fos and jun is not always co­
ordinated and usually the c-jun response is more persistent.
c-Jun is capable of transforming immortalized rat fibroblasts in co-operation with activated 
c-H-Ras (Bin6truy et al., 1991) independent of c-fos activity. Both oncogenes work in a 
common pathway whereby the upstream Ras stimulates c-Jun (see Figure 1.4.3.5.1) by 
inducing its phosphorylation through the activation of JNK. UV, a potent tumour 
promoting agent, is a very effective inducer of c-jun (via JNK) transcription but only 
modestly induces c-fos; this is one way in which c-jun can act as a mediator of tumour 
promotion by activating genes involved in proliferation (jun as transcription factor) in 
response to DNA damage such as UV light. JunB, a member o f the Jun family, 
antagonizes the transforming properties o f c-Jun (Schutte et al., 1989).
Evidence has been gathering in recent years that c-Jun has a role to play in the apoptotic 
pathway. c-Jun expression was induced in cultured neurons undergoing (3-Amyloid 
apoptosis and its expression was not induced in cells resistant to this type of apoptosis 
(Anderson, 1995); a possible role for JNK in gamma-irradiation induced apoptosis has 
also been proposed (Chen et al., 1996).
1.6.3.3 AP-1 Target Genes
Binding of the AP-1 complex to many gene promoters activates transcription of that gene. 
Collagenase, human metallothionein IIA and transin are all activated by binding of the 
AP-1 complex to its promoter recognition sequence; the osteocalcin gene is, however, 
repressed by such binding. An AP-1 site has been identified in the mdrl promoter region 
and has been shown to be necessary for correct functioning of this gene (Teeter et al., 
1991). Topoisomerase I has also been found to contain an AP-1 binding site (Kunze et al., 
1990) in its promoter and a putative AP-1 site lies upstream of the translational initiation 
site of the dTMP synthase gene (Takeishi et al, 1989).
1.6.3.4 AP-1 as a Cellular Response Element
The c-fos promoter is activated by a variety of signals (e.g. growth factors, cytokines, 
UV-light and other DNA damaging agents) via signal transduction pathways involving the 
Ras family through MAP-K (mitogen activated protein kinase) and eventually activation of
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the promoter at the serum response element (SRE) (Janknecht, 1995). c-Jun is activated by 
many cellular stimuli as well but regulation of its transcription unit is not as complex as 
that of c-fos. This kinase cascade is a common pathway shared by cell proliferation and 
stress-response signalling.
At least four different MAP-K proteins have been identified which activate the AP-1 
complex, each with their own substrate specificities (Deng and Karin, 1994; for review 
see Karin, 1995). ERK (extracellular signal regulated protein kinase) is activated by 
growth factors, such as EGF and PDGF, and phorbol esters; FRK (Fos regulated kinase) 
is activated by growth factors alone; and JNK (c-Jun N-terminal kinase) and p38 are 
activated by UV, TNF and very weakly by growth factors and other cellular shocks. In 
response to DNA damaging agents, such as ionising radiation or cisplatin, JNK MAP 
kinases are activated by a pathway dependent on the non-receptor tyrosine kinase, c-Abl 
(Kharbanda et al. , 1995). These kinases act by phosphorylating either the c-Fos or c-Jun 
proteins or proteins in the transcription unit of either gene (see Figure 1.6.3.4.1).
Figure 1.6.3.4.1 Cellular Response Signalling Cascade of AP-1
Signalling of cellular messages via the MAP and SAP kinase pathways induces the transcription of 
the AP-1 complex proteins, c-Fos and c-Jun, and activates subsequent transcription of AP-1 target 
genes. SAPK = Stress Activated Protein Kinase; MAPK = Mitogen Activated Protein Kinase; 
JNK = c-Jun N-terminal Kinase; ERK =  Extracellular Signal Regulated Protein Kinase; FRK = 
Fos Regulated Kinase; ATF = Activating Transcription Factor; TRE = TPA-Response Element; 
TCF =  Ternary Complex Factor; SRF =  Serum Response Factor; SRE =  Serum Response 
Element:
31
1.6.3.5 AP-1 Expression in Human Tumours as a Marker of Poor Prognosis
Both c-fos and c-jun were identified in osteosarcomas originally (Curran, 1988). 
Expression of both proteins has also been identified in breast cancer (Tiniakos et al., 
1994; Walker and Cowl, 1991) where Tiniakos et al. (1994) found 90% of all breast 
carcinomas studied to have c-Jun-specific nuclear staining. Down-regulation o f these genes 
was hypothesised to be involved in the pathogenesis of lung cancer in a study by Levin et 
al. (1995). A significant relationship was seen between P-glycoprotein expression in 
human lung carcinomas and c-Fos and c-Jun expression (Volm, 1993). Volm and co­
workers (1993) also found a significant relationship between c-jun expression in primary 
human small lung cancer and incidence of metastases, no correlation with c-fos expression 
was seen, however. Magrisso and co-workers (1993) found that c-Jun and c-Fos were 
important parameters in colorectal tumorigenesis.
A role for c-jun and c-fos in chemoresistance, especially to cisplatin, has been shown in 
vivo and in vitro. Zhao and co-workers (1995) demonstrated the up-regulation of c-jun by 
cisplatin in sensitive melanoma cell lines but less so in resistant variants. In vivo studies in 
head-neck tumours agreed with this finding (Los et al., 1995). Up-regulation of the c-Fos 
protein is associated with cisplatin resistance in some cell lines (Funato et al., 1992; 
Scanlon et al., 1991) and human tumours (Kashani-Sabet et al., 1990). The role c-Fos and 
c-Jun in drug resistance is discussed in greater detail in Section 4.1.3.
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1.7 Suicide Genes and their role in Apoptosis
Apoptosis is regulated by many genes in normal tissues, some of which are normal 
cellular counterparts of genes influential in the transformation o f normal to malignant 
cells. Human homologues of the Caenorhabditis elegans ced genes have been discovered 
and have added a wealth of knowledge to our understanding of cell suicide. The main 
players in the apoptotic pathway are the Bcl-2 family of genes, p53, ICE, CD95 (APO-1 
/Fas), Bcr-abl and c-Myc (see Figure 1.7.1). Many oncogenes, described previously, have 
also been found to influence the cell’s capacity to undergo apoptosis. These proteins can 
influence cell viability either by promoting or inhibiting cell death and it is the balance or 
interplay of this myriad o f proteins which influences a cell’s susceptibility to death. Over­
expression of apoptosis promoting proteins will tip the balance in favour of cell death 
whereas over-expression of apoptosis suppressing proteins will favour survival.
Figure 1.7.1 Molecular Regulation of the Apoptotic Pathway
Growth Factor Withdrawal Activation of Death
oting Genes
DNA damage 
(via wild type p53) Ligand Binding
CD95 (APO-l/FAS)
Central Cell Death Signal
Bax Bak induction
Bcl-2 BcI-Xl 
repression BAG Mcl-1
Bcl-xs Bad 
Bikl c-Myc
E1B-19K BHRF1 
Ced-9 bcr-abl 
mutant p53
Protease Activation 
(ICE)
Cell Suicide
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1.7.1 Bcl-2 Gene Family
The study of the Bcl-2 family as genes that influence cell viability and death independent 
of cell division represents a vast area of research in the whole field of cancer biology. 
Tsujimoto and Croce (1986) discovered the bcl-2 (B-cell leukemia/lymphoma 2) gene 
through studies of chromosomal rearrangements frequently observed in the great majority 
of human hematopoietic malignancies. In most cases o f follicular lymphoma a 
t(14; 18)(q32;q21) translocation was observed and the bcl-2 gene was discovered adjacent 
to this break-point. This head-to-tail juxtaposition of bcl-2 (from chromosome 18q21) to 
the immunoglobulin heavy chain locus (at chromosome 14q32) is associated with an 
increase in expression of bcl-2 believed to be due to the presence of enhancers in the 
immunoglobulin heavy (IgH) gene (Craig, 1995; Tsujimoto and Croce, 1986). In most 
follicular lymphomas studied the chromosome 18 break-points occur at the unusually long 
(5.4kb) untranslated 3 ’ end of the bcl-2 gene or are 3’ of the involved bcl-2 gene thereby 
preventing any interruption to the coding region of the bcl-2 gene.
Analysis by Tsujimoto and Croce (1986) indicated that the bcl-2 gene consists of at least 
two exons that produce three transcripts of 8.5kb, 5.5kb and 3.5kb long mRNAs. The bcl- 
2 cDNA sequence was analysed, from which two protein products were postulated, 
namely, bcl-2a (239a.a.) and bcl-2f3 (205a.a.), that differ only at their carboxyl terminus. 
The bcl-2a mRNA encodes a 26kDa protein that is homologous to the hypothetical 
Epstein-Barr virus protein BHFR1 (Cleary et al., 1986). M ost of the bcl-2 ORF is 
encoded within the 5’ exon. Structural analysis yielded no apparent transmembrane 
hydrophobic segment.
Studies of bcl-2 knock-out mice highlight the problems associated with a dysfunctional 
apoptotic pathway and the role Bcl-2 has to play in it. M ice lacking Bcl-2 complete 
embryonic development and appear normal during the first week after birth. Subsequently, 
growth is retarded and small ears and immature facial features are observed. Premature 
death occurred and severe apoptosis in the kidney, thymus and spleen was seen with an 
almost complete loss of lymphocytes (Veis et al., 1993).
1.7.1.1 Cellular Localisation and Function of Bcl-2
bcl-2 has a unique gene sequence without substantial homology to other proto-oncogene 
products. It lacks an N-terminal hydrophobic signal sequence, or obvious signal motifs,
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that would target it to the endoplasmic reticulum or plasma membrane, bcl-2 does possess 
a C-terminal hydrophobic 19 amino acid stretch similar to a membrane spanning segment, 
however, (Hockenbery et al., 1990) and experiments showed that the protein localised to 
the inner mitochondrial membrane, a novel location for proteins with an oncogenic role. 
The localisation of Bcl-2 to the inner mitochondrial membrane where metabolic functions 
such as oxidative phosphorylation and electron and metabolite functions are carried out 
could mean a role for these processes in the cell’s survival mechanism with a prominent 
role for Bcl-2 in a B-cell survival pathway. Susin and co-workers (1996) proposed that 
Bcl-2 functions as a repressor of apoptosis by favouring the retention of an apoptogenic 
protease, apoptosis-inducing factor (AIF), in the mitochondria. However, controversy 
over the subcellular localisation of Bcl-2 arose when the protein was discovered in other 
cellular membranes; indeed, a study by Jacobson et al. (1993) using a human fibroblast 
cell line completely depleted of mitochondrial DNA was still protected from apoptosis 
(induced by serum withdrawal) by the overexpression of Bcl-2, suggesting that neither 
apoptosis nor the protective effect of Bcl-2 depends on mitochondrial respiration. This 
study revealed the presence of the Bcl-2 protein bound to the continuous nuclear and 
endoplasmic reticulum membrane system. The Bcl-2 protein has also been found in the 
outer mitochondrial membrane, oriented so that the amino terminus faces the cytoplasm 
(Nakai et al., 1993; Nguyen et al., 1993). Cell-free systems studied by Janiak et al. 
(1994) suggest that Bcl-2 localises to the cytoplasmic side of multiple membranes, both in 
vitro and in human leukemic cells.
Although the Bcl-2 protein is found in different compartments the actual site(s) at which it 
exerts its function remains unknown. Results found by Nguyen et al. (1994) whereby 
deletion of the signal anchor sequence rendered Bcl-2 cytosolic and impaired its ability to 
prevent apoptosis in KB cells is consistent with a model in which the transmembrane 
segment contributes to the function of Bcl-2 by targeting and anchoring the protein to 
strategic membrane locations in the cell. Concentration o f Bcl-2 at these sites may 
contribute to its proposed role as a regulator or component of an anti-oxidant pathway.
The idea that Bcl-2 is involved in an anti-oxidant pathway (perhaps to counter apoptotic 
death caused by cellular accumultion of reactive oxygen species) is consistent with the 
multiple membrane localistions of the protein because reactive oxygens are produced in 
mitochondria and at the nuclear envelope and endoplasmic reticulum (Akao et al., 1994). 
The fact that Bcl-2 can interfere with a diverse set of apoptotic stimuli implies that it
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functions at a downstream step of what is ultimately a convergent and common mechanism 
of cell death (Nguyen et al., 1994).
A role for Bcl-2 in cell survival was first proposed by Vaux et al. (1988) when it was 
noted that stable transfer of bcl-2 expression vectors into immature pre-B-cells resulted in 
prolonged cell survival in the absence of IL-3 (known to maintain haematopoietic cell 
survival in vitro by preventing apoptosis), but without cell proliferation. The death 
suppressor activity of Bcl-2 has been extensively studied in neuronal cell death by 
Bredesen (1995). The role of Bcl-2 in Programmed Cell Death has been reviewed by Reed 
(1994); there is also some evidence to suggest that Bcl-2 can block necrosis (passive cell 
death) as well (Kane et al., 1993). Evidence has been found to suggest that Bcl-2 functions 
as an apoptosis repressing gene primarily by inhibiting the cell death function o f pro- 
apoptotic proteins such as Bax (Hunter and Parslow, 1996). The expression of Bcl-2 is not 
protective in all situations of cell death induction such as cell death induced, in some 
situations, by binding to the CD95 (APO-l/Fas) ligand (Nagata and Suda, 1995), implying 
that Bcl-2 dependent and independent mechanisms of apoptosis exist.
It has been suggested that Bcl-2 inhibits apoptosis by altering Ca2+ fluxes through 
intracellular organelles, a logical assumption as mitochondria and the endoplasmic 
reticulum are both sites of calcium storage, and also a calcium-dependent nuclease may be 
involved in the DNA fragmentation seen in apoptosis. As calcium can function as a second 
messenger in intracellular signalling this may be how Bcl-2 exerts its effect on cell death 
signal transduction pathways (Craig, 1995). It has been shown by Kinoshita and co­
workers (1995) that activation of the Ras pathway induces the expression o f Bcl-2 and Bcl- 
xL but not Bax. Further work (Blagosklonny et al., 1996) demonstrated that, following 
taxol treatment, c-Raf 1 induced the phosphorylation o f Bcl-2 and the subsequent induction 
of apoptosis. Taxol affects the integrity of microtubules (see Section 1.2.3) and analysis of 
other drugs with similar mode of action was also shown to phosphorylate Bcl-2 (in G2-M) 
(Haidar et al., 1997) suggesting that the normal physiological role o f Bcl-2 is as a 
“guardian” of microtubule integrity. It has also been shown that Bcl-2 interacts with the 
G-protein, R-Ras, and induces apoptosis (Fernandez-Sarabla et al., 1993). Cell cycle 
studies of the effect of over-expression of Bcl-2 suggest that expression of the protein is 
consistently associated with a retardation o f cell proliferation due to a prolongation o f the 
Gi phase (Borner, 1996; Mazel et al, 1996) and that Bcl-2 expression might exert its 
inhibition of apoptosis by regulating the kinetics of cell cycle progression at a critical
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control point.
The Bcl-2 protein may also play a role in transport across membranes or it may interfere 
with the function or activation of proteins involved in the delivery o f cell death signals i.e. 
Bcl-2 can inhibit p53 mediated apoptosis (for review see Nunez et al., 1994).
1.7.1.2 The Bcl-2 Family of Genes
A family of Bcl-2 related proteins have been discovered which share three highly 
conserved stretches in their carboxyl regions. These conserved regions have been named 
the bcl homology domain 1 (BH1), bcl homology domain 2 (BH2) (Yin et al, 1994) and 
bcl homology domain 3 (BH3) (Chittenden et al., 1995) have been shown to play a role in 
the interaction of members of the Bcl-2 family.
A number of different genes have been discovered recently as members of this gene 
group, namely, Bcl-x (Boise et al., 1993), Mcl-1 (Kozopas et al, 1993), Bax (Oltvai et 
al, 1993), Bak (Chittenden et al., 1995), BAG-1 (Takayama et al., 1995), Bad (Yang et 
al., 1995), Bik (Boyd et al., 1995), Bfl-1 (Choi et al., 1995) and A -l (Karsan et al.,
1996). These proteins can homo- or hetero-dimerise and the balance of the pro- or anti- 
apoptotic effect determines whether a cell should live or die (for review see Farrow and 
Brown, 1996; Sedlak etal., 1995).
Bcl-2 which represses cell death has been found to associate in vivo with a Bcl-2- 
associated X protein, namely Bax (Oltvai et al., 1993). Bax was identified as a 21kDa 
protein with extreme amino acid homology with Bcl-2, and which forms homodimers or 
heterodimers with Bcl-2 in vivo. When Bax predominates apoptosis is increased and the 
repressive activity of Bcl-2 is countered. The gene encoding Bax consists of six exons all 
within a 4.5kb region and all six exons contribute information for protein coding. Three 
alternative transcripts of the gene have been identified - baxa, p and y - baxa, codes for 
the 21kDa protein product of the gene. RNA splicing may act as a differential regulator of 
Bax activity and localisation with baxp providing an additional level of regulation; no 
function for baxy has been identified.
Bax accelerates apoptotic cell death only following a death signal, this implies that the 
inherent ratio o f Bax to Bcl-2 determines susceptibility to death following an apoptotic 
stimulus. The association between Bax and Bcl-2 has been described as “hand-to-hand 
combat” (Korsmeyer,1995) with Bax promoting cell death while Bcl-2 opposes it. Bcl-2
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and Bax are associated in cells even before a death signal is received. When Bcl-2 is in 
excess the cell is protected from death (Bcl-2 competes for normal state of Bax 
homodimers forming Bcl-2/Bax heterodimers), however, when Bax is in excess the cell is 
susceptible to apoptosis (Bax homodimers predominate). The Bcl-2 to Bax ratio therefore 
acts as a “cell-autonomous rheostat” that predetermines a cell’s life or death response to 
an apoptotic stimulus. In mutagenesis studies carried out by Yin et al. (1994) it was found 
that the same amino acids in the BH1 and 2 domains required for Bcl-2 function were also 
necessary for heterodimerization with Bax. Selective mutations enabled Bcl-2 to 
homodimerize but these homodimers were insufficient to protect cells from death, 
concluding that Bcl-2 must bind Bax to act as a death repressor. A “suicide” peptide 
sequence in bax was inserted into the bcl-2 gene and it was found that the Bcl-2 inhibitor 
was converted to an activator of cell death (Hunter and Parslow, 1996). These results 
demonstrate that Bax is an active inducer of the cell death pathway and that the function of 
Bcl-2 in repressing the apoptotic pathway may be primarily to suppress the activity of 
Bax.
The bax promoter has four motifs with homology to consensus p53-binding sites. The 
wild type but not the mutant p53 transactivates the bax gene promoter. Bax has been 
described as a p53 primary response gene involved in a p53 regulated pathway for 
induction of apoposis (Miyashita and Reed, 1995). Experiments described by Miyashita 
and Reed (1995) showed that increasing p53 levels resulted in an increased bax mRNA 
and protein levels and a simultaneous decrease in the steady state levels of bcl-2 mRNA 
and protein. p53 mediated elevations in Bax protein levels would render cells more 
susceptible to apoptotic cell death as lowering the Bcl-2:Bax ratio renders cells relatively 
more sensitive to induction of cell death by cytotoxic anticancer drugs. The Bax promoter 
region has also been identified as having binding sites for Myc, Mad, M ax and Mxi-1.
Boise et al. (1993) isolated the bcl-x gene from gene libraries by hybridization with a bcl- 
2 probe. Two distinct bcl-x mRNAs can form as a result of alternative splicing - the long 
form bcl-xL (233 amino acids) and the short form bcl-xs (170 amino acids) - the shorter 
form does not contain BH1 and BH2 domains.
Bcl-x can function as a Bcl-2-independent regulator o f apoptosis but both transcripts work 
in a reciprocal fashion to one another i.e. XL confers resistance to apoptosis whereas Xs, 
in a dominant manner, prevents increased levels of Bcl-2 from inducing resistance to 
apoptosis by acting in one of two proposed ways :
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(i) Xs can form an inactive heteromeric complex with Bcl-2
(ii) Xs or XLmay bind directly to the same downstream regulators of apoptosis as Bcl-2. 
There are close similarities between Bcl-xL and the functional form of Bcl-2 (Bcl-2a) and 
Bcl-xL functions in preventing apoptotic cell death at least as well, and under some 
circumstances better, than Bcl-2. Bcl-xL knock-out mice exhibit massive cell death in the 
nervous and haematopoietic system (Motoyama et al., 1995) unlike Bcl-2 knock-outs that 
die from polycystic kidney disease (Veis et al., 1993) implying different roles for the two 
anti-apoptotic genes. The residues required for Bcl-xL function are not identical to those 
required for Bcl-2 function. It has been suggested that Bcl-xL also requires Bax (which is 
up-regulated by p53) to exert its repressive function, however, a study by Cheng and co­
workers (1996) demonstrated that a Bax-independent inhibition of apoptosis by Bcl-xL 
does exist. Co-operation of Bcl-xL over-expression and loss of p53 was found to overcome 
a cell cycle check-point induced by mitotic spindle damage and result in genomic 
instability by allowing the accumulation of tetraploid cells (Minn et al., 1996).
X-ray crystallography and NMR studies of the human Bcl-xL protein revealed a strong 
similarity to the membrane translocation domain o f bacterial toxins such as diphtheria 
toxin and the colcicins (Muchmore et al., 1996). The diphtheria-toxin translocation 
domain is thought to dimerise and form a pH-dependent membrane pore, suggesting that 
the Bcl-2 proteins may also form pores in the cytoplasmic membranes where they localise. 
Minn and co-workers (1997) have now shown that Bcl-xL does indeed form an ion- 
conducting pore in either synthetic lipid vesicles or planar lipid bilayers. The channel is 
pH sensitive and becomes cation-selective at physiological pH implying that Bcl-xL may 
maintain cell survival by regulating the permeability of the intracellular membranes in 
which it is located.
Both Bc1-xl and Bcl-xs can form heterodimers and/or multimers with Bcl-2 (Sato et al.,
1994). The ratio of Bcl-xL to Bcl-xs in specific tissues is very important especially in 
hormone-dependent tissues (Krajewski et al., 1994a). A study by Heermeier and co­
workers (1996) on apoptosis in involuting mammary epithelial cells demonstrated that Bcl- 
xs could facilitate apoptosis even when Bcl-xL was present in excess.
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1.7.1.3 Expression of Bcl-2 Family Members in Normal and Malignant Tissue
It is known that apoptosis regulates œ il populations during embryonic growth and occurs 
widely in normal tissues to maintain a stable equilibrium with cell proliferation. A report 
has recently been published (Staunton and Gaffney, 1995) which assesses the extent of 
apoptosis in a wide range of different human tumour types. Results found suggest that 
each tumour type has a characteristic apoptotic index that reflects innate tumour cell 
susceptibility to undergo apoptosis. A high apoptotic index was found in rapidly growing 
tumours known to respond to chemotherapy (small cell carcinoma, Burkitt’s lymphoma) 
and low apoptotic index in more aggressive neoplasms (follicular lymphoma).
To decipher the role Bcl-2 plays in tumourigenesis and apoptosis in vivo, many studies 
have been carried out to determine the distribution of Bcl-2 in human tissues. During 
differentiation, lymphoid cells undergo selection with only a small fraction o f maturing 
cells surviving, the majority undergo apoptosis prior to terminal differentiation. These 
mature cells were found to be abundant in Bcl-2 protein (Hockenbery et al., 1991; Nunez 
et al., 1994). The role of Bcl-2 in normal differentiation, therefore, relates to the 
promotion of cell viability and it is to be expected then that this protein should be 
expressed in a variety of human lymphomas. The bcl-2 gene was first discovered in 
human follicular lymphoma (Tsujimoto and Croce, 1986), one of the most common human 
hematopoietic malignancies. The gene is also expressed in Hodgkin’s disease (Lorenzen et 
al., 1992; Corbally et al., 1994).
Bcl-2’s distribution profile is not limited to hematopoietic cells or tumours, indeed, the 
protein (or gene product) has been detected in a wide variety of tissues including breast, 
lung and neuroblastomas, among others (Hockenbery et al., 1991).
Bcl-2 is expressed in normal breast epithelium, therefore, a tumour derived from normal 
breast epithelial cells might also be expected to express bcl-2 (Hockenbery et al., 1991). A 
study by Leek et al. (1994) found a strong correlation between Bcl-2 expression and 
oestrogen receptor status in human breast carcinomas. The study showed 80% (70/88) 
Bcl-2 positive tumours to be oestrogen receptor (ER) positive compared with only 23% 
(7/30) of Bcl-2 negative tumours being ER positive. The converse relationship was found 
with Bcl-2 expression and epidermal growth factor receptor status, prompting the authors 
to suggest that Bcl-2 is an ER-regulated gene. Further evidence to support the association
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between ER status and Bcl-2 in human breast cancer was proposed by Johnston et al.
(1994). This study demonstrated Bcl-2 expression in 32% of invasive breast cancers and 
in 65 % of tumours treated with the anti-oestrogen, tamoxifen. A subset o f tumours lose 
expression of Bcl-2 at a later stage in their progression and this latter group has been 
associated with established markers of poor prognosis (e.g. EGFR, c-erbB-2, p53 
positivity and ER negativity). Bcl-2’s role in breast cancer progression may differ 
substantially from that seen in lymphoma, in which activation by translocation occurs (this 
translocation has never been described in breast carcinomas). Similar results were found 
by Doglioni et al. (1994) who found that the prevalence of Bcl-2 immunoreactivity is 
significantly higher in lobular carcinomas, in better differentiated and low-cycling tumours 
and in tumours lacking EGFR and p53 immunostaining; Bcl-2 positive immunostaining 
might indicate a less aggressive subset of breast carcinomas, a finding previously shown in 
squamous cell carcinomas of the lung (Pezzella et al., 1993). In agreement with these 
results, Hellemans et al. (1995) concluded that the absence of Bcl-2 expression in axillary 
node-positive breast cancer was an independent marker of poor prognosis and that the 
absence o f Bcl-2 expression in invasive ductal breast carcinoma possibly reflected the 
down-regulation of the Bcl-2 gene by mutant p53 suggesting an important role for Bcl-2 as 
a modulator of response to adjuvant therapy in breast cancer. Hurlimann et al. (1995) also 
found that Bcl-2 positivity conferred better prognosis as judged by overall survival at five 
years. The Bcl-2 protein seemed only to be an important prognostic factor in women over 
54 years of age. Although the numbers studied in this report was small the authors stress 
the importance of studying both bcl-2 and p53 together. Expression o f Bcl-2 protein was 
found in most (54/60) paraffin-embedded small cell lung carcinoma samples studied by 
Jiang et al. (1995). A number of studies have also been carried out on Bcl-2 expression in 
non-small cell lung carcinomas and findings were similar to those found for breast cancer 
i.e. an inverse relationship was seen with p53 expression and a survival advantage was 
seen in those patients expressing Bcl-2 (Fontanini et al., 1995; Pezzella et al., 1993).
Bcl-2 expression was found in tumours from patients with neuroblastomas who presented 
with poor stage disease (stage III/IV), unfavourable histology and N-myc amplification 
(Castle et al., 1993). Kanitakis et al. (1995) showed that benign nevi and malignant 
melanomas were Bcl-2 positive whereas metastatic melanomas had decreased positivity 
compared with primary tumours suggesting a role for the Bcl-2 oncogene in metastatic 
progression of melanoma. Studies have also been carried out which report the detection of 
Bcl-2 in cancers of thymic origin (Brocheriou et al., 1995), in hepatocellular carcinomas
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(Zhao et al., 1994), in prostate cancers (Bubendorf et al., 1996; Colombel et al., 1993; 
McDonnell et al., 1992), in ovarian tumours (Henriksen et al., 1995), in human gliomas 
(Alderson et al., 1995), in cancers originating from the follicular epithelium of the thyroid 
gland (Pilotti et al., 1994), in renal cell tumours (Paraf et al., 1995) and in colorectal 
carcinoma (Ofner et al., 1995). Many o f the above studies found that the expression of 
Bcl-2 in tumours unexpectedly resulted in a good prognosis.
Expression of Bcl-2 conferring good prognosis is not the expected scenario as tumours 
positive for Bcl-2 would be expected to avoid apoptosis, live longer and therefore confer a 
worse prognosis on the tumour.
The Bcl-2 story is not complete when one looks only at the expression of this member of 
the gene family, however, as a study by Bargou et al. (1995) showed. These authors 
found no difference in expression of Bcl-2 and Bcl-xL between normal breast epithelium 
and tumour tissue, in contrast, however, bax-a was found to be expressed in high amounts 
in normal breast tissue but only weakly, if at all, in malignant tissue. Lower Bax 
expression was also seen in studies on breast tumours by other groups (Krajewski et al., 
1995; Wagener et al., 1996). The prognostic significance o f Bcl-2 expression in breast 
carcinoma was enhanced in a study by Krajewski and co-workers (1997) when Bax and 
p53 expression was included. In this study a significant correlation was found between the 
poor prognostic c-erbB-2 marker and Bax expression. A strong correlation was also seen 
between Bax expression and c-erbB-2 and an inverse correlation with oestrogen receptor 
status (Binder et al., 1996). The importance of the Bax:Bcl-2 ratio was shown in a study 
on gastric carcinoma (Koshida et al., 1996) where the ratio was correlated with cellular 
proliferation. Neuroendocrine lung tumours which had a Bcl-2:Bax ratio of greater than 1 
showed a lower apoptotic index and survival rate (Brambilla et al., 1996). High Bax 
expression was observed in testicular cancers in a study by Chresta and co-workers (1996) 
which may explain the inherent sensitivity o f these tumours to chemotherapy. Thus, the 
unexpected results of Hurlimann’s (1995) and Hellemans’ (1995) groups and others of 
Bcl-2 as a predictor of good response may be biased as only expression o f the Bcl-2 gene 
was analysed without taking the other family members into consideration.
A study of the expression of Bcl-X in human and mouse tissues (Krajewski et al., 1994a) 
revealed a different pattern to that reported for Bcl-2, suggesting that Bcl-X and Bcl-2 
regulate cell life and death at different stages of cell differentiation through tissue-specific
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control of their expression. In this study Bcl-X immunostaining was prominent in (a) 
neuronal populations in the brain; (b) cortical thymocytes, activated lymphocytes; (c) bone 
marrow cells; (d) reproductive tissue; (e) variety of epithelial cells. A further study by the 
same group (Krajewski et al., 1994) found the expression o f bax in mouse to be more 
wide-spread than that of bcl-2; bax staining was found in the hepatocytes of liver, the 
exocrine pancreas and the renal tubule epithelial cells whereas Bcl-2 was absent from these 
tissues. Krajewska and co-workers (1996) found an increase in expression of Bcl-x in 
undifferentiated primary colorectal cancer and a concomitant decrease in Bcl-2 and Mcl-1 
expression. The authors concluded that in progression of colorectal cancer, expression of 
Bcl-2 and Mcl-1 is lost and Bcl-x takes over. This hypothesis was also suggested by 
Pezzella’s group (1993) who found that Bcl-2 expression was high in a less aggressive 
subset of breast carcinomas. Lipponen and co-workers (1995) also found expression of 
Bcl-2 in well differentiated breast tumours resulting in a good prognosis.
The most recently discovered member of the Bcl-2 family, Bfl-1, was found abundantly 
expressed in the bone marrow and in some other tissues including the stomach (Choi et 
al., 1995), and a correlation was seen between the expression of Bfl-1 and the 
development of stomach cancer.
1.7.1.4 Role of Bcl-2 Family Members and Chemoresistance
As Bcl-2 family members play a pivotal role in the apoptotic pathway in cells, it is not 
surprising that much research in recent years has concentrated on the role Bcl-2 family 
members play in the response o f tumours to chemotherapeutic drug treatment. The fact 
that gene transfer studies with elevated levels of Bcl-2 (Miyashita and Reed, 1992; Walton 
et al, 1993; Dole et al., 1994) and Bcl-xL (Dole et al., 1995; M inn et al., 1995; Kiihl et 
al., 1997) protect cells from apoptotic death induced by chemotherapeutic drugs and 
antisense-mediated reductions in Bcl-2 (Kitada et al., 1994) or over-expression of 
apoptosis-inducing family members sensitises cells to chemotherapeutic drugs (Wagener et 
al., 1996; Sumantran et al., 1995) has prompted the study o f Bcl-2 family members in 
drug resistant tumours and cell lines and offers new targets in the treatment of cancer. 
Further evidence to suggest that Bcl-2 family members are involved in response to drug 
treatment comes from the fact that p53 down-regulates expression of Bcl-2 and up- 
regulates expression of the apoptosis promoting agent, Bax. A partial list of studies on 
Bcl-2 family members and chemoresistance is shown in Table 1.7.1.4.1.; results are
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discussed in more detail in Section 4.1.5.
Table 1.7.1.4.1 Bcl-2 Family Members and Chemoresistance
Cell Type Drug Reference
neuroblastoma cisplatin/VP-16 Dole etal., 1994
ovarian cisplatin Eliopoulos etal., 1995
lymphoma methotrexate Kitada <?/«/., 1994
ovarian cisplatin Perego etal., 1996
breast VP-16/taxol Sumantran et al., 1995
leukaemia taxol Tang etal., 1994
breast adriamycin Teixeira etal., 1995
myeloma adriamycin/VP-16 Tu<?/a/.. 1996
breast epirubicin Wagener et al., 1996
glioma cisplatin Weller etal., 1995
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1.7.2 The c-Myc Oncogene
The myc gene was originally isolated as a transforming sequence of a subclass o f avian 
leukaemia retroviruses (MC29) (Erisman and Astrin, 1988). M yc is a member of a multi­
gene family consisting of at least three members, c-Myc, L-M yc (identified in small cell 
lung cancer) and N-Myc (expressed in neuroblastomas) (Erisman and Astrin, 1988); other 
related proteins have also been identified (Ingvarsson et al.,  1988; Sugiyama et al .,  1989). 
It is one of the immediate early growth response genes and is rapidly, but transiently, 
induced in quiescent cells upon mitogenic stimulation; mRNA and protein levels are 
sustained throughout the cell cycle in proliferating cells (Evan et al., 1992). The gene is 
composed of three exons and is transcribed from two initiation sites. The gene is 
frequently seen translocated to the heavy chain locus of the immunoglobulin gene in 
Burkitt’s lymphoma suggesting that c-myc has a primary role in transformation of some 
human haematopoietic cells (Watt et al., 1983). Indeed in tumour cells elevated or 
deregulated expression of c-Myc is so widespread as to suggest a critical role for c-Myc 
gene activation in carcinogenesis.
c-Myc is a member of the nuclear oncoproteins and acts as a transcription factor (as a 
heterodimeric partner to Max) to promote cell proliferation and has an elusive role to play 
in control of the cell cycle (Pardee, 1989). M ax is essential for Myc transformation 
activity. The Myc-Max heterodimer can transactivate several promoters containing 
CACGTG boxes, including p53 and ornithine decarboxylase. This partnership with Max 
allows cells to enter Gi and begin cycling (D’Amico and McKenna, 1994). Ornithine 
decarboxylase is necessary for G, progression (Mihich and Schimke, 1994) and also 
cooperates with Ras in the transformation o f NIH3T3 cells (Hibshoosh et al., 1991). It 
remains to be established if  the above mentioned genes are true downstream effectors of 
Myc. It has also been reported that Myc / Max binds to the 5 ’ flanking region of the 
DHFR gene involved in DNA replication and induces amplification of this gene (Mai,
1994); the author concludes that c-Myc’s contribution to cellular transformation may be 
based on the accumulation of genomic instabilities such as gene amplification. Recently, 
scientists at Cold Spring Harbor Laboratories (1996) discovered that the cdc25A 
phosphatase is a target of the c-Myc gene, thus confirming a role for c-Myc in cell cycle 
progression.
Myc usually stimulates proliferation, but if growth is inhibited by other factors, Myc-
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induced apoptosis will occur. M yc therefore has a dual role to play in the cell: myc 
stimulates growth in the presence of survival factors and induces apoptosis in the presence 
of growth inhibiting factors (Mihich and Schimke, 1994).
1.7.2.1 c-Myc and its Dual Role
c-Myc, or the “Janus” (Roman God of two faces) gene, has a dual role to play in cellular 
control. c-Myc has been described as a “switch” directing cells towards proliferation or 
death with Bcl-2 determining the direction of the switch (Figure 1.7.2.1.1). The opposing 
roles of c-Myc in cell proliferation and cell death (first shown by Shi et al., 1992) 
requires that this sort of molecular co-operation exists. It has been shown, for example, 
that c-Myc induces apoptosis in serum-starved fibroblasts. This can be overcome if Bcl-2 
is increased in these cells leading to a block in apoptosis and cell proliferation (Bissonnette 
etal., 1992).
Fig. 1.7.2.1.1 The Dual role of c-Myc in Response to Growth Factor
grow th factor withdrawal grow th factor
Bcl-2 can block the apoptotic role of c-Myc (due to the removal of growth factors) but it 
has no effect on the mitogenic function of the oncogene, therefore the combination of the 
block to apoptosis (by Bcl-2) and the induction of the mitogenic signal by c-Myc would 
allow a cell to proliferate. This is a novel mechanism of oncogene co-operation. 
Constitutive expression of c-Myc induces apoptosis only when combined with a negative 
growth signal e.g. serum withdrawal (cells proliferate to S-phase and then undergo 
apoptosis); growth arrest does not occur.
In order for cells to replicate they must enter the cell cycle consisting o f four different 
phases; G, (growth phase), S (DNA replication), G2 (cell pauses as it prepares to divide)
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and M (mitosis). The four phases are controlled by the actions of specific serine/threonine 
kinases, the cdc-2 related proteins, cdc-2 related proteins (or cyclin-dependent kinase 
proteins (CDK)) bind to cyclin proteins and form an active complex which is regulated 
throughout the cell cycle. c-Myc is involved in the priming o f quiescent cells in G0 into 
the cell cycle at Gi (Erisman and Astrin, 1988). T G F -p i, which arrests cell growth, 
specifically targets c-myc and reduces its mRNA levels and consequently leads to Gi arrest 
(Alexandrow and Moses, 1995). PDGF stimulates c-myc levels and it has been shown that 
over-expression of c-myc eliminates PDGF requirement in cells for cell cycle progression 
(Armelin et al., 1984). It is believed that the E2F transcription factor, which is active in 
the Gi phase of the cell cycle (due to the removal of the inhibitory Retinoblastoma protein 
as a result of phosphorylation by cyclinD-cdk4/6 complex), regulates the transcription of 
the c-myc gene which then exerts its effect on the cell cycle by targetting the cdc25A 
phosphatase which converts the M-phase cyclinB/cdc2 complex from its inactive 
phosphorylated state to its active de-phosphorylated state promoting progression through 
mitosis (Figure 1.7.2.1.2).
Figure 1.7.2.1.2 Regulation of the Cell Cycle
CyclinB
c-Myc
ACTIVE
CyclinB
CyclinD . CDK4/6
c-Myc transcribed
CDK2
INACTIVE
CyclinA
When cells become quiescent c-Myc is down-regulated and growth arrest occurs; equally 
c-Myc has the power to convert quiescent cells to proliferating cells. This is a dangerous 
balance to maintain as any mutation deregulating c-Myc could result in tumour 
progression; as c-Myc is also involved in programmed cell death by controlling genes
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involved in apoptosis (Evan et al, 1992) these cells will also be primed for cell death and 
therefore removal o f a possible tumour-forming mutation achieved. It has been suggested 
that c-Myc induces apoptosis (the normal intrinsic function of c-Myc) through sequence 
specific DNA binding, presumably by modulation of apoptotic and/or anti-apoptotic genes 
(Evan et al, 1992; Amati et al., 1993), complete overlap of structural sequence for 
transformation, dimerization and cell death functions is seen. Hermeking and Eick (1994) 
have shown that induction of p53 is part of the cellular response to activation of c-Myc in 
quiescent cells; c-Myc is dominant over p53 mediated growth arrest and can drive cells 
from Gi into S-phase even in the presence of large amounts of p53. p53-induced apoptosis 
may be a common tumour suppressive mechanism to eliminate cells (that express certain 
oncogenes) that inappropriately by-pass the Gi-S check-point; failure to do this, due to 
loss of wild-type p53, may lead to carcinogenesis.
1.7.2.2 c-Myc Expression in Human Tumours and Effect on Chemoresistance
Expression of c-myc gene occurs in most cell types and is detectable in almost all 
proliferating cells and is vital for normal development. Not surprisingly then deregulated 
c-myc is found in a wide variety of malignancies. Over-expression of c-myc was shown to 
co-operate with activated c-H-ras and transform primary fibroblasts (Land et al., 1983). 
c-Myc can become oncogenic in a number of ways including, chromosomal translocation 
(Burkitt’s lymphomas) and gene amplifications (colon, gastric, breast and other solid 
tumours) (Erisman and Astrin, 1988). Amplification of c-myc is infrequently found in 
primary tumours and it is therefore highly unlikely to be an initiating event in 
oncogenesis. Amplification may occur during tumour progression and may be an 
indication of advanced disease and a poor prognosis.
c-Myc has been found to be over-expressed or de-regulated in many clinical breast 
tumours (Escot et al., 1986; Mariani-Costantini et al., 1988; Berns et al., 1992; Kreipe et 
al., 1993) and amplification of the gene was found to be associated with early relapse and 
poor prognosis (Kreipe et al., 1993; Martiani-Costantini et al., 1988). c-Myc over­
expression in carcinoma of the uterine cervix was found to correlate with a risk of relapse 
(Riou et al., 1987). N-myc (a poor prognostic marker for small cell lung carcinoma, 
retinoblastoma and neuroblastoma (Knudson, 1985; Mizukami et al., 1995)) expression in 
breast cancer has also been implicated in poor prognosis of breast carcinoma (Mizukami et 
al, 1995) A number of in vitro studies have shown that elevated levels of c-myc result in
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increased drug resistance to a variety of chemotherapeutic drugs in tumour cell lines 
(Table 1.7.2.2.1). Results found are described in Section 4.1.3.
Table 1.7.2.2.1 c-Myc Over-expression and Chemoresistance
Cell Type Drug Reference
colon ciplatin/5 -fluorouracil Kashani-Sabet et al. , 1990
C H 09 methotrexate Mai, 1994
murine Friend Erythroleukaemia cisplatin Mizutani et al. , 1994
NIH3T3 fibroblasts cisplatin/adriamycin/cyclophosphamide Niimi et al. , 1991
prostate VP-16/cisplatin SinhaefflZ., 1995
small cell lung carcinoma cisplatin Sklar and Prochownik, 1991
bladder cisplatin VanWaardcnburg el al. , 1996
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1.8 Aims of Thesis
Observations in the literature suggest that proliferation promoting genes, such as c-erbB-2, 
c-H-Ras and the AP-1 complex, and genes involved in the process o f apoptosis, Bcl-2 and 
c-Myc, have the capacity to affect the response of tumour cells to chemotherapeutic drugs. 
Over-expression of the above oncogenes in drug-resistant cell lines has previously been 
seen and genetic modulation of these genes sensitise the resistant cell line to drug. Few 
studies, however, compared the expression of oncogenes involved in a signal transduction 
pathway and apoptosis-influencing genes in the same cell lines. In this thesis, it was 
proposed to study the expression of a wide variety of oncogenes, known to influence 
proliferation and cell death, in drug resistant variants o f the human lung carcinoma line, 
DLKP, developed by continuous exposure to commonly used chemotherapeutic drugs 
known to induce apoptosis, and in adriamycin-selected resistant variants of the human 
ovarian line, OAW42.
Many in vitro cellular models of drug resistant lines in common use have been developed 
by exposure to non-physiologically relevant levels of chemotherapeutic drug and it is not 
known if results from such studies accurately reflect the in vivo situation. To determine if 
oncogene over-expression may be a physiological response to clinically attainable levels of 
drug, a model o f low-level MDR resistance was to be developed by pulse exposure to 
clinically attainable levels of drug over a short period of time. It was proposed for this 
work to develop low-level resistant variants of clonal populations of the DLKP cell line. 
Little evidence has been reported in the literature defining the initial steps in the 
development of drug resistance. In this thesis, the effect of certain oncogenes in the 
establishment of the M DR phenotype was to be addressed. Pharmacological inhibition of 
signalling cascades was also to be attempted in the low-level pulse-selected resistant cell 
line.
Finally, the problem of predicting the development of drug resistance in vivo was to be 
undertaken by analysis of M DR related gene and oncogene levels in breast cancer patients.
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Materials and Methods
2.1 Preparation for Cell Culture
2.1.1 Water
Water used in the preparation of media and solutions was purified by passing it through a 
Millipore milli-RO Plus system with an Elga Elgastat UHP. A pre-treatment step 
involving activated carbon, pre-filtration and anti-scaling, was carried out followed by a 
reverse osmosis step. Organic adsorption, ion exchange, ultra-microfiltration, photo­
oxidation and ultra-filtration completed the process. The quality of water was monitored 
on-line and a measure of 16MQ/cm at 25°C was considered acceptable.
2.1.2 Glassware
All glassware and bottle-caps used were soaked, for 1-2 hours in a 2 %(v/v) solution of 
RBS (AGB Scientific; RBS-25) in warm water. The bottles were then scrubbed and both 
bottles and caps were rinsed in warm water and machine washed using Neodiser 
detergent, followed by rinsing twice in double-distilled water and once in ultra-pure water. 
The bottles were then prepared for autoclaving. Waste bottles containing spent medium 
from cells were autoclaved, rinsed in tap water and treated as above.
2.1.3 Sterilisation
Water, glassware and solutions containing thermostable compounds were sterilised by 
autoclaving at 120°C for 20min. at 15 p.s.i. pressure. Temperature labile compounds were 
filtered through a 0.22|jm  sterile filter (Millipore; millex-gv).
2.1.4 Medium Preparation
Growth media for cell culture was prepared as indicated in Table 2 .1 .4 .1 . The pH was 
adjusted to 7.45 - 7.55 by the addition of sterile 1.5M NaOH, and the volume adjusted to 
5 litres and filtered through a sterile 0.22^m  bell filter (Gelman; G.1423S) into sterile 
500ml bottles. Sterility checks were performed on each bottle by placing :
(a) 3ml in a sterile universal to check for turbidity
(b) 1ml streaked onto a Columbia (Oxoid; CM331) blood agar plate
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(c) 1ml in a 5ml sample of sterile Sabauraud (Oxoid; CM421) dextrose
(d) 1ml in a 5ml sample of sterile Thioglycollate (Oxoid; CM 173) broth.
Sterility checks were incubated at 37°C and 4°C for 1 month and checked every 24hrs. 
Blood agar plates were kept for 7 days. The media bottles were labelled, dated and stored 
at 4°C until required.
Table 2.1.4.1 Preparation of Growth Media.
Components DMEM
(Gibco;042-02501M)
Hams F12 
(Gibco;074-01700N)
RPMI 1640 
(Gibco;31870-025)
MEM
(Gibco;21430-020)
lOXMedium 500ml Powder 1XRPMI 500ml
Ultra-pure HjO 4300ml 4700ml 4300ml
IMHepes (pH7.5)* 100ml 100ml 100ml
7.5% NaH C03 45ml 45ml 100ml
* The weight equivalent o f 1M N-(2-Hydroxyethyl)piperazine -N ’-(2-ethanesulfonic acid) (Hepes) was 
dissolved in an 80% volume o f ultra-pure water and autoclaved. The pH was then adjusted to 7.5 with 5M 
NaOH.
2.2 Routine Management of Cells in Culture
All routine management of cells in culture, including cell feeding, sub-culturing, freezing 
and thawing, were performed aseptically in a down-flow re-circulating laminar flow 
cabinet (Holton or Gelman Cytoguard) which had been swabbed with 70% IMS (industrial 
methylated spirits). To maintain a sterile atmosphere inside o f the laminar flow all articles 
entering the cabinet were also swabbed with 70% IMS. Gloves were worn at all times 
during these procedures.
2.2.1 Cell lines
All cell lines used throughout this thesis are outlined in Table 2 .2 .1 .1 . All cell lines are 
anchorage dependent except the leukaemia cell line, HL60 and HL60/ADR, which are 
suspension cells.
Cells were routinely grown in 25, 75 or 175cm2 flasks (Costar; 3050, 3075: Nunc; 1- 
56502A, respectively). Cells were grown at 37°C and fed every 2-3 days or when a 
medium pH change was observed (colour change in medium due to the presence of a 
phenol red indicator). Waste media was removed from the cells at this stage and replaced
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with fresh media, as indicated in Table 2.2.1.1. Separate waste and medium-containing 
bottles were kept exclusive to each cell line to prevent cross-contamination. When feeding 
more than one cell line a minimum of 15min should be left before introducing a new cell
line in to the laminar flow to further ensure against cross-contamination.
Table 2.2.1.1 Cell lines used throughout the course of this Thesis.
Cell Line Growth M edium Cell Type Source
A549 ATC C1 Human lung cancer ATCC
BT-20 MEM2 Human breast cancer ATCC
DLKP A TC C 1 Human lung squamous cell carcinoma NCTCC
DLKP-A ATC C1 Adriamycin-selected M DR variant o f  DLKP NCTCC
DLKP-A2B A T C C 1 Clonal population o f  DLKP-A NCTCC
DLKP-A5F ATC C1 Clonal population o f  DLKP-A NCTCC
DLKP-C14 ATC C1 Carboplatin-selected M DR variant o f  DLKP NCTCC
DLKP-I ATC C1 Clonal population o f  DLKP NCTCC
DLKP-I»7£WRz2D4 AT C C 1 mdrl ribozyme DLKP-I transfectant NCTCC
DLKP-SQ A T C C 1 Clonal population o f  DLKP NCTCC
DLKP/VP-3 A T C C 1 VP-16-selected M DR variant o f  DLKP NCTCC
DLKP/VP-8 A T C C 1 VP-16-selected M DR variant o f  DLKP NCTCC
HL60 RPMI3 Human leukaemia cell line M. Center
HL60/ADR RPMI3 Adriamycin-selected M DR variant o f  HL60/S M. Center
MCF-7 ATCC4 Human breast cancer ATCC
O AW 42-A ATCC5 Adriamycin-selected M DR variant o f  OAW42-SR NCTCC
OAW42-A1 ATCC5 Adriamycin-selected M DR variant o f  OAW42-SR NCTCC
OAW42-S ATCC5 Human Ovarian Carcinoma - sensitive clone NCTCC
OAW42-SR ATCC5 Spontaneously resistant population o f  OAW42 ECACC
PA1 MEM2 Human ovarian cancer ATCC
1 50:50 mixture of Hams F12 medium and Dulbecco’s Modified Eagle’s medium supplemented
with 5% foetal calf serum and 2mM L-Glutamine (Gibco; 25030-024) prior to use. 2 MEM 
medium supplemented with 10% foetal calf serum, 2mM L-Glutamine, 1% MEM non-essential
amino acids (Gibco; 11140-035) and 1% Na-pyruvate (Gibco; 11360-039). 3 RPMI medium
supplemented with 10% foetal calf serum, 2mM L-Glutamine and 5%CCh4 50:50 mixture of Hams
F12 medium and Dulbecco’s Modified Eagle’s medium supplemented with 10% foetal calf serum, 
2mM L-Glutamine and 10p.g/ml Insulin (Sigma; 1-1882)5 50:50 mixture of Hams F12 medium and 
Dulbecco’s Modified Eagle’s medium supplemented with 10% foetal calf serum, 2mM L- 
Glutamine and 1% Na-pyruvate.
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2.2.2 Sub-Culture of Cell Lines
Monolayer cells grow attached to the bottom of flasks and upon reaching confluency (or 
when required for further studies) the cells were enzymatically detached from the flask 
base and sub-cultured. This involved removing waste medium from the flask of cells, 
rinsing the cells with 1ml of trypsin/EDTA (0.25% trypsin (Gibco; 043-05090), 0.01% 
EDTA (Sigma; EDS) solution in PBS (Oxoid; BR14a)) and then incubating with a further 
4ml of the trypsin/EDTA solution for 5-10min (or until a single cell suspension had been 
obtained) at 37°C. An equal volume of complete medium was then added to the flask and 
the total cell suspension was transferred to a 30ml sterile universal (Sterilin; 128a) and 
centrifuged at 120g. for 5min. The medium was poured off the cell pellet which was then 
resupended in an appropriate volume of complete medium and re-seeded into fresh flasks 
at the cell density required (estimated by a cell count; see section 2.2.3).
Suspension cells were sub-cultured simply by removing the cell suspension from the flask 
and pelleting the cells by centrifugation as above. Re-seeding and counting was carried out 
as for adherent cells.
2.2.3 Cell Counting
A sample of a single cell suspension was mixed in a ratio of 4:1 with trypan blue (Gibco; 
525) and incubated for 2min. after which 10(il of the cell mixture was applied to a 
haemocytometer in the area under the cover-slip. Cells in the 16 squares of the four outer 
corner grids were counted, and the average of the four squares was multiplied by 104 and 
the initial dilution factor to determine the number of cells per ml of cell suspension. Cells 
which stained blue were considered non-viable while those unstained were accepted as 
viable cells.
2.2.4 Large-Scale Cell Culture
Cells required in large numbers were cultivated in roller bottles. Approximately 100ml of 
growth medium was allowed to equilibrate in a roller bottle at 37°C after which a single 
cell suspension of approximately 2xl07 cells was added. The roller bottle was incubated at 
0.25rpm overnight and then the rotor speed was increased to 0.50rpm. The cells were 
allowed to grow to 80% confluency and were fed when determined necessary.
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2.2.5 Freezing Cells in Culture
Stocks of all cells used in this study were frozen to allow their long-term storage and 
adequate supply within a given passage number range.
A single-cell pellet suspension was prepared (Section 2.2.2) from a sub-confluent large- 
scale culture of cells (Section 2.2.4). The cell pellet was resuspended in foetal calf serum 
(FCS) and an equal volume of 10% (v/v) DMSO (Sigma; D5879) in FCS was added drop- 
wise, with constant agitation, to result in a final concentration of 107 (viable) cells/ml. 
1.5ml aliquots of the resulting cell suspension were placed in cryovials (Greiner; 122 278) 
(labelled with the cell line, passage number, date and operators initials) and stored in the 
vapour phase of liquid nitrogen for 2.5h. and then stored in the liquid phase until 
required. A vial of cells was thawed 2-5 days after freezing to determine the sterility and 
viability of the stock.
2.2.6 Cell Thawing
The required vial of cells was removed from its liquid nitrogen store and thawed in a 37°C 
water-bath. The thawed suspension was quickly transferred to a universal containing 5ml 
of medium and was centrifuged at 120g for 5min. The medium was poured off and the 
cell pellet was resuspended in 5ml of complete medium, transferred to a 25cm2 flask and 
incubated at 37°C. Following cell attachment, the cells were re-fed with fresh medium.
2.2.7 Mycoplasma Detection
All cell lines used in this study were routinely checked to ensure that Mycoplasma 
contamination had not occurred. These procedures were performed in isolation from the 
routine cell culture designated areas (by Dr. Mary Heenan and Mr. William Nugent) to 
avoid possible contamination of clean cell stocks. Two methods were used during 
analysis, namely the Hoechst 33258 indirect staining method and Mycoplasma culture 
methods.
The cell lines to be tested were grown in drug-free medium for a minimum of three 
passages following thawing. A 5ml aliquot of conditioned medium i.e. medium in which 
near-confluent cells had been grown for 2-3 days, was removed and analysed for the 
presence of Mycoplasma.
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2.2.7.1 Hoechst 33258 Indirect Staining
Indicator cells (NRK) were grown (2xl03) overnight on sterile coverslips in 1ml DMEM 
medium supplemented with 5 % FCS and 2mM L-Glutamine, in individual 35mm sterile 
petri-dishes. 1ml aliquots of the conditioned media (Section 2.2.7), from each cell line to 
be tested, were added to duplicate cover-slips of NRK cells and incubated for 5 days (to 
approximately 50% confluency). The cover-slips were then washed of media twice with 
PBS, once with a 1:1 solution of ice-cold PBS:Carnoy’s fixative (a freshly prepared 1:3 
solution of glacial acetic acid (Sigma; A0808) with methanol (BDH; 101584W) which had 
been stored at -20°C for 30min prior to use), and fixed for lOmin in Carnoy’s fixative. 
The cover-slips were then allowed to air dry. 2ml of Hoechst 33258 stain (Sigma; B2883), 
at a concentration of 50ng/ml in PBS, was added to each cover-slip and incubated in 
darkness for lOmin. The coverslips were then washed in water and mounted on a glass 
slide using 50% glycerol (BDH; 101184K) in 0.1M citric acid (Sigma; C2916), 0.2M 
disodium phosphate (Sigma; S9390), pH 5.5 as the mounting solution. The slides were 
examined for Mycoplasma contamination under oil immersion using a mercury fluorescent 
lamp. Hoechst 33258 stains nucleic acids and therefore staining in the NRK cell nuclei 
was observed, any extra-nuclear staining was an indication of the presence of Mycoplasma 
contamination of the cell line under analysis. Both positive (a sample of medium known to 
be contaminated) and negative (medium not exposed to cells) controls were included in 
this procedure.
2.2.7.2 Mycoplasma Culture Method
The substrate used for the Mycoplasma culture method of detection consisted of 90ml of 
Mycoplasma agar (Oxoid; CM401) and Mycoplasma broth (Oxoid; CM403) bases, which 
were supplemented with 16.33% FCS, 0.002% DNA (BDH; 42026), 2jxg/ml fungizone 
(Gibco; 05290), 2xl03 U penicillin (Sigma; Pen-3) and 10ml of a 25% (w/v) yeast extract 
solution (which had been boiled for lOmin. and filtered through a 0.2^m filter). A 0.5ml 
aliquot of sample medium from the cell line being tested was incubated with 3ml of the 
broth for 48h. at 37°C in a 5% C02 environment. An aliquot of the broth was then 
streaked onto a 10ml agar plate which was incubated for up to 3 weeks at 37°C in 5% 
CO2, and frequently monitored microscopically for colony formation. The presence of 
“fried egg”-type colonies were indicative of Mycoplasma contamination of the cell line.
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2.2.8 Serum Batch Testing
One of the main problems associated with the use of FCS in cell culture is its batch to 
batch variation. In extreme cases this variation may result in a lack of cell growth, 
whereas in more moderate cases growth may be retarded. To avoid the effects of the 
above variation, a range of FCS batches were screened for growth of each cell line. A 
suitable FCS was then purchased in bulk for a block of work with each particular cell line 
in use.
Screening involved growing cells in 96 well plates and growth was recorded as a 
percentage of growth of a serum with known acceptable growth rate.
Logarithmically growing cells were seeded into a 96 well plate (Costar; 3599) from a 
single cell suspension at a density of 103 cells/well in lOOp.1 of medium without FCS. 
100|il volumes of medium containing 10%, 20% or higher (if required by the particular 
cell line under analysis) (v/v) FCS was added to respective wells on the 96 well plate, 
resulting in final dilutions of the FCS to 5% and 10%, respectively. The first column of 
each plate was maintained as a control where FCS resulting in a known acceptable growth 
rate was used. Plates were placed at 37°C in 5 % C 02, for 5 days, after which growth was 
assessed by a crystal violet dye elution method or acid phosphatase (Martin and Clynes, 
1991). Crystal dye elution method involved removing the media from the wells and 
rinsing twice in PBS. The wells were then fixed in 10% formalin (Sigma; F1635) for 
lOmin, after which the formalin was removed and the plates allowed to dry. When the 
plates had dried lOOfxl of 0.25% crystal violet dye (Sigma; C3886) was added to each well 
of the plate for lOmin; the dye was then removed and the plates were washed under 
running tap water 4 or 5 times and allowed to dry. The dye was eluted with a 33% 
solution of glacial acetic acid (Sigma; A6283) 100|xl/well. The plates were then read in a 
dual beam plate reader at 570nm (reference wavelength 620nm) (Titertek; Multiskan). 
When growth was assessed by the acid phosphatase method, the plates were washed twice 
in PBS and incubated with 100^1 of acid phosphatase buffer (consisting of lOmM p- 
nitrophenyl phosphate (Sigma; C104) in 0.1M Na-acetate, pH5.5 and 0.1 % Triton X-100 
(Sigma; X-100) for 2 hours at 37°C. Following incubation, 50^1 of 1.0M NaOH was 
added to the buffer and the plates read in a dual beam plate reader at 405nm (reference 
wavelength 620nm) (Titertek; Multiskan).
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2.2.9 Growth of Cell Lines in Serum-Free Media
For many studies analysis of cell lines grown in the absence of serum is required. A 
serum-free media which supports the growth of the DLKP cell line was developed in this 
laboratory (P.Meleady, 1997), based on that described by Mendiaz et al. (1986). Basal 
Hams F12 media is supplemented with the following components :-
Table 2.2.9.1 Supplements for Serum-Free Media to Support the Growth of DLKP*
M edium Supplements** Concentration
Insulin 10|ig/ml
Transferrin 5|ig/ml
FeS04 5.0|xM
Na2Se03 3.0xl0'2(xM
CaCl2 6,0xl0'VM
Linoleic acid 3.0x101|i M
L-glutamine l.OxlOVM
Non-essential Amino Acids 1.0xl0'2|xM
Trace Elements :
CuS0„.5H20 1.0xlO‘3(iM
MnS04.5H20 l.OxlO'VM
ZnS04.7H20 5.0xl0'2|iM
SnCl2.2H20 5.0x10 VM
NiCl2.6H20 5. 0x1 O'4p.M
n h 4v o 3 5.0xl0'3|iM
Na2SiOj 5.0x10 VM
(NH4)öMo7024.H20 1.0x1 O'Vm
*The growth o f some DLKP variants required farther supplementation with fibronectin (Sigma; 
F2006) at a concentration o f 5^g/m l. ** All medium supplements were purchased from Sigma,
unless stated otherwise.
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2.3 Miniaturised Toxicity Assay
Logarithmically growing cells were used in all miniaturised toxicity assays. The day prior 
to setting up the assay the cells were fed with fresh, complete medium. On the first day of 
the assay the cells were sub-cultured and a single cell suspension was obtained (as 
described in Section 2.2.2).
2.3.1 Toxicity Assay - 96 well plate
Cells were seeded, from a single cell suspension, into a 96 well plate (Costar; 3599) at a 
cell density of lx l03cells/well in 100^1 medium; the first column of the plate was not 
seeded with cell suspension and was used as a control containing only medium. The cells 
were allowed to attach overnight at 37°C in a 5% C 02 environment. Drug concentrations 
used in each assay ranged from concentrations which would result in no kill (i.e. no drug) 
to approximately 100% kill. The required drug dilutions range was prepared (at twice the 
final concentration to be assayed) and 100(xl of each drug dilution was added to each well, 
in replicas of eight. The plates were covered in aluminium foil (most chemotherapeutic 
drugs are light sensitive) and incubated at 37°C in a 5 % C02 environment for a further 6 
days or until control wells (where no drug was added) reached 80-90% confluency. Drug 
toxicity was then determined by crystal violet dye elution method or acid phosphatase 
method (see Section 2.2.8).
2.3.2 Toxicity Assay - 25cm2 flask
25cm2 flasks were seeded at a density of 2xl05cells/flask 2-3 days prior to drug addition. 
When cells had reached 50% confluency, a IX concentration of drug was added to each 
flask in a 5ml volume. The drug was removed after a certain length of time (e.g. 4h). The 
flasks were rinsed twice in fresh medium, re-fed with 5ml of complete medium without 
drug and incubated at 37°C for a further 6 days. After this time the media was removed 
from the flasks which were then washed twice with PBS, fixed for lOmin in 3ml 10% 
formalin, this fixative was then removed and the flasks were allowed to dry. When the 
flasks had dried, 3ml of crystal violet dye was added for lOmin, removed, and the flasks 
were washed 4-5 times under running tap water. When dry, l-5ml of 33% glacial acetic 
acid was added to the flask and the dye eluted. Eight replicas of 100pl volumes of the
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eluted dye was placed in a 96 well plate for each drug concentration used. The toxicity of 
the drug was analysed as described previously (see Section 2.2.8). A variation of the acid 
phosphatase assay was also used to analyse growth in 25cm2 flasks where 5ml of acid 
phosphatase was added to the flask and incubated at 37°C for 2 hours. Growth was 
analysed as described previously (Section 2.2.8).
2.4 Safe Handling of Drugs
There are many potential safety risks when using cytotoxic drugs and in order to minimise 
such dangers extreme care was exercised in handling and disposing of cytotoxic agents. 
All work with such drugs was performed in a Gelman “Cytoguard” laminar air flow 
cabinet (CG Series), face masks and double gloves were worn when dealing with 
concentrated stocks and all drug waste (pure or diluted in medium or in contaminated 
plastics) was disposed of as recommended by the manufacturers (outlined in Table 2.4.1).
Table 2.4.1 Storage and Disposal of Cytotoxic Drugs
Cytotoxic Agent Stock
concentration
Storage Disposal
Adriamycin1 2 mg/ml 4°C in darkness Inactivate with 1% hyperchlorite
(Doxoxrubicin) Autoclave
Vincristine2 1 mg/ml 4°C in darkness Autoclave
Dispose with excess water
VP-163 (Etoposide) 20mg/ml R.T. in dark Incinerate
Carboplatin2 10mg/ml R.T. in dark Incinerate
Methotrexate4 5mg/ml -20°C in dark Autoclave
Dispose with excess water
5-Fluorouracil2 25mg/ml R.T. in dark Neutralise with 5M NaOH
Incinerate
Cyclophosphamide5 2mg/ml 4°C in darkness Autoclave
Dispose with excess water
Emodin6 0.1M -20°C in dark Incincrate
Genistein7 0.1M -20°C in dark Incinerate
Cyclosporin A8 50|ig/ml -20°C in dark Incinerate
Cytotoxic drugs used were supplied by 1 Farm atalia; 2 David Bull Laboratories, L td.; 3 Bristol 
Myers Pharm aceuticals;4 Lederle Lab., Gosport, Hampshire, E n g land ;5 the cyclohexylamine salt, 
mafosfamide (D-17272) was a generous gift from D r.J.Pohl, ASTA M edica, Frankfurt; 6 Sigma 
(E 7881);7 Alexis Corporation (LC-G-6055-M025); 8 Sandoz: (R .T. =  room temperature)
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2.5 Selection of MDR Resistant Variant from a Sensitive Parental Cell Line
Throughout the course of this study a number of low-level MDR-variant cell lines were 
developed by selection of the sensitive parental cell line, DLKP-SQ, with Adriamycin.
2.5.1 Continuous selection of DLKP-SQ with Adriamycin
DLKP-SQ were grown to 50% confluency in 25cm2flasks. The cells were then exposed to 
an initial selecting concentration of 25ng/ml Adriamycin which was equivalent to 80% kill 
when calculated using a 96 well plate miniature toxicity assay (see Section 2.3.2). The 
cells were re-fed with this drug concentration every 3-4 days and when the cells had 
regained a state of near 50% confluency, the concentration of drug to which they were 
exposed was increased approximately two-fold. This was repeated until the cells were 
exposed to a final drug concentration of 250ng/ml. When the cells were seen to grow in 
this concentration of drug, toxicity assays were carried out to monitor any changes in drug 
sensitivity when compared with the untreated parental population.
2.5.2 Pulse selection of Clonal Populations with Adriamycin
Cells were grown to 50% confluency in 25cm2 flasks. The cells were then exposed to 
250ng/ml Adriamycin for 4h. after which time the drug was removed and the cells rinsed 
twice with fresh media; the cells were then re-fed with 5ml of complete media without 
drug and incubated at 37°C for 6 days (re-feeding with fresh media every 2-3 days). This 
was repeated tor at least 4 “pulses” after which time sensitivity to the selecting drug was 
monitored using a miniaturised toxicity assay (see Section 2.3.2).
2.6 Dilution Cloning
To propagate a clonal population from a mixed parent population, individual cells were 
plated into wells of a 96 well plate and allowed to grow as an individual clonal sub­
population of the parental line. To achieve this a single cell suspension (see Section 2.2.2) 
was prepared at a density of approximately 1 cell per 300|d of media. The cell suspension 
was then plated out by placing 100^1 into each well of a 96 well plate. The plates were 
then incubated at 37°C and 5 % C02 and monitored after 2 days for cell attachment; wells
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that were seen to have only one cell adhered after 2 days were chosen for expansion as 
clonal populations. When each individual well of the 96 well plate containing a clonal 
population had reached 80% confluency the cells were sub-cultured in to a well of a 24 
well plate (Greiner; 662160) and grown again to confluency after which time they were 
transferred to a 25cm2 flask. Frozen stocks of all clonal populations were made (Section 
2.2.5) as soon as possible after propagation.
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2.7 Subcellular Distribution of Adriamycin
The subcellular localisation of adriamycin in a number of cell lines was investigated by 
fluorescence microscopy.
Microscope glass coverslips (Chance Propper LTD) were washed with 70% alcohol and 
flamed with a bunsen burner. The sterile cover slips were placed in 35mm petri dishes 
(Greiner 627160). The cells used in the studies were grown until approximately 80% 
confluent and trypsinised while in exponential growth. The cells were pelleted by 
centrifugation and a single cell suspension of 1x10s cells per ml was prepared. 1ml of the 
cell suspension was added to each of the petri dishes which were then incubated overnight 
at 37°C in 5% C 02 to allow attachment of the cells to the sterile coverslips. The following 
day the medium was carefully removed from the petri dishes and the cells incubated with 
lml of medium containing 10 adriamycin for 4.5 hours. After this time the drug 
containing medium was decanted and the cells were washed twice with ice-cold PBS. The 
coverslips were inverted onto clean glass slides and the edges sealed with silicon grease to 
protect the cells against dehydration. The cells were viewed for fluorescence under 
ultraviolet illumination using a Nikon microscope equipped with a mercury lamp. The 
ultraviolet illumination induced an orange fluorescence at the site of adriamycin 
accumulation. The cells were viewed immediately after mounting, as fading of the 
fluorescence occurred very rapidly.
2.8 Time-lapse Video Microscopy
Time-lapse video microscopy was carried out on a Nikon diaphot inverted microscope 
(Micron Optical, Bray, Ireland) equipped with phase contrast optics, linked to a 
Mitsubishi CCD-100 colour video camera. Images were recorded in S-VHS onto a 
Mitsubishi HS-S5600 video recorder with time-lapse capabilities. All time-lapse video­
equipment was obtained from Laboratory Instruments (Ashbourne, Ireland). Recording 
speed was set at 3.22sec/field (480 hour mode), which at normal playback speed resulted 
in an acceleration factor of 160.
The temperature of the culture vessel was controlled by a Linkam CO 102 warm stage 
controller. This controller was adjusted to keep the culture medium inside the vessel at 
37°C, as measured using a TB3301 probe.
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2.9 Preparation for RNA Analysis
Due to the labile nature of RNA and the high abundance of RNase enzymes in the
environment a number of precautionary steps were followed when analysing RNA
throughout the course of these studies.
• General laboratory glassware and plasticware are often contaminated by RNases. To 
reduce this risk, glassware used in these studies was baked at 180°C (autoclaving at 
121°C does not destroy RNase enzymes) for at least 8h. Sterile, disposable 
plasticware is essentially free of RNases and was therefore used for the preparation 
and storage of RNA without pre-treatment. Polyallomer ultracentrifuge tubes, 
eppendorf tubes, pipette tips, etc. were all autoclaved prior to use. All spatulas 
which came in contact with any of the solution components were baked, chemicals 
were weighed out onto baked aluminium-foil and a stock of chemicals for “RNA 
analysis only” was kept separate from all other laboratory reagents.
• All solutions (which could be autoclaved) that came into contact with RNA were all 
prepared from sterile ultra-pure water and treated with 0.1% diethyl pyrocarbonate* 
(DEPC) (Sigma; D5758) before autoclaving (autoclaving inactivates DEPC), with 
the exception of Tris-containing solutions (DEPC reacts with amines and so is 
inactivated by Tris). The Tris-containing solutions were made with previously 
DEPC-treated ultra-pure water.
• Disposable gloves were worn at all times to protect both the operator and the 
experiment (hands are an abundant source of RNase enzymes). This prevented the 
introduction of RNases and foreign RNA/DNA into the reactions. Gloves were 
changed frequently.
• All procedures were carried out under sterile conditions when feasible.
•  DEPC is a strong, but not absolute inhibitor o f  RNases. It is also a suspected carcinogen.
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2.10 Total RNA Isolation, Preparation and Analysis by RT-PCR
Total RNA was extracted from cultured cell lines and human tumour specimens 
throughout the course of these studies and analysed by the reverse transcriptase 
polymerase chain reaction.
2.10.1 Total RNA Extraction from Cultured Cell Lines
The following procedure was carried out in a laminar flow cabinet to maintain sterile 
conditions. Adherent cells were grown in 175cm2 tissue culture flasks until approximately 
80% confluent. The medium was removed and the cells in two replica flasks were rinsed 
twice with DEPC-treated PBS. Non-adherent cells were pelleted then resuspended and 
pelleted twice in DEPC-PBS. Cells prepared by either method were then lysed directly in 
a 4M guanidium thiocyanate (GnSCN) solution (Appendix K) (25ml per cell sample). The 
pooled cell lysate was centrifuged at 120g. for 5min and layered on 5.5ml of a 5.7M 
caesium chloride (Appendix K) cushion in a polyallomer ultracentrifuge tube. The mixture 
was spun at 100,000g. at 15°C for 21-24h in a swinging bucket centrifuge. This resulted 
in the separation of protein (at the top of the GnSCN layer) and DNA (at the GnSCN:CsCl 
interface) from the RNA pellet (at the bottom of the tube). Care was taken to prevent 
disturbing the RNA pellet or contaminating the RNA with DNA. The GnSCN solution 
and the “jelly-like” layer below the GnSCN:CsCl interface was removed by aspiration 
(using a pasteur pipette), until approximately 1ml of CsCl remained. The bottom of the 
tube (containing the RNA pellet and 1ml of CsCl) was cut from the rest of the tube using 
a heated scalpel blade. The tube bottom was inverted and the pellet rinsed with 95% 
ethanol at room temperature and resuspended in 200(.U of DEPC-treated water by gently 
pipetting up and down whilst keeping on ice. The resuspended pellet was transferred to an 
eppendorf tube and the suspension remains were rinsed into the eppendorf with a further 
200nl of DEPC-treated water. The RNA was precipitated out of solution by the addition 
of 3M sodium acetate, pH 5.2, (to result in a final volume of 0.3M) and 2 volumes of ice- 
cold absolute ethanol, overnight at -20°C. The RNA was pelleted by spinning at 4°C, at 
maximum speed in a microfuge. The pellet was washed with 70% ethanol, the supernatant 
removed and the pellet was briefly air-dried*. The pellet was resuspended in lOOfil of 
DEPC-treated water and stored at -80°C.
* The pellet was not allowed to dry completely as this greatly decreases its solubility. The solubility of RNA 
can be improved by heating to 55-60°C with intermittent vortexing or by passing through a pipette tip.
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2.10.2 Total RNA Extraction from Paraffin-Embedded Tissue
100|im of formalin-fixed paraffin embedded sections were cut into a sterile eppendorf. 
The paraffin wax was removed from the sections by incubating in 400|.l1 octane (BDH; 
294 075A) for lOmin at 60°C. The eppendorf was then spun at maximum speed in a 
microfuge at 4°C for lOmin. and the wax layer on top was removed from the pelleted 
tissue using a sterile pipette tip. A second wash in octane was then carried out followed by 
two washes in 70% ethanol and spinning in between each wash at maximum speed in a 
microfuge at 4°C for lOmin. The tissue pellet was then air-dried and resuspended in 400fil 
of digestion buffer (R&D Systems; MBK-001-25) to which 0.1-2.0(ig/ml Proteinase K 
(Promega; V3021) had been added immediately prior to use. The tissue was incubated at 
50°C with constant agitation for 4-18h after which time the tissue had fully digested. 600)_lI 
of water-saturated phenol (pH 4) was then added to the digested tissue and vortexed 
vigorously for lOmin. after which 120^1 of chloroform:isoamyl alcohol (24:1) was added 
to the digest/phenol, mixed and centrifuged for lOmin. at maximum speed in a microfuge 
at 4°C. The upper aqueous phase was then removed and washed with 600|il 
chloroform:isoamyl alcohol (24:1) and spun as above. The aqueous phase (containing the 
extracted total RNA) was precipitated out of solution by the addition of 2M sodium 
acetate, pH 4.0, (to result in a final volume of 0.2M) and 2 volumes of ice-cold absolute 
ethanol, overnight at -20°C. The RNA was pelleted by spinning at 4°C, at maximum speed 
in a microfuge. The pellet was washed with 70% ethanol, the supernatant removed and the 
pellet was briefly air-dried. The pellet was resuspended in 20fxl of DEPC-treated water 
and stored at -80°C.
2.10.3 Total RNA Extraction from Fresh Tissue
Fresh tissue was transported from St.Vincent’s Hospital, Dublin 4, in complete media and 
reached the laboratory within 1-4 hours of operation. On arrival the tissue was cut into 
small pieces and snap frozen in liquid nitrogen. The sample was then either stored at - 
80°C or used directly. A sample was taken for RNA extraction. The specimen was 
digested in 400|il of digestion buffer (R&D Systems; MBK-001-25) to which 0.1- 
2.0jxg/ml Proteinase K (Promega; V3021) had been added immediately prior to use. The 
tissue was incubated at 50°C with constant agitation for 4-18h after which time the tissue
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had fully digested. The digest was then stored at -80°C for RNA extraction or extracted 
directly as described in Section 2.10.2.
2.10.4 RNA Quantitation
RNA was quantified spectrophotometrically at 260nm and 280nm. An optical density of 1 
at 260nm is equivalent to 40mg/ml RNA. An A260/A280 ratio of 2 is indicative of pure 
RNA. Partially solubilised RNA has a ratio of <1 .6  (Ausubel et al., 1991). The yield of 
RNA from most lines of cultured cells is 100-200(j.g/90mm plate (Sambrook et al., 1989). 
In these studies 200ngRNA/175cm2 flask was retrieved.
2.10.5 RNA Quality
RNA quality was checked by running a quantity of RNA on a 1 % formaldehyde/agarose 
gel. For a 100ml, 1% gel, lg of agarose was combined with 73.4ml sterile distilled water 
and dissolved by heating in microwave. In a fume hood 10ml of 10X MOPS buffer 
(0.25M MOPS (Sigma; M8899), 0.05M Na-acetate, 0.01M EDTA, pH 7.0) and 16.6ml 
formaldehyde (BDH; 15513) were added to the molten agarose. 2.5(xl of ethidium bromide 
(Sigma; E8751) (lOmg/ml) was added and the gel was then poured. 1.0|xl formaldehyde, 
5.0|il formamide (BDH; 33272), 0.5fxl loading buffer (50% glycerol (Sigma; G5576), 
lmg/ml xylene cyanol FF (BDH; 44306), lmg/ml bromophenol blue (Sigma; B5525), 
ImM EDTA) was added to 1,75(il of RNA, and incubated at 65°C for 15 minutes, placed 
on ice and then loaded onto the gel. The gel was run in IX MOPS buffer. Intact RNA is 
detected as two ribosomal (28S and 18S) RNA bands.
2.10.6 Micropipette Accuracy Tests
Accuracy and precision tests were carried out routinely on all micropipettes used in all 
steps of the RT-PCR reactions. The accuracy and precision of the pipettes was determined 
by standard methods involving repeatedly pipetting specific volumes of water and 
weighing them on an analytical balance. The specifications for these tests were supplied by 
Gilson.
67
2.10.7 Reverse Transcription of total RNA to form cDNA
cDNA was formed on mRNA templates extracted from either cell lines (see Section
2.10.1), paraffin-embedded (see Section 2.10.2) or fresh tissue (see Section 2.10.3) using 
the following procedures. All reactions were incubated on ice under sterile conditions.
2.10.7.1 Reverse Transcription of RNA isolated from cell lines
The following components were used in the reverse transcriptase (RT) reaction for RNA 
isolated from cell lines, ljal oligo (dT)i2.i8 primers (ljag/ja.1) (Promega; C1101), 1^ 1 of 
total RNA (l|ig/|il), and 3^1 of DEPC-H20  were mixed together and heated at 70°C for 
lOmin and then chilled on ice to remove any RNA secondary structure formation and 
allow the oligo (dT) primers to bind to the poly (A)+ tail on the mRNA. 4|xl of a 5X 
buffer (consisting of 250mM Tris-HCl, pH 8.3, 375mM KC1 and 15mM MgCl2), 2^1 of 
DTT (lOOmM), l\xl of RNasin (40U/pi) (Promega: N2511), l|o,l of dNTPs (lOmM each of 
dATP, dCTP, dGTP and dTTP), 6(xl of water and 1 jal of Moloney murine leukaemia 
virus-reverse transcriptase (MMLV-RT) (40,000U/fil) (Gibco; 5108025 SA) was then 
added to the heat-denatured RNA complex and the mixture was incubated at 37°C for lh 
to allow the MMLV-RT enzyme catalyse the formation of cDNA on the mRNA template. 
The enzyme was then inactivated and the RNA and cDNA strands separated by heating to 
95°C for 2min. The cDNA was used immediately in the PCR reaction or stored at -20°C 
until required for analysis.
2.10.7.2 Reverse Transcription of RNA isolated from Paraffin Sections
The basic procedure used for the reverse transcription of mRNA isolated from paraffin 
sections was similar to that used for mRNA from cell lines (see Section 2.9.7.1). Due to 
the degraded nature of such mRNA, however, alterations had to be made to the priming of 
this mRNA during reverse transcription (see Section 3.13.1).
2.10.7.3 Reverse Transcription of RNA isolated from Fresh Tissue
RNA extracted from fresh tissue was reverse transcribed as described in Section 2.10.7.1.
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2.10.8 Polymerase Chain Reaction (PCR) Analysis of cDNA
The cDNA formed in the above reaction was used for subsequent analysis by PCR for the
expression of specific mRNAs.
2.10.8.1 PCR Analysis of cDNA formed from mRNA isolated from cell lines
Typical PCR reactions were set up as 50|j.l volumes using 5(xl of cDNA formed during the 
RT reaction (see Section 2.9.7.1). cDNA was amplified for varying cycle numbers but 
where possible amplification was carried out in the exponential phase of amplification. 
Each PCR reaction tube contained 26.5^1 of water, 5^1 lOXbuffer (lOOmM Tris-HCl, pH
9.0, 50mM KC1, 1% Triton X-100), 2pl 25mM MgCk, 1^ 1 of first strand target primer* 
(250rig/fxl), 1 (j.1 of second strand target primer* (250r|g/(xl), 0.5^1 of first strand 
endogenous control primer* (250r|g/pl), and 0.5(xl of second strand endogenous control 
primer* (250rig/|xl). 5|xl of cDNA (pre-heated to 95°C for 3min. to separate strands and 
remove any secondary structure if the sample had been stored at -20°C) was added to the 
above and heated to 94°C for 5min (reduces non-specific binding of primers to template). 
8^1 of 1.25mM dNTP and 0.5|ji of Taq DNA Polymerase enzyme (Promega; N1862) was 
then added to the above and a drop of liquid paraffin (BDH; 29436) was added to each 
reaction tube. The cDNA was then amplified by PCR (Techne; PHC-3) using the 
following program:
• 94°C for 1.5min (denature double stranded DNA);
• 15-35 cycles 94°C for 1.5min (denature double stranded DNA);
54 or 60°C for lmin (anneal primers to cDNA);
72°C for 3min (extension);
• 72°C for 7min (extension).
* All oligonucleotide primers used throughout the course of this thesis were made to order on an 
“Applied BioSystems 394 DNA/RNA Synthesiser” by R&D Systems Ltd., 4-10 The Quadrant, 
Barton Lane, Oxon, England. Sequences of primers used are shown in Table 3.1.1 and Appendix
C
All reaction tubes were then kept at 4°C until analysed by gel electrophoresis followed by
densitometry.
A lOjxl aliquot of tracking buffer, consisting of 0.25% bromophenol blue (Sigma; B5525)
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and 30% glycerol in water, was added to each tube of amplified cDNA products. 10[.d of 
cDNA products from each tube were then separated by electrophoresis overnight at 30mV 
through a 4% agarose (Promega; V3122) gel containing ethidium bromide (Sigma; 
E8751), using TBE (22.5mM Tris-HCl, 22.5mM boric acid (Sigma; B7901), 0.5mM 
EDTA) as running buffer. Molecular weight markers “(|>-X174” Hae III digest (Promega; 
G1761) were run, simultaneously, as size reference.
The resulting product bands were visualised as pink bands (due to the intercalation of the 
cDNA with the ethidium bromide) when the gels were placed on a transilluminator (UVP 
Transilluminator). The gels were photographed and the negatives produced were analysed 
by densitometry (Imaging Densitometer, Bio-Rad. Model GS-670).
2.10.8.1.1 Densitometrlc Analysis
Densitometric analysis was carried using the MS Windows 3.1 compatible Molecular 
Analyst software/PC image analysis software available for use on the 670 Imaging
Densitometer (BioRad, CA) Version 1.3.
Negatives of PCR gels were scanned using transmission light and the image transferred to 
the computer. The amount of light blocked by the DNA band is in direct proportion to the 
intensity of the DNA present. A standard area is set which is scanned and a value is taken 
for the OD of each individual pixel on the screen. The average value of this OD (within a 
set area) is normalised for background of an identical set area. This normalised reading is 
taken as the densitometric value used in analysis.
2.10.8.2 PCR Analysis of cDNA formed from mRNA isolated from Paraffin Sections
PCR analysis of cDNA from paraffin sections was carried out as in Section 2.10.8.1 but 
amplification was carried out for all target genes for at least 30 cycles - no analysis on 
exponential phase was undertaken.
2.10.8.3 PCR Analysis of cDNA formed from mRNA isolated from fresh tissue
PCR analysis of cDNA from paraffin sections was carried out as in Section 2.10.8.1. 
Amplification was carried out for all target genes for at least 30 cycles of PCR.
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2.10.8.4 Restriction Digestion of RT-PCR Products
Products formed after RT-PCR amplification were digested with an appropriate enzyme as 
follows. A 10^1 aliquot of the particular RT-PCR product, 10 Units of the relevant 
endonuclease restriction enzyme (Table 2.10.8.4.1), 5|o.l of 10X buffer (supplied with each 
restriction enzyme) and the appropriate volume of water to result in a total volume of 
50(4.1, were mixed in an eppendorf tube and incubated at 37°C for lh. A 20(il aliquot of the 
resulting products was analysed by electrophoresis through a 4% agarose gel (see Section 
2 . 10.8 . 1).
Table 2.10.8.4.1 Restriction Enzymes used to Identify RT-PCR Products
Amplified Product Restriction Enzyme Supplier Catalogue Number
bcl-2a BamHI Promega R602A
bcl-2ß BamHI Promega R602A
bcl-XL Bspl2861 Promega R674A
bcl-xs Kpnl Promega R634A
bax-a/ß PvuII Bochringer Mannheim 642 690
bax-ß BamHI Promega R602A
c-fos Hinfl Boehringer Mannheim 779 652
c-jun HincII Promega R603A
c-myc Haelll Promega R6171
c-Ha-ras-1 FokI Promega R6781
c-erbB-2 PvuII Boehringer Mannheim 642 690
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2.11 RNA Analysis by In Situ Hybridisation
Non-isotopic in situ hybridisation (NISH) was carried out on formalin-fixed paraffin- 
embedded sections using a digoxigenin(DIG)-labelled mdrl riboprobe and detected using 
an alkaline phosphatase-conjugated antibody.
2.11.1 Digoxigenin Labelling of mdrl Riboprobe
pHDR5A, consisting of a 1.4kb insert of mdrl in transcription vector pGEM4, was a 
generous gift from Dr.M.M.Gottesmann and was used as a template to create a 
digoxigenin-labelled riboprobe of mdrl for use in in situ hybridisation.
To generate the mdrl antisense probe, the plasmid was linearised with BamHI (Promega; 
R602A) and transcribed using Sp6 polymerase; the sense probe was generated by 
linearising the plasmid with Nhel (Promega; R6502) and transcribed using T7 polymerase. 
A transcription kit (Boehringer-Mannheim; 1-175-025) was used to digoxigenen(DIG)- 
label the riboprobes according to the manufacturer’s instructions. Incorporation of labelled 
nucleotides was measured using a dot-blot assay (see Section 2.11.1.1) and showed yields 
of ~5fig of RNA per |ig of template cDNA. Sp6 labelling efficiency was increased 
greatly when an incubation temperature of 40°C was used in preference to the 
recommended 37°C.
A poly-dT probe, used to assess RNA preservation, was purchased as part of a kit from 
R&D Systems (BBS8). A p-actin probe (also used to assess RNA preservation in tissue) 
was purchased pre-labelled with digoxigenin (Boehringer-Mannheim; 1-498-045). An In 
Situ Workstation kit (R&D Systems; BBS1) was used for optimisation of digestion and 
post-hybridisation steps.
2.11.1.1 Dot-blot assay to estimate digoxigenin-labelled probe
1^ 1 of each probe was dotted onto a nylon membrane (Amersham; Hybond N, 
RPN.3050N); standard controls of known labelling intensity were dotted in decreasing 
concentration on the top line, probes of unknown labelling concentration were placed on a 
lower line (Figure 2.11.1.1.1).
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Figure 2.11.1.1.1 Dot-Blot Analysis to quantify DIG-labelled RNA
standards of known labelling 
intensity
DIG-labelled RNA of 
unknown concentration
The detection procedure is a variation of that used by Boehringer-Mannheim (described in 
Boehringer-Mannheim; 1-175-041) and was carried out at room temperature.
The membrane was washed in 20ml 0.1M Tris-Cl, 0.15M NaCl, pH7.5 and 0.2% Triton 
X-100 for lmin followed by a 30min wash in 20ml 0.1M Tris-Cl, 0.15M NaCl, pH7.5 
with 2% sheep serum. The membrane was then incubated for 30min in 20ml of a 1:5000 
antibody conjugate in 0.1M Tris-Cl, 0.15M NaCl, pH7.5 and 1% sheep serum. The 
membranes were washed twice for 15min. in 0.1M Tris-Cl, 0.15M NaCl, pH7.5 and then 
equilibrated for 2min in 0.1M Tris-Cl, 0.1M NaCl, 0.05M MgCl2, pH9.5. To assess 
probe intensity, the membranes were incubated in the dark in colour solution consisting 
of 0.1M Tris-Cl, 0.1M NaCl, 0.05M MgCl2, pH9.5, 35|j1 BCIP (Boehringer Mannheim; 
1-383-221) and 33.75jxl NBT (Boehringer Mannheim; 1-383-213). When the colour had 
developed, the membranes were washed in lOmM Tris-Cl, ImM EDTA, pH 8.0 and 
under running tap-water to stop colour development. The labelled probe concentration was 
estimated visually by comparing the probes of interest with the known standard 
concentrations.
2.11.2 Optimisation of In Situ Hybridisation Protocol for detection of mdrl mRNA
Many conditions were optimised in order to achieve successful specific hybridisation of 
probe to the tissue; these steps included -
• identifying a suitable digestion enzyme and concentration for the tissue
• optimising hybridisation conditions
• successful removal of unbound labelled probe subsequent to hybridisation
• sufficient blocking of slides prior to detection steps.
Proteinase K and pepsin are common digestion enzymes used for in situ hybridisation. To 
determine which enzyme was appropriate in this study, an In Situ Instructor kit (R & D
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Systems; BBS1) was utilised to assess the effect of different digestion conditions on 
hybridisation of a labelled insulin probe to rat pancreas sections. It was found that 
Proteinase K, up to a concentration of 30|ig/ml, allowed sufficient detection of the 
hybridised probe. The concentration of pepsin used (2mg/ml) was found to be sufficient to 
allow hybridisation of rat insulin probe and a small poly-dT probe to sections. This latter 
digestion was used thoughout the course of this work since it has generally been found to 
be effective on a wider range of tissues than Proteinase K.
Hybridisation conditions are the most critical steps to optimise for in situ hybridisation. 
Hybridisation with a buffer containing excess blocking agents or inappropriate stringency 
conditions prevents binding of the probe to the section while insufficient blocking allows 
for non-specific binding of probe and the generation of false positives. Probe 
concentration was also found to play an important role, with excess probe leading to high 
background and insufficient probe quantities resulting in the loss of signal from some 
cells. Hybridisation temperature is also important and pre-heating of sections to 95°C for 
15min. resulted in a reduction of optimal hybridisation time at 50°C from 18 hours to 2 
hours.
Initially hybridisation buffers were used which contained formamide, salt solutions, 
dextran sulphate (effectively increases the concentration of probe in the hybridisation 
buffer by forming a matrix in the hybridisation mixture; including dextran sulphate in the 
buffer can increase the hybridisation reaction by a factor of 3) and a detergent such as 
Triton-XlOO (Sigma; X-100), but no blocking agents. When blocking agents, such as 
herring sperm DNA and transfer RNA, were added to the buffer a dramatic decrease in 
non-specific staining was observed. High stringency washes in formamide with SSC were 
found to be sufficient to remove any unbound labelled probe. The blocking steps used in 
this protocol were also sufficient as no staining was detected in control sections hybridised 
with control probes such as the sense (T7) probe or hybridised with the positive anti-sense 
probe (Sp6) pre-treated with RNase.
Specific staining of mdrl expression in erythroid precursors (haemopoeitic cells) in the 
sinusoids of foetal liver was detected using this procedure on formalin-fixed paraffin- 
embedded sections (Dr.S.Kennedy pers. comm.).
2.11.3 Non-Isotopic In Situ Hybridisation of mdrl riboprobe to Paraffin Sections
5|oni sections were mounted onto poly-L-lysine (Sigma; P1274) coated slides. Sections
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were deparaffinized twice in Xylene (2X lOmin) and rehydrated in 99% ethanol (2X 
2min), 95% ethanol (2X 2min) and incubated in DEPC-H20  at 37°C for lOmin. Tissues 
were digested in Pepsin/HCl (immediately prior to use 5mg Pepsin (Sigma; P6687) was 
dissolved in 2.17ml DEPC-H20; 0.33ml 1.5M HC1 was then added slowly to the pepsin 
solution) at 37°C for 20min and then rinsed in 1XPBS at 37°C. Control sections were 
treated with RNaseA (Sigma; R9009) (100^ig/ml) for 30min at 37°C to destroy all RNA. 
Post-fixation in 0.4% paraformaldehyde (in 1XPBS (Appendix K)) was then carried out at 
4°C for 20min. and the slides were rinsed in DEPC-H20 . Slides were pre-hybridised in 
pre-hybridisation buffer (50% deionized formamide (BDH; 33272), 2XSSC (Appendix K), 
5% dextran sulfate, 0.3% Triton X-100, IX Denhardt’s solution (100X consists of 
2%(w/v) bovine serum albumin (Sigma; A2153), 2% (w/v) Ficoll 400 (Sigma; F4375), 
2% (w/v) polyvinylpyrrollidone (Sigma; PVP40) in water), 150(xg/ml herring sperm DNA 
(Promega; D181A), 150ug/ml tRNA (Sigma; R8508), in DEPC-H20) for lh at 37°C in a 
humid chamber. The slides were covered in hybridisation buffer (as for pre-hybridisation 
buffer but supplemented with the specific probe required (0.1-2.5(ig/ml)) and cover- 
slipped; hybridisation was carried out at 95°C for 15min followed by 50°C for 2hour. To 
remove any unhybridised probe the slides were washed twice in solutions containing 30% 
formamide and (a) 4XSSC, (b) 2XSSC and (c) 0.2XSSC for 5min each at 50°C.
To detect the hybridised probe an alkaline phosphatase anti-DIG antibody Fab fragments 
(Boehringer Mannheim; 1-093-274) was used. The slides were blocked first in 1XTBS 
(Appendix K)/0.1%BSA/0.1%Triton X-100 for 25min at room temperature with gentle 
shaking. The antibody was then added to the slides (1:500 in 1XTBS/0.1%BSA) for 
35min at room temperature. To remove any unbound antibody the slides were then 
washed twice in 1XTBS/0.1 %BSA for 5min each at room temperature with vigorously. 
The revealing step involved the formation of a purple precipitate at the site of 
hybridisation due to the enzymatic action of alkaline phosphatase with NBT/BCIP. The 
slides were washed 2-3 times in lOOmM Tris-HCl, pH9.5, lOOmM NaCl and 50mM 
MgCl2 and then colour solution (lOOmM Tris-HCl, pH9.5, lOOmM NaCl and 50mM 
MgCl2, 17.5f.il BCIP (Boehringer Mannheim; 1-383-221), 16.88^1 NBT (Boehringer 
Mannheim; 1-383-213) per 5ml and levamisole (Dako; X3021)) was added for lOmin in 
the dark. When the colour developed the slides were washed under running tap water and 
allowed to dry. The sections were counter-stained with 3% methylene green for 15sec and 
the slides mounted with an aqueous mounting gel such as G l y c e r g e l  (Dako; C563).
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Notes
• Parafilm was used as cover-slips during hybridisation
• All hybridisation steps were carried out in a humid atmosphere. This was achieved
simply by lying tissue soaked in 2XSSC at the base of a sealed hybridisation 
chamber.
• The amount of solution required during hybridisation was reduced (thus lowering
the overall cost of the procedure) by circling the area of the slide containing the 
section with an Immuno-pen (Dako; S2002) that forms a seal with the slide.
• For accurate analysis of mRNA expression by NISH, a number of controls must be 
set up with the positive slide, namely, hybridisation with (i) sense probe, (ii) control 
probe (gene not present in cells under investigation), (iii) oligo-dT or p-actin probe 
(to assess mRNA quality throughout the cell sample), (iv) pre-treatment with RNase 
and (v) hybridisation buffer without labelled probe.
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2.12 Gene Induction by Adriamycin and Analysis by RT-PCR
To determine the effect Adriamycin has on gene expression, DLKP-SQ cells were exposed 
to varying concentrations of drug and after set time points total RNA was extracted from 
the cells and analysed by RT-PCR.
2.12.1 Extraction of total RNA for analysis of Gene Induction by Adriamycin
DLKP-SQ cells were grown to 50% confluency in 25cm2 flasks. The cells were then 
exposed to adriamycin (at 25ng/ml continuously or 250ng/ml for 4h after which the drug 
was removed, the cells washed twice in complete media and re-fed in media without drug) 
and total RNA was extracted after 0, 8, 15, 30min and 1, 2, 4, 6, 9, 24, 48 and 72h. 
Control samples were also taken from cells, at the same time-points, which had been fed 
with fresh media without drug. Total RNA was extracted from the cells using the 
Ultraspec-D kit (Biotecx; BL-12200). Briefly, this involved lysing the cells with 1ml of 
lysis buffer (guanidine and phenol) and further chloroform extraction. Once the cells had 
been lysed directly in the flask the sample was stored at -80°C for further processing; this 
involved a chloroform extraction by adding 0.2ml of chloroform to the 1ml cell lysate, 
centrifuging and precipitating the total RNA in the aqueous layer out of solution by 
incubating overnight at -20°C in 2 volumes of absolute ethanol and sodium acetate, pH
4.0. The RNA was pelleted at 4°C and resuspended in 20fd of DEPC-H20.
2.12.2 RT-PCR Analysis of Gene Induction
Total RNA extracted to analyse gene induction by Adriamycin was amplified by RT-PCR 
as described in Sections 2.10.7.1 and 2.10.8.1
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2.13 Protein Analysis
Protein analysis was carried out by Western blotting using whole cell extracts and purified 
nuclear extracts.
2.13.1 Whole Cell Extract Preparation
Cells were grown in 175cm2 flasks until they reached 80-90% confluency. The cells were 
then trypsinised and centrifuged at 120g. for 5 min. The pellet was washed in PBS and re­
pelleted twice. 1ml of lysis buffer (PBS, 1% NP-40 (Sigma; N-3516), IX protease 
inhibitors and 0.2mg/ml PMSF(Sigma; P7626)) was added to the pellet and left on ice for 
20 min. A 100X stock solution of protease inhibitors consisted of 400mM DTT (Sigma; 
D5545), lmg/ml aprotonin (Sigma; A1153), lmg/ml leupeptin (Sigma; L2884), lmg/ml 
soybean trypsin inhibitor (Sigma; T9003), lmg/ml pepstatin A (Sigma; P6425) and 
lmg/ml benzamidine (Sigma; B6506). If cell lysis had not occurred after 20 min the cells 
were subjected to sonication. Whole cell extracts were aliquoted and stored at -80°C.
2.13.2 Nuclear Extract Preparation
Cells were grown in 175cm2 flasks until they reached 80-90% confluency. The cells were 
trypsinised and centrifuged at 120g. for 5 min. The cell pellet was then washed in TE 
buffer and re-pelleted twice. The cells were re-suspended in lOmM Tris-HCl, pH7.5, 
lOmM NaCl, 3mM MgCl2, 0.5% NP-40, 0.2mg/ml PMSF and IX protease inhibitors at 
lx l07cells/ml on ice until cell lysis was observed, as determined by trypan blue staining. 
The lysate was centrifuged at 800g. for lOmin to pellet the nuclear extract. The pellet was 
washed in lOmM Tris-HCl, pH7.5, lOmM NaCl, 3mM MgCl2, IX protease inhibitors, 
0.2mg/ml PMSF and centrifuged. To lyse the nuclei, the nuclear pellet was incubated in 
350mM NaCl, 5mM KH2P04, pH7.0, 2mM MgCl2, O.lmM EDTA, 0.2mg/ml PMSF and 
IX protease inhibitors on ice for 30 min at a cell density of lx l08cells/ml. The lysate was 
aliquoted and stored at -80°C.
2.13.3 Quantification of Protein
Protein levels were determined using the Bio-Rad protein assay kit (Bio-Rad; 500-0006)
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with a series of bovine serum albumin (BSA) (Sigma; A9543) as standards. The dye 
reagent was provided as 5-fold concentrate. The appropriate standards (0.02ml) and test 
samples (0.02ml) were placed in clean, dry test tubes. The diluted dye reagent (1ml) was 
added and the mixture vortexed. After a period of 5 min to lh, the OD595 was measured, 
against a reagent blank. From the plot of the OD595 of BSA standards versus their 
concentrations, the concentration of protein in the test samples was determined.
2.13.4 Gel electrophoresis
The protein present in the cell preparations were separated on a size basis using SDS 
polyacrylamide gel electrophoresis (SDS-PAGE)
Table 2.13.4.1 SDS-PAGE Recipes for 2 x 0.75m m  Thick Gels
7.5%
Resolving Gel 
12% 15%
Stacking Gel 
5%
Acrylamide Stock* 3.8ml 5.25ml 7.5ml 0.8ml
Distilled H20 8.0ml 6.45ml 4.3ml 3.6ml
1.875M Tris, pH 8.8 3.0ml 3.0ml 3.0ml
1.25M Tris, pH 6.8 0.5ml
10% SDS 150jj.1 150(0.1 150(j.l 50(11
10% NHrpersulphate 60(j.l 50(j.l 50j.il 17(il
TEMED 9.0(d 10p.l 7.5)0.1 8(0,1
* Acrylamide stock solution consists of 29.lg acrylamide (Sigma; A8887) and 0.9g NN’- 
methylene bis-acrylamide (Sigma; 7256) dissolved in 60ml UHP water and made up to 100ml 
final volume. The solution was stored in the dark at 4°C for up to 1 month. All components were 
purchased from Sigma; SDS (L4509), NH4-persulphate (A1433) and TEMED, N,N,N’,N’- 
tetramethylethylenediamine (T8133).
The resolving gel was immediately poured into two clean 10cm x 8cm gel cassettes 
comprising of a glass and aluminium plate separated by two 0.75cm spacers on either 
outer edge. The gel was overlayed with a 10% SDS solution and allowed to set. Once set, 
the SDS solution was poured off and the stacking gel layered on top of the resolving gel. 
A comb of appropriate thickness and well size was immediately inserted and the gel 
allowed to set. When the wells had formed, the gel combs were removed and the gels 
transferred to a mini-electrophoresis apparatus. The gels were flooded with running buffer 
(1.9M glycine (Sigma; G6761), 0.25M Tris, 0.1% SDS, pH 8.3 without adjustment).
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Protein samples were loaded into the wells, based on equal protein loading. The samples 
to be loaded were diluted 1:1 with loading buffer (50mM Tris-HCl, pH 6.8; 0.1% SDS; 
5% 2-mercaptoethanol (Sigma; M6350); 5% glycerol and 0.1% bromophenol blue) and 
boiled for 2 min. They were then loaded onto the gel, as were the appropriate molecular 
weight markers (New England Biolabs; 77085). The gels were run for approximately 1.5 
hours with voltage set at 250V and current set at 45mA.
2.13.5 Western Blotting Procedure
Following electrophoresis, the acrylamide gels were equilibrated in transfer buffer (25mM 
Tris; 192mM glycine; pH 8.3 - 8.5 without adjustment). Nitrocellulose filter (Amersham; 
Hybond-ECL RPN2020D), which was cut to the same size as the gel, was soaked in 
transfer buffer for 5 min. Six stacked sheets of gel-size Whatman 3mm filter paper were 
soaked in transfer buffer and placed on the cathode plate of a semi-dry blotting apparatus. 
Excess air was removed from between the filters by sliding a pipette over and back on the 
filter paper. The nitrocellulose was placed over the filter paper, again ensuring no air 
bubbles became trapped. The acrylamide gel was placed on the nitrocellulose and the 
nitrocellulose was marked at the sites of the gel lanes and size markers. Six more sheets 
of pre-soaked filter paper was placed on top of the gel. The protein was transferred from 
the gel to the nitrocellulose at a current of 0.34mA/0.15V for 30 min. The nitrocellulose 
was then blocked in blocking buffer and exposed to specific antibodies. Negative blots 
were also performed whereby the primary antibody was replaced with antibody diluent.
2.13.5.1 P-glycoprotein
Total protein was separated on a 7.5% SDS polyacrylamide gel. Following transfer of the 
protein to the nitrocellulose, the nitrocellulose was blocked for 3 hr at room temperature 
in TBS (500mM NaCl; 20mM Tris, pH 7.5) containing 0.5% non-fat dried milk 
(Cadbury; Marvel skimmed milk). The nitrocellulose was rinsed twice with TBS and was 
exposed to the primary antibody (1 in 2 dilution of supernatant (BRI)) at 4°C overnight. 
The nitrocellulose was washed three times in TBS containing 0.5% Tween-20 (Sigma; 
P I379). The nitrocellulose was exposed to the secondary antibody (horse radish 
peroxidase-conjugated (HRP)) (1:1000 dilution of anti-mouse-HRP (Sigma; A6782) in 
TBS, 0.1% Tween-20) for 1.5 hours at room temperature. The nitrocellulose was again
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washed three times in TBS and was developed as outlined in Section 2.13.6.
2.13.5.2 c-erbB-2
Total protein was separated on a 7.5% SDS polyacrylamide gel. Following transfer of the 
protein to the nitrocellulose, the nitrocellulose was blocked for 2 hours at room 
temperature in TBS (500mM NaCl; 20mM Tris, pH 7.5) containing 0.5% non-fat dried 
milk (Cadbury; Marvel skimmed milk). The nitrocellulose was rinsed twice with TBS and 
was exposed to the primary antibody at a dilution of 1:500 (c-erbB-2, D a k o ;  A0485) at 
4°C overnight. The nitrocellulose was washed three times in TBS containing 0.5% Tween- 
20 (Sigma; P1379). The nitrocellulose was exposed to the secondary antibody (1:1000 
dilution of anti-rabbit-HRP (Sigma; A4914) in TBS, 0.1% Tween-20) for 1 hour at room 
temperature. The nitrocellulose was again washed three times in TBS and was developed 
as outlined in Section 2.13.6.
2.13.5.3 c-Fos
Nuclear protein was separated on a 12% SDS polyacrylamide gel. Following transfer of 
the protein to the nitrocellulose, the nitrocellulose was blocked overnight at 4°C in TBS 
(500mM NaCl; 20mM Tris, pH 7.5) containing 0.5% non-fat dried milk (Cadbury; 
Marvel skimmed milk). The nitrocellulose was rinsed twice with TBS and was exposed to 
the primary antibody (c-Fos(Ab-2), Calbiochem; PC05) at 2.5jig/ml at room temperature 
for 2 hours. The nitrocellulose was washed three times in TBS containing 0.5% Tween-20 
(Sigma; P1379). The nitrocellulose was exposed to the secondary (1:1000 dilution) anti- 
rabbit-HRP antibody (Sigma; A4914) in TBS, 0.1% Tween-20 for 1 hour at room 
temperature. The nitrocellulose was again washed three times in TBS and was developed 
as outlined in Section 2.13.6.
2.13.5.4 Bcl-x
Total protein was separated on a 15% SDS polyacrylamide gel. Following transfer of the 
protein to the nitrocellulose, the nitrocellulose was blocked for 2 hours at room 
temperature or over-night at 4°C in TBS (500mM NaCl; 20mM Tris, pH 7.5) containing 
0.5% non-fat dried milk (Cadbury; Marvel skimmed milk). The nitrocellulose was rinsed
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twice with TBS and was exposed to the primary antibody (Bcl-x(Ab-l), 
Calbiochem;PC67), at 2.5(xg/ml, for 2 hours at room temperature. The nitrocellulose was 
washed three times in TBS containing 0.5% Tween-20 (Sigma; P1379). The nitrocellulose 
was exposed to the secondary antibody (1:1000 dilution of anti-rabbit-HRP (Sigma; 
A4914) in TBS, 0.1% Tween-20) for 1.5 hours at room temperature. The nitrocellulose 
was again washed three times in TBS and was developed as outlined in Section 2.13.6.
2.13.6 Development of Western Blots by ECL
Western blots were developed by a chemiluminescence method. An equal volume of ECL 
solutions 1 and 2 (Amersham; RPN2209) were mixed together (3ml/blot). The 
nitrocellulose was placed, protein side up, on a piece of flat cling-film and covered with 
the detection reagent for 1 min at room temperature. Excess detection reagent was poured 
off and the membranes were wrapped in cling-film, ensuring no air-pockets were created. 
A sheet of autoradiography film was placed on top of the membranes and exposure time 
varied. Film was developed and fixed using standard methods.
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2.14 Transfection of Mammalian Cells with Exogenous DNA
Throughout the course of this thesis it was found necessary to introduce foreign DNA into 
host cells either to increase the level of expression of a particular gene (by transfecting 
with an expression plasmid) or decrease the level of expression of a particular gene (by 
transfecting with a plasmid containing a ribozyme).
Sufficient plasmid was produced by transforming JM109 with the plasmid required, 
growing up a large stock of these cells and isolating the plasmid from them; this isolated 
plasmid was then transfected into the chosen cell line.
2.14.1 Plasmids used
The c-fos ribozyme was cloned into the pMAM-«eo inducible mammalian expression 
vector and was a generous gift from Dr. Kevin Scanlon. The plasmid is induced by adding 
dexamethasone to the growth medium. The bcl-xs cDNA was a generous gift from Dr. 
Gabriel Nunez.
2.14.2 MgCl2 / CaCl2 Transformation of JM109 Cells
10ml of LB broth (Appendix K) was inoculated with a single colony of JM109 bacteria 
from an agar plate and incubated overnight at 37°C at 200r.p.m. The following day 500fd 
of this suspension was inoculated into 50ml of LB broth and grown to an OD600nm of 0.3. 
The cells were then pelleted at 3000r.p.m. for lOmin, the supernatant removed and the 
pellet was resuspended in 10ml of lOOmM MgCl2, on ice for 15min. The cells were again 
precipitated at 3000r.p.m. for lOmin and the pellet was resuspended in 10ml of lOOmM 
CaCl2 on ice for a further 15min. The precipitation step was then repeated and the pellet 
was resuspended in l-2ml of lOOmM CaCl2 and left on ice for at least 15min. The cells 
were now competent and ready for transformation with the foreign DNA required.
100|ji of the competent cell suspension was mixed with 20ng DNA and placed on ice for 
40min after which the mixture was heat-shocked at 42°C for 90sec and then placed on ice 
for 3min. 1ml of LB broth was added to the competent cell suspension and incubated at 
37°C for 40min. 400|jl of this suspension was spread on a selecting agar plate 
(Ampicillin/AMP (Boehringer Mannheim; 835 269)) and incubated overnight at 37°C. 
Single colonies which grew on these selecting plates were further colonised on another
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selecting plate and allowed to grow overnight.
2.14.2.1 Isolation of Plasmid from JM109 cells
A single colony (from 2.14.2) was inoculated into 10ml of LB AMP 50|ag/ml and grown 
overnight; 2ml of this suspension was added to 200ml of TB AMP 50p.g/ml and left to 
grow overnight at 37°C for large scale isolation of plasmid from JM109 cells. The 
following day the cells were pelleted and pZ523 spin columns (5 Prime -» 3 Prime Inc.; 
5-523523) were used to isolate the plasmid according to the manufacturer’s instructions. 
This procedure involved lysing the pellet in 20ml of an ice-cold solution containing 50mM 
glucose, 25mM Tris-Cl, lOmM EDTA, pH8.0 and 5mg/ml lysozyme (Sigma; L6876) at 
room temperature for 10-15min. 40ml of a 0.2N NaOH and 1.0% SDS solution was 
gently mixed with the lysate until the suspension became clear and incubated on ice for 
lOmin. 30ml of 3M K-Acetate, pH5.2 was added to the above and mixed gently until a 
flocculent precipitate appeared at which stage the mixture was stored on ice for at least 
lOmin. The sample was centrifuged at 35,000g. for lh at 4°C after which the supernatant 
was recovered and added to 0.6 volume of 100% Isopropanol, mixed gently and left at 
room temperature for 20-30min. The suspension was then centrifuged at 35,000g. for 
30min at 20°C after which the supernatant was discarded and the pellet washed in ice-cold 
70% ethanol and resuspended in 5ml of TE, pH8.0. To remove any contaminating RNA 
the plasmid solution was treated with RNase Plus (5 Prime -> 3 Prime Inc.; 5-461036) (to 
a final dilution of 1:250) for 30min at 37°C followed by phenol:chloroform:isoamyl 
alcohol extractions. 10M ammonium acetate was added to the aqueous phase to a final 
concentration of 2.0M and 0.6 volume of 100% Isopropanol was added to the sample, 
mixed and stored at room temperature for 20-30min. The sample was centrifuged at 
maximum speed in an epifuge and the DNA pellet was washed in 70% ethanol and 
resuspended in 3.6ml of lOmM Tris-Cl, ImM EDTA, and 1.0M NaCl, pH8.0. 1.8ml of 
this sample was loaded into one of two pZ523 columns (following the manufacturer’s 
instructions) and the column effluent was precipitated with 0.6 volume 100% Isopropanol, 
as described previously. The DNA was pelleted at maximum speed in an epifuge, washed 
in 70% ethanol and resuspended in TE. The DNA concentration was determined by 
measuring the OD260mn.
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2.14.3 CaP04 Transfection of Mammalian Cells
On the day prior to transfection the cells to be transfected with plasmid DNA were plated 
from a single cell suspension (Section 2.2.2) and seeded into a 75cm2 flask at 5x10s cells 
per flask. The plasmid DNA was diluted to ljig/^1 in TE and lOjag DNA was stored 
overnight in 410|xl H20  at 4°C.
On the day of the transfection the diluted DNA was incubated at 37°C for lh 60^1 2M 
CaCl2 was added dropwise to the DNA with continual mixing. Immediately the DNA- 
CaCl2 mixture was added dropwise into the 2XHBS (Appendix K) solution with continual 
mixing and left at room temperature for 30min to form a DNA-CaP04 mixture. The 
DNA-CaP04 mixture was added to the flask of cells (containing media) dropwise, swirling 
constantly to ensure even mixing. The cells were then incubated for 4h at 37°C after which 
time the cells were “shocked” with glycerol to aid the entry of the DNA into the cells. 
Glycerol-shocking was done by removing the media from the cells and adding 5ml of 10% 
glycerol in 1XHBS to the cells for 3min. The glycerol was then removed, the cells rinsed 
twice in 5ml serum-free media and then re-fed with 10ml fresh growth media and 
incubated for 2-3 days at 37°C.
2.14.3.1 Selection and Isolation of Colonies
In order to study the true effect of transfection studies, single colonies of stably 
transfected cells were selected and isolated. The selection process was carried out by 
feeding the “transfected” cells with media containing geneticin (Sigma; G9516) - the 
plasmids used had a geneticin-resistant gene, therefore, only those cells containing the 
plasmid will survive treatment with geneticin, 2 days after transfection the flask of cells 
was fed with 200(j,g/ml geneticin in complete media, when the cells grew readily in this 
concentration of selecting agent, the concentration was increased step-wise to a final 
concentration of 600^g/ml. At this stage the cells were plated at clonal density (see 
Section 2.6) and clonal populations were propagated, as described previously. Transfected 
cells were periodically challenged with geneticin to establish stability of transfectants.
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To assess the effect of the c-fos ribozyme in cells, the plasmid was induced by feeding 
cells in 5 |jM dexamethasone (Sigma; D1756) 24 hour prior to drug addition.
2.14.4 Induction of c-Fos Ribozyme
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Results
3.1 Design of Oligonucleotide Primers for RT-PCR Studies of Oncogene mRNAs
Primer pairs were designed to allow detailed analysis of the expression of a number of 
oncogenes, in multi-drug resistant cell lines and human tumours, in order to determine if 
any of these genes have a role to play in MDR in vitro or in vivo.
The genes chosen for study were those of the bcl-2 family, including bcl-2a, bcl-2/3, 
baxa, bax/3, bcl-xL and bcl-xs', also 3 nuclear oncogenes were studied, namely, c-fos, c- 
myc, c-jun; two other oncogenes, c-erbB-2 and c-Ha-ras 1, were also included in this 
study. All other primers used for the study of MDR-related genes have been published 
previously (O’Driscoll et a l,  1993).
/3-actin was used as a control in all reactions as it has previously been found to be most 
suitable for the study of mRNA expression in MDR-related studies (O’Driscoll et al., 
1993). Depending on the target length to be amplified, one of two pairs of PCR primers 
were used - a 383bp (previously published) or a 142bp /3-actin template was amplified in 
all reactions with the gene of interest. Some primers were co-amplified initially with /3-2- 
microglobulin (114bp product produced) as control.
All primers were chosen to conform to as many as possible of the guidelines discussed in 
Appendix A. The guideline that was adhered to most vigorously was that of sequence 
specificity with the uniqueness of each primer checked via the DNA data-base at EMBL. 
It was not possible to comply with all of the guidelines for each primer pair and the 
primers chosen were found to be the best compromise in each individual situation. All 
primers chosen maintain 100% homology with the gene in question. The primers chosen 
contain no common homologies with the internal control primers to amplify /3-actin. The 
specific criteria of base composition, length, Tm and amplified target length for each 
primer pair can be seen in Table 3.1.1 (see also Appendix A).
3.1.1 Examples of chosen Primer Pairs
The primers chosen for the amplification of members of the bcl-2 family of genes and the 
guidelines followed for their selection are discussed below.
(a) Bcl-2 a  and bcl-2(3
A common 5’primer for bcl-2 a  and bcl-2/3 but different 3’ primers were chosen (to 
distinguish the a- from the /2-form); this latter primer was chosen from different locations
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on the template, thus allowing both forms to be differentiated by size. The a- and /5-forms 
of bcl-2 are identical in exonl but have different second exons where a  has a very long 
3’untranslated region and /3 does not.
The 5’primer was chosen from exonl and the 3’primer of the a-form was chosen from 
exon2 (Figure 3.1.1.1). bcl-2 commonly forms a hybrid with immunoglobulin heavy chain 
transcripts as a result of t(14;18 translocations). These hybrids consist of the 5’ half of the 
bcl-2 mRNA fused to a “decapitated” Ig heavy chain mRNA. All of the break-points 
identified thus far in the bcl-2  a  gene have been found at the 3’ end of the second exon and 
care was taken not to include this region in the primers. Although these primers will not 
distinguish between an amplified sequence in a normal bcl-2 mRNA or the hybrid mRNA, 
no other common homologies between the primers were identified.
The 3’ primer of the yS-form was chosen from its second exon and no homology to the a- 
form was apparent. The primers were chosen from the open reading frame.
Figure 3.1.1.1 Gene structure o f bcl-2 a  and p  and location o f  primers chosen on template
—►► PCR primer
(b) B cI-Xl and  bel-x s
The bcl-x gene is transcribed to give two alternatively spliced forms of the gene, a long 
form (bcl-xL) and a short form (bcl-xs). The sequences of both transcripts are identical 
except that the shorter form has a central exon spliced from the mRNA. The primers used 
were designed to flank this missing exon and therefore could be used to amplify both 
templates and differentiate between them by size.
Figure 3 .1 .1 .2  Gene structure o f  bcl-xL and bcl-Xs and location o f primers chosen on template
bel-x T
bcl-xc
PCR primer
(c) Bax-a and bax-fi
When designing primers for the bax genes the 3’ region of the «-form was avoided as it 
was found to be highly homologous to other human sequences; to compensate for this a 
pair of common a/p  primers were chosen and also a specific 3’ primer to the fi-ibrm as 
the a- and /3-forms differ only in their 3’ regions, specifically in the sixth exon. The 3’ 
primer of the /Worm is very close to the 3’ end of the gene and this is important to note if 
analysing degraded mRNA.
The 5’ primer is located on exon3 and the 3’primer for a /ft on exon 5; the 3’ primer for 
the /Mbrm was chosen from exon6.
Figure 3 .1 .1 .3  Gene structure o f bax-a  and bax-fi and location o f primers chosen on template
•**— PCR primer
3.1.2 Trial Amplification and Restriction Digestion of Amplified Oncogene Products
Trial amplification of all genes to be studied by RT-PCR was carried out to ensure that 
each primer pair chosen amplified a specific cDNA, producing a single band of the 
predicted size. PCR reactions were set up as described in Section 2.10.8.1 using cDNA 
formed on mRNA templates extracted from a number of cell lines included in this study, 
some of which were known to express the specific cDNA in question.
All reactions were set up in duplicate and an endogenous control (fi-actin) was co- 
amplified with the required oncogene product. Primers to produce a short (3-actin band of 
142bp were included in the PCR reaction mix with primers for each of the following 
oncogenes; bcl-x, bax, bcl-2, c-fos, c-jun, c-myc and c-erbB-2. Co-amplification of c-Ha- 
rasl was carried out with (3-actin primers to amplify a band of 383bp. Results are shown 
in Fig. 3.1.2.1. (In preliminary studies /3-2-microglobulin (114bp band) was used as an 
internal control). Amplification of all products was successful, resulting in a single band 
of appropriate size (Figure 3.1.2.1).
An aliquot of each amplified product (after 30 cycles of PCR) was digested with an
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appropriate restriction enzyme. An example of these results (from DLKP variant cDNA 
analysis) is illustrated in Figure 3.1.2.1(i). Co-amplification of a 383bp /3-actin band is 
seen with bcl-2 (Figure 3.1.2.l(i)); /3-2-microglobulin internal controls (114bp) are 
included with the c-fos and c-erbB-2 digests (Figures 3.1.2.1(i)).
All PCR products are run with <|)X174/HaeIII digested DNA marker comprising of 1,353; 
1,078; 872; 603; 310; 281; 271; 234; 194; 118 and 72bp fragments.
3.2 Establishing Exponential PCR Cycle Range
To allow for semi-quantitative analysis of PCR products formed during the course of these 
studies, the exponential PCR cycle range for each primer pair described in Table 3.1.1 
was determined. cDNA formed on mRNA templates extracted from DLKP and DLKP-A 
cell lines, which were used as representative sensitive and drug resistant variants, 
respectively, were used in this analysis.
lOOjj.1 reaction volumes were set up in a tube for each PCR reaction and lOjil volumes 
were removed at a number of time points, ranging from 15 to 35 cycles. Exponential 
range studies were carried out in duplicate, from two independent RNA extractions. All 
results were analysed by densitometry.
A representative study is illustrated in Figure 3.2.1 of the exponential range of box 
expression in DLKP and DLKP-A.
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Gene Primer length 
(bases)
A + T :G + C Tm Amplified cDNA length 
(bases)
Diagnostic
R.E.
Restriction product 
length (bases)
Amplified DNA sequence length 
(bases)
Location on template 
(accession #)
bcl-2a (a) 22 11:11 66 306 BamHI 97+209 Not Known 1925-1946 (M13994)
(b) 24 14:10 68 2207-2230
bcl-2p (a) 22 11:11 66 145 Bam HI 97+48 Not Known 613-634 (M13995)
0>) 21 11:10 62 737-757
bcl-XL (a) 20 9:11 62 396 Bspl286I 235+161 Not Known 345-364 (L20121)
(b) 19 8:11 60 Kpnl 91+305 722-740
bcl-xs (a) 20 9:11 62 207 Kpnl 91 +116 Not Known 345-364 (L20122)
(b) 19 8:11 60 533-551
bax-a/p (a) 21 11:10 62 230 Pvun 88+142 Not Known 202-222 (L22473/4)
(b) 20 9:11 62 412-431
bax-p (a) 21 11:10 62 439 BamHI 251 +  188 Not Known 202-222 (L22474)
(b) 21 12:9 60 619-639
c-fos (a) 20 10:10 60 343 Hinfl 84+259 457 2514-2533 (K00650)
(b) 20 10:10 60 2951-2970
c-jun (a) 20 10:10 60 292 HmcII 178+114 292 234-253 (J04111)
(b) 20 10:10 60 506-525
c-rayc (a) 18 7:11 58 336 HaeUI 74 +262 1712 1154-1171 (V00568)
(b) 21 10:11 64 1469-1489
c-Ha-ras-1 (a) 20 10:10 60 129 FokI 65+64 302 2177-2196 (V00574)
(b) 19 8:11 60 2460-2478
c-erbB-2 (a) 20 10:10 60 332 Pvun 82+250 Not Known 2478-2497 (X03363)
(b) 20 10:10 60 2790-2809
p-Actin (a) 23 11:12 68 142 Fnu4HI 44+98 254 901-923 (X00351)
(b) 22 11:11 66 1021-1042
Table 3 .1 .1  Primers to am plify cDNA formed by reverse transcription on mRNA templates for oncogene expression analysis
Figure 3.1.2.1 Trial Amplification and Product Restriction of Oncogene Products
(a)
bcl-xL
(b) le) lw
t
h. -4  »
1
bcl-2a
[3-act in
(d)
S
(e)
c-fos
*  «  %• * *
p-actin
(0
c-jun
P-actin
c-mvc
P-actin
PCR Amplification for (a) b c l - X L  (396bp) and bcl-xs (207bp); ( b )  bax. (230bp); (c) bcl-2 (306bp); 
(d) c-tbs (343bp); (e) c-jun (292bp); (f) c-niyc (336bp); (g) c-erbB-2 (332bp) and (h) c-H a-rasl 
(129bp) co-amplitied with a 142bp (a-g) or 383bp (h) p-actin product. Restriction digest o f PCR 
products is shown in (i). All PCR products are run with <))Xi74/HaeIII digested DNA marker 
comprising of 1,353; 1,078; 872; 603; 310; 281; 271; 234; 194; 118 and 72bp fragments.
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Figure 3.2.1 Exponential Range of PCR Amplification for Bax Expression in DLKP and DLKP-A
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cDNA from DLKP® and DLKP-A (ii) was used as template to establish exponential phase for the amplification 
of the b o x  gene. 100|il reaction volumes were set up for PCR and 10j.il aliquots were removed after 15, 20, 23,
26, 30 and 35 cycles. Equal volumes for each cycle were run on agarose gels (a) and analysed by densitometry 
(b). This representative study would suggest semi-quantitative analysis of b a x  gene levels in DLKP and DLKP- 
A be carried out between 23 and 26 cycles of PCR.
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3.3 Analysis of mRNA Transcripts of Oncogene Products in Sensitive vs MDR Cell 
Line Variants of DLKP
Total RNA was extracted from the parental DLKP cell line and a number of well 
characterised resistant variants of that cell line, namely, DLKP-A (adriamycin selected 
variant), DLKP/VP-3, DLKP/VP-8 (VP-16 selected variant) and DLKP-C14 (carboplatin) 
cell lines (see Appendix D for fold resistance levels). This RNA was used as template for 
reverse transcription as described previously (Section 2.10.7.1). cDNA was analysed by 
PCR in the exponential phase for each of the following genes : bcl-x, bax, bcl-2, c-fos, c- 
jun, c-myc, c-erbB-2 and c-H-rasl.
The resulting bands were analysed to determine if any change in expression of these genes 
was evident between the sensitive parental cell line, DLKP, and DLKP-A, DLKP/VP-3 
DLKP/VP-8 or DLKP-C14 (see Figures 3.3.1 and 3.3.2). No analysis on c-jun levels is 
shown as this gene is intronless and mRNA amplification and DNA contamination could 
not be differentiated between by PCR analysis.
Initial observations revealed that bcl-xL gene expression was increased in the resistant lines 
studied; bax levels were also increased in the variants, however no expression of bcl-2 
was detected even after 30 cycles of PCR (Figure 3.3.1). Increased levels of c-erbB-2 was 
detected in all the resistant lines studied compared to the sensitive DLKP line, c-fos 
expression was increased only in the adriamycin selected line and not in those cell lines 
selected with carboplatin or VP-16, c-myc levels were increased in the DLKP-C14 line but 
decreased in the adriamycin and VP-16 selected lines. Slight alteration in c-Ha-rasl levels 
was evident under these conditions (Figure 3.3.2).
3.3.1 Expression of Oncogene Products in Clonal Populations of DLKP-A
DLKP-A is a well characterised heterogeneous population of an MDR cell line. Clonal 
populations with differing resistance profiles have previously been isolated from this 
resistant line (Heenan et al., 1997). In the current study total RNA isolated from the least 
resistant clonal population (DLKP-A2B) and the highest resistant population (DLKP-A5F) 
of DLKP-A was analysed by RT-PCR to determine if alterations in oncogene expression 
play a role in the development of sensitive and resistant populations within a single 
heterogeneous population.
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RT-PCR analysis after 30 cycles of PCR revealed differential expression of bcl-2a 
(referred to as bcl-2 in further analysis) mRNA in DLKP-A and the clonal variants 
analysed. Increased levels of c-fos were observed in both the DLKP-A and DLKP-A5F 
variants but not in DLKP-A2B cells relative to the parental DLKP-A cell line (Figure
3.3.1.1). RT-PCR analysis revealed differential expression of bcl-xL in the three resistant 
cell lines studied (Figure 3.3.1.2(a)). bcl-xL levels were increased in DLKP-A5F cells 
relative to DLKP-A2B cells. Analysis of bax-a/3 (referred to as box in further analysis) 
levels also revealed differential expression among the variants with increased levels seen 
in DLKP-A2B relative to DLKP-A and DLKP-A5F (Figure 3.3.1.2(b)). From these 
studies it was seen that the most sensitive clone, DLKP-A2B, had a higher bax:bcl-xL ratio 
than the most resistant DLKP-A5F clone. Higher levels of c-erbB-2 were detected in 
DLKP-A5F relative to DLKP-A2B cells, although the ratio of the clones to the parental 
DLKP-A cell line was seen to differ between reactions (Figure 3.3.1.3(a)). Elevated levels 
of c-Ha-rasl were observed in the DLKP-A5F clone as compared to DLKP-A and DLKP- 
A2B which had expressed similar amounts of c-Un-rasJ mRNA (Figure 3.3.1.3(b)).
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Figure 3.3.1 RT-PCR Analysis of Oncogene Expression in Resistant Variants of DLKP
(c)
bcl-2a
cDNA from DLKP (■), DLKP-C14 (■) (carboplatin-selected line), DLKP-A ( ) (adriamycin-selected 
cell line), DLKP-VP3 (■) and DLKP-VP8 (■) (VP-16-selected cell lines) was amplified by PCR for 
the expression of (a) b c l-X L  (23 cycles of PCR); (b) b c l - 2 a  (30 cycles of PCR) and (c) b o x - a ß  (23 
cycles of PCR). A 142bp ß-actin product was co-amplified in all PCR reactions. Densitometrie O.D.* 
is given as the ratio of the levels o f the specific gene product to the internal ß - a c t in  control and is 
normalised to 100% for DLKP. No bands were detected for the expression of b c l - 2 a * * .
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Figure 3.3.2 RT-PCR Analysis of Oncogene Expression in Resistant Variants of DLKP
(b)
c-myc
(3-actin
c-erbB-2
/3 -a c tin
c-fos
(3-actin
-
80.5
a
c
(3 -cictin
c - H a - r a s l
c - m y c
620
c - e r b B - 2
c-Ha-ras
cDNA from DLKP (■), DLKP-C14 (■), DLKP-A ( ), DLKP VP3 (■) and DLKP-VP8 (■) was 
amplified by PCR for the expression of (a) c - m y c  (25 cycles); (b) c - e r b B - 2  (24 cycles); (c) c - fo s  (30 
cycles) and (d) c - H a - r a s l  (30 cycles). A 142bp (3 -a c ttn  product is co-amplified with c - m y c , c - e r b B - 2  
and c - fo s  products. A 383bp (3 -a c tin  band is co-amplified with die c - H a - r a s l  product. Densitometric 
O.D.* is presented as the ratio of the levels o f specific gene product to the internal (3 -a c tin  control and
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Figure 3.3.1.1 RT-PCR Analysis of Oncogene Expression in DLKP-A and Clonal Variants
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□
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c - fo s c - fo s
cDNA from DLKP-A ( ), DLKP-A2B (■) and DLKP-A5F (■) was amplified by PCR for the 
expression of (a) b c l - 2 a  (30cycles of PCR) and (b) c - fo s  (30 cycles of PCR) from two independent 
RNA extractions. A 142bp or 383bp ß - a c t i n  product was co-amplified in all reactions. 
Densitometrie O.D.* is presented as the ratio of the levels of b c l - 2  and c - fo s  gene product to the 
internal ß - a c t i n  control and is normalised to 100% for DLKP-A.
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Figure 3.3.1.2 RT-PCR Analysis of Oncogene Expression in DLKP-A and Clonal Variants
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cDNA from DLKP-A, DLKP-A2B and DLKP-A5F was amplified by PCR for the expression of (a) 
bcl-X L  (23 cycles of PCR) and (b) b a x - a ß  (23 cycles o f PCR) from two independent RNA 
extractions. A 142bp ß - a c t i n  product was co-amplified in all reactions. Densitometrie O .D .* is 
presented as the ratio of the levels o f b c l - x  and b o x  gene product to the internal ß - a c t in  control and 
is normalised to 100% for DLKP-A.
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Figure 3.3.1.3 RT-PCR Analysis of Oncogene Expression in DLKP-A and Clonal Variants
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cDNA from DLKP-A ( ), DLKP-A2B (■) and DLKP-A5F (■) was amplified by PCR for the 
expression of (a) c - e r h B - 2  (2 5  cycles of PCR) and (b) c - H a - r a s l  (30 cycles) from two independent 
RNA extractions. A 142bp or 383bp ß - a c t in  product was co-amplified in all reactions. Densitometrie 
O.D.* is presented as the ratio of the levels of c - e r b B - 2  or c - H a - r a s l  gene product to the internal ß -  
a c t in  control and is normalised to 100% for DLKP-A.
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3.3.2 Western Blot Analysis of Oncogene Expression in Resistant Variants
Analysis of c-erbB-2, c-Fos and Bcl-x protein expression was performed using Western 
blotting techniques. Successful analysis was achieved using the Dako c-erbB-2 polyclonal 
antibody. Two specific bands were detected for this antibody (p i85 and p i70), in 
agreement with previous results (Slamon et al., 1989a). An increase in expression of c- 
erbB-2 protein was seen in DLKP-A, DLKP-A2B, DLKP-VP3 and DLKP-VP8 cell lines 
relative to the parental DLKP cell line (Figure 3.3.2.1(a)). c-erbB-2 protein levels were 
not found to be over-expressed in the DLKP-A5F cell line. Slightly elevated levels were 
seen in the DLKP-C14 cell line. Differential expression was seen between the two bands 
detected for the c-erbB-2 protein, the significance of this is unknown. The trend at the 
protein level is different to that previously seen at the mRNA level (Figure 3.3.2(b)). 
mRNA levels, as analysed by RT-PCR, of c-erbB-2 demonstrated overexpression of the 
gene in all the resistant variants of DLKP analysed with greatest overexpression observed 
in the DLKP-C14 cell line.
Nuclear protein extracts were used to analyse c-Fos levels in cells, limited success was 
achieved (Fig. 3.3.2.1(b)). A very faint band was seen for the 62kDa c-Fos protein in the 
DLKP cell line. Stronger bands were detected for the resistant variants. However, a band 
in the negative control was also seen at 62kDa for DLKP-A. Highest expression of c-Fos 
protein was seen in the DLKP-C14 cell line and to a lesser extent in the DLKP-A5F and 
VP-16-selected DLKP-VP3 and DLKP-VP8 variants. This was not the observed trend 
when mRNA levels were analysed (Figure 3.3.2(c) and Figure 3.3.1.1(b)) as c-fos mRNA 
was only detected in the DLKP-A and DLKP-A5F cell lines.
Total protein was analysed for the expression of Bcl-x protein by Western blotting without 
success (results not shown).
Analysis was carried out on one protein extraction from each cell line. Time constraints 
prevented further analysis.
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Figure 3.3.2.1 Western Blot Analysis of c-erbB-2 and c-Fos Expression in DLKP Variants
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(a) Total protein isolated fi'om DLKP, DLKP-A, DLKP-A2B, DLKP-A5F, DLKP-C14, DLKP- 
VP3 and DLKP-VP8 was analysed for the expression of c - e r b B - 2  protein using a 1:500 dilution of 
an anti-c-e/-6B-2 antibody (Dako). (b) Nuclear protein isolated from DLKP, DLKP-A, DLKP-A2B, 
DLKP-A5F, DLKP-CI4, DLKP-VP3 and DLKP-VP8 was analysed for the expression of c-Fos 
protein using an anti-c-Fos antibody at 2.5|.ig/iul (Calhiochem). Positive blots are shown in (a)(i) 
and (b)(i); negative controls are shown in (a)(ii) and (b)(ii).
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3.4 c-fos Ribozyme Transfection and Effect on Toxicity in DLKP-A cells
A c-fos-specific ribozyme was transfected into DLKP-A. Expression of this ribozyme was 
induced by dexamethasone. The transfection technique involved calcium-phosphate 
precipitation of the ribozyme onto monolayer cultured cells followed by glycerol shocking 
as described previously (Section 2.14.3). Six individual colonies were maintained as 
individual cell lines after selection in 600^g/ml geneticin. The resulting cell lines were 
designated DLKP-A//o.?RzB4, DLKP-A//o,sRzB5, DLKP-A//osRzB6, DLKP-A//asRzE2, 
DLKP-A//osRzC 11 and DLKP-A//b.vRzF3.
3.4.1 Adriamycin Toxicity Analysis of Transfected Clones
The toxicity profile of adriamycin in the c-fos ribozyme transfected cell lines revealed 
minimum effect of ribozyme induction on adriamycin toxicity in the selected cells. The 
ribozyme was induced with 5|iM dexamethasone (used previously by Funato et al., 1992) 
24 hours prior to addition of drug. The drug was added in dexamethasone supplemented 
medium. The IC50 of adriamycin in DLKP-A cells is in the order of 3.7^ig/ml which is 
substantially higher than that seen in any of the fos-ribozyme transfected clones (see 
Figure 3.4.1.1). As DLKP-A is composed of a mixed population of varying resistance 
levels it is not known whether transfection has selected inherently sensitive clones. The 
least resistant DLKP-A clone, DLKP-A2B, has an IC50 value of 0.5|ag/ml adriamycin 
whereas the most resistant clone, DLKP-A5F, has an adriamycin IC50 value of 4.8|ig/ml. 
A two-fold decrease in adriamycin resistance, as determined by comparing IC50 values, 
was seen in clones B6 (Figure 3.4.1.1(C)) and C ll (Figure 3.4.1.1(D)) when cells were 
treated with 5(iM dexamethasone (see Table 3.4.1.1); no decrease in toxicity was seen in 
the other clones isolated (Figure 3.4.1.1(A),(B),(E),(F)) when treated with 
dexamethasone.
Table 3.4.1.1 Adriamycin Toxicity Level in c-fos Ribozyme Transfected DLKP-A Cells
IC50 Hg/ml** ATCC (-Dex) ATCC (+D ex)*
DLKP-A 3.7
DLKP-A2B 0.5
DLKP-A5F 4.8 .......
DLKP-A/avRzB6 1.2 0.625
DLICP-A/avRzCl 1 0.5 0.25
**IC5o values for the fos ribozyme transfected cells is significantly lower than the value for the parental DLKP-A cell line with 
or without dexamethasone treatment. Treatment with 5jiM dexamethasone* for 24 hours reduced the ICjo values of the 
ribozyme-expressing cells two-fold. The parental DLKP-A cell lines were not analysed in the presence of dexamethasone.
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Figure 3.4.1.1 Adriamycin Toxicity Profile of c-fos Ribozyme Transfected Clones
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Adriamycin toxicity profile is shown for six clones of DLKP-A transfected with the c-fos ribozyme. 
Cells were pre-treated for 24 hours with 5(.iM dexamethasone (+D ex) to induce the ribozyme and then 
treated with adriamycin in dexamethasone-supplemented media. Control assays were set up without 
dexamethasone (-Dex).
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3.4.1.1 Transfection of DLKP-A5F with c-fos Rz and effect on Adriamycin Toxicity
To determine if a clearer result could be found on the effect c-fos ribozyme expression has 
on adriamycin toxicity in the DLKP-A cell line, DLKP-A5F, a highly resistant clonal 
population of DLKP-A shown to over-express c-fos when compared to DLKP, was 
transfected with the c-fos ribozyme using those methods described in Section 2.14.3. 
Individual colonies were not isolated from the transfected population.
The resulting transfected population, DLKP-A5F/asRz, was analysed, in the presence and 
absence of dexamethasone, for adriamycin toxicity levels. Results revealed no significant 
effect of c-fos ribozyme transfection on resistance levels in this cell line (Table 3.4.1.1.1).
Table 3.4.1.1.1 Adriamycin Toxicity (IC50) in DLKP-A5F c-fos Ribozyme Transfected Cells
DLKP-A5F DLKP-A5F/ojRz (-Dex) DLKP-A5F/0sRz (+Dex)
[ADR](ig/ml 1.9 ± 0.1 2.2 ±0.4 1.7+ 0.3
Adriamycin toxicity levels in DLKP-A5F cells and c-fos ribozyme transfected DLKP-A5F cells fed 
with (+Dex) or without (-Dex) 5fj.M dexamethasone as control.
3.4.2 RT-PCR Analysis of c-fos Ribozyme Variants
To determine if the c-fos ribozyme was induced by basal levels of dexamethasone in 
serum RNA was extracted from five of the ribozyme transfected clones which had not 
been treated with dexamethasone. RNA was also extracted from the cell lines following 24 
hour incubation in 5(iM dexamethasone. Results found show that the ribozyme is induced 
in some of the cell lines (E2, Cl l ,  B6) by basal levels of dexamethasone in serum (Figure 
3.4.2.1(a)). All cell lines analysed (except for control DLKP-A) expressed the ribozyme 
following dexamethasone treatment.
c-fos mRNA levels were also analysed in these cell lines (Figure 3.4.2.1(b)). Analysis 
revealed expression of the c-fos mRNA in all cell lines. However, expression was not 
detected in the C ll clone following dexamethasone treatment. These analyses were not 
repeated.
To determine if c-fos down-regulation affects mdrl levels in these clones, RT-PCR was 
carried out on the same RNA extractions for the expression of the mdrl gene. A band for 
the mdrl gene was detected for DLKP-A (following 20 cycles of PCR) but not for the c- 
fos ribozyme-expressing cell lines (Figure 3.4.2.1(c)). It is not known if this down-
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regulation in expression is due to inherently sensitive clonal sub-populations in the DLKP- 
A cell line or if it a result of the c-fos ribozyme expression.
Figure 3.4.2.1 RT-PCR Analysis in c-fos Ribozyme transfected DLKP-A cells
/3-actin
c-fosRz
/3-actin
mdrl
RT-PCR analysis, for the expression of (a) c - fo s  ribozyme (Rz), (b) c - f o s ,  (c) m d r l , on DLKP-A 
and c - f o s  ribozyme transfected clonal sub-populations DLKP-A/wRzE2 (E2), D L K P-A /arR zC ll 
(C l 1), DLKP-A/avRzB4 (B4), DLKP-A/avRzB5 (B5), DLKP-A/avRzB6 (B6), in the presence 
(+D E X ) and absence (-DEX) of 5j.iM dexamethasone for 24 hours.
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3.4.3 Culturing of DLKP-A//osi?zB6 in serum free media
As dexamethasone is a component of serum and the cell lines analysed in Section 3.4.1 
were grown in serum-supplemented media the true effect of the fos ribozyme may be 
masked, as it may already be induced in the cell lines without the need for supplemented 
dexamethasone (see Figure 3.4.2.1(a)). To reduce the effect of residual steroid levels in 
serum supplemented media, attempts were made to grow DLKP-A//osRzB6 cells in a 
serum free media developed in this laboratory (P.Meleady, 1997). This serum-free 
medium (Section 2.2.9) was developed to support the growth of the parental DLKP-A cell 
line. The cell line DLKP-A//ayRzB6 did not grow in this serum-free medium, however, 
and analysis of the true effect of fos ribozyme induction could not be determined.
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3.5 Analysis of Low-level MDR cell lines
The cell lines analysed in Section 3.3 are highly resistant cell lines and do not accurately 
reflect resistance levels seen in vivo. In order to establish if RT-PCR can detect low-level 
changes in resistance at the mRNA level, well characterised low-level resistant variants of 
an ovarian cell line, OAW42, were analysed by RT-PCR for the expression of common 
MDR markers such as mdrl, mrp, GSTtt, Topoisomerase I  and Topoisomerase IIa  
(Appendix C). Duplicate PCR reactions were prepared for each resistant variant, 
OAW42A, OAW42A1 (adriamycin-selected resistant lines) and the parental population 
OAW42SR (spontaneously resistant variant of OAW42) and OAW42S (a sensitive clone 
previously isolated in this laboratory from the parental OAW42 population). The 
OAW42A cell line is the most resistant variant and was established by further exposure of 
the OAW42A1 cell line to adriamycin (for fold resistance levels see Appendix D). The 
results of this analysis are shown in Figure 3.5.1.1. Analysis of mdrl levels revealed 
expression of the gene in the most resistant variants (OAW42A and OAW42A1) and to a 
lesser extent in OAW42SR, but not in the sensitive OAW42S line (Figure 3.5.1.1(a)). 
Expression of mrp (analysis shown in Figure 3.5.1.1(b)) and GSTtt (results not shown) 
mRNA was observed in all cell lines analysed, however, no consistent differential 
expression was evident between the sensitive and resistant variants. Decreased mRNA 
levels of Topoisomerase Ha  (Figure 3.5.1.1(c)) were observed in the more resistant lines 
relative to the OAW42S cells. Topoisomerase /  levels (Figure 3.5.1.1(d)) were decreased 
relative to the sensitive clone, OAW42S, but increased expression relative to OAW42SR 
was observed. Average densitometric values for each duplicate reaction is presented in 
Figure 3.5.1.1. Levels of bcl-x, bax, bcl-2 and c-fos were also analysed in these cell lines 
(Figure 3.5.1.2). c-fos expression was detected in the sensitive OAW42SR and OAW42S 
cell lines with decreasing levels observed in the resistant variants (Figure 3.5.1.2(d)); this 
is in direct contrast to the situation observed in the DLKP variants where over-expression 
of the c-fos gene was seen in highly resistant adriamycin-selected cell lines (Figure 
3.3.2(c) and Figure 3.3.1.1(b)) bcl-2 mRNA levels were also reduced in the resistant 
variants relative to the sensitive OAW42SR and OAW42S cells (Figure 3.5.1.2(a)). 
Decreased levels of bcl-xL and bax were seen in the resistant OAW42 variants (Figure 
3.5.1.2(b),(c)) compared to the sensitive variants.
3.5.1 Gene Expression Analysis by RT-PCR in Low-level Resistant Ovarian Cell Line
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Figure 3.5.1.1 RT-PCR Analysis of MDR-related Gene Expression in OAW42SR Variants
m r p
Topoisomerase I
cDNA from OAW42A (■) (adriamyin-selected variant of OAW42SR), OAW42A1 (■) (adriamyin- 
selected variant o f OAW42SR), OAW42SR ( ) and OAW42S (■) (sensitive clone from OAW42SR) 
was amplified by PCR for the presence of (a) m d r l ,  (b) m r p , (c) T o p o is o m e r a s e  I I a  and (d) 
T o p o is o m e r a s e  I . A 383bp ß - a c t in  product was co-amplified in all reactions. Densitometrie O .D.* is 
presented as the ratio of the levels of each specific gene product to the internal ß - a c t in  control and is 
normalised to 100% for OAW42SR.
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Figure 3.5.1.2 RT-PCR Analysis of Oncogene Expression in OAW42SR and Resistant Variants
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cDNA from OAW42A (■), OAW42A1 (■), OAW42SR ( ) and OAW42S (■) was amplified by PCR 
for the presence of (a) b c l - 2 a ,  (b) b c l - x t ,  (c) b a x - a ß  and (d) c - fo s . A 383bp ß - a c t in  product was co­
amplified in (a) and a 142bp ß - a c t in  product was amplified in all other reactions. Densitometrie 
O .D .* is presented as the ratio o f the levels of each specific gene product to the internal ß - a c t in  
control and is normalised to 100% for OAW42SR.
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3.5.2 Selection of Low-level MDR Cell Lines from A Clonal Cell Population
Adriamycin-selected resistant variants of a sensitive clonal population, DLKP-SQ, were 
selected during the course of this work by two methods described below.
3.5.2.1 Selection of Low-level MDR Cell Line by Continuous Exposure to 
Adriamycin
The clonal population DLKP-SQ was made resistant by stepwise selection in increasing 
concentrations of adriamycin as described in Section 2.5.1. The cells were initially 
exposed to 25ng/ml adriamycin continuously until they readily adapted to growth, at this 
concentration. At this stage the concentration was increased in a step-wise manner to 
approximately two-fold concentration of drug. This selection process was continued until 
the cells grew in 250ng/ml adriamycin, and were then maintained in the absence of drug. 
This selected cell line was designated DLKP-SQ/A250c (c for continuous exposure to 
drug). Analysis of resistance stability was not addressed for this cell line.
3.5.2.2 Selection of Low-level MDR Cell Line by Pulse Exposure to Adriamycin
A concentration of adriamycin (250ng/ml) shown to be clinically attainable in blood 
(Piscitelli et al., 1993) was used to develop a resistant variant of DLKP-SQ by pulse 
exposure. A number of time schedules, with the selecting drug concentration, were 
attempted in the development of a selected line, including selection for 1, 4, 8, 24 and 48 
hours. Pulses were repeated once every week. Following the first pulse only those cells 
which had been exposed to drug for 1 and 4 hours maintained some degree of viability; no 
cells survived following exposure to drug for 24 or 48 hours. Although an individual 
colony survived from the cells that were exposed to drug for 8 hours, further propagation 
in the absence of adriamycin did not result in increased resistance when compared to 
DLKP-SQ (this line was called DLKP-SQ/lx8h ADR) (Figure 3.5.2.2.1(C)). A slight 
increase in resistance was noted when DLKP-SQ/ lx8h ADR was compared to the DLKP 
mixed population which is slightly more sensitive to drug than the DLKP-SQ cell line 
(Figure 3.5.2.2.1(C)). Cells exposed to drug for 1 and 4 hours were further treated with 
drug for at least 4 pulses after which time toxicity was assessed. DLKP-SQ/4xlh ADR 
(DLKP-SQ exposed to ADR for four 1 hour pulses) was not found to have increased
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resistance compared to the parental population DLKP-SQ (Figure 3.5.2.2.1(B)). DLKP- 
SQ/4x4h ADR (DLKP-SQ exposed to ADR for four 4 hour pulses) was found to have 2 
fold increased resistance over DLKP-SQ (see Table 3.5.2.2.1); further pulses with ADR 
did not result in any significant increase in resistance levels(DLKP-SQ/8x4h ADR) 
(Figure 3.5.2.2.1(D)).
Repeat exposure of DLKP-SQ to 250ng/ml adriamycin for four weekly pulses resulted in 
the development of a 4 fold resistant variant and this line was called DLKP-SQ/A250p (p 
for pulse exposure) (Figure 3.5.2.2.1(E)). Further pulsing of this variant with 250ng/ml 
adriamycin, until the cells grew in this concentration of drug, resulted in the development 
of the DLKP-SQ/A25010p variant (after 10 pulses); this variant was found to be more 
resistant than the A250p variant (Figure 3.5.2.2.1(F)). Repeat selection of DLKP-SQ with 
adriamycin resulted in a similarly resistant cell line named DLKP-SQ/A25010p2 (Table
3.5.2.2.3). Selection of another clonal population of DLKP, namely DLKP-I, under the 
same conditions resulted in the development of a resistant variant, DLKP-I/A25010p 
(Table 3.5.2.2.3).
Selection of cells with adriamycin results in the establishment of a multiple drug resistance 
phenotype where cells are cross-resistant to adriamycin, the epipodophyllotoxins, the 
vinca alkaloids and taxol among others but are not cross-resistant to drugs such as 5- 
fluorouracil or the platinum compounds. The resistant variants of DLKP-SQ and DLKP-I 
established in these studies demonstrate this specific cross-resistance profile (Table
3.5.2.2.1 and 3.5.2.2.3). Although the lower resistant variant, DLKP-SQ/4x4hADR, 
showed similar levels of cross-resistance to adriamycin, vincristine and VP-16 (Table
3.5.2.2.1), the variants with greater resistance profiles (DLKP-SQ(I)/A25010p) showed 
alterations in cross-resistance levels with the greatest increase in resistance seen for 
vincristine, to a lesser extent for adriamycin, and lowest resistance to VP-16 (Table
3.5.2.2.4). A similar cross-resistance profile was evident in the resistant variants of DLKP 
and OAW42SR developed by continuous exposure to adriamycin (see Appendix D).
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Figure 3.5.2.2.1 Pulse selection of DLKP-SQ with Adriamycin
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Table 3.5.2.2.1 Fold Resistance of DLKP-SQ/4x4hADR compared to DLKP-SQ
[ADR] [VP-16] [VNC] [CBP] [5-FU]
DLKP-SQ/4x4hADR 2.23 ± 0.28 2.31 ± 0.31 2.53 ± 0.41 1.34 ± 0.58 1.0 ± 0
Fold resistance levels of DLKP-SQ/4x4hADR (adriamycin pulse-selected variant established after 
exposure of DLKP-SQ to four weekly four hour pulses of 250ng/ml adriamycin) for adriamycin 
(ADR), VP-16, vincristine (VNC), carboplatin (CBP) and 5-fluorouracil (5-FU) relative to DLKP- 
SQ.
Table 3.5.2.2.2 Adriamycin ICS0 Values (ng/ml) for Low-level Resistant DLKP-SQ cell lines
DLKP-SQ DLKP-SQ/A250p DLKP-SQ/A2501Op DLKP-A250C
IC50 13.9 ± 3.5 73.6 ± 8.5 139.2 ± 58.8 323
Adriamycin toxicity levels of adriamycin-selected resistant variants of DLKP-SQ established after 
four (DLKP-SQ/A250p) and ten (DLKP-SQ/A25010p) weekly pulse exposures (of 250ng/ml 
adriamycin for 4 hours) and continuous selection (to a final concentration of 250ng/ml 
adriamycin).
Table 3.5.2.2.3 ICso values of resistant variants of DLKP-SQ and DLKP-I
[ADR]ng/ml [VNC]ng/ml [VP-16]ng/ml [5-FU] fig/ml
DLKP-SQ 13.9 + 3.5 1.1 ±0.4 333.3 ± 100.0 0.7 ±0.4
DLKP-SQ/A25010p 139.2158.8 47.2 ± 15.7 980.4 ±454.3 1.4 ± 1.1
DLKP-SQ/A25010p2 110.6 + 60.2 33.1 ±28.6 1058.5 ± 153.4 0.7 ±0.1
DLKP-I 10.0 ±2.4 2.7 ±0.4 171.8 ± 71.4 0.9 ±0.2
DLKP-I/A25010p 165.6 ± 119.8 161.5 ± 50.2 598.0 ± 164.0 0.7 ±0.5
Toxicity profile of resistant variants of DLKP-SQ (DLKP-SQ/A25010p and DLKP-
SQ/A25010p2(repeat selection)) and DLKP-I (DLKP-I/A25010p) developed by ten weekly 
exposures to 250ng/ml adriamycin for 4 hours.
Table 3.5.2.2.4 Fold Resistance of DLKP-SQ and DLKP-I Resistant Variants.
[ADR] [VNC] [VP-16] [5-FU]
DLKP-SQ/A25010p* 10.0 ±4.2 42.9 ±14.3 2.9 ±1.4 2.0 ± 1.6
DLKP-SQ/A25010p2* 8.0 ±4.3 30.1 ±26.0 3.2 ±0.5 1.0 ± 0.1
DLKP-I/A25010p** 16.6 ± 12.0 59.8 ± 18.6 3.4 ± 1.0 0.8 ±0.6
Fold resistance profile of resistant variants of DLKP-SQ/A2501 Op and DLKP-SQ/A2501 Op2 (repeat 
selection), relative to DLKP-SQ*, and DLKP-1/A25010p, * Relative to DLKP-I, developed by ten 
weekly exposures to 250ng/ml adriamycin for 4 hours.
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3.5.2.2.1 Stability of the DLKP-SQ/A25010p Cell Line
To determine if the resistant phenotype of the DLKP-SQ/A25010p cell line was stable 
following sub-culturing and freezing of cells, adriamycin toxicity levels were analysed in the 
resistant variant over a range of five passages and six months following freezing. Initial 
toxicity analysis on this cell line prior to freezing produced an IC50 value of 113.8 ± 6.6ng/ml 
adriamycin at passage 38. Two months following freezing analysis was repeated on passage 38 
and an IC50 value of 80ng/ml adriamycin was obtained. These cells were maintained in culture 
for four to six weeks and analysed by three consecutive toxicity assays, the average result of 
which can be seen in Figure 3.5.2.2.1.1 (value obtained in analysis in Table 3.5.2.2.3). The 
passage numbers used in this analysis ranged from passage 40 to 43. A stable adriamycin 
resistance profile was seen following two months of freezing. Further analysis of the latter 
passages of cells following six months storage in liquid nitrogen revealed a stable adriamycin 
resistant phenotype also. Therefore, this pulse selected cell line maintained stable resistance 
over six months storage in liquid nitrogen.
The stable resistance profile of DLKP-SQ/A2501 Op, maintained throughout the course of this 
work without further exposure to adriamycin, is also supported by similar resistance levels of 
clonal populations of the cell line (C.O’Loughlin, pers.comm.).
Figure 3.5.2.2.1.1 Stability of Adriamycin Resistance in DLKP-SQ/A25010p Cell Line
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two (2months,post-freezing) and six (6months,post-freezing) months post-freezing and maintained in 
culture without further exposure to adriamycin.
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3.5.2.3 RT-PCR Analysis of Low-level DLKP-SQ Resistant Variants
RT-PCR analysis was carried out on mRNA extracted from the low-level resistant variants 
selected from the parental DLKP-SQ cell line. RNA extracted from DLKP-SQ/A250p, 
DLKP-SQ/A25010p and DLKP-SQ/A250c was analysed by RT-PCR for the expression of 
m drl, c-erbB-2, bcl-x, bax and c-fos gene levels.
The results obtained indicate an increase in m drl expression in DLKP-SQ/A250c and to a 
lesser extent in DLKP-SQ/A25010p (Figure 3.5.2.3.1(a)) relative to DLKP-SQ. No 
increase in m drl levels was seen in the DLKP-SQ/A250p cell following 25 cycles of PCR 
(Figure 3.5.2.3.1(a)) although further amplification to 30 cycles resulted in a slight 
increase in m drl mRNA levels (results not shown). Levels of c-fos were also found to be 
elevated in the resistant variants, but most obviously in DLKP-SQ/A25010p (Figure 
3.5.2.3.1(b)). Previous results on the DLKP resistant variants have shown elevated levels 
of c-fos in the adriamycin-selected lines expressing the highest levels of m drl mRNA 
(Figure 3.3.1.1(b) and Appendix E); the results on the DLKP-SQ variants suggest that this 
is not the case and that higher levels of c-fos are seen in the pulse-selected cell line when 
compared to the continuously-selected variant, although higher m drl levels are seen in the 
latter cell line. Analysis of bcl-xL and bax levels in these variants have shown greater 
expression in the resistant variants relative to the sensitive DLKP-SQ cell line (Figure 
3.5.2.3.2(a),(b)); this was also seen for the resistant variants of DLKP (Figure 3.3.1). 
Initial studies revealed little alteration in c-erbB-2 levels between variants (Figure 
3.5.2.3.3(ai)) however further extractions have shown increased c-erbB-2 expression in 
DLKP-SQ/A25010p relative to DLKP-SQ (Figure 3.5.2.3.3(aii)). The poor amplification 
of (3-aclin mRNA in the former reaction (Figure 3.5.2.3.3(ai)) may account for the 
absence of observed alteration of c-erbB-2 mRNA levels in the cell lines.
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Figure 3.5.2.3.1 RT-PCR Analysis of Low-level DLKP-SQ Resistant Variants
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cDNA from DLKP-SQ (■), DLKP-SQ/A250p (■), DLKP-SQ/A25010p ( ) and DLKP-SQ/A250c (□) 
was amplified by PCR for the expression of (ai) mdrl (25 cycles of PCR) and (bi) c-fos (30 cycles of 
PCR). Further analysis on repeat extractions of DLKP-SQ and DLKP-SQ/A25010p was also carried 
out ((aii) and (bii)). Densitometrie O.D.* is presented as mdrl I c-fos; ß-actin and is normalised to 
100% for DLKP-SQ.
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Figure 3.5.2.3.2 RT-PCR Analysis of Low-level DLKP-SQ Resistant Variants
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cDNA from DLKP-SQ (ß), DLKP-SQ/A250p (■), DLKP-SQ/A25010p ( ) and DLKP-SQ/A250c (□) 
was amplified by PCR for the expression of (ai) bcl-x (25 cycles of PCR) and (bi) box (25 cycles of 
PCR). Further analysis on repeat extractions from DLKP-SQ and DLKP-SQ/A25010p was also 
carried out ((aii) and (bii)). Densitometrie O.D.* is presented as bcl-x/bax:ß-actin and is normalised 
to 100% for DLKP-SQ.
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Figure 3.5.2.3.3 RT-PCR Analysis of Low-level DLKP-SQ Resistant Variants
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cDNA from DLKP-SQ (■), DLKP-SQ/A250p (■), DLKP-SQ/A25010p ( ) and DLKP-SQ/A250c (C) 
was amplified by PCR for the expression of (ai) c-erbB-2 (25 cycles of PCR). Further analysis on 
repeat extractions of DLKP-SQ and DLKP-SQ/A25010p was also carried out (aii). Densitometrie 
O.D.* is presented as c-erbB-2:ß-actin and is normalised to 100% for DLKP-SQ.
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3.5.2.4 Analysis of P-glycoprotein levels in DLKP-SQ Variants
P-glycoprotein protein expression was analysed in DLKP-SQ, DLKP-SQ/A250p, DLKP- 
SQ/A2501 Op and DLKP-A250c. Protein expression was detected at a similar level in 
DLKP-SQ, DLKP-SQ/A250p and DLKP-SQ/A25010p. Greater expression was seen in the 
DLKP-SQ/A250c variant (Figure 3.5.2.4.1). DLKP-SQ/A250c also showed the greatest 
overexpression of m drl mRNA (Figure 3.5.2.3.1(a)). Elevated m drl mRNA was also 
observed in the DLKP-SQ/A25010p cell line (Figure 3.5.2.3.1(a)) although 
overexpression was not obvious at the protein level.
Figure 3.5.2.4.1 P-glycoprotein Expression in DLKP-SQ Resistant Variants
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P-glycoprotein expression in DLKP-SQ and the adriamycin-selected variants DLKP-SQ/A250p, 
DLKP-SQ/A25010p and DLKP-SQ/A250c. Positive blot is shown in (i) and control blot (without 
primary antibody) is seen in (ii).
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3.S.2.5 Adriamycin Uptake in DLKP-SQ Variants
Alterations in drug uptake and accumulation is a hallmark of drug resistance. To 
determine if alterations in drug accumulation were associated with the drug resistance 
profile seen in the DLKP-SQ resistant variants, adriamycin uptake was monitored in the 
resistant cell lines. DLKP-SQ, DLKP-SQ/A25010p and DLKP-SQ/A250c were incubated 
in 10f.iM adriamycin for 4.5 hours. Cells were then washed free of any residual drug. 
Cells were viewed under ultraviolet light; at this wavelength adriamycin appears as bright 
orange fluorescence. Sensitive cells accumulate adriamycin mainly in the nucleus whereas 
resistant variants accumulate less drug and it is concentrated in the cytoplasm; degree of 
drug accumulation is indirectly proportional to the level of cellular resistance. In the 
sensitive cell line DLKP-SQ, bright nuclear fluorescence was evident (Figure 
3.5.2.5.1(a)). Minimal cytoplasmic fluorescence was visible, most likely due to the length 
of incubation in drug. The resistant variant, DLKP-SQ/A25010p, is clear of nuclear 
fluorescence and the adriamycin was seen to accumulate in the cytoplasm (Figure 
3.5.2.5.1(b)). The more resistant cell line DLKP-SQ/A250c had no nuclear accumulation 
of adriamycin (Figure 3.5.2.5.1(c)) and less cytoplasmic accumulation of adriamycin than 
the pulse-selected variant, DLKP-SQ/A25010p.
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Figure 3.5.2.5.1 Adriamycin Uptake in DLKP-SQ Variants
(a) (b)
DLKP-SQ variants were exposed to IO|_iM adriamycin for 4.5 hours, drug was then removed and 
cells washed free of any residual drug. Adriamycin uptake is observed as orange fluorescence. 
Adriamycin accumulation is observed in the nucleus of DLKP-SQ (a) but is greatly reduced in the 
adriamycin-resistant pulse variant DLKP-SQ/A25010p (b) where cytoplasmic staining is observed. 
The more highly resistant cell line DLKP-SQ/A250c (c) shows no nuclear fluorescence and some 
cytoplasmic fluorescence.
3.5.2.6 Effect of Co-treatment on Adriamycin Toxicity in DLKP-SQ/A25010p Cells
DLKP-SQ and DLKP-SQ/A25010p were analysed for the effect cyclosporin A (an 
inhibitor of P-glycoprotein), emodin (shown previously to affect the activity of c-erbB-2) 
and genistein (a tyrosine kinase inhibitor) had on adriamycin toxicity in these cell lines. 
DLKP-SQ cells were treated with 15ng/ml adriamycin and DLKP-SQ/A25010p were 
treated with 150ng/ml adriamycin in a 7 day 96-well toxicity assay in triplicate (set up on 
the same day) (see Figures 3.5.2.6.1 and .2). The sensitive and resistant cell lines were 
co-treated with three different concentrations of cyclosporin A (2|j.g/ml; 1 ug/ml or 
0.5|a.g/ml), genistein (15jiM, 7.5jiM or 3.75(.iM) or emodin (25^M, 12.5pM or 6.25pM).
Increasing concentrations of cyclosporin A had a dramatic effect on the toxicity of 
adriamycin in the DLKP-SQ/A25010p cells, the highest concentration (2ug/ml) decreased 
cell survival from 90.9% (cyclosporin A alone) to only 4.9% (cyclosporin A and 
adriamycin) (Table 3.5.2.6.1), implying that P-glycoprotein plays a prominent role in the 
development of resistance in these cells. Cyclosporin A also affected survival in the 
DLKP-SQ cell line but the effect seen was less dramatic and less dependent on 
concentration of cyclosporin A (Table 3.5.2.6.1). The average of the results for three 
toxicity plates set up on the same day is given in Table 3.5.2.6.1
Table 3.5.2.6.1 Effect of CyclosporinA on Adriamycin Toxicity in DLKP-SQ variants.
% growth DLKP-SQ DLKP-SQ/A25010p
control 100* 100*
adriamycin 79.9 ±4 .1 87.3 ± 7 .9
cyclosporinl 88.0 ± 2 .8 98.1 ± 3 .2
cyclosporinl + adriamycin 63.1 ± 5 .0 60.0 ± 1 .2
cyclosporin2 90.5 ± 2 .2 96.4 ± 4 .0
cyclosporin2 + adriamycin 58.1 ± 1.2 20.5 ± 3 .0
cyclosporin3 82.6 ± 5 .4 90.9 ± 1 .2
cyclosporin3 + adriamycin 46.7 ± 4 .7 4.9 ± 1 .4
DLKP-SQ and DLKP-SQ/A25010p were exposed to 15ng/ml and 150ng/ml adriamycin, 
respectively. Control survival is given as 100% growth (100*) in the absence of any drug for each 
plate analysed. Three concentrations of cyclosporin A - 0.5ug/ml (cyclosporinl); 1.0|ig/ml 
(cyclosporin2) or 2.0p.g/ml (cyclosporin3) - were used with both cell lines.
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Increasing concentrations of genistein also increased the effect co-treatment of genistein 
and adriamycin had on survival in the DLKP-SQ/A25010p and DLKP-SQ cell line (Table 
3.5.2.6.2) but to a lesser extent than that seen for cyclosporin A. At higher concentrations 
of genistein the effect was lost as genistein alone caused dramatic cell kill. Co-treatment of 
cells with emodin and adriamycin over seven days did not enhance the toxicity of 
adriamycin in DLKP-SQ or DLKP-SQ/A25010p cell lines (Table 3.5.2.6.3).
Table 3.5.2.6.2 Effect of Genistein on Adriamycin Toxicity in DLKP-SQ variants.
% growth DLKP-SQ DLKP-SQ/A25010p
control 100* 100*
adriamycin 80.5 ± 1.3 93.9 ± 2 .4
genisteinl 72.6 + 0.7 84.7 ± 7 .4
genisteinl + adriamycin 41.8 + 8.3 57.1 ± 3 .8
genistein2 36.4 + 1.7 61.3 ± 5.1
genistein2 + adriamycin 2 4 .1 + 2 .5 38.5 ± 5 .4
genistein3 1.0 ± 1 .0 2 2 .1 + 2 .5
genistein3 +  adriamycin 1.4 ± 1.0 14.4 + 0.7
DLKP-SQ and DLKP-SQ/A25010p were grown in 15ng/ml and 150ng/ml adriamycin, 
respectively. Control survival is given as 100% growth (100*) in the absence of any drug for each 
plate analysed. Three concentrations of genistein - 3.75p.M (genisteinl); 5.7 /j.M (genistein2) or 
15uM (genistein3) - were used with both cell lines.
Table 3.5.2.<5.3 Effect of Emodin on Adriamycin Toxicity in DLKP-SQ variants.
% growth DLKP-SQ DLKP-SQ/A25010p
control 100* 100*
adriamycin 73.8 ± 7 .3 92.4 ± 3 .0
emodinl 84.9 ± 6 .0 90.7 ± 13.8
emodinl + adriamycin 60.2 ± 7 .4 89.9 ± 7 .6
emodin2 54.2 ± 6 .3 72.5 ± 5 .2
emodin2 + adriamycin 41.6 ±8 .1 68.7 ± 6 .3
emodin3 2.8 ± 2 .6 3.5 ± 1 .9
emodin3 + adriamycin 3.0 ± 2 .6 5.4 ± 0 .9
DLKP-SQ and DLKP-SQ/A25010p were exposed to 15ng/ml and 150ng/ml adriamycin, 
respectively. Control survival is given as 100% growth (100*) in the absence of any drug for each 
plate analysed. Three concentrations of emodin - 6.25fiM (emodinl); 12.5jjM  (emodin2) or 25fxM 
(emodin3) - were used with both cell lines.
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Figure 3.5.2.6.1 Enhancement of Adriamycin Toxicity in DLKP-SQ
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DLKP-SQ cells were analysed in a 96-well toxicity assay co-treated with 15r]g/ml adriamycin (ADR) 
and (a) 0.5ug/ml (cycl), 1.0|ag/ml (cyc2), 2.0(ig/ml (cyc3) cyclosporinA; (b) 3.75|iM (genl), 7.5(iM 
(gen2), 15|iM (gen3) and (c) 6.25|iM (emodl), 12.5j.iM (emod2), 25 (.iM (emod3) emodin.
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Figure 3.5.2.6.2 Effect of Co-treatment on Adriamycin Toxicity in DLKP-SQ/A25010p
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DLKP-SQ/A25010p cells were analysed in a 96-well toxicity assay co-treated with 150r]g/ml 
adriamycin (ADR) and (a) 0.5 fig/ml (cycl), l.O^g/ml (cyc2), 2.0|.ig/ml (cyc3) cyclosporinA; (b) 
3.75|iM (genl), 7.5^M (gen2), 15p.M (gen3) and (c) 6.25|iM (emodl), 12.5|aM (emod2), 25|jM  
(emod3) emodin.
■  p l a t e  1
■  p l a t e  2
■  p l a t e  3
126
3.6 Transfection of Bel-xs cDNA and Effect on Toxicity in DLKP-SQ/A25010p cells
The bcl-Xs cDNA was transfected into DLKP-SQ/A25010p cells by the calcium phosphate 
method (Section 2.14.3). Five colonies were maintained as individual cell lines following 
selection in 600^g/ml geneticin. The resulting cell lines were designated DLKP- 
SQ/A25010p-2>dxs.l (clonel), DLKP-SQ/A25010p-6ctcs.2 (clone 2), DLKP-SQ/A25010p- 
bclxs.3 (clone 3), DLKP-SQ/A25010p-&cfcc5.4 (clone 4) and DLKP-SQ/A25010p-fcdxs.5 
(clone 5).
3.6.1 Toxicity Profile of Bcl-xs Transfected Clones
Toxicity analysis of four of the bcl-xs  transfected clones was carried out for adriamycin, 
vincristine, VP-16 and 5-fluorouracil and the results shown in Table 3.6.1.1. Clones 1 and 
4 showed a slight decrease in toxicity to adriamycin, vincristine and VP-16. Clone 2 
showed a slight increase in resistance to adriamycin and VP-16 but a two-fold increase in 
vincristine resistance. Clone 3 showed a much greater sensitivity to the three multi-drug 
resistance drugs, vincristine, VP-16 and adriamycin, the decrease being most significant 
for adriamycin. No significant alteration was seen in sensitivity to 5-fluorouracil in any of 
the clones analysed.
3.6.2 RT-PCR Analysis of Bel-xs Transfected Clones
RT-PCR analysis for the expression of bcl-xs  was carried out on the five clones. Analysis 
revealed the presence of a 207bp bcl-xs band in all five clones (Figure 3.6.2.1). The 
greatest expression was seen in clone 3 which showed the greatest reversion to sensitivity 
of the four clones analysed (Table 3.6.1.1). RT-PCR analysis of m drl expression in the 
least resistant clone (DI .KP-SQ/A250 lOp-fecfe. 3) did not reveal any alteration in m drl 
levels when compared to the parental DLKP-SQ/A25010p (result not shown).
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Table 3.6.1.1 Toxicity Profile of DLKP-SQ/A25010p-bclxs transfected clones
IC50 [ADRlng/inl [VNC]ng/ml [VP-16]ng/ml [5’FU]|j,g/mI
DLKP-SQ 13.9 ± 3 .5 1.1 ± 0 .4 333.3 ± 100.0 0.7 ± 0 .4
D LKP-SQ/A2501 Op 139.2 ±58.8 47.2 ± 15.7 980.4 ±454.3 1.4 ± 1.1
DLKP-SQ/A25010p-bclxs. 1 100.0 ± 28.4 34.7 ± 2 .9 736.2 ±298.1 0.8 ± 0 .5
DLKP-SQ/A25010p-bclxs.2 177.5 ±94.3 101.2 ±7 .6 1269.3 ±881.7 0.8 ± 0 .4
DLKP-SQ/A25010p-bclxs.3 46.7 ± 10.7 28.9 ± 9 .9 437.5 ±212.6 0.8 ± 0 .5
DLKP-SQ/A25010p-bclxs.4 100.9 ±42.5 45.3 ± 18.8 851.3 ±509.8 1.2 ± 1.0
Toxicity profile of DLKP-SQ/A25010p cells transfected with the bcl-Xs cDNA.
Figure 3.6.2.1 RT-PCR Analysis of Bel-x s transfected DLKP-SQ/A25010p clones
Expression of bcl-xs in DLKP-SQ/A25010p cells transfected with the bcl-xs cDNA. Parental cell 
line (DLKP-SQ/A25010p) is shown in the first lane. DLKP-SQ/A25010p-bd-\‘s . l , .2, .3, .4 and .5 
are named as lOpxs. 1, .2, .3, .4 and .5, respectively.
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3.7 Adriamycin selection of an mdrl ribozyme expressing DLKP clone
A clonal population of DLKP, DLKP-I, was transfected previously with an mdrl 
ribozyme plasmid (S.McBride, 1995). No significant change in toxicity profile was seen 
in the transfected clone (Table 3.7.1). The clone which most strongly expressed the 
ribozyme, DLKP-IwdriRz2D4 (as determined by S.McBride, 1995) was used in this 
study to determine if the presence of m drl is essential in the development of resistance in 
this cell line.
The parental line, DLKP-I, and the m drl ribozyme expressing clone, DLKP-Imdr/Rz2D4, 
were exposed to ten weekly four-hour exposures of 250ng/ml adriamycin. Both cell lines 
developed resistance as shown in Table 3.7.1. Selection of DLKP-I with adriamycin 
resulted in the development of a 16 fold adriamycin-resistant variant, DLKP-I/A25010p. 
Selection of the m drl ribozyme expressing clone produced a 10-fold adriamycin resistant 
cell line, DLKP-Iwi/r/Rz2D4/A25010p.
3.7.1 RT-PCR Analysis of DLKP-I Resistant Variants
RT-PCR analysis was carried out on DLKP-I and DLKP-ImdriRz2D4 and their resistant 
variants. Levels of m drl cDNA were faintly detected in the sensitive cell lines, after 30 
cycles of PCR, and were increased in DLKP-I/A25010p and to a lesser extent in DLKP- 
ItfZ£/riRz2D4/A25010p (Figure 3.7.1.1). This change in m drl levels in the resistant 
variants was not significantly expressed in toxicity levels of these cell lines to adriamycin 
or vincristine, two P-glycoprotein-associated drugs (Table 3.7.1). Technical difficulties 
prevented the detection of the m drl ribozyme in these cell lines. However, the ribozyme- 
transfected cells did grow in the presence of geneticin.
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Table 3.7.1 Toxicity Profile of DLKP-I Variants
IC50 [ADR]ng/ml [VNC]ng/ml rVP-16]ng/ml [5’FU]ng/ml
DLKP-I 10.0 ± 2 .4 2.7 ± 0 .4 171.8 ± 71.4 0.9 ± 0 .2
DLKP-I/A2501 Op 165.6 ± 119.8 161.5 ±50.2 598.0 ± 164.0 0.7 ±0.5
DLKP-I/raWRz2D4 9.8 ±5 .6 2.7 ± 0 .4 199.7 ±45.6 1.6 ± 0.5
DLKP-Iwk//'/ Rz2D4/ A2501Op 103.7 + 54.3 189.0 ±42 .4 446.7 ±47.1 2.1 ±0.1
Toxicity profile of DLKP-I and resistant variant, DLKP-I/A25010p, and an mdrl ribozyme expressing 
clone, D LK P l/ndrlRz2D4, and its resistant variant, DLKP-Iwi/riRz2D4/A25010p. Resistant variants 
were developed by pulse exposure of the sensitive parental cells to ten weekly four hour pulses of 
250ng/ml adriamycm.
Figure 3.7.1.1 RT-PCR Analysis of mdrl Gene Expression in DLKP-I Variants
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cDNA extracted from DLKP-I (■), DLKP-I/A25010p (■), DLKP-lmdrlRz2D4 ( ) (DLKP-IRz), and 
DLKP-lmi//'/Rz2D4/A25010p (■) (DLKP-IRz/A25010p) was analysed for the expression of the mdrl 
gene. A 383bp fi-aclin product was co-amplified in all reactions. Densitometric O.D.* is presented as 
the ratio of the levels of each specific gene product to the internal p-actin control and is normalised to 
100% for DLKP-I.
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3.7.2 Adriamycin Uptake in DLKP-I Variants
To determine if the difference in m drl expression seen in the resistant variants of DLKP-I 
and DLKP-Ittidr/Rz2D4 affected drug accumulation as a means of resistance, adriamycin 
accumulation was analysed in the sensitive and resistant variants. Adriamycin uptake 
analysis in DLKP-I and DLKP-I/A25010p and DLKP-Imdr/Rz2D4 and DLKP- 
hndr/Rz2D4/A25010p showed a dramatic decrease in nuclear accumulation of adriamycin 
in the resistant variants following incubation of all cells in 10pM adriamycin for 4.5  
hours.
Nuclear accumulation of adriamycin was observed in DLKP-I with very little cytoplasmic 
accumulation of drug (Figure 3.7.2.1(a)). The resistant variant of DLKP-I, DLKP- 
I/A25010p, had adriamycin-free nuclei and some cytoplasmic accumulation (Figure 
3.7.2.1(b)) but much less total cellular accumulation of drug. DLKP-im drlRz2D4 cells 
appeared to have more accumulation of drug in their nucleus relative to the DLKP-I 
parental cell line (Figure 3.7.2.1(c)) suggesting a role for P-glycoprotein mediated drug 
accumulation in sensitive cells. The resistant variant DLKP-ImdriRz2D4/A2501 Op were 
seen to be a heterogenous population with some cells displaying nuclear fluorescence and 
others free of nuclear accumulation; this may indicate that the ribozyme is only expressed 
in some cells or that these cells have lost resistance. Most cells in this population, 
however, showed clear nuclei with cytoplasmic accumulation of adriamycin (Figure 
3.7.2.1(d)), more so than the DLKP-I/A25010p variant (Figure 3.7.2.1(b)) suggesting that 
decreased m drl mRNA levels may result in increased drug accumulation. This increased 
drug accumulation does not appear to affect toxicity levels of the cell line (Table 3.7.1).
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Figure 3.7.2.1 Adriamycin Uptake in DLKP-I Variants
1 •:: :::::::::::::
DLKP-I variants were exposed to 10(.lM adriamycin for 4.5 hours, drug was then removed and cells 
washed free of any residual drug. Adriamycin uptake is observed as orange fluorescence. Adriamycin 
accumulation is observed in the nucleus of the sensitive DLKP-I (a) but is greatly reduced in the 
adriainycin-resistaiU pulse variant DLKP-I/A250 lOp (b). The sensitive cell line DLKP-Iw/i//7Rz2D4
(c) appears lo have much more intense nuclear staining than DLICP-I. DLKP-I/;/i/WRz2D4/A25010p
(d) (resistant variant) are a mixed population with less nuclear fluorescence than its sensitive 
parental line: greater cytoplasmic fluorescence is observed in these cells.
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3.8 Adriamycin Selection from Five DLKP-SQ Bd-Jts-expressing Clones
DLKP-SQ was transfected with the bcl-xs cDNA using calcium-phosphate precipitation 
and glycerol shock method (Section 2.14.3). Five clones were maintained as individual 
cell lines following selection in 600ug/ml geneticin and included DLKP-SQ/bdxs .l ,  
DLKP-SQ/bclxs.2, DLKP-SQ/bclxs.3, DLKP-SQ/ôcfe.4 and DLKP-SQ/bclxs.5.
The five isolated clones were exposed to weekly four-hour exposures of 250r|g/ml 
adriamycin. Four of the clones were found to grow readily in increasing pulses of 
adriamycin, further analysis was not carried out. One clone, DLKP-SQ/bclxsA , did not 
survive exposure to the first weekly pulse of 250ng/ml adriamycin. Repeat analysis 
confirmed this result.
3.8.1 Adriamycin Toxicity Analysis of DLKP-SQ/bcl-xs clones
Adriamycin toxicity analysis was carried out for four of the original DLKP-SQ/bcl-xs 
clones described in Section 3.8. Initial results indicated that the IC5o for the clones was 
quite similar to that of the parental line, DLKP-SQ. Further analysis of three clones, 
DLKP-SQ/bcl-Xs.l, DLKP-SQ/bcl-XsA and DLKP-SQ/&c/-jcs.5, confirmed this result 
(Table 3.8.1.1).
3.8.2 RT-PCR Analysis of DLKP-SQ/bcl-xs clones
RT-PCR analysis was carried out on the five DLKP-SQ/£c/-xs clones to show the presence 
of bcl-xs cDNA. A 207bp bd-xs band was detected for all clones after 30 cycles of PCR. 
Highest levels of expression were seen in DLKP-SQ/bd-xs.3 compared to the other clones 
(Figure 3.8.2.1); however, this was not reflected in increased sensitivity to adriamycin 
treatment, m drl mRNA levels were not detected in the DLKP-SQ/frc7-xs clones (result not 
shown).
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Table 3.8.1.1 Adriamycin IC50 values of DLKP-SQ/£d-x,s- clones
DLKP-SQ DLKP-SQ/bcl-xs A DLKP-SQ//;c/-a-,-.4 DLKP-SQ/ftd-^.5
[ADR]ng/ml 13.9 ± 3.5 17 .5+6.6 15.5 + 0.7 17.6 + 0.9
Adriamycin toxicity in DLKP-SQ and clonal populations transfected with the bcl-Xs gene (DLKP- 
SQ!bcl-Xs. 1, which did not survive exposure to adriamycin, and DLKP-SQ//;«:/-^.4 and ,5, which 
grew readily in repeated pulses of adriamycin).
Figure 3.8.2.1 RT-PCR Analysis of DLKP-SQ/ftc/-.Vi clones
bcl-x L
bcl-Xs
p-actin
Expression of bcl-xs in DLKP-SQ cells transfected with the bcl-Xs cDNA. Parental cell line 
(DLKP-SQ) is shown in the first lane (SQ). DLKP-SQ//Jc/-Jc.y. 1, .2, .3, .4 and .5 are named as 
SQxs.l, .2, .3, .4 and .5, respectively.
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3.8.3 Time-lapse Analysis of DLKP-SQ/bcl-xs. l  exposed to Adriamycin
DLKP-SQ and DLKP-SQ/bcl-xs. 1 cell growth was monitored by time-lapse video­
microscopy for four days either in the absence of drug or following exposure to 250ng/ml 
adriamycin for 4 hours. Results are shown in Figures 3.8.3.1 and 3.8.3.2. Cells growing 
in 25cm2 flasks were monitored at 10X magification by time-lapse video-microscopy 
equipment described in Section 2.8. To analyse cell death or mitotic events the recording 
was played back at accelerated speed. Groups of cells were chosen and the time at which 
either apoptotic or mitotic events was seen was recorded. Apoptotic cells round up and 
cell blebbing is then observed with destruction of the cell. Mitotic events also begin with 
rounding up of the cell and subsequent cell division.
Pulse exposure of DLKP-SQ cells with 250ng/ml adriamycin for 4 hours revealed cell kill 
by apoptosis after a lag phase of 0 - 25 hours (Figure 3.8.3.1 - cell blebbing and apoptotic 
events observed). Only five apoptotic events were seen up to 25 hours after addition of 
drug. 40 cells (80%) underwent apoptosis between 25 and 80 hours (Figure 3.8.3.3). Nine 
mitotic events were observed between 35 and 95 hours, six of which occurred between 35 
and 47 hours (Figure 3.8.3.1(f) - mitotic event is marked with M). Mitotic events in 
untreated (without ADR) DLKP-SQ cells is shown for comparison (Figure 3.8.3.4).
The DLKP-SQ/^d-x.s-. 1 cell line was also exposed to 250ng/ml adriamycin for 4 hours and 
monitored by time-lapse video-microscopy. Drug was removed after 4 hours and cells 
were maintained in adriamycin-free media. Again a lag-phase of up to 35 hours was seen 
for this cell line where only 6 apoptotic events were observed. After 35 hours, however, 
apoptotic events were more frequent and 50 (100%) cells observed had died by 100 hours 
(Figure 3.8.3.3). These cells were found to swell dramatically between 4 and 24 hours 
(prior to induction of increase in apoptotic events) when drug had been removed (see 
Figure 3.8.3.2). The rate of apoptosis was quite similar in both the DLKP-SQ and DLKP- 
SQ/bclXs.i cell line (see Figure 3.8.3.3). No mitotic events were seen in the DLKP- 
SQ/bclxs. 1 cell line, however (Figure 3.8.3.4).
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Figure 3.8.3.1 Time-lapse Video-microscopy of DLKP-SQ in the presence of 250ng/ml adriamycin
Adriamycin was added at time t=0 and removed at time t= 4  (a). Cell survival was monitored by 
time-lapse video-microscopy for 4 days (t=24hour (b); t=48hour (c); t=60hour (d); t=72hour (e); 
t=801iour (f)). Mitotic event in (f) is marked as M.
t =  4hour
t =  24hour
t = 48hour
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Figure 3.8.3.1 (cont.) Time-lapse Video-microscopy of DLKP-SQ in the presence of 250ng/ml adriamydn
t = 80hour
t = 60hour
t = 72hour
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Figure 3.8.3.2 Time-lapse video-microscopy of DLKP-SQ/bclxs-i in the presence of 250ng/ml adriamydn
(a)
t = 4hour
(b)
t = 24hour
(c)
t - 48hour
Adriamycin was added at time t=0 and removed at time t=4 (a). Cell survival was monitored by 
time-lapse video-microscopy for 4 days (t=24hour (b); t=481iour (c); t=60hour (d); t=72hour (e); 
t=80hour (f)).
« o r
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Figure 3.8.3.2 (cont.) Time-lapse Video-microscopy of DLKP-SQ/bcLxs.l in the presence of 250ng/ml adriamydn
t = 60hour
t = 72hour
t = 80hour
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Figure 3.8.3.3 Rate of Apoptotic events in DLKP-SQ and DLKP-SQ/£c£rs.l cell lines
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Apoptotic events were monitored by time-lapse video microscopy in the DLKP-SQ and DLKP-SQ/£>c7- 
x$. 1 cell line following 4 hour treatment with 250ng/ml adriamycin. Drug was added at time t= 0  and 
removed at t=4 when cells were fed in fresh media without adriamycin.
Figure 3.8.3.4 Mitotic Events in DLKP-SQ
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Mitotic events were monitored by time-lapse video microscopy in the DLKP-SQ and DLKP-SQ/frc/- 
xs. 1 cell line following 4 hour treatment with 250ng/ml adriamycin and DLKP-SQ without adriamycin 
(ADR) treatment (DLKP-SQ without ADR). Drug was added (to DLKP-SQ and DLKP-SQ/bcLxs-l) at 
time t=0 and removed at t= 4  when cells were fed in fresh media without adriamycin.
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3.9 Adriamycin Selection of DLKP-SQ clones transfected with c-fos Ribozyme
DLKP-SQ cell line was transfected (Section 2.14.3) with an inducible c-fos ribozyme 
plasmid. Individual colonies were propagated in 600fig/ml geneticin and maintained as the 
following cell lines - DLKP-SQ/bsRz/E 1, DLKP-SQ/osRz/A6 and DLKP-SQ/osRz/BlO. 
The c-fos ribozyme was induced by 24 hour incubation in 5(xM dexamethasone (used 
previously by Funato e ta l . ,  1992).
Triplicate flasks of each cell line were pre-treated for 24 hours in 5p.M dexamethasone and 
then exposed to 250ng/ml adriamycin (in dexamethasone containing medium) for 4 hours; 
control selections were set up without dexamethasone treatment. These treatments were 
carried out once weekly. Selection failed with each cell line tested, including those cells 
set up without dexamethasone, as all cells died following exposure to the first pulse with 
adriamycin.
3.9.1 Adriamycin Toxicity Profile of DLKP-SQ/bsRz clones
Adriamycin toxicity analysis of the DLKP-SQ c-fos ribozyme expressing clones was 
carried out on one representative clone, namely DLKP-SQ/avRzA6. No significant 
alteration to adriamycin sensitivity levels was seen between the parental DLKP-SQ cell 
line and the c-fos ribozyme-expressing cell line in serum-supplemented media (Table 
3.9.1.1).
3.9.2 RT-PCR Analysis of c-fos Ribozyme transfected cells
RT-PCR analysis was carried out on mRNA extracted from the c-fos ribozyme expressing 
clones either in the presence or absence of dexamethasone-supplemented medium. 
Analysis of c-fos ribozyme expression, c-fos mRNA levels and m drl mRNA levels was 
undertaken. The c-fos ribozyme expression was detected in the two clones analysed (El 
and A6) in the presence and absence of dexamethasone (Figure 3.9.2.1(a)). c-fos mRNA 
was detected in the parental DLKP-SQ cell line but not in the ribozyme-transfected clones 
(Figure 3.9.2.1(b)). No mdrl mRNA was detected in the cell lines after 25 cycles of PCR 
(Figure 3.9.2.1(c)).
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Table 3.9.1.1 Adriamycin IC50 values of DLKP-SQ//iwRz done
IC50 DLKP-SQ DLKP-SQ//av/?zA6
[ADR]ng/ml 13.9 ± 3.5 18.6 ±  12.5
Adriamycin toxicity in DLKP-SQ and a clonal population (DLKP-SQ//offlzA6) transfected with the 
c-fos ribozytne cDNA.
Figure 3.9.2.1 RT-PCR Analysis in c-fos Ribozyme transfected DLKP-SQ cells
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RT-PCR analysis, for the expression of (a) c-fos ribozyme, (b) c-fos, (c) mdrl, on DLKP-SQ and 
c-fos ribozyme transfected clonal sub-populations DLKP-SQ/avRzEL (E l), DLKP-A/o.vRzA6 (A6), 
in the presence ( + DEX) and absence (-DEX) of 5(.iM dexamethasone for 24 hours.
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3.9.3 Culturing of DLKP-SQ/bsRz clones in serum-free media
As serum is known to contain certain levels of dexamethasone which could be enough to 
induce the expression of the c-fos ribozyme, attempts were made to grow these cell lines 
in serum-free media.
Initially cells were grown in a serum-free media designed to support the growth of the 
DLKP cell line (P.Meleady, 1997). This media was insufficient to support the growth of 
the c-fos ribozyme transfected cell lines. Media was then supplemented with fibronectin at 
a concentration of 5(xg/ml which resulted in readily adherent cell lines but did not induce 
mitotic events. As growth in serum-free media proved unsuccessful attempts were made to 
grow cells in serum-free media supplemented with 1% serum. This media was insufficient 
to support the growth of the c-fos ribozyme transfected clones.
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3.10 Effect of Potential Toxicity Enhancing Agents on Adriamycin Toxicity
Three drugs (cyclosporin A, emodin, genistein) were chosen as potential enhancing agents 
with adriamycin to determine if they could act as toxicity enhancers in these studies. Non­
toxic levels of the three drugs were used (Figure 3.10.1), as determined by duplicate toxicity 
assays set up in 25cm2 flasks (see Section 2.3.2). The pulse concentration of adriamycin used 
in this analysis was 250ng/ml for 4 hours and included the appropriate co-selecting agent 
where appropriate. The adriamycin was then removed from the cells which were then re-fed 
for 24 hours either in media without any drug or supplemented with the appropriate potential 
toxicity enhancing agent.
Each analysis shown (Figures 3.10.2 and .3) is the average of at least two 25cm2 flasks set 
up on the same day.
Figure 3.10.1 Effect of 28 hour exposure to selecting agent on DLKP-SQ
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DLKP-SQ cells were set up in 25cm2 flasks until 50% confluent; cells (in triplicate flasks) were then 
fed in fresh media (control) or media supplemented with 2.0|_ig/ml Cyclosporin A (cyclosporin A), 
25|.iM Emodin (emodin) or 15(j.M Genistein (genistein) for 28 hours. Media was then removed and 
cells were grown in control media until control flasks reached 90% confluency. Cell growth was then 
assessed as previously described (Section 2.3.2).
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3.10.1 Co-selection of DLKP-SQ with Adriamycin and Cyclosporin A
DLKP-SQ cells were exposed to 250ng/ml adriamycin for 4 hours in medium containing 
2.0ng/ml cyclosporin A, followed by removal of adriamycin and re-fed for 24 hours in 
2.0|ig/ml cyclosporin A. This process was carried out once a week for 2 weeks. Cell 
survival was analysed at the end of the second week and it was found that co-selection 
with the non-toxic level of cyclosporin A reduced cell survival from 100% (adriamycin 
alone) to 4.0% (Figure 3.10.2). Further analysis following 1 weekly pulse reduced 
survival to 50% and a second pulse, one week later, reduced survival to 13.2% (Figure 
3.10.3).
3.10.2 Co-selection of DLKP-SQ with Adriamycin and Emodin
DLKP-SQ cells were exposed to 250ng/ml adriamycin for 4 hours in media containing 
25fiM emodin, followed by removal of adriamycin and re-fed for 24 hours in 25 p,M 
emodin. This process was carried out once a week for 2 weeks. Cell survival was analysed 
at the end of the second week and it was found that co-selection with the non-toxic level of 
emodin increased cell survival from 100% (adriamycin alone) to 140% (Figure 3.10.2). 
Further analysis following 1 weekly pulse increased survival to 161% and a second pulse, 
one week later, increased overall survival, relative to adriamycin only treated cells, to 
172% (Figure 3.10.3).
3.10.3 Co-selection of DLKP-SQ with Adriamycin and Genistein
DLKP-SQ cells were exposed to 250ng/ml adriamycin for 4 hours in media containing 
15(j,M genistein, followed by removal of adriamycin and the cells were then re-fed for 24 
hours in 15pM genistein. This process was carried out once a week for 2 weeks. Cell 
survival was analysed at the end of the second week and it was found that co-selection 
with the non-toxic level of genistein decreased cell survival from 100% (adriamycin alone) 
to 7.6% (Figure 3.10.2). Further analysis following 1 weekly pulse did not affect cell 
survival, however, a second weekly pulse reduced survival to 44% (Figure 3.10.3).
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Figure 3.10.2 Effect of Potential Toxicity Enhancing Agents on Adriamycin Toxicity
c o n tro l  c y c lo sp o r in A  em o d in  g e n is te in
DLKP-SQ cells were set up in 25cm2 flasks until they reached 50% confluency. Cells were then fed in 
medium supplemented with 250ng/ml adriamycin only (control) or adriamycin and 2.0|ag/ml 
Cyclosporin A (cyclosporin A), 25|iM Emodin (emodin) or 15(iM Genistein (genistein) for 4 hours; 
after 4 hours adriamycin-supplemented medium was removed, cells rinsed in fresh medium and re-fed 
for a further 24 hours in control medium or medium supplemented with the appropriate selecting 
agent. All flasks were then re-fed in fresh medium. Cells were allowed to grow for a further 6 days 
and then the procedure was repeated. Following the second 6-day recovery phase growth was assessed 
as described previously (Section 2.3.2).
Figure 3.10.3 Effect of CyclosporinA, Emodin and Genistein on Adriamycin Toxicity
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c o n t r o l  c y c lo s p o r in A  e m o d i n  g e n i s t e i n
DLKP-SQ cells were set up in 25cm2 flasks until they reached 50% confluency. Cells were then fed in 
media supplemented with 250ng/ml adriamycin only (control) or adriamycin and 2.0^g/ml 
Cyclosporin A (cyclosporin A), 25nM Emodin (emodin) or 15|.iM Genistein (genistein) for 4 hours; 
after 4 hours adriamycin-supplemented medium was removed, cells rinsed in fresh medium and re-fed 
for a further 24 hours in control mediumor medium supplemented with the appropriate selecting agent. 
All flasks were then re-fed in fresh medium. Cells were allowed to grow for a further 6 days after 
which time cell survival was assessed (pulse 1). The procedure was repeated. Following the second 6- 
day recovery phase growth was assessed (pulse 2) as described previously.
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3.11 Gene Induction Studies with Adriamycin
Previous results have indicated a role for a number of oncogenes in the expression of the 
MDR phenotype. To determine if alterations in the expression of these genes occurs as an 
early response to the selecting drug DLKP-SQ was used as a model to follow gene 
induction. After exposure to the drug concentrations used in the development of resistant 
variants, e.g. 25ng/ml adriamycin continuously or 250ng/ml adriamycin for 4 hours, total 
RNA was extracted as previously described (Section 2.12.1) after a certain timeframe 
(from 0 minutes to 72 hours) had elapsed. RNA was subsequently reverse transcribed and 
studied by PCR for the expression of the bcl-xL, c-erbB-2 and c-fos genes.
3.11.1 Effect of Adriamycin treatment on expression of bd-x mRNA in DLKP-SQ
RT-PCR analysis of bd-xL expression in RNA extracted from cells 0, 8, 15, 30min, 1, 2, 
4, 6, 9 and 24 hours after addition of 25ng/ml adriamycin revealed a gradual induction in 
expression of this gene with time after 30min exposure to the drug (see Figure 
3.11.1.1(a)). A repeat of this experiment did not display the same trend in expression (see 
Figure 3.11.1.1(d)).
Similar analysis of RNA extracted from cells that were treated with 250ng/ml adriamycin 
for 4hours also revealed an increase in bd-xL levels with time, although the increase was 
not seen until further time had elapsed (see Figure 3.11.1.1(b)). Repeating this experiment 
did not reveal the same trend (Figure 3.11.1.1(e)).
Figure 3.11.1.1(c) is a control experiment where cells had not been exposed to 
adriamycin.
3.11.2 Effect of Adriamycin treatment on c-erbB-2 mRNA expression in DLKP-SQ
Initial results following continuous treatment of DLKP-SQ with 25ng/ml adriamycin 
revealed an induction of c-erbB-2 transcripts after 2hours exposure to adriamycin (Figure 
3.11.2.1(a)). Repeat analysis of a second extraction showed increased expression after 4 
hours in drug but this increase was not maintained at 6 hours (see Fig. 3.11.2.1(d)).
The trend when cells were treated with 250ng/ml adriamycin for 4 hours was similar to 
that of 25ng/ml adriamycin continuously with a steady increase evident, beginning at 4 
hours (Figure 3.11.2.1(b)). Repeated analysis did not concur with the trend found in
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initial experiments (Figure 3.11.2.1(e)).
Figure 3.11.2.1(c) is a control experiment where cells had not been exposed to 
adriamycin.
3.11.3 Effect of Adriamycin treatment on expression of c-fos mRNA in DLKP-SQ
c-fos levels were increased in response to serum addition to cells and reached a maximum 
at 30 minutes (see Fig.3 .11.3. Ic); higher levels of expression were maintained for longer 
periods when cells were exposed to drug (see Fig. 3.11.3. le). The effect of adriamycin on 
c-fos levels is not conclusive as repeat analysis did not reveal a similar trend.
Figure 3.11.3.1(c) is a control experiment where cells had not been exposed to 
adriamycin.
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Figure 3.11.1.1 Gene Induction Analysis of bcl-xL in DLKP-SQ following Exposure to Adriaraycin
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RT-PCR analysis (after 25 cycles) of bcl-xL on RNA extracted from DLKP-SQ exposed to adriamyin 
at (a) 25ng/ml continuously (1st extraction); (b) 250ng/ml for 4 hours (1st extraction); (c) Ong/ml (2‘mi
extraction); (d) 25ng/ml continuously (2nd extraction) and (e) 250ng/ml for 4 hours (2ni1 extraction).nri
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Figure 3.11.2.1 Gene Induction Analysis of c-erbB-2 in DLKP-SQ following Exposure to Adriamycin
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RT-PCR analysis (after 25 cycles) of c-erbB-2 on RNA extracted from DLKP-SQ exposed to adriamyin at (a) 
25ng/ml continuously ( l sl extraction); (b) 250ng/ml for 4 hours (1st extraction); (c) Ong/ml (2nd extraction);
(d) 25ng/ml continuously (2'“1 extraction) and (e) 250ng/ml for 4 hours (2nd extraction).
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Figure 3.11.3.1 Gene Induction Analysis of c-fos in DLKP-SQ following Exposure to Adriamycin
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RT-PCR analysis (after 30 cycles) of c-fos on RNA extracted from DLKP-SQ exposed to adriamyin 
at (a) 25ng/ml continuously (1st extraction): (b) 250ng/ml for 4 hours (1st extraction); (c) Orig/ml (2nd
extraction); (d) 25ng/ml continuously (2nd extraction) and (e) 250ng/ml for 4 hours (2ncl extraction)n d
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3.12 Development of a Resistant variant of BT-20
Attempts were made throughout the course of this work to develop a resistant variant of 
the breast cell line BT-20 (derived from a patient not previously treated with 
chemotherapy). Drug resistance profile of BT-20 is shown in Table 3.12.1. The selection 
process was initiated with 25ng/ml adriamycin which had little effect on the growth of 
these cells. Continuous selection was then attempted with higher adriamycin 
concentrations (e.g. 30 and 35ng/ml adriamycin); these higher concentrations caused 
dramatic cell kill and selection was not successful as the cells did not recover from 
exposure to adriamycin at these concentrations. Pulse exposure of a clonal population of 
BT-20, BT-20/B10, to 250ng/ml adriamycin for 4 hours also failed to select a resistant 
variant.
The ease with which DLKP-SQ could be selected with adriamycin compared to the 
difficulty in selecting BT-20 with this drug is surprising as toxicity levels of adriamycin in 
both cell lines are quite similar (see Table 3.5.2.2.2 (IC50 value of ADR in DLKP-SQ is 
13.9 ± 3.5ng/ml) and Table 3.12.1). Observations made while maintaining the parental 
BT-20 population in culture revealed a strong dependence on high cell density for 
successful growth of this cell line under normal culturing conditions. This was not the 
case for DLKP-SQ which grew readily at all cell densities tested.
Attempts were also made to co-select the BT-20 cell line with cyclophosphamide 
:methotrexate:5-fluorouracil (CMF), a regimen frequently used in the treatment of breast 
cancer. Initial toxicity work (Table 3.12.1) revealed an extraordinarily high resistance in 
this cell line to methotrexate (IC50 of MCF-7 for methotrexate is only 0.04 ± 0.01 fig/nil). 
This is quite surprising as the patient from whom the BT-20 cell line was derived had not 
been treated with chemotherapy.
Table 3.12.1 ICS0 Values for BT-20
[ADR] [VNC] [VP-16] [MTX] [CPM] [5-FU]
ng/ml ng/ml ng/ml ug/ml Ug/ml Ug/ml
ICso 17.5 ±  1.9 1.0 ±  0 80* 27.9 + 7.3 2.33 ±  1.53 0.43 + 0.12
Toxicity profile of a sensitive breast cell line, BT-20. ADR =  adriamycin; VNC =  vincristine; 
MTX = methotrexate; CPM = mafosfamide; 5-FU =  5-fluorouracil: *analysis was only carried 
out once.
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Unpublished observations found in this laboratory previously, and throughout the course 
of this work, have shown that cell lines vary in their tendencies to develop resistance - 
some lines develop resistance readily (e.g. DLKP) whereas others do not (e.g. BT-20,
DLKP-SQ/bclXsA and DLKP-SQ//o,vRz clones) (see Table 3.12.1.1). A group of six cell
lines was chosen in this study to examine the level of common MDR markers and 
oncogene expression in paired lung (DLKP and A549), breast (MCF-7 and BT-20) and 
ovarian (OAW42SR and PA-1) cell lines to determine if any trends could be seen among 
groups. The BT-20 and PA-1 cell lines did not grow well at low cell density, perhaps 
explaining in part the fact that they do not develop resistance. The A549 cell line does,
however, grow well at low cell densities.
3.12.1 RT-PCR Analysis of Cell Lines with Varying Tendencies to Develop
Resistance
Table 3.12.1.1 Tendencies of Cell Lines to Develop Drug Resistance
Cell Line DLKP A549 MCF-7 BT-20 OAW42SR PA-1
Resistance
Development X V X V X
Cell lines that do (V) and do not (X) develop resistance.
All of the genes previously described (e.g. bcl-2, bcl-x, bax, c-fos, c-jun, c-myc, c-erbB-2, 
c-Ha-rasl) and common MDR-related genes (m drl, mrp, Topoisomerases, GSTri) were 
analysed. Varied expression was evident for some genes in different cell lines e.g. bcl-2 
expression high in MCF-7 but not in BT-20 or the lung cell lines analysed. No consistent 
trend, at the mRNA level as detected by RT-PCR, was observed between the group of cell 
lines that do and those that do not develop resistance readily. RT-PCR analysis of m drl, 
c-erbB-2, bcl-x and c-fos in these cell lines is shown in Figure 3.12.1.1
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Figure 3.12.1.1 RT-PCR Analysis of Sensitive Cell Lines
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RT-PCR analysis of paired lung (DLKP and A549), breast (MCF-7 and BT-20) and ovarian 
(OAW42SR and PA1) sensitive cell lines. Analysis was carried out for (a) mdrl for 25 cycles; (b) 
c-erbB-2 for 24 cycles; (c) bcl-xL for 25 cycles and (d) c-fos for 30 cycles of PCR amplification.
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3.13 Clinical Studies of mRNA levels in Fresh and Archival Tissue
3.13.1 RT-PCR Analysis of mRNA Extracted from Archival Sections
Total RNA was extracted from formalin-fixed paraffin-embedded sections and mRNA 
levels analysed by RT-PCR. Successful extraction and amplification of mRNA from foetal 
liver, tonsil and placental tissue was achieved (Figure 3.13.1.1(a) to (c)) using a 
previously described protocol (O’Driscoll et al., 1996).
When this protocol was applied to a broad range of 15 paired tumours from breast cancer 
patients (identified as pre- and post-chemotherapy paired samples) success was limited 
(results not shown). This protocol was found to be insufficient to digest many of these 
tumours. Increased de-waxing steps and longer digestion times (up to 72 hours) with 
increased enzyme concentrations did not significantly improve the success rate. RT-PCR 
analysis on 18 of these tumour sections revealed a very faint /3-actin band in two sections 
and a faint m drl band in another. No bands were seen for any other tissue sections (results 
not shown). RNA extracted from a section of normal breast was analysed for the 
expression of Topoisomerase IIa and /3-actin and very faint bands, at the expected sizes, 
were evident (Figure 3.13.1.1(c)).
To address these problems tissue sections were digested in different digestion buffers. The 
buffer described in Section 2.10.2 was found to digest all tissues analysed to date. 
However, the RNA isolated from these tissues was not of sufficiently high quality to be 
reverse transcribed and used for PCR amplification by the method described previously 
(O’Driscoll et al., 1996). To overcome this problem, steps were taken to optimise the 
reverse transcription step taking into account the degraded nature of the mRNA in these 
studies. As oligo-dT and random primers were not sufficient to act as primers to reverse 
transcribe degraded mRNA a mixture of the reverse primers used in the PCR reaction was 
prepared and used to prime the degraded RNA during reverse transcription. This cDNA 
was subsequently analysed by PCR for the expression of /3-actin and c-erbB-2 after 40 
cycles of PCR. A band was evident at the expected size for /3-actin although background 
bands were also present (Figure 3.13.1.1(d)), no band was seen at the expected site for c- 
erbB-2 amplification. Further optimisation of this protocol is required.
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Figure 3.13.1.1 RT-PCR Analysis of RNA Extracted from Archival Sections
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RT-PCR analysis (30 PCR cycles) of RNA extracted from (a) 3 placenta samples; (b) 3 foetal liver 
sections; (c) 2 tonsil sections and 1 normal breast section and (d) RT-PCR analysis (40 PCR cycles) 
of degraded RNA using specific primers to reverse transcribe the RNA; amount of RNA used in the 
RT step was either 0.5. 1.0 or 2.0|jg.
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3.13.2 RT-PCR Analysis of mRNA Extracted from Fresh Breast Tissue
Analysis of mRNA extracted from fresh tumour samples was carried out using a similar 
procedure to that used for extraction from formalin-fixed paraffin-embedded sections 
(Section 2.10.3). The aim of this study was to compare mRNA extraction from tumour 
samples pre- and post-fixation and embedding procedures. In the space of 6 months 14 
tumours were received from breast cancer patients attending St. Vincent’s Hospital, 
Dublin 4. Total RNA was extracted from these tumours and analysed by RT-PCR for the 
expression of MDR-related genes and oncogene products. Successful amplification of ¡3- 
actin was achieved for all tumours, however, amplification of a range of specific gene 
products was achieved for only four of these tumours. The gene expression detected in 
these four tumours is summarised in Table 3.13.2.1.
Table 3.13.2.1 Gene Expression in Fresh Tumour
434992
Patient Number
434992a 435329 364788
mdrl + + - +
mrp + / - + / - + / - + / -
Topoisomerase Ha + + + / - + / - + / -
bcl-2 + + + + + + +
bcl-xL + + + +
bax + + + + + +
c -fos + + + +
c -myc + + + + + +
c-erbB-2 + + / - - -
RNA isolated from axillary node (434992) and breast (434992a, 435329 and 364788) tissue was 
analysed for the expression of a range of genes by RT-PCR. Expression is indicated by (+), weak 
expression by (+/ -) and absence of expression by (-). All analysis was carried out following 30 
cycles of PCR.
Patient history or prognosis is unknown. Time constraints prevented extraction or analysis 
of RNA from formalin-fixed and paraffin-embedded sections of the same tissue.
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3.13.3 mdrl Analysis by Non-Isotopic In Situ Hybridisation of Archival Tissue
A protocol was developed throughout the course of this study to analyse m drl gene 
expression in archival formalin-fixed paraffin-embedded tissue. Foetal liver was used to 
optimise hybridisation conditions as this tissue is known to express high levels of m drl 
gene (van Kalken el a l., 1992). A digoxigenin-labelled riboprobe was used to identify the 
mRNA of interest.
Specific staining of m drl expression in erythroid precursors (haemopoeitic cells) in the 
sinusoids was detected using this procedure on foetal liver sections (Dr,S.Kennedy pers. 
comm.) (Figure 3.13.3.1(a)). Immunohistochemical analysis of P-glycoprotein levels in 
the same tissue block was carried out by Ms. Annemarie Larkin and is included for 
comparison (Figure 3.13.3.1(b)).
Four paired pre- and post-chemotherapy tumour blocks were chosen at random from the 
thirty blocks used in the archival RT-PCR studies. Successful staining for poly-A mRNA 
and m drl were seen by in situ hybridisation in these studies. All patients had been treated 
with courses of CMF.
Table 3.13.3.1 Archival Breast Tumour Blocks Used in In Situ Hybridisation Studies
Pre-chemotherapy Post-chemotherapy
Patient # Block # Tissue Type Block # Tissue Type
306246 1349/89 breast 5136/90 skin
335969 17210/89 breast 18131/90 node
301897 19705/88 breast S6683/1/94 breast
229544 13536/87 breast 5843/92 node
Analysis of m drl mRNA expression in these sections was successful, although the quality 
of mRNA in some tumour blocks was not preserved throughout the entire specimen. 
Analysis of poly (A) staining with a poly (dT) digoxigenin labelled probe and specific 
m drl staining is shown for block numbers 19705/88, S6683/1/94, 13536/87 and 5843/92 
in Figures 3.13.3.2, .3, .4 and .5, respectively. Control hybridisations included RNase 
pre-treatment and hybridisation with labelled sense probe. All control hybridisations were 
negative (results not shown).
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Figure 3.13.3.1 Expression of m d r l Gene and Protein Products In  S itu  on Foetal Liver Tissue
(a) hybridisation of the mdrl riboprobe to foetal liver tissue (20X); (b) staining of P-glycoprotein 
in foetal liver tissue (photograph courtesy of Ms.Annemarie Larkin).
Figure 3.13.3.2 In  S itu  hybridisation analysis of tumour block it 19705/88
(a) hybridisation of poly (dT) probe (10X); (b) hybridisation of the mdrl riboprobe (20X)
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Figure 3.13.3.3 In Situ hybridisation analysis of tumour block # S6683/1/94
( a )  h y b r i d i s a t i o n  o f  p o l y  ( d T )  p r o b e  ( 1 0 X ) ;  ( b )  h y b r i d i s a t i o n  o f  t h e  mdrl r i b o p r o b e  ( 2 0 X )
Figure 3.13.3.4 In Situ hybridisation analysis of tumour block ft 13536/87
( a )  h y b r i d i s a t i o n  o f  p o l y  ( d T )  p r o b e  ( 1 0 X )  ( b )  h y b r i d i s a t i o n  o f  t h e  rridrl r i b o p r o b e  ( 2 0 X )
1 6 2
Figure 3.13.3.5 In Situ hybridisation analysis of tumour block # 5843/92
( a )  h y b r i d i s a t i o n  o f  p o l y  ( d T )  p r o b e  ( 1 0 X ) ;  ( b )  h y b r i d i s a t i o n  o f  t h e  mdrl r i h o p r o b e  ( 2 0 X )
1 6 3
Discussion
4.1 Analysis of Oncogene Expression in Multidrug Resistance
The observation that malignant cells commonly become resistant to chemotherapeutic 
drugs while normal cells rarely do suggests that molecular processes involved in 
malignancy, such as oncogene activation, may play a role in drug resistance (Sklar and 
Prochownik, 1991).
The focus of this project was to determine if alterations in oncogene expression could 
affect the MDR phenotype seen in highly resistant MDR variants of the DLKP cell line or 
clinically relevant resistant variants of a clonal population of DLKP. The oncogenes 
chosen in this study were representative of each class of known oncogenes involved in the 
signalling cascade from the plasma membrane to the nucleus. Expression of the genes 
chosen had previously been shown to result in poor prognosis in the clinic. Initial studies 
included analysis of c-erbB-2, c-Ha-rasl, c-fos, c-jun, c-myc and the bcl-2 family of 
proteins.
4.1.1 c-erbB-2 and its role in MDR
Although some of the literature is conflicting, much evidence has been gathered which 
implies that c-erbB-2 may account for insensitivity to commonly used chemotherapeutic 
regimens in some human cancers, especially lung and breast and increased c-erbB-2 levels 
were seen in the tumours of ovarian carcinoma patients with recurrent or persistent disease 
after chemotherapy (van Dam, 1994).
Muss et al. (1994) showed that patients whose tumours over-expressed c-erbB-2 were 
relatively resistant to chemotherapy at conventional doses of the topoisomerase II inhibitor 
doxorubicin. Using higher dose doxorubicin improved survival in these patients. The 
authors concluded that over-expression of c-erbB-2 may be a useful marker in identifying 
patients who are most likely to benefit from high doses of adjuvant chemotherapy. 
However, a study by Bitran et al. (1996) on 25 patients with high-risk breast cancer found 
that those patients over-expressing c-erbB-2 were at risk for relapse, even when treated 
with high-dose chemotherapy.
Klijn et al. (1993) found that c-erbB-2 over-expression was a predictor of good response 
to cyclophosphamide:methotrexate:5-fluorouracil (CMF) chemotherapy in patients with 
metastatic disease. Other investigations, however, have shown that tumours over­
expressing c-erbB-2 are less responsive to CMF regimens (Bacus et a l., 1994) whereas c-
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erbB-2 over-expressing tumours were found to respond to high doses of 
cyclophosphamide:adriamycin:5-iluorouracil (CAF). Sensitivity of c-erbB-2 over­
expressing breast carcinomas to doxorubicin was also shown by Paik (1992) where over­
expression of c-erbB-2 was associated with resistance to several other cytotoxic agents. 
Bottini et al. (1996) described a study of breast cancer patients whose response to CMF 
treatment could not be correlated with c-erbB-2 expression.
Direct in vivo evidence of a role for c-erbB-2 in MDR came from studies by Schneider 
and co-workers (1994) in a sub-group of aggressive, locally advanced, inoperable 
carcinomas. This study showed a highly significant co-expression of P-glycoprotein and c- 
erbB-2. Volm et al. (1993) also demonstrated a significant relationship between the 
common MDR markers, P-glycoprotein, GST-7: and Topoisomerase II, and c-erbB-2 in 
third or fourth passages from primary renal cell carcinomas in culture. Jarvinen et al. 
(1996) also showed a significant correlation between c-erbB-2 and Topoisomerase Hoc 
expression in breast cancer patients.
In vitro studies on the effect of c-erbB-2 on MDR have also been undertaken and it has 
been shown by many groups that cell lines transfected with c-erbB-2 display varying 
degrees of resistance to chemotherapeutic drugs. Sabbatini et al. (1994) demonstrated that 
co-transfection of activated c-Ha-ras and c-erbB-2 into MCF-10A (human breast epithelial 
line, m drl negative) resulted in the establishment of a de novo m drl-expressing cell line 
with slight increase in resistance to adriamycin. Benz et al. (1992) showed that 
transfection of breast tumour cells with c-erbB-2 resulted in resistance to tamoxifen. Yu et 
al. (1996) demonstrated that over-expression of c-erbB-2 due to introduction of the human 
c-erbB-2 gene into the very low c-erbB-2 protein-expressing MDA-MB-435 (human breast 
cancer) cell line resulted in increased taxol resistance. No increase in P-glycoprotein levels 
was seen. c-erbB-2 over-expression and in vitro resistance to 5-fluourouracil and cisplatin 
(non-MDR drugs) has been reported by Dickson et al. (1990). Zhang and Hung (1996) 
described a study of non-small cell lung cancer cell lines that over-expressed the c-erbB-2 
protein with concomitant increases in resistance to cisplatin, doxorubicin and etoposide. In 
this thesis resistant variants of the lung cell line, DLKP, developed by continuous 
exposure to carboplatin, adriamycin and VP-16 also displayed elevated levels of c-erbB-2 
mRNA. Not all cell lines over-expressing c-erbB-2 resulted in resistant variants, however, 
which reflects work by Slamon (1992) where MCF-7 cells transfected with the c-erbB-2 
cDNA were not found to have increased chemo-resistance.
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4.1.2 c-Ha-ras and its role in MDR
c-Ha-ras is involved in signal transduction pathways governing many regulatory pathways 
in the cell and is expressed in 30% of all human cancers and is a marker of poor 
prognosis in many cancers. The role of c-Ha-ras and in vivo MDR has yet to be 
addressed, however, much in vitro work has been carried out and results found implicate a 
role for c-Ha-ras in the establishment of the MDR phenotype.
Burt et al. (1988) showed that transfection of rat liver epithelial cells with v-H-ras or v- 
raf, independently of chemical exposure, resulted in the establishment of an MDR 
phenotype. Increased expression of m drl and GSTn was observed in the resistant cell lines 
with concomitant increase in resistance to adriamycin, vinblastine and 2- 
acetylaminofluorene. As mentioned previously (Sabbatini et al., 1994), co-transfection of 
activated c-Ha-ras and c-erbB-2 into MCF-10A cells also resulted in the establishment of a 
de novo m drl-expressing cell line with slight increase in resistance to adriamycin. Direct 
evidence for the regulation of m drl by the ras family of proteins came from studies by 
Chin et al. (1992) and Cornwell and Smith (1993) which showed that the human mdrl 
gene promoter is activated by Ras and p53, and c-Raf kinase, respectively. In this thesis 
elevated levels of c-Ha-ras mRNA were detected in the MDR cell lines DLKP-A (selected 
with adriamycin) and DLKP-VP3 but not DLKP-VP8 (selected with VP-16). Elevated 
levels of c-Ha-ras were seen in a 10-fold resistant variant of the human prostate PC3 cell 
line (Sinha et al., 1995) which is resistant to a wide variety of anticancer agents including 
VP-16 and cisplatin.
A role for c-Ha-ras in cisplatin resistance has been demonstrated by many groups on a 
variety of cell lines. A ras-transformed variant of the non-malignant mammary epithelial 
cell line, HBL100, displayed a selective 2.7 fold increased resistance to cisplatin but not 
to other DNA interacting agents such as adriamycin (Levy et al., 1994). Increased 
resistance to cisplatin was found to be specific for H-ras transformants and did not include 
K-ras transfected cell lines (Shinohara et a l ,  1994); induction of cisplatin resistance was 
mainly due to a reduction of cisplatin accumulation and an impairment of Na+,K+-ATPase 
activity in the membrane fraction. NIH3T3 fibroblasts transfected with several types of 
cellular and viral ras oncogenes were shown to have increased resistance to the non-MDR 
drug, cisplatin (Sklar, 1988). The carboplatin resistant line used in this thesis, DLKP- 
C14, also expressed elevated levels of c-Ha-ras mRNA. Isonishi and co-workers (1991) 
also showed that over-expression of a mutant c-Ha-ras gene in murine NIH3T3 cells
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conferred increased resistance (8.2 ± 1 . 3  fold) to cisplatin without altering cellular 
glutathione content or the activity of glutathione-S-transferase in the transfected cells. 
Studies by Niimi et al. (1991) disagreed with these results when they showed that NIH3T3 
cells transfected with c-Ha-ras had increased resistance to alkylating agents (e.g. 
melphalan) but not to adriamycin, VP-16 or cisplatin.
4.1.3 Transcription Factors and their role in MDR
Transcription factors are known to be early responders to cellular stress from 
chemotherapeutic drugs. Evidence in the literature suggests that the three oncogenic 
transcription factors, c-fos, c-jun and c-myc, affect chemoresistance in cancer cell lines.
A study by Zhao et al. (1995) demonstrated that c-jun is induced by exposure to cisplatin 
in a sensitive melanoma cell line but less so in cisplatin-resistant variants of the human 
melanoma line, RPMI8322, and may be involved in a cisplatin-induced apoptosis 
pathway. A preliminary in vivo study described the induction of c-jun mRNA in head-neck 
tumour biopsies from patients responding to cisplatin-based chemotherapy, but not in 
samples from resistant tumours (Los et al., 1995). Ribozyme-mediated reduction of c-fos 
levels has previously been shown to affect drug sensitivity in cisplatin resistant cell lines 
(Funato et al., 1992; Scanlon et al., 1991) and other multidrug resistant variants (Scanlon 
et al., 1994). In these studies it was observed that c-fos mRNA was only over-expressed 
in the adriamycin-selected DLKP-A variant and not the carboplatin or VP-16 selected cell 
lines. A correlation has been shown between expression of P-glycoprotein and c-fos and c- 
jun products in human lung carcinomas (Volm et al., 1993). In renal cell carcinomas a 
significant relationship also existed between P-glycoprotein, GST-tt and Topoisomerase II 
and c-fos (Volm et al., 1993). The AP-1 transcription factor (complex of Fos/Jun dimers - 
see Section 1.4.3) was previously shown to be crucial for full promoter activity of the 
Chinese hamster P-glycoprotein (Teeter et a l., 1991).
Cell lines derived from a patient presenting with adenocarcinoma of the colon and treated 
with cisplatin and 5-fluorouracil showed a two fold amplification in DNA copy number of 
the c-myc gene and a fifteen fold increase in c-fos amplification (and also c-Ha-ms (4 
fold)) (Kashani-Sabet et al., 1990). More direct evidence of a role for Myc family 
members in clinical drug resistance came from a study by Bordow and co-workers (1994) 
who showed that expression of the MRP gene correlated with amplification and over­
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expression of the N-myc oncogene in childhood neuroblastoma; no correlation was found 
with P-glycoprotein expression.
In vitro studies carried out by Niimi et al. (1991) demonstrated that NIH3T3 cells 
transfected with c-myc had increased resistance to cisplatin, 4-hydroxycyclophosphamide, 
adriamycin, melphalan and CPT-11 and were the first to report a role for c-myc in drug 
resistance. Mai (1994) found that c-myc over-expression precedes amplification of the 
dihydrofolate reductase gene in CHO-9 cells which has been shown to affect resistance to 
methotrexate. Levels of c-myc and c-jun were increased in resistant variants of the human 
prostate PC3 cell line and treatment with VP-16 or cisplatin induced c-myc mRNA in 
sensitive PC3 cells (Sinha et a l., 1995). Walker and co-workers (1996) found that the rat 
c-myc gene displayed a sustained (analysed after 2 and 7 days) 2-fold elevation in 
expression following single-dose of 1 mg/kg cisplatin chemotherapy. Antisense approaches 
targeted at the c-myc gene reduced cell growth rate and the authors concluded that 
antisense therapy directed at c-myc in combination with cisplatin may achieve therapeutic 
efficacies in vivo. Sklar and Prochownik (1991) also demonstrated a direct link between 
levels of c-myc expression in Friend murine erythroleukaemia cells and cisplatin 
resistance. The increased expression of c-myc in the carboplatin resistant cell line, DLKP- 
C14, is in agreement with these findings in the literature of increased c-myc expression in 
cisplatin resistant cell lines.
4.1.4 Oncogene Expression in Resistant Variants of DLKP
As has been discussed in previous sections, evidence is gathering in the literature to 
suggest that expression of several oncogenes affects chemosensitivity levels in cell culture 
systems. In this thesis analysis of expression of c-erbB-2, c-Ha-rasl, c-fos, c-myc and the 
bcl-2 family members, bcl-2, bcl-x and bax, was carried out on multidrug resistant 
variants of the human lung cancer cell line, DLKP. These variants were previously 
established by continuous exposure to adriamycin, (DLKP-A; Clynes et al., 1992), 
carboplatin (DLKP-C14; I.Cleary, 1995) and VP-16 (DLKP-VP3 and DLKP-VP8; 
M.Heenan, 1994). Analysis of oncogene expression in a variety of different multidrug 
resistant variants selected by exposure to different drugs has not previously been carried 
out on such a broad range of oncogenes. These cell lines display differing cross-resistance 
profiles, as can be seen in Table 4.1.4.1. As these resistant variants are composed of 
heterogenous populations, analysis of gene expression can be masked by different genetic
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clonal populations co-existing in the parental line. To address this problem clonal 
populations of the adriamycin selected line, DLKP-A, were also included in this study. 
The least resistant clone, DLKP-A2B, and the most resistant clone, DLKP-A5F, (Heenan, 
1997) were analysed for the expression of oncogene levels. Fold resistance of the clonal 
populations is also given in Table 4.1.4.1.
Table 4.1.4.1 Fold resistance o f DLKP Variants
Adriamycin Cisplatin Vincristine VP-16 5-Fluorouracil
DLKP-A 254 + 119 1.46 + 0.42 1504 ± 707 61 ± 8 1.75 + 0.74
DLKP-A2B 37 + 16 0.57 + 0.07 228 ±71 18 ± 8 1.28 ±0.77
DLKP-A5F 3 3 1+ 69 1.39 + 0.03 1275 ± 625 51 ± 8 0.98 ±0 .47
DLKP-VP3 90 ±13 0.32 ±0.17 1089 ±161 58 ± 2 0.47 ±0 .38
DLKP-VP8 272 ± 38 0.22 ± 0.06 1737 ± 348 101 ± 7 0.90 ±0 .43
DLKP-C14 1.67 12.2 1.12 1.9 0.77
This analysis was carried out by Dr.M.Heenan and Dr.I.Cleary.
Signalling cascades of cellular messages begins at the plasma membrane. The first players 
in this cascade are proteins such as growth factor receptors. In this work multidrug 
resistant cell lines were shown to over-express the c-erbB-2 gene, a plasma membrane 
protein that is highly homologous to the epidermal growth factor receptor, relative to the 
sensitive parental DLKP line. c-erbB-2 expression levels (by RT-PCR) were increased 
dramatically in the resistant lines selected by exposure to adriamycin, carboplatin and VP- 
16 studied. Levels of c-erbB-2 mRNA in the sensitive cell line, DLKP, were barely 
detectable by densitometry (Figure 3.3.2(b)). This result is in direct agreement with a 
previous study which showed increased resistance to adriamycin, cisplatin and VP-16 in a 
study of human non-small cell lung cancer cell lines (Zhang and Hung, 1996). Western 
blot analysis for the c-erbB-2 p i85 protein also showed elevated levels in the DLKP-A 
and VP-16 selected, DLKP-VP3 and DLKP-VP8, resistant variants of DLKP.
The study of these highly resistant cell lines suffers from two major disadvantages. The 
first is the high levels of resistance seen in these cells (DLKP-A is 200 fold more resistant 
than DLKP to adriamycin) which may distort the effect of a single gene, or a group of 
genes, in these systems. The second is the heterogenous nature of these cell lines making 
it difficult to study the true effect of gene expression in individually selected cells. To 
overcome the latter problem clonal populations of the adriamycin-selected cell line,
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DLKP-A, were analysed for oncogene expression by RT-PCR. From the resistant line, 
DLKP-A, clonal populations of varied resistance levels were isolated (Heenan et al., 
1997). The least resistant clone, DLKP-A2B, and the most resistant clone, DLKP-A5F, 
were used in this study. Analysis was carried out on two RNA extractions for each gene 
analysed. Analysis revealed higher c-erbB-2 mRNA expression in the more resistant 
DLKP-A5F cell line relative to DLKP-A2B. The over-expression of c-erbB-2, at the 
mRNA level, in all resistant variants analysed implies a general role for c-erbB-2 in 
response to a variety of mechanistically different chemotherapeutic drugs and supports 
some clinical studies that suggest that c-erbB-2 expressing tumours would benefit from 
more aggressive treatment. A few reports have suggested that c-erbB-2 over-expressing 
tumours maintain sensitivity to adriamycin (Bacus et al., 1994; Paik, 1992). In this thesis, 
however, MDR lines developed by exposure to adriamycin also over-expressed c-erbB-2. 
Highest mRNA levels were seen in the DLKP-C14 variant, however, which suggest that a 
c-erbB-2 over-expressing tumour should not be treated with carboplatin containing 
regimens.
Previous results have shown that the signal transducer protein, c-Ha-ras, is important in 
the resistance of cell lines to cisplatin and VP-16 (Sinha et a l., 1995). However, Niimi et 
al. (1991) demonstrated conflicting results when they showed that NIH3T3 cells 
transfected with c-Ha-ras had increased resistance to alkylating agents but not to 
adriamycin, VP-16 or cisplatin. In this thesis, c-Ha-ras levels of expression were elevated 
in the carboplatin-selected line, DLKP-C14, the adriamycin-selected line, DLKP-A and 
the VP-16 selected variant, DLKP-VP3, but not in DLKP-VP8 (Figure 3.3.2(d)). 
Increased expression of the poor prognostic marker c-Ha-rasl was also seen in the DLKP- 
A5F cells relative to DLKP-A2B cells (Figure 3.3.1.3(b)). c-Ha-ras has previously been 
shown to regulate the transcription of c-fos which has been shown to control transcription 
of m drl (responsible for resistance in DLKP-A and the VP-16 selected lines) and 
metallothionein (responsible for resistance in DLKP-C14), therefore, elevations in the 
levels of c-Ha-ra.v is not unexpected in the DLKP resistant variants. Why decreased 
expression is seen in the DLKP-VP8 line relative to DLKP-VP3 is unknown as DLKP- 
VP8 is more resistant than the DLKP-VP3 variant. However, P-glycoprotein levels 
(Appendix E) are not always over-expressed in the DLKP-VP8 cell line relative to DLKP- 
VP3 (M.Heenan, 1994).
170
Transcription factors are the ultimate target of cellular signalling and are known to be 
early responders to cellular stress from e.g. chemotherapeutic drugs. Expression of three 
transcription factors, c-fos, c-jun and c-myc, which are known oncogenes, was analysed in 
drug resistant variants of the DLKP cell line.
c-myc expression was decreased in the adriamycin and VP-16 selected cell lines, although 
higher levels were observed in the carboplatin-variant (Figure 3.3.2(a)). c-myc has been 
shown to induce apoptosis in the presence of growth inhibiting factors (Mihich and 
Schimke, 1994), therefore, reduced c-myc in cells may give cells a survival advantage, c- 
myc levels are reduced in DLKP-A, DLKP-VP3 and DLKP-VP8 cell lines. The increased 
resistance of c-myc in the carboplatin selected line, DLKP-C14, is in agreement with 
previous studies by other laboratories (Niimi et al., 1991; Sklar and Prochownik, 1991; 
Walker et al., 1996).
c-fos expression was not detected (or detected at very low levels) in the sensitive cell line, 
DLKP, nor was it detected in the carboplatin or VP-16 selected lines, increased expression 
was, however, seen in the adriamycin-selected variant (Figure 3.3.2(c)). Expression of c- 
jun was detected, by RT-PCR, in the cell lines analysed but as it is an intron-less gene and 
its mRNA produces the same sized fragment as its amplified DNA sequence, it was not 
included in any further studies, as RT-PCR could not be relied on for definitive analysis. 
Pre-treatment of the RNA with a DNase enzyme was performed (results not shown) to 
reduce contaminating DNA but could not be relied on to destroy all residual DNA. 
DLKP-A, DLKP-VP3 and DLKP-VP8 all over-express the m drl gene (see Appendix E) 
and it is surprising to find that the VP-16 selected cell lines do not over-express c-fos. The 
AP-1 complex can substitute its c-Fos counterpart for a c-Jun homo-dimer or can be 
substituted by another member of the c-Fos family of genes such as Fral (Kim and Beck,
1994). Therefore AP-1 activity may be increased in these latter resistant variants without 
presenting an increase in c-Fos expression. The protein found to be responsible for 
resistance in the DLKP-C14 cell line is the metallothionein protein (I.Cleary, 1995), 
which also has an AP-1 site in its promoter (Scanlon et al., 1991).
Analysis of c-fos levels in the clonal populations revealed high levels of expression in 
DLKP-A and DLKP-A5F, with very low levels of expression seen in the DLKP-A2B 
clone (Figure 3.3.1.1b). This trend was also seen for m drl expression in these cell lines 
(see Appendix E).
Resistant variants of an ovarian cell line, OAW42SR, were used as a model of well 
characterised low-level resistant cell lines in this study. The adriamycin-selected resistance
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variants OAW42A and OAW42A1 are 14 and 26 fold more resistant to adriamycin 
respectively, than the sensitive OAW42S clone, respectively (Appendix D). Differential 
expression of common MDR-related genes such as m drl and Topoisomerase Ha and 
Topoisomerase I  could be detected in these OAW42SR variants, as shown in Figure 
3.5.1.1. In these resistant cell lines, however, a dramatic reduction was seen in the 
expression of c-fos mRNA in the resistant OAW42A and OAW42A1 cell lines.
4.1.5 Bcl-2 family and their role in MDR
Evidence is accumulating over the past ten years to suggest that expression of bcl-2, the 
apoptosis suppressing gene, in malignancies results in a poor prognosis, with 
chemotherapy having minimal impact on the disease (Horning and Rosenberg, 1984). The 
resulting “drug-resistant” tumours would, therefore, be expected to express elevated levels 
of survival genes as these cells have survived an attack from an apoptosis-inducing agent 
and subsequently developed resistance to that agent. The balance of expression of 
members of the Bcl-2 family determines if a cell should live or die. Increased expression 
of the apoptosis-suppressing genes would favour survival while pre-dominance of 
apoptosis-promoting genes would result in cell death (Section 1.7).
Reports in the literature are often conflicting in attempts to determine the role Bcl-2 plays 
in vivo as a prognostic marker for response to chemotherapy. Maung et al. (1994) 
demonstrated that increased expression of Bcl-2 in blasts from patients with acute 
leukaemia is associated witii a poor initial response to chemotherapy and that expression is 
higher in patients on relapse than on presentation. Expression of the Bcl-2 protein and 
resistance to doxorubicin was shown in a study of squamous cell carcinomas (Volm and 
Mattern, 1995) where a correlation was found in these tumours between expression of P- 
glycoprotein and glutathione S-transferase-rc, the common MDR markers. These results 
indicate that Bcl-2 may be a good parameter by which to determine the likelihood of 
developing resistance. Ironically, many reports have suggested that Bcl-2 expression is an 
indicator of good prognosis in response to chemotherapy (Gasparini et al., 1995; 
Hurlimann et al., 1995) whereas a study on Bcl-2 expression in 231 colorectal 
adenocarcinomas treated with 5-fluorouracil showed no influence of gene expression on 
treatment outcome (Schneider et al., 1997). Stoetzer et al. (1996) demonstrated a 
significant correlation between the ratio of Bcl-2 to Bax expression, clinical response and
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failure to achieve complete remission in patients with a Bcl-2:Bax ratio >  1.
The importance of expression of Bcl-2 family members in tumour types which readily 
respond to chemotherapy or frequently develop resistance has been addressed in vitro. 
Metastatic testicular cancers are curable (Frei, 1985) whereas most other solid tumours are 
not e.g. bladder cancers. Three testicular cancer cell lines were analysed and they were all 
found to contain high expression of Bax and did not express the Bcl-2 protein; the three 
bladder cell lines analysed expressed Bcl-2 but did not express the Bax protein thereby 
adding further support to the relevance of Bax:Bcl-2 ratio and response to chemotherapy 
(Chresta et a l., 1996) in human tumours. This finding adds further support to the work of 
Stoetzer et al. (1996) who demonstrated the importance of Bax:Bcl-2 ratio and response to 
chemotherapy in vivo. Small cell lung carcinoma tumours are initially responsive to 
chemotherapy but multidrug resistance tends to develop on relapse, however, these 
tumours express relatively low levels of P-glycoprotein. The expression of Bcl-2 in small 
cell lung carcinoma cell lines was studied by Ikegaki et al. (1994) and found to be high in 
five out of six cell lines and the authors suggest that the high level of expression of Bcl-2 
in these cells may account, in part, for the development of multidrug resistance in these 
tumours. A significant number of ovarian tumours (tumours which also frequently develop 
resistance) have been shown to express Bcl-2 and the Bcl-2 protein was found to be over­
expressed in an ovarian cell line, A2780, developed by continuous exposure to cisplatin 
(Eliopoulos et al., 1995). The relevance of Bcl-2 in ovarian carcinoma drug resistance in 
vivo is still unknown, however. Human malignant gliomas are largely resistant to current 
strategies of surgery, chemotherapy, radiotherapy and immunotherapy, Weller et al. 
(1995) described stable bcl-2 transfected human glioma cell lines with increased resistance 
to chemotherapeutic drugs such as cisplatin.
High levels of Bcl-2 protein in pre-B human leukaemia 697 cells delayed taxol-induced 
DNA fragmentation and apoptosis (Tang et al., 1994). Taxol has been shown to induce 
Bcl-2 phosphorylation (via Raf-1 activation (Blagosklonny et al., 1996) or independently 
of Raf-1 activation (Ibrado et a l. , 1997)) in prostate cancer cell lines (Haidar et a l., 1996), 
which results in the inhibition of the hypo-phosphorylated protein binding to Bax. The 
authors conclude that taxol may be the treatment of choice for Bcl-2 positive tumours. Tu 
et al. (1996) demonstrated that treatment of myeloma cell lines with doxorubicin, 
etoposide and hydrogen peroxide consistently induced a concentration and time-dependent
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up-regulation o f Bcl-2 in all cell lines tested. Levels o f  Bcl-x w ere not affected. Results 
found by Lasorella et al. (1995) indicate that the over-expression o f Bcl-2 detected after 
retinoic acid-induced differentiation o f neuroblastom a cells represents a likely mechanism 
that contributes to deregulation o f the apoptotic response to anticancer agents and drug 
resistance. (It is possible that tum our cells expressing a m ore differentiated phenotype 
resist apoptosis or that therapy itself induces differentiation.) T he results found indicate a 
strong association between differentiation induced by retinoic acid, a dim inished apoptotic 
response to cytotoxic agents, and increased bcl-2  expression in neuroblastom a cells. 
W alton e t al. (1993) showed that a m urine IL-3 dependent cell line, FL 5 .12 , transfected 
with bcl-2  was tw o-fold m ore resistant to both nitrogen m ustard and cam ptothecin, two 
m echanistically different DNA -dam aging drugs. This indicates a ¿>d-2-dependent apoptotic 
pathway involved in  determ ining the extent o f drug-induced death and a novel mechanism 
o f drug-resistance.
Dole e t al. (1994) transfected bcl-2  plasm ids into a Bcl-2 negative hum an neuroblastom a 
cell line (Shep-1) and found that clones expressing high levels o f Bcl-2 w ere resistant to 
cisplatin and etoposide induced cytotoxicity in a dose dependent m anner, supporting the 
hypothesis that Bcl-2 enhances the m alignant phenotype o f neuroblastom a by prom oting 
tum our resistance to chem otherapeutic agents. T he effects o f Bcl-2 expression appeared to 
be especially im portant when the cells are exposed to chem otherapeutic agents like 
cisplatin for short periods o f tim e (as w ould be the case during therapy). After pulsed 
treatm ent with cisplatin (lO ^g/m l for 4 hours), Bcl-2 expressing cell lines show an 
enhanced survival and a sustained proliferative advantage as com pared to cells which do 
not express the protein. These findings support the notion that Bcl-2 expression may 
provide a m echanism  for drug resistance in vivo.
To examine the relevance o f Bcl-2 to drug resistance, K itada e t al. (1994) used anti-sense 
techniques to reduce the levels o f steady state Bcl-2 protein levels in t(14; 18) containing 
hum an lym phom a cell lines. Treatm ent o f the t(14;18)-containing lym phom a line, SU- 
DHL-4, w ith 18-mer synthetic M -2-an tisense  oligonucleotides produced sequence-specific 
reductions in the relative levels o f bcl-2  m RN A  within one day; a corresponding reduction 
in protein levels took  longer ( ~  3 days) probably due to the long half-life o f the Bcl-2 
protein ( ~  10-12 hours). This antisense-m ediated reduction in Bcl-2 protein levels in 
these cells did not accelerate the ra te o f cell death but rather it rendered cells m ore prone 
to apoptosis caused by an additional stress i.e. growth factor loss or treatm ent with 
chem otherapeutic drugs. In conclusion, these investigators found that antisense approaches
174
that resulted in average reductions o f  30-40%  in the relative levels o f  Bcl-2 protein 
enhanced the sensitivity o f t(14;18)-expressing lym phom a cell lines to conventional 
chem otherapeutic drugs such as m ethotrexate and arabinoside C. Thus, a putative new 
chem otherapeutic strategy could include the induction of D N A  dam age w ith conventional 
chem otherapeutic drugs, while sim ultaneously m odulating regulators o f the apoptotic 
pathway acting downstream  o f the conventional cytotoxic drugs, thereby enhancing the 
relative sensitivity o f cancer cells to drug-induced damage.
Previous reports indicate that bcl-2  is regulated by oestrogen. To study this regulation in 
vitro , M C F-7 (oestrogen receptor positive cell line) cells w ere used (Teixeira et a l .,
1995). M C F-7 cells express the bcl-2  m RN A  when grow n in m edia containing oestrogen 
and m RNA levels are down-regulated when oestrogen is rem oved from  the media, 
coincidental w ith this finding was that oestrogen depletion doubled the sensitivity o f  the 
M CF-7 cells to the cytotoxic effects o f  adriam ycin. No change in Bax levels w ere seen. 
M CF-7 cells transfected with bcl-2  expression plasm id displayed a m arked increase in 
resistance to adriam ycin, in the absence o f oestrogen. In the presence o f oestrogen, M CF- 
7 cells expressing bcl-2  antisense transcripts w ere partially sensitised to the effects o f 
adriam ycin (Teixeira e t a l., 1995). This result supports the theory that som e anti- 
oestrogens increase the sensitivity o f breast cancer cells to adriam ycin by decreasing 
cellular levels o f  Bcl-2.
Further evidence o f the role bcl-2  plays in drug resistance was show n by M iyashita and 
Reed (1992). M iyashita and Reed (1992) published evidence to support the theory that 
Bcl-2 interferes with a (but not the only) pathway for cell death that is activated by 
m ultiple drugs used for the treatm ent o f cancer. W hen cultured for one day in the 
continuous presence o f 10^M  m ethotrexate, 1.5¡j.M 1-p-D-arabinoside or lp M  vincristine,
S49.1 and W EH I cells tranfected with the bcl-2  cD NA underw ent m uch less DNA 
fragm entation and cell death than the untransfected control cells. T reatm ent o f the same 
cells with 35fiM o f VP-16 produced com parable levels o f DNA fragm entation and 
percentage cell death in control and transfected cells, indicating that Bcl-2 did not confer 
resistance to this drug (at least at the concentration used in this study). The drugs to which 
Bcl-2 producing S49.1 and W E H 17.2 (T-lym phoid clones) cells displayed increased 
resistance have diverse mechanisms o f action thereby showing that bcl-2 functions in a 
final com m on pathway of P rogram m ed Cell Death that can be activated by m ultiple 
mechanisms. H ow ever, treatm ent o f  the bcl-2 expressing cells w ith H 20 2 resulted in cell 
death and DN A  fragm entation, revealing that bcl-2 does not protect cells from  all types o f
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drugs that induce cell death and that bcl-2 dependent and independent pathways exist for 
the regulation o f cell survival. A study on the effect o f etoposide-induced (exposed to 
17.3f.iM for 1 hour) apoptosis revealed that bcl-2  had little effect on the form ation 
/disappearance o f DNA strand breaks (initial D N A  dam age by the drug) although it did 
inhibit apoptosis (secondary DNA fragm entation) induced by the cytotoxic agent 
(Kamesaki e t a l . , 1993), supporting the theory that bcl-2  m ust w ork dow nstream  o f drug- 
mediated damage.
F isher e t  al. (1993) surm ised that the survival o f  DNA dam aged cells, and the delay in the 
onset o f apoptosis, prom oted by Bcl-2 expression may lead to increased m utation o f the 
genom e and the later em ergence o f cells with greater oncogenic potential and/or drug 
resistance i.e. may allow for the alteration seen in “typ ical” drug resistant m arkers. This 
m ay be the reason for the significant correlation o f P-glycoprotein levels w ith Bcl-2 
expression in studies by Volm  and M attern (1995).
The data collected on the role o f the Bcl-2 fam ily and chem oresistance has been used to a 
favourable advantage by enforcing the expression o f Bcl-2 in bone m arrow  cells, thereby 
circum venting m yelosuppression (bone m arrow  cell death) by increasing the resistance of 
bone m arrow  cells to apoptosis caused by Topoisom erase inhibitors (Kondo e t a l . , 1994).
4.1.5.1 Bax and role in MDR
Studies have been described to suggest that the ratio o f Bcl-2 to Bax (Bax acts as a 
prom oter o f cell death (Section 1.7)) is im portant in chem oresistance (Chresta, 1996; 
Stoetzer,1996). Those tum ours that express high levels o f Bcl-2:Bax are m ost likely to fail 
in response to chem otherapy (Stoetzer, 1996).
It has been shown that low Bax expression m ight contribute to the pathogenesis o f breast 
cancer (Bargou e t a l . ,  1995) and results by Krajewski and co-w orkers (1995) indicated 
that m arked reductions in Bax expression occurred in a th ird  o f advanced breast cancers 
which w ere expected to respond poorly to chemotherapy (Krajewski e t a l ,  1995). 
Krajewsji e t a l  (1995) hypothesised that Bax m ay play an im portant role in the apoptotic 
elim ination o f tum our cells following exposure to DNA dam aging drugs and radiation. To 
test this hypothesis, a group o f 121 wom en with m etastatic adenocarcinom a o f the breast 
were studied for the expression o f the Bax protein, by immunohistochemical methods. The 
material studied was from  archival prim ary tum ours of patients who had enrolled for a
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tw o-arm  study designed to com pare efficacy and toxicity o f  com bination chemotherapy 
delivered in either four weekly divided doses or once a m onth (total drug dose and 
duration being equal) - the response ra te was higher in those who received therapy once a 
m onth. Bax status was found to correlate with the response ra te in the weekly dose group 
but not the m onthly dose group (also found for Bcl-2). O f the  119 prim ary breast tum our 
samples immunostained, 34%  had reduced Bax expression in greater than 90%  o f the cells 
com prising the invasive com ponent. Bax negative tum ours tended to achieve less 
frequently a partial response or com plete response than those with Bax positive tum ours 
(i.e. 21%  vs. 43% ). Bcl-2 status was not found to be o f  prognostic significance for 
response rate or overall survival. Loss o f  Bax staining w ithin tum our cells infiltrating 
through the strom a may be o f significance to m etastatic disease - decreased Bax could 
represent a mechanism  that contributes to acquisition o f a m etastatic phenotype (decreased 
tendency o f  these cells to undergo apoptosis when they lose attachm ent w ith extracellular 
m atrix proteins). Elevations in the Bcl-2:Bax ratio did not p revent drug-induced apoptosis 
but rather shifted the dose response curve so that an increased concentration o f drug was 
required to achieve an equivalent tum our cell kill. W om en w ith Bax negative tum ours 
m ight benefit, therefore, from m ore aggressive chem otherapy. U nlike Bcl-2, no 
correlation was found between Bax expression and oestrogen or progesterone receptor 
status in this study.
In vitro  studies have dem onstrated a definite role for Bax and sensitisation to 
chem otherapeutic drugs. W agener e t al. (1996) transfected the b ax-a  gene into the  breast 
cancer cell lines R30C and M CF-7; the transfection did not affect viability by itself but 
strongly increased chem osensitivity to epirubicin. Reduced expression o f bax  m RNA was 
seen in cisplatin resistant variants o f the IGROV-1 ovarian carcinom a cell line (Perego et 
a l., 1996). In the resistant variants o f DLKP analysed in this thesis, elevated levels o f bax  
m RNA was seen, however. T he carboplatin-resistant variant, D LK P-C 14, which showed 
m inim um  resistance to adriam ycin, vincristine and VP-16 did express the highest level of 
bax  m RNA . A high Bax to Bcl-2 ratio was found to be associated with hypersensitivity to 
etoposide-induced apoptosis in hum an testicular tum our cell lines (Chresta e t a l . ,  1996).
4.1.5.2 Bcl-x and its role in MDR
Studies on Bcl-x levels and response to chem otherapeutic drugs in cancer have been
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addressed. The short from  o f  the gene, bcl-xs , acts as an inducer o f  apoptosis whereas the 
long form , bcl-xL, inhibits the apoptotic response o f  cells. O ver-expression o f bcl-xs 
should, therefore, result in sensitisation o f cells to chem otherapy which was shown by 
Sum antran e t al. (1995). O ver-expression o f b d -x s  in M C F-7 cells sensitised the cells to 
apoptosis induced by low  concentrations o f V P -16 and taxol (9- and 4-fold respectively) 
(Sum antran e t a l . ,  1995). This result suggests that bcl-xL or bcl-2  m ay play a role in 
modulating apoptosis and chem oresistance in these cells.
Increased expression o f Bcl-xL w ould be expected to confer a survival advantage on cells 
and a resulting chem oresistant phenotype. M inn e t al. (1995) showed that the expression 
o f Bcl-xL could confer a m ultidrug resistant phenotype on F L 5 .12  m urine cells. Bcl-xL 
expression was found to dram atically reduce the cytotoxicty o f bleom ycin, cisplatin, 
etoposide and vincristine; its expression did not prevent cells from  undergoing cell cycle 
arrest in response to these drugs rather it prevented the treated  cells from  undergoing 
apoptosis. b d -X i can protect cells in Gi, S and G2/M  phase and although it is generally 
accepted that S-phase cells are m ore susceptible to apoptosis, this study showed that Bcl-xL 
effectively protects cells arrested in S-phase by etoposide and cisplatin. V incristine-treated 
cells expressing Bcl-xL becam e polyploid after drug rem oval and the ability of Bcl-xL to 
prevent apoptotic death in response to chem otherapeutic induced DN A  damage and cell- 
cycle arrest may allow the accum ulation of chromosom al aberrations frequently seen in 
hum an tum ours. T he findings in this report that show Bcl-xL conferring a m ultidrug 
resistant phenotype and allowing cells to rem ain arrested until they reacquire the ability to 
proliferate, make Bcl-xL expression a potential tum our prom oter. A spontaneously resistant 
variant o f the m urine P388 leukaem ia cell line was found to  over-express Bcl-xL (Kuhl et 
a l., 1997). This cell line was found to have an unusual phenotype w ith cross-resistance to 
M D R  and non-M DR related cytotoxins such as cam ptothecin, alkylators and U V  light. 
Transfection with the bcl-xL cD N A  also resulted in a sim ilarly  broad cross-resistance 
profile. P-glycoprotein was found to play a m oderate ro le  in the resistance o f this 
spontaneously resistant cell line. Over-expression o f bcl-xL m R N A  was seen in all resistant 
variants o f the DLK P cell line which exhibited cross-resistant profile only to the M D R  
cytotoxins. D ole e t al. (1995) found that over-expression of bcl-xL in a neuroblastom a line, 
Shep-1, also conferred a survival advantage on cells by inhibiting both cisplatin and 4- 
hydroxycyclophospham ide-induced cell death; how ever, after treating these cells with VP- 
16 only a short-term  delay in the onset o f apoptosis was seen. In the analysis o f  the DLKP
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variants, the VP-16 selected lines (DLKP-VP3 and D LK P-V P8) expressed the highest 
levels o f bcl-Xi m RNA. The finding o f D ole and co-w orkers (1995) m ay be o f therapeutic 
im portance as it suggests that VP-16 may be able to  bypass the protective effects o f  bcl-xL 
in neuroblastom a tum ours. It is possible that an extended exposure to drugs that directly 
target Topoisom erase II could m ake transit through m itosis im possible and trigger 
apoptosis irrespective o f the presence o f bcl-xL.
4.1.6 Expression of BcI-2 Family Members in MDR variants of DLKP
Resistant variants o f the hum an squamous lung cell line, D LK P, developed by continuous 
exposure to M D R  (adriam ycin, VP-16) and non-M D R  (carboplatin) drugs w ere analysed 
for the expression o f the bcl-2  family m em bers, nam ely bcl-2 , bcl-x  and box.
Elevated levels o f expression o f the apoptosis suppressing gene, bcl-xL, m RNA in the 
m ultidrug resistant lines analysed in Section 3.3. are expected, as these cell lines are 
resistant to the apoptosis-inducing chem otherapeutic drugs adriam ycin, etoposide and 
carboplatin. bcl-2  did not appear to play a part in the resistance mechanism  o f these cell 
lines as expression at the m RNA level was undetected.
Increased expression o f  the apoptosis suppressing gene, bcl-xL, was seen in m ultidrug 
resistant variants o f the hum an lung cell line, DLKP, as detected after 23 cycles o f PCR. 
A slight increase was seen in expression o f this gene, by R T-PCR  analysis, in a 
carboplatin-selected line, D LKP-C14. Levels o f bcl-xL m R N A  w ere increased to 134% of 
that o f  D LKP in an adriam ycin-selected variant, DLK P-A and to over 200%  in VP-16 
selected variants (Figure 3.3 .1a). No expression o f b c l-2 a , another apoptosis suppressing 
gene, was detected by R T-PCR  after 30 cycles o f PCR  (F igure 3 .3 .1b).
Elevated levels o f the apoptosis-prom oting gene, bax, is also seen in the resistant lines, an 
unexpected result as it has been shown previously that decreased Bax is seen in resistant 
lines (Chresta, 1996; Perego, 1996; W agener, 1996). H ow ever, it is interesting to note, as 
the inherent ratio o f bcl-2 /bcl-xL to bax/bcl-xs  determ ines the ce ll’s susceptibility to death 
following an apoptotic stimulus (K orsm eyer, 1995) that the least resistant line D LKP-C14 
(see Appendix D) expresses the highest bax  levels and low est bcl-xL levels. The fact that 
these cell lines have been selected with different drugs and express different drug resistant 
m arkers (e.g . DLK P-A , -VP3 and -VP8 over-express m d r l  (M .H eenan, 1994) and 
DLKP-C14 over-expresses m etallothioneins (I.C leary, 1995)) m ay suggest that these 
findings are co-incidental and do not affect resistance m echanism s in these cells.
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W hen analysing clonal populations o f  the heterogenous D LK P-A  cell line an increase in 
m RNA expression o f bcl-xL in the D LK P-A 5F clone relative to DLKP-A2B (Figure 
3 .3 .1 .2a) and a relative increase in box expression in DLKP-A 2B relative to DLKP-A 5F 
(Figure 3 .3 .1 .2b) was observed. The inherent ratio o f bcl-2/bcl-xL to bax/bcl-xs determines 
the cell’s susceptibility to death following an apoptotic stim ulus (K orsm eyer, 1995) and 
results found in this study indicate that this may be o f relevance in the M D R  profile o f the 
DLK P-A variants : the increase o f  bcl-xL and relatively low er bax levels m ay give the 
D LK P-A 5F cells a survival advantage whereas the increase in  bax levels and relatively 
lower bcl-Xi m RN A  levels m ay m ake the DLKP-A2B clone m ore susceptible to apoptosis. 
C om parable results w ere obtained at the protein level by W estern  blotting (L .C onnolly, 
unpublished results); this w ork is on-going.
B cl-2  expression was detected in these cell lines (F igure 3 .3 .1 .1 (a)), although previous 
analysis o f DLKP-A revealed no expression o f the gene in  D LK P-A cells (Figure 
3 .3 .1(b)). The trend seen at the cD N A  level was increased bcl-2  expression in DLKP-A2B 
cells relative to DLKP-A 5F cells. Bcl-2 protein was not detected in these cells by W estern 
analysis (L .C onnolly, unpublished observations).
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4.2 Ribozymes as a Method for Circumventing MDR
The use o f  chem otherapy in the treatm ent o f som e cancers is lim ited due either to the 
tum our’s inherent resistance to therapy or developm ent o f  acquired resistance during the 
course o f treatm ent. A lternative treatm ents, involving gene therapy, are being actively 
sought in the treatm ent o f  cancer. O ne m ethod in use is tha t o f “ ribozym e cleavage” of 
key genes identified as playing a role in M DR.
Cech, in 1982, was the first to discover that RNA  splicing (rem oval o f introns and ligation 
o f exons to produce processed poly-A tail mRNA) (Freifelder, 1983) could be catalysed 
by RN A m olecules now know n as ribozym es (molecules that undergo intram olecular 
catalysis (e.g. self-splicing) or that act as enzymes (Cech, 1988)). Certain ribozym es can 
cleave substrate RNAs in a sequence-specific m anner (Cech, 1988).
A num ber o f catalytic R N A  m olecules have now been identified and are characterised by 
containing stretches o f nucleotides that base-pair with a com plem entary RNA region. Once 
the ribozym e has bonded to the substrate the catalytic region is in a position to cleave the 
bound RNA. Ribozym es differ in their three-dim ensional shape and have been term ed 
ham m er-head, hair-pin or axe-head (Barinaga, 1993).
Ribozym e-m ediated reduction o f the c-H a-ras oncogene expression in a cultured hum an 
bladder carcinom a cell line (EJ) resulted in a reduction in tum our form ation and invasion 
when these cells were im planted in nude m ice (Kashani-Sabet e t a l . ,  1992), thus 
supporting the role o f c-H a-ras in tum ourigenesis. C linical trials with ribozym e 
technology in HIV-1 infected patients is underway (Barinaga, 1993). Reversal of 
m ultidrug resistance by introducing a ham m erhead ribozym e against m d r l  into a P- 
glycoprotein positive cell line was shown to be  successful previously (Holm  e t a l . ,  1994a; 
Daly e t a l ., 1996).
Ribozymes directed against c-fos w ere targetted to drug resistant cell lines in which the 
gene was over-expressed. T he resulting reduction in fo s  gene expression was shown to 
enhance senitivity to a num ber o f chem otherapeutic drugs (Scanlon e t a l ., 1991). 
Interestingly, the expression o f the c-fos ribozm e in the hum an ovarian carcinom a cell 
line, A2780S, not only decreased the expression o f c -fos m R N A  but also decreased the 
expression o f the m d r l,  cfu n  and p53 genes. Reversal o f the M D R  phenotype by an anti- 
m dr  ribozym e occured one-fourth as rapidly as that induced by the c -fos ribozym e 
(Scanlon a l.,  1994).
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c-fos levels w ere found elevated in DLKP-A cells in this study by R T-PC R  analysis. To 
determ ine if  increased levels o f this gene affect drug resistance in the DLKP-A cell line, a 
ribozym e was transfected into DLKP-A cells. Six clones containing the ribozym e were 
maintained and assayed for effect on resistance in these cell lines. A driam ycin toxicity 
assays revealed m inim al effect o f the ribozym e on toxicity. This ribozym e is in an 
inducible plasm id and its expression is turned on in  the presence o f dexamethasone. 
How ever, naturally occurring steroids are present in serum  which may induce ribozym e 
expression also. As these assays were set up in m edium  containing serum , the true  effect 
o f the ribozym e m ay be masked. Studies including analysis in serum -free m edium  failed 
as the m edia used could not support the growth o f the cell lines analysed. The DLKP-A 
cell line is a highly resistant heterogenous population and analysis o f c-fos expression in 
clonal populations revealed that the gene is over-expressed only in the m ore resistant 
clones (Figure 3 .3 .1 .1(b)). A m ore accurate representation o f the effect o f c-fos ribozym e- 
mediated reduction in the expression o f this gene m ay have been realised if, when the 
ribozym e had been transfected into the D LK P-A 5F clonal population, individual DLKP- 
A5F'fos ribozym e clones had been isolated. As DLK P-A  is highly resistant to  many 
chem otherapeutic drugs (see Appendix D) and over-expresses the m d rl  gene and protein 
product (see Appendix E) it m ay be that c-fos has little effect on the M D R  phenotype 
observed in these cells. It is also unknown if  c-fos m ediates its effect on M D R  in DLKP-A 
cells by activating the m d r l  gene alone or as part o f  the AP-1 com plex. If  the latter is the 
case, a reduction in c-fos levels does not necessitate a reduction in AP-1 activity as the 
gene can be replaced by other family m embers in the com plex; therefore a reduction in c- 
fo s  levels in DLKP-A cells m ay have little effect on drug resistance profiles. Kim and 
Beck (1994) found elevated activity o f the AP-1 com plex in the hum an leukaem ic cell line, 
CCRF-CEM , which was due to c-jun m RNA induction and not increased c-fos levels; in 
these cell lines it was found that AP-1 activity was preferentially mediated by  c-j'wn/Fra-l.
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4.3 Development of a Clinically Relevant in vitro Model of MDR
To m ore accurately assess in vivo  levels o f  resistance, low-level resistant cell lines act as a 
m ore legitim ate in v itro  m odel. Clinically relevant resistance levels are in the order o f 2-8 
fold (Antman e t a l . ,  1987). Although m ost resistant lines are developed by continuous 
exposure o f  cells to drug over long periods o f  tim e (Clynes e t a l . ,  1993) in the clinic, 
patients m ay develop drug resistance after only several courses o f  chemotherapy.
To m im ic clinical drug resistance, m ethods o f in v itro  developm ent have altered in the 
recent past to favour the development o f drug resistant cell lines by pulse exposure o f cells 
to clinically attainable levels o f drug, over short periods o f tim e. R esistant variant o f the 
hum an colon tum our line, LoVo, has been developed by pulse-selection w ith adriam ycin 
(Yang and Trujillo , 1990) and was shown to possess a m ore stable and different toxicity 
profile to a variant developed by continuous exposure to the sam e drug. Lu e t al. (1988) 
described the establishm ent o f  a cisplatin-resistant cell line following weekly 1 hour 
exposures to cisplatin for 6 months. Interm ittent exposure o f  the hum an m yeloleukaem ic 
K562 cell line to either epirubicin or vinblastine over a 3-m onth period resulted in the 
establishm ent o f resistant variants which w ere m aintained w ith exposure to the selecting 
drug for a period o f 4 days every 4-5 weeks (M arks e t a l ,  1993); anthracycline resistant 
variants o f this cell line have also been established (H argrave e t a l . ,  1995). R esistant 
variants o f  the H L60 prom yelocytic cell line w ere also developed by treatm ent w ith low, 
clinically relevant levels o f epirubicin and vinblastine, for 18 hours over a 3-m onth period 
(Su et a l . ,  1994). C isplatin-resistant sub-lines o f the hum an m elanom a cell line RPM I- 
8322 w ere obtained by repetitive 30min exposures to increasing concentrations o f cisplatin 
during a period o f 3 years (Zhao e t a l . , 1995)
4.3.1 Selection of Low-level Resistant Variants from a Clonal Population
To date, m ost m ultidrug resistant cell lines have been selected from  non-clonal parental 
populations. Establishing drug resistant cell lines in this m anner gives rise to the 
possibility that inherently resistant cells, or cells with a survival advantage, are being 
selected from  the m ixed population. It is not know n, therefore, if the resistance seen in the 
selected variant is due to selection o f an inherently resistant cell in the parental population 
only or if it is due to the effect that the selecting drug had on the genetic m ake up o f the 
cell. To dem onstrate that an initially sensitive clonal cell population exposed to drug could
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develop resistance to adriam ycin the sensitive D LK P cell line, from  which DLKP-A, 
DLKP-VP3, D LKP-V P8 and DLKP-C14 cell lines w ere established, was used.
A resistant variant was selected from  DLKP-SQ , a clonal population isolated previously in 
this laboratory from  the parental DLK P cell line (S .M cBride, 1995), by continuous 
exposure to adriam ycin to a final concentration o f 250ng/m l. The selection process was 
carried out over two to three months. This selection resulted in the developm ent o f a 
resistant cell line, DLKP-SQ/A250c, that was 20 fold resistant to adriam ycin and also had 
increased resisitance to vincristine. Further characterisation of this cell line was not 
carried out.
Continuous exposure o f cells in culture to chem otherapeutic drugs does not accurately 
reflect drug concentrations to which patients are exposed in vivo . Pharm acokinetic studies 
of adriam ycin (a com m only used M D R -drug in the treatm ent o f prim ary breast and lung 
cancer) in  lung cancer patients (Piscitelli e t  a l . , 1993) revealed that drug concentrations of 
100 - 500ng/m l are attainable in serum  up to 4 hours after drug adm inistration.
It was therefore attem pted to use a selecting drug concentration o f 250ng/m l adriam ycin to 
develop a resistant variant o f DLKP-SQ, by weekly pulse exposure to the drug. A weekly 
pulse was chosen to allow any genetic m utation establish itself in the genom e. Successful 
selection o f a tw o-fold resistant line (to adriam ycin, VP-16, vincristine but not 5- 
fluorouracil or carboplatin) was achieved after pulse exposure to the selecting drug 
concentration for 4 hours once every 4 weeks (D LKP-SQ /4x4hA DR). Selection with the 
same drug concentration for 1 hour pulses did not result in resistance; this exposure to 
drug did not achieve the same cell kill as exposure for 4 hours, as this exposure tim e may 
not have allowed sufficient uptake o f drug. Exposing cells to drug for 8 hours killed all 
the cells initially, except for one colony w hich was not found to have significantly altered 
resistance.
This pulse exposure m ethod was repeated on  DLK P-SQ cells and after four pulses a four 
fold resistant variant was isolated (DLKP-SQ/A 250p). Continuing exposure (to ten pulses) 
of this cell line to adriam ycin resulted in the isolation o f the D LK P-SQ /A 25010p variant 
which grew readily following exposure to 250ng/m l adriam ycin for four hours. This 
resistant variant was found to be ten fold resistant to  adriam ycin, greater than forty fold 
resistant to vincristine bu t only three fold resistant to VP-16. No alteration in resistance to 
5-fluorouracil was seen for this cell line. Sim ilar trends in toxicity profile was seen for the
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highly resistant M D R  cell line DLKP-A, which was developed by continuous selection to 
adriam ycin.
Table 4.3.1.1 Fold resistance of DLKP-A
Adriamycin Vincristine VP-16 5-Fluorouracil
DLKP-A 254 + 119 1504 + 707 61 ± 8 1.75 + 0.74
Fold resistance of DLKP-A relative to its sensitive parental line DLKP (analysis M.Heenan, 1994)
To determ ine if  pulse exposure o f cells to drug is a stable and reproducible model to 
induce the developm ent o f m ultidrug resistance, replica selections w ere carried out with 
DLKP-SQ and another clone isolated from  the heterogenous DLKP population, DLKP-I. 
Analysis was confirm ed by the developm ent o f a resistant D LKP-SQ /A25010p2 and 
DLKP-I/A25010p cell line with sim ilar trends in toxicity profiles. Clonal populations o f 
DLKP-SQ/A25010p maintain stable resistance to adriam ycin (C .O ’Loughlin, 
pers.com m .).
O ther laboratories have also reported the selection o f resistant lines by pulse-exposure to 
clinically relevant concentrations o f drug.
H argrave e t al. (1995) treated the m yeloleukem ia cell line, K562, w ith 20ng/m l (34nM) 
doxorubicin for 3 days over a period o f 2 m onths. T he doxorubicin resistant variant 
(K/DOX) showed only low  levels o f cross-resistance to epirubicin (1.7 fold), daunoribicin 
(1.5 fold) and doxorubicin (1.5 fold). No cross-resistance to etoposide was seen and less 
than 5 fold resistance was seen for vinblastine, taxol and actinom ycin D. Interm ittent 
exposure o f K562 cells to epirubicin or vinblastine resulted in the establishm ent of 
resistant variants with cross-resistance profiles; as the selecting drug concentration 
increased, so too did the level o f  cross resistance (M arks et a l . ,  1993). All cell lines were 
slightly sensitised to VP-16. H ighest levels o f resistance w ere seen for vincristine which is 
in agreem ent with results found in this and previous studies.
Four treatm ents o f  H L60 cells with 8ng/m l epirubicin for 18-20 hours resulted in a 2.8 
fold resistant cell line which increased to 30 fold following a fifth treatm ent (H/E8 
subline); this cell line was m aintained w ithout loss o f resistance for over 12 months 
w ithout further drug treatm ent (Su e t a l . ,  1994). Increased resistance to idarubicin, 
vinblastine, taxol, etoposide and actinom ycin D was also seen for this cell line. HL60 
cells w ere slow er to adapt to growth in vinblastine, however 9 treatm ents induced a 4 fold
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resistant variant (H /V8) (Su et a l . , 1994).
Lu e t al. (1988) established a cisplatin resistant variant o f  the ovarian cell line, A2780. 
This A 2780C D D P (cisplatin-resistant) variant was established by treatm ent with 50^M  
cisplatin for 1 hour weekly for 6 months.
A pulse selected LoVo subline (SRA1.2) (Yang and T rujillo , 1990) was obtained by 
pulsing cells nine times with l.2 |ig /m l adriam ycin for one hour. T he resulting cell line, 
SRA 1.2 LoV o was found to be 2 .5  fold resistant to adriam ycin and dem onstrated a cross- 
resistant profile to the other M D R  drugs analysed. The resistance o f the cell line was 
stably m aintained.
T he establishm ent o f the D LK P-SQ/A 25010p cell line in this thesis dem onstrates a low, 
m ore clinically relevant, level resistant variant w hich may act as an in v itro  m odel o f  drug 
resistance. T he cell line was established after ten weekly pulses to adriam ycin to m imic 
clinical scheduling. DLKP-SQ/A25010p dem onstrates a cross-resistant profde to 
adriam ycin, vincristine and V P -16 but not 5-fluorouracil. A stable adriam ycin resistant 
phenotype was m aintained over a six-month period without further exposure to drug, and 
is therefore preferential to m any o f the other pulse-selected variants established in  other 
laboratories (Table 4 .3 .1 .2 ) which were m aintained by interm ittent exposure to drug.
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Figure 4.3.1.1 Selection of Adriamycin Resistant Variants from DLKP-SQ
DLKP-SQ
continuous exposure to increasing 
concentrations of adriamycin^
DLKP-SQ/A250C
exposure of DLKP-SQ 
to 4 pulses of 25Qng/ml 
adriamycin
!
DLKP-SQ/A 250p
repeat exposure of DLKP-SQ to 10 
pulses of 250ng/ml adriamycin
D LK P-SQ /A 25010p2
further exposure of 
DLKP-SQ/A250p to a 
total of 10 pulses of 
250ng/ml adriamycin
1
D LK P-SQ/A25010p
Figure 4.3.1.2 Selection of Adriamycin Resistant Variant from DLKP-I
D LK P-I
exposure of DLKP-SQ 
to 10 pulses of 250ng/ml 
adriamycin
D LK P-I/ A 2501Op
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Cell line Cell type Selecting Drug Drug concentration 
Time-scale
Fold-resistance 
(selecting drug)
Stability Reference
A549 lung adriamycin uM, 24 hour (3 months) stable without drug Chevillard et al., 1992
K/DNR myeloleukemic daunorubicin 35t)M, 3 days 
2 months
2.5 intermittent drug exposure Hargrave el a l., 1995
K/DOX myelolekemic doxorubicin 34r|M, 3 days 
2 months
1.5 intermittent drug exposure Hargrave et al., 1995
K/EPR myeloleukemic epirubicin 34t|M, 3 days 
2 months
6.8 intermittent drug exposure Hargrave et al., 1995
K/IDA myeloleukemic idarubicin 36r|M, 3 days 
2 months
1.0 intermittent drug exposure Hargrave et al., 1995
A549(VP)28 lung adenocarcinoma etoposide 1 hour weekly 
28 weeks
8.1 Long et al., 1991
A549(VM)28 lung adenocarcinoma teniposide 1 hour weekly 
28 weeks
6.8 Long et al., 1991
HCT116(VP)35 colon carcinoma etoposide 1 hour weekly 
35 weeks
8.6 Long et al., 1991
HCT116(VM)34 colon carcinoma teniposide 1 hour weekly 
34 weeks
6.6 Long et al., 1991
A2780DDP ovarian cancer cisplatin 50(j.M, 1 hour weekly 
6 months
17.2 stable Lu et al., 1988
K562/E40 myeloleukemic epirubicin 40r|g/ml, 3-14 days 
3 months
3.3 intermittent drug exposure 
18 months
Marks et al., 1993
K562/V8 myeloleukemic vinblastine 8r|g/ml, 3-14 days 
3 months
8.0 intermittent drug exposure 
18 months
Marks et al., 1993
CCRF-CEM/P TLL methotrexate 3jj.M, 24 hour Pizzomo et al., 1988
H/E8 promyelocytic epirubicin 8T]g/ml, 18-22 hours 
3 months
2.8 (4 pulse) 
30 (5 pulse)
stable without drug 
12 months
Su et al., 1994
H/V8 promyelocytic vinblastine 8T|g/ml, 18-22 hours 
3 months
4.3 stable without drug Su et al., 1994
SRA1.2 LoVo colon tumour adriamycin 1.2|a.g/ml, 9 x 1  hour 2.5 stable without drug 
10 months
Yang and Trujillo, 1990
Drug-resistant human cell lines developed by pulse exposure to chemotherapeutic drugs. CCRF/CEM is the human T lympoblast leukemic (TLL) cell line. K =  
K562 myeloleukemic cell line; H =  HL60 promyelocytic cell line. Stability of the drug-resistant phenotype is stated when reported in the literature.
Table 4.3.1.2 Human Drug-resistant Cell Lines selected by Pulse-exposure to Chemotherapeutic Drugs.
4.4 Drug Accumulation Studies in Pulse Variants
Decreased drug accum ulation has been im plicated as a m echanism  o f resistance in many 
animal (Inaba and Johnson, 1978; Skovsgaard, 1978; Breier e t a l . ,  1994) and hum an (Fojo 
e t a l ., 1985; W iebe e t a l . ,  1992) M D R  cell lines and usually  occurs as a result of over­
expression o f the m d r l  gene, which encodes the P-glycoprotein trans-m em brane pump. In 
addition to a reduction in accum ulation, M D R  cell lines may also exhibit altered 
distribution and com partm entalisation o f drug in vesicles, away from  the nucleus (target 
site) and into the cytoplasm  (Chauffert e t a l . , 1984). A driam ycin is com m only used in 
drug accum ulation studies as it fluoresces under ultraviolet illum ination and is readily 
visualised by fluorescent m icroscopy. Sensitive cells have been shown to accumulate 
adriam ycin in the nucleus whereas resistant variants contain m ainly cytoplasm ic 
accum ulation (W illingham e t a l . , 1986; H indenburg e t a l . ,  1987; Versantvoort e t a l., 
1993; Barrand et a l . ,  1993).
A driam ycin accum ulation was analysed in the resistant variants o f  DLKP-SQ and DLKP-I 
to determ ine if  drug accum ulation is involved in the resistance m echanism  o f these cell 
lines. In the sensitive parental lines, intense nuclear accum ulation was observed, in 
agreem ent with previous findings, after 4 .5  hours o f exposure to lOpM  adriam ycin. The 
nucleoli o f  these cells w ere free o f adriam ycin as was the cell cytoplasm . T he resistant 
variants developed by pulse exposure to adriam ycin, DLKP-SQ/A2501 Op and DLKP- 
I/A 25010p, accum ulate adriam ycin in the cytoplasm , in agreem ent with other studies on 
m ultidrug resistant cell lines. D LKP-SQ/A 250c, developed by continuous selection with 
adriam ycin, did not accum ulate adriam ycin in its nucleus and less drug was seen in these 
cells’ cytoplasm  com pared to that seen in the pulse-selected variants. Adriam ycin 
accum ulation in these cell lines was therefore found to  be inversely proportional to the 
degree o f resistance.
Analysis o f m d r l  m RNA levels was carried out in these cell lines and it was found that 
DLK P-SQ/A 25010p, D LKP-I/A 25010p and D LK P-SQ /A 250c had elevated expression of 
the m d rl  gene with highest levels seen in DLKP-SQ/A250c. This is supportive o f results 
o f P-glycoprotein m ediated drug exclusion. The total exclusion o f  adriam ycin from  the 
nucleus o f these resistant variants is interesting as the pulse-selected cell lines are only 10 
and 16 fold resistant to adriam ycin, respectively. The level o f  m d r l  gene expression in
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DLKP-SQ and D LK P-I resistant variants was m uch less than that detected in highly 
resistant lines such as DLKP-A (see Appendix E) but these DLK P-SQ and DLKP-I 
resistant variants w ere as effective in preventing drug accum ulation in the cell. Previous 
adriam ycin accum ulation studies on highly resistant variants o f the D LK P cell line 
dem onstrated reduced drug accum ulation in the resistant variants following 2 hour 
incubations in IO(iM adriam ycin. In the m ost sensitive DLK P-A  clone, DLKP-A2B, 
intense nuclear fluorescence was observed in 65%  of the cells (I. C leary, 1995). Level of 
adriam ycin resistance in DLKP-A2B is som ewhat sim ilar to that seen in  D LK P-SQ/A250c 
cells although drug exclusion from  the nucleus o f the D LK P-SQ /A 250c cell line was 
absolute. The m ost resistant clone, DLKP-A 5F, had very faint nuclear fluorescence but 
intense staining in distinct areas in the cytoplasm  (I. C leary, 1995). As the pulse-selected 
variants w ere exposed to sim ilar concentrations o f drug for a longer length o f tim e (4.5 
hours vs. 2  hours) it was assum ed that the lower resistant cell lines w ere as effective in 
preventing drug accum ulation as the highly resistant DLK P-A variants and that the result 
was not an artifact o f  drug exposure tim e. This im plies that m uch o f the P-glycoprotein 
detected in highly resistant lines may be redundant or that other mechanisms may be 
involved in drug exclusion in these low-level resistant variants. H ow ever, studies on the 
DLKP-A variants were not carried out at the sam e tim e as the D LK P-SQ  / DLKP-I 
variants and, therefore, cannot be used as an absolute standard. Further analysis, which 
should include a com plete study w here the DLK P-A  variants could be com pared to the 
DLKP-SQ variants.
The sensitive DLKP-I clone was transfected with the m d r l  ribozym e (S.M cBride, 1995) 
and adriam ycin accum ulation studies analysed. G reater nuclear accum ulation o f 
adriam ycin was seen in the m d rl  ribozym e expressing clone than the parental DLKP-I 
clone, a novel observation which shows a ro le  for P-glycoprotein in adriam ycin uptake 
studies in sensitive cells. Selection o f the m d r l  ribozym e expressing clone, DLKP- 
b«cW Rz2D 4, by pulse exposure to adriam ycin produced the resistant variant DLKP- 
brctfr7Rz2D4/A25010p with a sim ilar cross-resistant profile to  that o f  DLKP-I/A 25010p. 
This variant was shown to express m d r l  but to a lesser extent than that seen in its sister 
cell line DLK P-I/A 25010p. A driam ycin accum ulation studies revealed greater localisation 
o f drug in the cytoplasm than that seen in either the D LK P-SQ /A 25010p or DLKP- 
I/A25010p variants which suggests a ro le  for P-glycoprotein drug exclusion in this 
system. As no significant difference in toxicity levels w ere seen between DLKP-
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I/A25010p and D LK P-bnrfriR z2D 4/A 25010p but less m d r l  m RN A  was detected in the 
ribozym e expressing variant, results m ay imply that m echanism s other than P-glycoprotein 
is involved in adriam ycin accum ulation, such as bcl-xL, o r else only a small threshold of 
m d rl m RN A  is necessary and has been attained by the ribozym e-expressing resistant 
variant. Some cells in the resistant population shows strong nuclear accum ulation o f 
adriam ycin suggesting a m echanism  other than P-glycoprotein m ediated drug accum ulation 
in these cells or that these cells have lost their resistant phenotype. To investigate this, 
clonal sub-populations should be isolated and analysed for resistance profile and 
adriam ycin accumulation.
As no over-expression o f the m d r l  gene was seen in the 4 fold resistant variant DLKP- 
SQ/A250p after 25 cycles o f PCR  and only a slight increase in m RNA levels (relative to 
DLKP-SQ) w ere seen when am plification was increased to 30 cycles, future drug 
accum ulation studies should include this cell line as a possible m odel for non- or low-level 
P-glycoprotein mediated drug accum ulation. Analysis o f  adriam ycin accum ulation in the 
DLK P-SQ /A250p cell line could determ ine if a low er threshold o f P-glycoprotein 
expression is sufficient to reduce drug accum ulation to the sam e extent as that seen in the 
DLKP-SQ(I)/A25010p variant. Also to determ ine if  m echanism s other than P-glycoprotein 
m ediated drug accum ulation are involved in resistance m echanism s in the DLKP-SQ 
pulse-selected model, the bcl-xs  transfected variant w ith reduced resistance, DLKP- 
SQ/ A25010pbclxs .3, should be included in such studies as this cell line has no apparent 
altered m d r l  levels (results not shown).
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4.5 Analysis of Oncogene Expression in Resistant Variants of DLKP-SQ
By tim e-lapse video-m icroscopy it was shown that exposure o f  DLKP-SQ cells to 
250ng/m l adriam ycin for 4  hours induced an apoptotic pathw ay in these cells. A cell line 
that grows readily in this concentration o f drug w ould therefore be expected to have 
increased resistance to apoptosis and perhaps altered expression o f apoptosis-related genes 
or other genes known to affect cell proliferation.
Initial studies, by R T-PCR analysis, on RNA isolated from  D LK P-SQ, D LKP-SQ/A 250p 
DLKP-SQ/A25010p and D LKP-SQ/A 250c revealed and increase in bcl-xL (the apoptosis 
repressing gene) expression in DLKP-SQ /A250p, D LK P-SQ /A 250c and to a greater extent 
in DLKP-SQ/A 25010p. Levels o f the antagonistic bax gene was also elevated in the m ore 
highly resistant cell lines bu t not in the DLK P-SQ/A250p variant. This trend was also 
seen in the highly resistant D LK P variants studied in Section 3.3 w here up-regulation of 
apoptosis supporting and repressing genes was detected in all resistant variants. 
Expression o f bcl-2  was not detected in these cell lines by R T-PCR .
The balance o f m em bers o f  the bcl-2  family (including bcl-2, bcl-x, bax, and others 
decribed in Section 1.7.1.2) o f proteins in the cell determ ines the cell’s inherent ability to 
undergo apoptosis. Cell death will occur in either o f two w ays, the first being an increase 
in apoptosis-supporting genes such as bcl-xs or bax or a reduction in apoptosis-repressing 
genes such as bcl-xL or bcl-2.
Previous studies have shown that introduction o f bcl-xL or bcl-2 into cells increases 
resistance to apoptosis-prom oting agents such as chem otherapeutic drugs cD NA 
(M iyashita and Reed, 1992; D ole et al., 1995; M inn et a l., 1995). Equally introduction of 
bcl-Xs or bax sensitises cells to apoptotic stimulus (Sum antran et a l., 1995; W agener et 
al., 1996).
As bcl-xL m RNA was found to be over-expressed in the DLK P-SQ /A 25010p resistant cell 
line it was decided to introduce the antagonistic bcl-xs cD N A  into this cell population to 
determ ine if  expression o f the gene (which was not detected in the parental cell) could 
sensitise the m ultidrug resistant variant to chem otherapeutic drugs.
F ive stably transfected clones w ere isolated and grow n as individual cell lines. Toxicity 
levels o f four o f these cell lines w ere analysed as the fifth clone was lost to fungal
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contam ination. It was found that two o f these bcl-xs expressing cell lines (DLKP- 
SQ/A25010p-&c£cs . 1 and .4) were slightly m ore sensitive to adriam ycin, vincristine and 
V P -16 but not to 5-fluorouracil (all o f which are know n to induce apoptosis). The DLKP- 
SQ /A 2501 Op-bclxs.2 cell line showed increased resistance to the M D R  drugs but not 5- 
fluorouracil. T herefore bcl-xs expression sensitised cells only to drugs that the resistant 
line was m ore resistant to. Analysis o f DLKP-SQ/A25010p-Z?cfe.3 (shown, by R T-PCR 
analysis, to express the highest levels o f the bcl-xs  gene) revealed a 66%  decrease in 
adriam ycin toxicity levels, a 55%  decrease in V P -16 toxicity levels to alm ost DLKP-SQ 
sensitive levels bu t only a 38 % decrease in vincristine toxicity  levels which in the resistant 
line were increased 43 fold. As adriam ycin and vincristine m ediate their toxicity via the P- 
glycoprotein pum p the difference in resistance levels in  the  bcl-xs  transfected variant is 
interesting. No sta tis tica l alteration to 5-fluorouracil toxicity  was observed. The lack o f 
effect on 5-fluorouracil toxicity may imply that the apoptotic pathway induced by this 
pathway is not affected by the bcl-2 family in this system .
Table 4.5.1 Fold Resistance of DLKP-SQ/A25010pZ>cZ-xs.3
Adriamycin Vincristine VP-16 5-Fluorouracil
DLKP-SQ 1 1 1 1
DLKP-SQ/A25010p6cto.3 3.4 26.3 1.3 1.1
DLKP-SQ/A25010p 10.0 42.9 2.9 2
Fold resistance of bcl-xs expressing cell line relative to the parental resistant DLKP-SQ/A25010p 
line and sensitive DLKP-SQ cell line.
bcl-Xs cDNA was transfected into the DLKP-SQ cell line and toxicity pro fde analysed. No 
change in sensitivity to adriam ycin or vincristine, V P -16, 5-fluorouracil (analysis by 
S.Touhey, pers.com m .) was seen for the D L K P -S Q /bclxs . 1 clone com pared to the parental 
DLKP-SQ cell line. This observation agrees with the result found for the resistant variant 
whereby bcl-xs only appears to act against the MDR phenotype and not intrinsic/sensitivity 
levels of the cell lines. As bcl-xs only affects drugs to which D LK P-SQ/A25010p has 
increased resistance it appears that the over-expression o f  bcl-xL in the resistant variant has 
a functional effect on resistance levels in this cell line.
Analysis o f other oncogene products by R T-PCR  on resistant variants o f  DLKP-SQ 
revealed over-expression o f  c-fos gene in the three resistant variants with greatest
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expression seen in DLKP-SQ/A25010p. T he m d r l  gene has previously been shown to 
have an AP-1 prom oter site and to be induced in the presence o f AP-1 (c-Fos/c-Jun). In 
clinical studies on lung cancer, levels o f P-glycoprotein w ere shown to correlate with the 
expression o f c -fos and c-jun (Volm et a l.,  1993). Previous analysis on expression o f c -fos 
levels in clonal populations o f DLKP-A revealed over-expression o f m d r l  in DLKP-A and 
DLKP-A 5F relative to DLKP-A2B; a sim ilar trend was seen for the expression o f c-fos. 
Analysis o f D LKP-SQ variants dem onstrated an over-expression o f c-fos in DLKP- 
SQ/A250p and D LK P-SQ /A 250c and to a greater extent in D LK P-SQ /A 25010p. Analysis 
o f m d rl  levels was shown to be highest in the D LK P-SQ /A 250c variant and therefore 
expression o f elevated expression o f c-fos did not agree with elevated expression o f m d r l.
c-crbB -2  m RN A  levels w ere over-expressed in the D LKP resistant variants. Analysis of 
DLKP-SQ variants revealed no over-expression o f the gene product in these low-level 
resistant lines. Further analysis, however, o f  DLKP-SQ and DLKP-SQ/A 25010p revealed 
up-regulation o f c-erbB -2  gene expression in the D LKP-SQ /A25010p resistant variant.
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4.6  Induction vs. Selection in the DLKP-SQ M odel o f Resistance
The general opinion in the field is that drug resistance is fundam entally a result o f  genetic 
m utations establishing them selves in the genom e o f inherently sensitive cells. M ost 
resistant cell lines established to date have been selected from  heterogenous populations. 
In this scenario it is unknow n if  the resulting resistant cell line is due to the selection of 
pre-existing, intrinsically resistant cells, or cells with a survival advantage, from  the 
mixed parental cell line. To overcom e this problem  in part, sensitive clonal sub­
populations o f the DLK P cell line were used to act as a m odel to develop resistance. Any 
genetic change which occurs in the resulting resistant population is, therefore, directly 
caused by exposure to the chem otherapeutic drug. To determ ine if  resistance developm ent 
in the DLKP-SQ model is a result o f  drug-induced m utation or induction o f a set of 
resistance-related genes, further studies m ust be undertaken. Such studies could include 
the exposure o f DLKP-SQ to one pulse o f adriam ycin and subsequent isolation and 
propagation o f a num ber o f clonal sub-populations. Should all these sub-populations 
respond to a second pulse with adriam ycin in a sim ilar m anner, the initial event in the 
developm ent o f resistance is m ost likely as a resu lt o f  gene induction, rather than 
spontaneous m utation.
Gene expression follow ing exposure o f D LK P-SQ cells to adriam ycin was m onitored in 
these studies to determ ine if  adriam ycin could induce the expression o f M D R-related 
genes or oncogenes believed to play a role in drug resistance.
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4.7  Gene Induction following Adriamycin administration
To successfully design im proved or alternative therapies to overcom e the developm ent of 
drug resistance in vivo, it w ould be advantageous to study the effect chem otherapeutic 
drugs have on transcription o f genes associated w ith the developm ent o f resistance. 
Sensitive cell lines vary in their ability to develop resistance (Section 3 .5 .4) and 
com parison o f the ability o f these cell lines to respond to chem otherapeutic drugs, at the 
transcriptional level, m ay yield valuable inform ation on initial events in the development 
o f drug resistance - prevention being better than cure! A driam ycin was chosen in  these 
prelim inary studies to determ ine what genes, if any, are induced by drug exposure in the 
DLKP-SQ cell line that readily develops resistance to adriam ycin. R T-PCR  analysis was 
used to m onitor gene expression.
4.7.1 Induction of m d rl Expression Following Adriamycin Administration
Kohno and co-w orkers (1989) w ere the firs t to report the direct activation o f the m d rl  
gene prom oter by anticancer agents such as adriam ycin, daunom ycin, vincristine and 
colchicine in transient expression systems. Later w ork by Chaudhary and Roninson (1993) 
analysed the effect of short-term  chem otherapeutic drug adm inistration on levels of the 
m d rl  gene in a num ber o f sensitive cell lines derived from  leukaem ias or solid tum ours. 
M ost cell lines displayed transient induction o f the m d r l  gene follow ing short-term  
exposure to adriam ycin, daunorubicin, vinblastine, etoposide, cisplatin and other drugs. 
Induction o f m d r l  in the K562 leukaemia cell line was stable for a num ber o f  weeks. 
Induction in all cell lines analysed was only evident in the presence o f m orphologically 
detectable cell damage.
Gekeler and co-w orkers (1994) also found increased m d r l  m RN A  levels in the T- 
lym phoblastoid hum an cell line, CCRE-CEM , following adm inistration o f sub-lethal 
concentrations o f actinom ycin D or adriam ycin. Increased m d r l  m RN A  levels w ere also 
seen in the hum an sarcom a cell line, M ES-SA, following treatm ent with 40nM  adriam ycin 
for 14 days (Chen e t a l .,  1994). Hu and co-w orkers (1995) also found up-regulation of 
m d rl m RNA in a M D R  variant o f the C CRF-CEM  T-cell lym phoblastic leukaem ia cell 
line following 4 hour exposure to 1 .5^g/m l daunorubicin and epirubicin and 6 hour 
exposure to a sim ilar concentration o f  adriam ycin. Previous studies in this laboratory 
revealed up-regulation o f m d r l  gene expression in OAW 42SR cells, but not D LK P cells,
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after exposure to 0.1 or l.O^g/ml adriamycin for 72 hours (O’Driscoll, 1994).
In this thesis, D LKP-SQ  cells w ere exposed to concentrations o f  drugs used previously in 
these studies to select resistant variants (Section 3 .5 .2 ). Cells w ere exposed to adriam ycin 
at 25ng/m l continuously and at 250ng/m l for 4hours. R N A  was extracted after certain 
time-spans had elapsed and analysed by R T-PCR  for the expression o f m drl m RNA. This 
study did not show  induction o f the m drl gene under these conditions, suggesting either a 
failure in detection by R T-PCR or that up-regulation o f this gene is not an initialising 
event in developm ent o f  resistance in the DLKP-SQ model.
To determ ine if m drl is im portant in initialisng resistance in the D LK P model, a 
previously transfected DLKP-I expressing the m drl ribozym e (S.M cBride, 1995) was used 
as a model for resistance developm ent in the absence o f m d rl gene up-regulation. Pulse 
selection o f D L K P-Im driR z2D 4 and its sister cell line, DLKP-I, with 250ng/m l 
adriam ycin for 4hours resulted in the developm ent o f resistance variants. The DLKP- 
I/A25010p was found to be 16 fold resistant to adriam ycin whereas the ribozym e variant 
was only 10 fold resistant (although difference was not statistically relevant). Up- 
regulation o f  the m drl gene was seen in both variants but expression in the ribozym e- 
expressing cell line was reduced relative to D LK P-I/A 25010p. These results m ay indicate 
the presence o f a partially effective ribozym e or that som e cells have lost ribozym e 
expression. Som e cells, when analysed for adriam ycin accum ulation, showed strong 
nuclear staining w hereas others did not. This is the first study in the literature to describe 
selection from  an m d rl ribozym e expressing cell line. It is inconclusive from  this result 
whether m drl gene induction is an initialising event in the developm ent o f the m ultidrug 
resistant phenotype.
4.7.2 Induction of c-fos Expression Following Adriamycin Administration
Levels of early transcription factors such as c-fos, c-jun or c-myc have previously been 
shown to be induced following short-term  exposure to chem otherapeutic drugs. Kim and 
Beck (1994) reported induction o f c-jun m RN A  in the hum an leukem ic lym phoblast cell 
line, C CRF-CEM , following 6 hour treatm ent with 10(xM VM -26. A dm inistration o f 
cisplatin for 1 hour induced expression o f c-fos m R N A  (Kashani-Sabet e t a l., 1990a). 
Treatm ent o f the hum an prostate PC3 cell line with lOO^M VP-16 caused significant 
increases in c-myc expression in a tim e-dependent m anner but had little effect on
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expression o f c-jun, however (Sinha et a l., 1995). In  contradiction to the up-regulation of 
c-myc by V P-16, down-regulation o f c-myc levels were seen when M CF-7 cells were 
exposed to IOjxM VM -26 (O rr e t a l., 1995) or 50nM  adriam ycin (Fornari et a l., 1994) for 
up to 72 hours and lead to growth arrest (but not apoptotic death) in those cells. Fornari 
and co-workers (1996) dem onstrated that acute exposure o f M CF-7 cells to lp M  
adriam ycin also resulted in a decrease in c -myc expression.
c-fos is an “ im m ediate early gene” w hose expression is up-regulated in response to 
cellular stress and has also been shown to be im portant in the developm ent o f drug 
resistance, c-fos levels were increased in D LKP-SQ  on exposure to adriam ycin. Addition 
o f fresh m edia only, however, induced c-fos levels to som e extent as well (F igure 3 .6 .3 .1 ) 
so the extent o f  the adriam ycin effect w ould need further interpretation.
Up-regulation o f c-fos has been show n as an early response to m any cellular stress signals 
including chem otherapeutic drugs (Janknecht, 1995). The response is im m ediate and 
expression peaks w ithin 15min; levels o f expression are norm ally returned to basal level 
w ithin 30min.
To determ ine the effect o f  c-fos on initialising events in the developm ent o f drug 
resistance, DLKP-SQ cells were transfected with the c-fos ribozym e. All clones isolated 
grew  well in serum -supplem ented media. Unsuccessful attem pts were m ade to grow  the 
clones in serum -free media. Three clones w ere used as m odels in the pulse-selection 
process. These clones were set up in norm al ATCC m edia (control) and in 
dexamethasone-supplemented m edia (which induced the expression o f the c-fos ribozym e). 
On pulse exposure to adriam ycin none o f the clones assayed, either in the presence or 
absence o f dexam ethasone survived. Death o f the control cells m ay indicate the induction 
o f the c-fos ribozym e by basal levels of dexam ethasone in serum  (as was shown by RT- 
PCR analysis, F igure 3 .9 .2 .1); therefore, it appears that c-fos expression is an im portant 
m echanism o f  stress response to adriam ycin in  the DLKP-SQ  model.
P-glycoprotein is known to contain an AP-1 site in its prom oter region. Recently another 
prom oter site in the m drl prom oter region for a newly discovered transcription factor, 
YB-1, was found (Rubin et a l., 1992). Expression o f this transcription factor was 
localised in the cytoplasm  in sensitive cells but was detected in the nucleus o f  drug- 
resistant cells and was associated with m drl expression (Bargou et a l . , 1997).
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4 .7 .3  Induction o f bcl-xL Expression Following Adriam ycin Adm inistration
bcl-xL was chosen to determ ine if  an apoptosis-suppressing gene expressed in resistant 
variants o f D LK P is induced as an early response to chem otherapeutic drug treatm ent. 
Initial studies on the inductive effect o f  continuous exposure to 25ng/m l adriam ycin on 
bcl-xL expression revealed a steady increase o f gene levels w ith tim e, as studied by RT- 
PCR. Induction was also seen w ith pulse exposure to adriam ycin (F igure 3 .11 .1 .1). 
Repeat analysis did not, however, reveal a sim ilar trend, so unfortunately no conclusion 
can be drawn. T im e constraints prevented further repeats.
B d -x L is an apoptosis repressing gene and levels o f expression are up-regulated in all 
resistant variants analysed. Any gene that gives a cell a survival advantage would be 
favoured in the selection process and m ay allow for the later developm ent or over­
expression o f  com m on M DR m arkers such as P-glycoprotein. Prelim inary gene induction 
studies in this thesis m ay indicate a role for b d -x L in initial events in the developm ent o f 
the m ultidrug resistant phenotype. A previous report (Tu e t a l . ,  1996) dem onstrated the 
induction o f b d - 2  m RNA in response to doxorubicin (0.2 or l.OfiM) in the 8226 myeloma 
cell line as early as 4 hours after treatm ent.
To address the role o f b d -x L in initial stages in the developm ent o f drug resistance the 
antagonistic b d -x s  gene (which prom otes apoptosis) was introduced in the D LK P-SQ  cell 
line. Stable expression of the b d -x s gene was seen in the five isolated clones, without 
alteration in adriam ycin sensitivity. Pulse exposure o f these cells to adriam ycin resulted in 
total cell kill o f  one clone, DLKP-SQ/&c/-jcs . 1; all other cell lines survived and grew 
readily in repeated pulses with adriam ycin. No alteration in IC 50 values for adriam ycin, 
VP-16, vincristine or 5-fluorouracil was seen between DLKP-SQ and DLKP-SQ /bclxs . 1 
(S.Touhey pers.com m .). As this response was only seen w ith one out o f five clones, 
further analysis is essential to prove that this effect was indeed due to the forced over­
expression o f the bd-X s  gene. No change in the rate o f  apoptosis was seen betw een DLKP- 
SQ and this b d -x s  transfectant. Kitada and co-w orkers (1994) also found that the sim ilar 
effect o f reducing the b d - 2 /b d - xL to bax/bcl-xs ratio by b d -2  anti-sense technology did 
not accelerate the basal rate o f cell death but rather it rendered the cells m ore prone to 
apoptosis caused by an additional stress such as chem otherapeutic drugs.
As bd-Xs sensitises cells to apoptotic-inducing agents it w ould be expected that b d -x s 
over-expression would sensitise DLKP-SQ to adriam ycin treatm ent. Expression o f b d -x s
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in the DLKP-SQ  cell line prevented the developm ent o f resistance in one o f  the clones and 
may support the idea that bcl-xL is an initialising event in the developm ent o f the 
m ultidrug resistant phenotype. The basis o f resistance developm ent is in the stable 
establishm ent o f  m utations in the cell’s genom e. The DLK P-SQ  cell line readily adopts 
m utations caused by adriam ycin and develops into the resistant population, DLKP- 
SQ/ A25010p. Resistance was not established in the D L K P -S Q /^cfe . 1 cell line following 
pulse treatm ent with adriam ycin. T he over-expression o f bcl-xL in the DLK P-SQ  pulse- 
m ethod m ay allow  m utations to establish in the genome by giving the cells a survival 
advantage, as proposed for bcl-2  by F isher (1993). The fact that the DLK P-SQ  transfected 
with bcl-Xs does not develop resistance suggests that this gene is neutralising the effect 
seen by bcl-xL.
4.7.4 Induction of c-erbB-2 Expression Following Adriamycin Administration
c-erbB -2  was studied as it is a well accepted m arker o f poor prognosis in lung and breast 
cancer. R ecent evidence has show n that the protein plays a ro le  in the developm ent o f 
drug resistance and it was also shown in previous w ork to be over-expressed in all 
resistant variants o f the DLK P line studied (Figure 3 .3 .2b). c-erbB -2  levels w ere also 
increased on exposure to adriam ycin but repeat analysis did not concur (F igure 3 .6 .2 .1).
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4.8  In vitro M odel used in Search o f Chemical Inhibitors o f R esistance Developm ent
The oncogenes studied in this thesis are part o f signalling cascades w hereby a m essage is 
received at the plasma m em brane and transduced through the  cytoplasm  to the nucleus. 
Intracellular signalling pathways m ediating the effects o f oncogenes on cell growth or 
transform ation offer novel targets for the developm ent o f anticancer drugs (Powis, 1994). 
M ost anti-cancer agents developed to date target the cell’s DN A  and as only 12% of 
hum an cancers are cured by chem otherapy treatm ent a rationale for new  approaches to 
drug design is essential. In  the circum vention o f the m ulti drug resistance phenotype 
minim al success has been realised w ith agents such as verapam il and cyclosporin A as 
these agents have significantly toxic side effects (Ford, 1995). To achieve reversal of 
M DR in vivo  w ith m ost o f  the com m on circum venting drugs require doses o f modulators 
near to or even exceeding the m axim um  tolerated doses o f those drugs leading to 
unacceptable toxicity (Philip e t a l . ,  1992). This area o f research actively needs new agents 
to either prevent the developm ent o f the resistance phenotype or circum vent the 
established phenotype thus allowing the com m on chem otherapeutic drugs to exert their 
effect.
Protein phosphorylation and de-phosphorylation is fundamental to cellular signalling. The 
two m ajor signalling pathways in the eukaryotic cell consist o f phosphorylation on 
serine/threonine or tyrosine residues in proteins and are controlled by serine/threonine or 
tyrosine kinases and phosphatases, respectively. Com m on m ediators o f  serine/threonine 
phosphorylation signals are protein kinase C, c-AM P dependent protein kinase A, 
m itogen-activated protein kinases and cdc2 kinase. T yrosine kinases include receptor 
kinases such as ras fam ily and non-receptor protein tyrosine kinases such as c-src. 
Evidence has indicated a ro le  for the calcium - and phospholipid-dependent protein kinase 
C in the regulation o f P-glycoprotein activity (Chaudhary and Roninson, 1992) and some 
reports indicate that inhibitors o f  protein kinase C (e.g. staurosporine, calphostin C) 
increase drug accum ulation in M D R cells (reviewed by Skovsgaard, 1994). O ver­
expression o f protein kinase C alone has been shown to produce an M D R  phenotype 
without changes in P-glycoprotein expression (Fan e t a l . ,  1992).
4.8.1 Inhibition of the MDR Phenotype by P-glycoprotein Inhibitors
Cyclosporin A , a hydrophobic cyclic peptide o f 11 amino acids that is widely used as an
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im m unosuppressive agent in hum an organ transplantation, has been found to reverse 
resistance to anthracyclines, vincristine and V P -16 (but not cisplatin and radiation) in 
m any M D R  cell lines (reviewed by Stewart and Evans, 1989). C yclosporin A has been 
found to act as a P-glycoprotein substrate and antagonises P-glycoprotein, at least in part, 
through com petitive inhibition o f cytotoxic drug efflux (Ford, 1995).
In this study, standard toxicity assays were carried out on D LK P-SQ  and DLKP- 
SQ/A25010p cells to analyse the effect cyclosporin A had on adriam ycin toxicity in these 
cell lines. Concentrations o f adriam ycin w ere chosen which w ere close to the average IC50 
value for adriam ycin i.e. 15ng/ml for DLKP-SQ  and 150ng/m l for DLKP-SQ/A25010p. 
In this assay however, this drug concentration only achieved 10 - 30%  cell kill. Three 
concentrations o f each o f the co-selecting drugs was used. Increased cell kill was seen in 
DLKP-SQ and DLKP-SQ/A25010p cells when co-treated w ith cyclosporin A (results are 
sum m arised in Table 4 .8 .2). This effect was dose-dependent and higher concentrations of 
cyclosporin A achieved greater cell kill with sim ilar concentrations o f adriam ycin. The 
highest concentration o f cyclosporin A used achieved only 10-20% kill in  control (not 
treated w ith adriam ycin) cells.
This assay was carried out on triplicate plates on the same day, tim e constraints prevented
further analysis.
4.8.2 Effect of Tyrosine Kinase Inhibitors on the MDR Phenotype
To determ ine if signalling events are involved in the establishm ent o f the clinically 
relevant in v itro  model o f drug resistance in the DLKP-SQ cell line, a num ber o f putative 
inhibitors o f the phosphorylation pathways w ere used. These inhibitors have also been 
shown to affect com m on m arkers o f  M D R  such as M RP (genistein; Versantvoort e t a l . ,  
1993, 1995, 1995a and 1996) and Topoisom erase II (emodin; M uller e t a l . ,  1996).
Genistein is a naturally occurring dietary protein tyrosine kinase inhibitor that is 
hypothesized to be reponsible for the low er rate o f  breast, colon and prostate cancer in 
asian populations (Steele e t a l . ,  1995). T he chemical has exhibited various biological 
properties relevant to chem oprevention, including antioxidant and anti-inflam m atory 
activity, anti-angiogenic properties and anti-m etastatic activity. Akiyam a and co-workers 
(1987) and Sibley et a l. (1987) described a ro le for this chemical in inhibiting tyrosine 
kinase activity, an activity inherent to approxim ately one-half o f the know n oncogenes
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(Hunter, 1984). Since then, genistein is frequently em ployed as a chemical probe to 
explore signal transduction pathways. Korom a and de Juan (1997) suggest, however, that 
the efficacy o f genistein as an inhibitor o f protein tyrosine kinase is very low in 
endothelial cells. In agreem ent with this result is the finding by Peterson and Barnes 
(1996) that genistein inhibited the grow th o f breast cancer cells in culture without gross 
inhibition o f protein tyrosine kinase activity. Okura and co-w orkers (1988) reported the 
inhibition o f H -ras m orphological transform ation in NIH -3T3 cells by genistein. C lark e t  
a l. (1996) dem onstrated the inhibition o f breast cancer cell proliferation by genistein 
m ediated through the ras signalling pathway. Induction o f  c-fos expression by platelet 
activating factor in hum an epiderm oid A-431 cells could be inhibited by genistein 
(Tripathi e t a l ., 1992). Inhibition o f protein tyrosine kinase activity by genistein caused a 
decrease in c-myc expression in two colon cancer cell lines, H CT8 and SW 837 (Heruth e t 
a l.,  1995). Liu and co-w orkers (1994) postulated a role for ty rosine kinase activity in 
induction o f apoptosis (and reduction in b c l-2 a  m RNA levels) by the chem otherapeutic 
drug taxol which could be blocked by genistein in the hum an OV2008 ovarian tum our cell 
line.
Genistein, a non-DN A intercalator, also inhibits the activity o f topoisom erase II in vitro  
with IC 5o values around 111 |iM  (M arkovits e t a l., 1989). V ersantvoort e t a l. (1993, 1995, 
1996) have reported that genistein is a potent inhibitor o f  M R P- but not P-gp-m ediated 
daunorubicin transport.
Em odin, an anthraquinone with clinical cathartic properties, exhibits a variety o f 
biological effects including im m unosuppressive and vasorelaxant activities and is 
frequently used as a laxative and anticancer agent in  Chinese m edicine (Su e t a l ., 1995). 
Su and co-w orkers (1995) dem onstrated an antim utagenic effect o f em odin against the 
carcinogenic nitro-polycyclic arom atic hyrocarbon, 1-NP. Em odin was found to be a 
potent inhibitor o f  topisom erase II activity (M uller e t  a l . ,  1996), by inhibiting the 
interaction between topisom erase II and D NA , and reduced D N A  dam age effects caused 
by etoposide. Jayasuriya and co-w orkers (1992) found that em odin inhibits the protein 
tyrosine kinase p56lck isolated from  Polygonum  cuspidatum . Chan e t a l. (1993) reported a 
growth-inhibiting effect o f  em odin on -transform ed cells. Zhang et a l. (1995) 
dem onstrated the preferential inhibition o f c-erbB -2  tyrosine kinase activity, without 
changing c-erbB -2  protein levels, and thus blocked grow th o f the c-erbB -2  over-expressing 
hum an breast cancer cell lines and induced differentiation o f these cells. Genistein, at a
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concentration known to inhibit EG FR , showed no obvious effect on tyrosine 
phosphorylation o f c-erbB -2  protein in this study. Zhang and H ung (1996) also found that 
em odin decreased tyrosine phosphorylation o f c-erbB -2  and preferentially suppressed the 
proliferation o f erb-B -2  over-expressing non-small cell lung cancer cells. T he authors also 
found that 30p.M em odin sensitised NSCLC cells to cisplatin, adriam ycin or etoposide. A 
study by Liu e t a l. (1996) dem onstrated the down-regulation o f c-m yc expression by 
emodin.
Toxicity assays w ere carried out on DLKP-SQ and D LK P-SQ /A 25010p cells to analyse 
the effect genistein and em odin had on adriam ycin toxicity in these cell lines.
T he concentrations o f adriam ycin chosen w ere 15ng/ml fo r D LK P-SQ  and 150ng/ml for 
DLKP-SQ/A25010p. These drug concentrations achieved 10-30% cell kill. Three 
concentrations o f each o f the co-selecting drugs was used; 3 .75, 7 .5  and 15uM  genistein 
and 6 .25, 12.5 and 25|xM em odin. Increased cell kill was seen in DLKP-SQ/A25010p 
cells, but not DLKP-SQ, when co-treated with genistein (Table 4 .8 .1). The higher 
concentrations o f em odin and genistein were quite toxic to the cells. Co-treatm ent o f cells 
with em odin did not increase the toxicity (but rather induced cell grow th) o f adriam ycin in 
these cell lines (Table 4 .8 .1 ). No reduction in adriam ycin toxicity  profile was seen with 
emodin in DLK P-SQ/A25010p, perhaps suggesting that c-erbB -2  is not over-expressed in 
this cell line. As it has been shown that the resistant variants o f  D LK P over-express this 
protein it may be interesting to test this chemical on cell lines such as DLKP-A.
T he expected non-synergistic effect o f com bination treatm ent o f  adriam ycin with 
cyclosporin A, em odin and genistein is shown in Table 4 .8 .1  for DLKP-SQ and DLKP- 
SQ/A2501 Op. This assay was carried out on triplicate plates on the sam e day, tim e 
constraints prevented further analysis.
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Table 4.8.1 Effect of Co-treatment on Survival in DLKP-SQ and DLKP-SQ/A25010p cells
% growth DLKP-SQ* 
(expected value)
DLKP-SQ* 
(actual value)
DLKP-SQ/A25010p’
(expected value)
DLKP-SQ/A25010p’
(actual value)
0.5(ig/ml cycA 70.3 63.1 ± 5 .0 85.6 60.0 ± 1 .2
1.0|ig/m l cycA 72.3 58.1 ± 1 .2 84.2 20.5 ± 3 .0
2.0fj.g/ml eye A 66.0 46.7 ± 4 .7 79.4 4.9 ± 1.4
3.75|iM gen. 58.4 41.8 ± 8.3 79.5 57.1 ± 3 .8
7.5|^M gen. 29.3 24.1 ±2 .5 57.6 38.5 ± 5 .4
15^.M gen. 0.8 1.4 ± 1.0 20.8 14.4 ± 0 .7
6.25(o.M emodin 62.7 60.2 ± 7 .4 83.8 89.9 ± 7 .6
12.5|xM emodin 39.9 41.6 ±8 .1 66.9 68.7 ± 6 .3
25|iM emodin 2.1 3.0 ± 2 .6 3.2 5.4 ± 0 .9
Values are presented as percentage growth relative to 100% control for untreated D LK P -S Q * or 
DLK P-SQ /A 25010p’ . The expected percentage growth is given as the sum o f the effect o f co­
treatment o f cells with adriamycin and cyclosporin A  (cycA), genistein (gen.) and emodin 
(emodin) without synergistic effect o f co-treatment. Actual growth found is the average o f three 
toxicity assays set up on the same day under the same conditions.
Table 4.8.2 Synergistic/Antagonistic Effect of Co-treatment on DLKP-SQ Variants.
% growth D LK P -SQ * D LK P -S Q /A 25010p**
non-synergistic response 100.0 100.0
0.5fig /m l cycA 89.8 70.1
1.0(xg/ml cycA 80.4 24.4
2.0fj.g/ml eye A 70.8 6.2
3.75(xM gen. 71.6 71.8
7.5|j.M gen. 82.3 66.8
15^tM gen. 175.0 69.2
6.25).lM  emodin 96.0 107.3
12.5(.lM  emodin 104.0 102.7
25pM  emodin 143.0 169.0
Values presented in Table 4 .8 .2  are given as a percentage o f the expected (non-synergistic) growth 
values described in Table 4 .8 .1 . Values less than 100% describe a synergistic effect o f co­
treatment with adriamycin; values greater than 100% indicate antagonism between the two drugs. 
Cyclosporin A  (cycA) was found to enhance cell k ill by adriamycin in D LKP-SQ and D LK P - 
SQ/A25010p. Genistein (gen.) produced a synergistic effect in DLKP-SQ/A25010p and at lower 
concentrations only in DLKP-SQ cells. Emodin (emodin) was found to stimulate cell growth in the 
presence o f adriamycin in this analysis.
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4 .8 .3  Effect o f Inhibitors on Developm ent o f Drug R esistance
Cyclosporin A , a known inhibitor o f P-glycoprotein (Ford, 1995) was used at a non-toxic 
level as a co-treatm ent w ith adriam ycin. Follow ing two w eekly pulses o f  adriaw yrin and 
cyclosporin A, cell survival o f DLKP-SQ was reduced to  4%  com pared to 100% for 
adriam ycin only treated cells. Genistein, a tyrosine kinase inhibitor and also shown to 
inhibit the M R P pum p (V ersantvoort e t  a l . ,  1993, 1995, 1996), displayed a sim ilar 
response, reducing cell survival to 7%  o f control. Co-selection with em odin (previously 
shown to inhibit the activity o f c-erbB -2  (Zhang e t a l .,  1995; Zhang and H ung, 1996)) 
was not found to increase cell death and seemed to increase cell survival. A non-toxic 
level of em odin was used during the pulse selection process o f DLKP-SQ with 
adriam ycin.
To establish if the decrease in cell survival caused by co-treatm ent with genistein and 
cyclosporin A was due to increased toxicity o f adriam ycin o r an actual effect on signalling 
pathways repeat analysis was carried out w here cell grow th was analysed after the first 
and second pulses.
Co-treatm ent with cyclosporinA  after the first pulse reduced survival to 50%  and after the 
second week survival was expected to be 25% . This was not the case, how ever, as 
survival was reduced to only 12%. As cyclosporin A increased toxicity in DLKP-SQ cells 
in 96 well toxicity assays, the com bination treatm ent m ay be increasing toxicity of 
adriam ycin by increasing the intracellular level o f adriam ycin; w ithout affecting a 
biochemical pathway in the development o f  resistance. T reatm ent o f DLKP-SQ with 
250ng/m l adriam ycin for eight hours killed all cells except for one colony, therefore if 
cyclosporinA is m erely increasing toxicity o f adriam ycin by prolonging drug accum ulation 
it is not as effective as an eight hour treatm ent with the drug.
Co-treatm ent with genistein after one pulse had no synergistic effect on cell death, 
however, after a second pulse, in the presence o f genistein, cell survival was reduced to 
40% . As genistein had no effect on toxicity o f adriam ycin in 96 well toxicity assays on 
DLKP-SQ it m ay imply that genistein is actually sensitising cells to adriam ycin by 
affecting som e biochem ical pathway involved in the developm ent o f resistance. Further 
w ork needs to be done to confirm /deny this hypothesis and should include alternative 
scheduling o f drugs etc. To determ ine if, after the first pulse, genistein has somehow 
sensitised cells to adriam ycin treatm ent by affecting a signalling pathway, cells could be
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grown for one pulse in adriam ycin and genistein and in die second pulse in adriam ycin 
alone. If survival remained at 100% (relative to adriam ycin-treatm ent alone) following the 
first and second pulses then it is unlikely that genistein had sensitised the cells; however, 
if a sim ilar trend was seen to the results presented in this thesis it would appear that 
genistein has acted by affecting som e signalling pathway.
The use of DLKP-SQ pulse-selection as a model for the development of MDR and 
assessment of co-selectLng agents is confirmed by these results.
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4.9 Ability of Cell Lines to Develop Resistance
It has been found in this laboratory that m any cell lines readily develop resistance whereas 
others do not. DLK P is a cell line that readily adapts to grow th in chem otherapeutic drugs 
and variants stably resistant to adriam ycin, etoposide and carboplatin have been 
established. The A549 cell line, in our hands, has failed attem pts to develop resistant 
variants although other laboratories have published variants o f this cell line (Long, 1991; 
Chevillard e t a l . ,  1992).
Throughout the course o f this w ork attem pts w ere m ade to develop resistant variants o f  a 
breast cell line, BT-20, by continuous and pulse exposure to adriam ycin. Clonal 
populations o f BT-20 and A549 were used in pulse selections but resistant variants could 
not be selected. A clonal population o f M CF-7 (F .O ’Sullivan, pers.com m .) was used as 
well but the concentrations o f adriam ycin used w ere not suitable to establish a resistant 
variant.
In an attem pt to determ ine why DLKP readily develops resistance a num ber o f genetically 
manipulated cell variants w ere established and used in the pulse-selection method 
developed. DLKP-SQ  transfected with bcl-xs  prevented the establishm ent o f a resistant 
variant from  one clone. DLKP-SQ transfected with c-fos ribozym e (thus reducing c-fos 
levels) prevented the establishm ent o f a resistant variant from  the three clones tested. 
Selection from  an m d r l  ribozym e transfected clone, DLKP-I, was successful, however, 
the degree o f efficiency o f the ribozym e is unknow n as the resistant variant expressed 
m d rl mRNA.
R T-PCR analysis was carried out on a group o f six cell lines, three of which have been 
shown to develop resistance readily (e.g. D LK P (Clynes e t  a l . ,  1992), M C F-7 (Scaddan 
and Dufresne, 1995) and OAW 42SR (Redm ond e t a l . ,  1993; M oran e t a l ., 1997)) and the 
other cell lines have not been successfully selected w ith com m on chem otherapeutic drugs 
in this laboratory (see Section 3.5.3). No genes w ere identified which could be used to 
predict sensitivity to  chem otherapeutic drugs, by RT-PCR.
208
4.10 Breast Cancer - A Model for Acquired Drug Resistance
35 % o f wom en diagnosed with breast cancer die as a consequence o f the disease which is 
now the leading cause o f death among wom en in the W estern  w orld (H arris e t a l ,  1992). 
Tum ours are initially sensitive to chem otherapy bu t frequently relapse giving rise  to 
untreatable disease.
A num ber o f studies have suggested a role for P-glycoprotein in drug resistant breast 
tum ours (for review  see Giaccone e t a l ,  1995) and as a m arker for a m ore malignant 
phenotype. O ther com m on M D R m arkers such as M R P, LR P, Topoisom erases have also 
been im plicated. Schneider e t  al. (1994) found a significant association between m d r l  and 
c-erbB -2  expression in operable m am m ary carcinom as indicating that m d r l  m ay be a 
m arker o f  tum our aggressiveness.
4.10.1 Treatment of Breast Cancer
Anthracyclines are the m ost effective single agents in the treatm ent o f breast cancer 
(Bonadonna e t a l . ,  1993). These com m only used agents have the unfortunate side effect 
o f  resulting in the  developm ent of the m ultidrug resistant phenotype com m only seen in 
relapsed breast cancer patients. These relapsed patients previously treated with 
anthracyclines are known to have a very poor prognosis and second line chemotherapy 
with unrelated drugs e.g. cyclophospham ide : m ethotrexate : 5-fluorouracil is ineffective. 
For this reason it is very im portant that predictive m arkers be found for patients 
presenting with prim ary tum our; this m ay be done by studying pre- and post­
chemotherapy patient tum ours and identifying com m on genetic alterations which could 
then be used as predictive m arkers o f  treatm ent outcom e.
4.10.2 A Cellular Model for Drug Resistance in Breast Cancer
It was attem pted in this study to develop a resistant variant o f  BT-20 (derived from  a 
tum our which had not been treated by chem otherapy) to adriam ycin (used to treat prim ary 
breast cancer) and to the com bination cyclophospham ide, m ethotrexate and 5-fluorouracil 
(secondary chem otherapy regimen).
Initial observations when assessing the toxicity profile o f this cell line revealed an 
extraordinarily high resistance to m ethotrexate but relative sensitivity to other drugs
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assayed (Table 3 .12.1). This was quite surprising as the patient from  whom  BT-20 cell 
line had been established had not been treated with chem otherapy. C om bination selection 
was not attem pted on finding this result. M ethotrexate toxicity levels in M C F-7 were 
relatively quite low. M ethotrexate is an  analogue o f folic acid and exerts its cytotoxic 
effect by com petitive inhibition o f the cytosolic enzym e dihydrofolate reductase (Waltham 
e t a l . , 1988). M echanism s of resistance to m ethotrexate include increased dihydrofolate 
reductase activity, altered binding to the enzyme, decreased drug uptake and decreased 
polyglutam ination (for review  see Skovsgaard e t a l . ,  1994). It will be interesting to study 
these aspects in the BT-20 cell line.
Selection w ith adriam ycin was also undertaken but proved unsuccessful for both 
continuous selection process and selection by pulse exposure (Section 3.12).
A previous report states that this cell line is oestrogen and progesterone receptor negative 
(Koechli e t a l . ,  1994), which are predictive o f good prognosis (Sirvent et a l . ,  1995). It 
also expresses die p53 gene but not the bcl-2  gene. M CF-7 cells, which do develop 
resistance readily, are known to have the opposite expression o f the above m arkers of 
prognosis. C om paring the effect o f adriam ycin on these cell lines, as described in Section 
3.11, should be  undertaken as a m odel o f gene induction by adriam ycin in breast cancer.
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4.10.3 Analysis of mRNA levels in archival breast tissue
Tum origenesis is a m ulti-factorial problem  with alterations to m any genes observed both 
at the transcriptional and translational stages. A  sim ilar problem  is seen in the 
phenom enon o f m ultidrug resistance whereby a w ide range o f gene expression alterations 
have been identified. To determ ine clinically relevant m arkers to predict the development 
and identification o f drug resistant tum ours a panel o f genes needs to be  studied. Clinical 
specimens are often lim iting in size, however, and m ay prevent the analysis o f  a broad 
range o f putative M D R  m arkers by traditional approaches such as im m unohistochem istry, 
thereby jeopardising a correct diagnosis.
Analysis o f m any oncogenes has shown alterations in expression either by am plification or 
an increase in transcription levels; the sam e is true  for many o f the com m on hallm arks of 
m ultidrug resistance. Changes in both gene am plification and transcription are reflected in 
the resulting m RN A  levels and it is for this reason (and the fact that very sensitive 
techniques such as R T-PCR require small amounts o f tissue) that m RN A  levels can be 
used to study gene expression and alterations in drug resistant cell lines and hum an 
tum ours.
The m RNA levels o f specific genes are generally studied using such techniques as 
‘N orthern B lot’ (A lwine et a l . ,  1977), ‘RNA slot/ dot b lo t’ (Kafatos el a l . ,  1979.), 
‘RNase protection assay’ (Reyes and W allace, 1987), lin situ  hybrid isation’ (review of 
method see Leitch, 1994) and R T-PCR (for review  see W right and W ynford-Thom as, 
1990).
N orthern blotting is sem i-quantitative but is insensitive and 5-lOp.g o f purified  poly (A) +  
RNA is required to produce a signal. It is also tim e consum ing as it frequently necessitates 
the use o f  32P-labelled probes. The am ount o f RNA and the length o f tim e required to 
carry out analysis by N orthern blot is, therefore, unfavourable in a clinical setting where 
specimen size is lim iting and a diagnosis required  in as little tim e as possible.
RN A slot/blot technique also faces criticism  for routine use in a clinical situation. The 
technique is also sem i-quantitative but also insensitive, requiring 1-lO ^g o f poly (A) + 
RNA to produce a signal. In addition, the m ethod is not dependable for detecting 
extrem ely rare  sequences because o f background problem s.
Analysis by RNase protection assays are m ore sensitive than the N orthern  or slot/dot
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blotting (lOOng to l|xg o f  poly (A )+  m RN A  is required for each assay). T he method is, 
however, quite tim e consum ing due to the use of radioactive detection m ethods and a 
specific probe for each mRNA.
The m ost sensitive techniques used for analysis o f m RN A  levels, especially in a clinical 
setting, a re  hybridisation and R T-PCR analysis.
In situ  hybridisation can detect 10 to 100 molecules o f m R N A  in a given cell and in a 
clinical specim en can be used to detect m RN A  in a 3-D environm ent in the way that 
im m unohistochem istry can be used to detect the 3-D localisation o f specific antigens. The 
main disadvantages o f  in situ  hybridisation are that it is technically difficult and, similarly 
to im m unohistochem istry, is tim e consum ing and requires sim ilar am ounts o f tissue to 
process a panel o f  genes. This m ethod does not allow  for quantification o f  transcripts. 
R everse-transcriptase polym erase chain reaction (RT-PCR) analysis is 1,000 to 10,000 
times m ore sensitive than traditional blot techniques and can be used to detect m ultiple 
m RNA signals in  as little as 1 to 1,000 cells. T he procedure has the added advantage of 
speed which w ould be benificial in a clinical situation and can be  used to analyse RNA of 
extrem ely rare abundance or in small am ounts o f total R N A  - an obvious advantage if 
dealing with m inim al biopsy m aterial. A m ajor disadvantage o f R T-PC R  analysis is 
intrinsic to the procedure itself and that is the exponential nature o f the reaction which 
could lead to false positives. F rom  a diagnostic view -point the m ajor disadvantage of 
analysis by R T-PCR  is the fact that no inform ation on 3-D distribution is seen - this would 
be im portant if a specific gene was only expressed in a certain  num ber o f cells, it is also 
very im portant if  this procedure is being used for tum our analysis to insure that the tissue 
being analysed does not contain norm al tissue as well.
An In situ  - R T -PC R  procedure is now being developed to com bine the advantages o f  both 
techniques, the procedure is as yet in its infancy and great care is needed to m inim ise on 
background contam ination leading to false positives.
4,10.3.1 Analysis of mRNA by RT-PCR
RT-PCR analysis was first published by Veres e t a l. (1987) as an adaptation o f the basic 
PCR  m ethod for the study o f m RNA in a m anner sim ilar to that o f D NA. 
m RNA is produced by transcription from  D N A  in all cells; an enzym e was discovered, 
however, which allows the reverse o f this fundam ental m olecular control to take place and
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produce D N A  from  an RNA tem plate. This reverse transcriptase enzym e was first 
discovered by Tem in (1972) and was shown to have three enzym atic activities:
(i) copy an RNA m olecule to yield double-stranded D N A -R N A , using a prim er and
jo ining deoxynucleotide triphosphates in a 3 ’-5 ’ linkage;
(ii) degrade RNA in a DNA -RN A hybrid;
(iii) copy a prim ed single strand o f D N A  to form  double-stranded DNA: 
on which the R T-PCR  m ethod is based.
R T-PCR is a disruptive m ethod (unlike in situ  hybridisation) whereby R N A  is extracted 
from  cells or tissue. Total RNA is sufficient for m ost R T-PCR  analysis, how ever, some 
situations dem and the use o f poly (A )+  m RN A . The extraction o f undegraded RNA from 
cells and tissues can often prove difficult (due to the labile nature o f RN A and the 
presence o f active ribonuclease enzymes in the specimen). To prevent this problem  cells 
or tissues are usually lysed in a solution containing a strong protein denaturant e.g. 
guanidium  thiocyanate.
Extracted m RN A  is selectively prim ed to act as a tem plate on which double-stranded 
DNA (com plem entary DN A ) can be  form ed by the reverse transcriptase enzyme. The 
cDNA form ed can then be amplified and studied as in a typical PCR  reaction for the 
presence o f  specific genes. A choice o f prim ers can be used to selectively prim e the 
m RNA and these include:
(i) oligo (dT) prim ers (for eukaryotic RNA);
(ii) random  hexanucleotide prim ers;
(iii) 3 ’ antisense gene-specific prim er used in the PCR reaction.
It should be possible to prim e undegraded m RN A  with oligo (dT) prim ers only. However, 
degraded m RN A  (from  clinical specimens) m ay need a com bination o f  all o f  the above 
prim ers to produce am plified cD NA by RT-PCR.
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Figure 4.10.3.1.1 Analysis of mRNA by RT-PCR
Tissue
J Total RNA Extraction
J Priming of mRNA
-NNNNNNN. . ^ ^ A U C G C C A  .
— y  TAGCGG'P------S
lAAAAAA
<^T!> n n n n n n n  .
*  " \ 1M M M i\N ----- *
_  _ XAAAAAAA
J Reverse Transcription of mRNA
mRNA ---------------------- AAAAAAA
<---------------------------------r i n  i n  r cdna
j
Double-stranded cDNA
Degradation of mRNA 
r I I  vl^TTTT
i
1st strand PCR product
PCR amplification of specific cDNA sequence 
TTTTTTTT
i
T ,d strand PCR product
Amplification after 30 cycles of PCR 
-«Hma amplified PCR product
TGGCGAT - hypothetical 3 'antisense gene-specific primer used in the PCR reaction 
MMMMM - random hexanucleotide primers - 5'sense gene-specific primer
TTTTTTT - oligo (dT) primer EZHBn - 3 'antisense gene-specific primer
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4.10.3.1.1 RT-PCR Analysis in Clinical Studies
Analysis by R T-PCR  o f clinical samples suffers from  one m ajor flaw  and that is its failure 
to correlate with histological findings. Tum ours com prise o f  heterogenous cell populations 
som e o f which express the gene o f  interest, others may not. A n added problem  when one 
analyses a piece o f  tissue by R T-PCR  is that the specim en under analysis m ay not be pure 
tum our.
Studies have been published on R T-PCR  analysis o f  fresh tissue and to  a lim ited extent on 
form alin fixed paraffin em bedded archival tissue. It is relatively sim ple to extract good 
quality RN A , suitable for RT-PCR , from  fresh tissue and a num ber o f com m ercially 
available kits are now  available for quick extraction o f total R N A  or poly (A) m RN A  e.g. 
U ltraspec (Biotecx) or M ini-M essage M aker (R&D System s). Extraction o f R N A  from  
fixed tissue is much m ore difficult, however, as the R N A  is often degraded by such 
fixation m ethods. A num ber o f studies have reported successful am plification o f m RNA 
by PCR  from  paraffin em bedded tissue; these reports have only been successful for the 
am plification o f one or two genes that are expressed at high levels in all cells e.g . p-actin 
(Ben-Ezra e t a l ., 1991), A ldolase A (Finke e t a l . , 1993), G A PD H  and H PR T (Foss e t a l .,  
1994). A recent report published by this laboratory (O ’D riscoll e t a l . , 1996) dem onstrated 
successful am plification o f m RN As for a variety o f  M D R -related genes in 10 breast 
tum ours. A study including a larger group o f specimens has not yet been published.
4.10.3.1.2 Analysis of mRNA levels in breast tissue by RT-PCR
A m ethod has previously been reported in this laboratory which allow ed for the extraction 
of m R N A  from  6 archival paraffin-em bedded breast tissue (O ’D riscoll e t a l ., 1996) and 
successful am plification o f M D R -related genes. A study was undertaken in this thesis to 
extract RNA from  a broader range o f breast tum ours, including 15 paired pre- and post­
chem otherapy patient blocks. Success was lim ited in this study as the previously described 
protocol (O ’Driscoll e t a l . ,  1996) did not sufficiently digest tissue and therefore a possible 
source o f RNA was lost.
Im provem ents to the digestion protocol w ere undertaken and this included increasing 
digestive enzyme concentrations and frequency of addition (up to  every 2 hours). This 
im proved digestion o f som e tissues, but not all.
To allow for easier and m ore efficient tissue digestion, a num ber o f com m ercially
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available digestion or lysate buffers w ere used. Lysis o f a section from  tonsil was carried 
out in a solution containing guanidine and acid phenol (from  U ltraspec II kit, Biotecx). 
RN A was previously isolated from  this tissue using standard m ethods (O ’Driscoll e t a l . ,
1996) and successfully am plified by R T-PCR for the analysis o f  Topoisom erase I la  and p- 
actin. RNA extracted from  the tissue by lysis in the guanidine/phenol solution was not 
am plified successfully by RT-PCR. A m ilder buffer was then used to digest archival 
tissue, this buffer (from  R& D  Systems m ini-m essage m aker kit) does not contain 
guanidine or phenol and digestion o f all tissue to date using this buffer has been 
successful. The buffer was further supplem ented with P roteinase K.
Isolation o f RN A from  tissues using this protocol was not o f  sufficiently high quality to be 
reverse transcribed by the m ethod described previously (O ’D riscoll e t a l . ,  1996) which 
used random  and oligo (dT) prim ers to reverse transcribe m R N A . These steps take into 
account the degraded nature o f m RN A  as random  prim ers b ind  to sequences throughout 
the length o f the m RNA m olecule and not ju st at the 3 ’ end o f a full m RN A , which may 
be degraded in archival tissue (see F igure 4 .10 .3 .1 .1 ).
It was found, however, that the above rationale was not sufficient to reverse transcribe 
m RN A  isolated in this study. R everse transcription is used to transcribe, w here possible, 
total m RNA populations. W hen studying degraded m R N A  o f particular genes it is 
possible to hom e-in on the actual m RN A  sequence o f the gene to be analysed by PCR and 
specifically reverse transcribe that m RNA fragm ent. This can be done using the 
3 ’antisense prim er used in subsequent PC R  reactions, the justification for this is described 
in F igure 4 .1 0 .3 .1 .2 .1 . Using this m ethod o f reverse transcription, am plification o f a band 
for /3-actin (Figure 3 .13 .1 .1 ) was observed for RN A extracted from  a tum our block which 
did not amplify previously w hen reverse transcription was carried  out using random  and 
oligo(dT) prim ers only.
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Fig. 4.10.3.1.2.1 Reverse Transcription of mRNA - Rationale for Using 3 ’Specific anti-sense primers
mRNA ------------------------------------------AAAAAAA
-<-----------------------------------TTTTTTTT cDNA
^  Degradation of mRNA
Double-stranded ^ __________________
cDNA ------------------------------------- >
PCR amplification of specific 
T  cDNA sequence
—  ___ ^  ^  ^  r j i r j i r j i rj i r j i r j p r j i r j i
1st strand PCR product ----------------------►
------------------------jssama 2nd strand PCR product
 1  ’
amplified PCR product
1st strand PCR product =  mRNA sequence 
-----------------  2nd strand PCR product = cDNA sequence
51 sense gene-specific primer —  3 '1 anti-sense gene-specific primer
Full length undegraded mRNA is transcribed above using poly(dT) primers. cDNA is formed 
which is complementary to this mRNA strand. The mRNA strand is then degraded and a second 
cDNA strand is formed, complimentary to the cDNA to produce double stranded cDNA. This 
second cDNA strand has the identical sequence to mRNA.
In the PCR reaction a specific 5’sense primer binds to the first cDNA strand and produces a 1st 
strand PCR product. A specific 3’anti-sense primer binds to the second cDNA strand (identical to 
the mRNA) and produces a 2nd strand PCR product.
As the 3’anti-sense primer binds to an identical site on the second strand cDNA (identical to 
mRNA), it will also bind to mRNA and can be used to prime mRNA for reverse transcription.
M ore recently a study was begun to analyse m RN A  levels o f specific genes isolated from  
fresh breast tissue. To date success has been achieved on 14 fresh breast tissues for the 
expression o f fi-actin  although analysis o f  a range o f specific genes was only successful on 
four o f these tum ours. Sim ilar samples from  the sam e tum ours have been processed in 
St.V incent’s Hospital (Dublin) for paraffin-em bedding and studies will be carried out on 
the recovery o f RN A extracted from  archival tissue com pared to corresponding fresh 
tissue. Further optim isation o f RT-PCR o f m RN A extracted from  archival tissue is 
required, however.
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4.10.3.2 Analysis of mRNA by In situ Hybridisation
Analysis o f  m RN A by In situ  hybridisation involves the d irect hybridisation (i.e. RN A is 
not extracted from  the specim en) o f a specific probe to the material in question e.g. 
paraffin-em bedded archival tissue, frozen sections or cell preparations (cytospins or cell 
sections cut from  em bedded agar plugs). The probe can either be single-stranded D N A or 
anti-sense RNA  and is either isotopically (with e.g . 35S) or non-isotopically (D igoxigenin 
or Biotin) labelled. RNA : R N A  duplexes are m ost stable and therefore a labelled RN A 
probe is preferred for hybridisation with m RNA. The hybridised probe is then detected in 
situ  using isotopic developm ent or fluorescent or colorim etric non-isotopic protocols.
For accurate analysis o f m RN A  expression by in situ  hybridisation a num ber o f controls 
m ust be set up with the positive slide. These controls should include hybridisation with (i) 
sense RNA probe, (ii) control probe (gene not present in specim en under investigation),
(iii) oligo-dT or ft-actin  probe (to assess m RNA quality throughout the specim en), (iv) 
pre-treatm ent with RN ase (to ascertain if  p robe is actually binding m RNA) and (v) 
hybridisation without labelled probe.
Figure 4.10.3.2.1 In situ Hybridisation of Labelled Probe to mRNA
Permeabilise Fixed 
Cells / Tissue
I  labelled probe
auto-radiography
colorimetric/fluorescent
Add hybridisation 
buffer containing 
labelled probe
Labelled probe 
hybridises to mRNA 
of interest
Detection of 
Hybridisation 
Product
4.10.3.2.1 In situ  Hybridisation Analysis in Clinical Studies
In situ  Hybridisation is a relatively new histological technique to be used as a diagnostic 
tool and its current uses are m ainly for the detection o f  viral infections w ithin cells and 
analysis o f gene expression in cancer (Lloyd e t a l . ,  1994). T he technique can be used on 
frozen or paraffin-em bedded sections therefore has the added advantage o f being used in 
retrospective studies.
A num ber o f reports have been published on m d r l  expression by in situ  hybridisation on
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paraffin-em bedded sections (M arie et a l., 1992; V ergier et a l., 1993; Ram ani and 
Dewchand, 1995).
4.10.3.2.2 Optimisation of In situ  Hybridisation Protocol for the detection of m drl
Analysis o f tum our tissue by R T-PCR has a m ajor disadvantage in that it is a disruptive 
technique, analysis o f m RN A  levels by in situ hybridisation is used to detect expression of 
particular m RNAs in intact tissue sections. T he technique is, how ever, tim e-consum ing 
and technically difficult and thus lim its its use as a com m on diagnostic tool to probe 
tissues for expression o f m RNAs. As R T-PCR  analysis from  paraffin sections is limited, 
in situ hybridisation m ay be the method o f  choice for analysing m RNA levels in archival 
sections.
It was intended in this study to develop a protocol which w ould allow specific detection of 
m drl expression in archival paraffin-em bedded breast tissue, pre- and post-chem otherapy, 
and if possible com pare results to that found by RT-PCR.
Optim isation o f this protocol (described in Section 2 .11 .2) on foetal liver sections (known 
to express m d rl) was carried out. Specific staining in the erythroid  pre-cursor cells was 
detected and staining pattern agreed with that seen by im m unohistochem istry for P- 
glycoprotein (F igure 3 .13 .3 .1 ) expression, m drl expression was also detected by RT-PCR 
on m RNA extracted from  the sam e foetal liver block (F igure 3 .13.1 .1(b)). Previous 
reports have also described detection of m drl expression by in situ hybridisation (M arie et 
a l., 1992; V ergier et a l., 1993; Ram ani and Dewchand, 1995). A study, for the detection 
o f m drl by in situ hybridisation, on pre- and post-chem otherapy paired tum ours has not 
been published to date. In this study successful in situ on eight tum our blocks from  breast 
cancer patients. These tissue blocks consisted o f four paired pre- and post-chem otherapy 
blocks from  patients who had been treated with a CM F regim en. Successful staining with 
poly(dT) to assess m R N A  levels throughout the sections was achieved, although it was 
observed that m RN A  preservation throughout the section was not uniform , m drl 
expression was detected in all sections analysed. No conclusion can be m ade as to the 
significance o f  this expression as com parison with im m unohistological detection o f P- 
glycoprotein levels is awaited.
The surprising conclusion draw n from  this study is that m R N A  extraction from  archival 
sections is not dependable as the m RNA extracted is highly degraded. Ironically,
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therefore, in situ  hybridisation could be used to detect the presence o f the poIy-A tail, the 
“hallm ark” o f m RNA preservation, in the same tissue sections. In situ  hybridisation was 
also successful in detecting a specific gene product, using a probe o f approxim ately lkb . 
These results would imply that mRNA analysis in archival sections is best achieved by in 
situ  hybridisation, although analysis by this method is tim e-consum ing.
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4.11 Summary and Conclusions
1. This thesis investigated the role o f oncogene expression, at m RNA level, in m ultidrug 
resistance o f  hum an cancer. Analysis o f oncogene expression in drug resistant variants 
o f  the hum an squam ous lung cell line, D LK P, and the hum an ovarian cell line, 
OAW 42, was carried. Expression o f  c-erbB -2 , c -R a -ra s l,  c-fos, c-m yc  and the bcl-2  
fam ily m em bers, bcl-x  and box, was investigated on adriam ycin- (DLKP-A, OAW 42A, 
OAW 42A1), VP-16- (DLKP-VP3, DLKP-VP8) and carboplatin- (DLKP-C14) selected 
variants o f the D LK P and OAW 42 cell lines. Increased expression o f  the bcl-xL, bax  
and c-erbB -2  genes was seen in all the resistant variants o f  D LK P analysed, c-fos levels 
were elevated only in  the DLKP-A variant, c-m yc  was up-regulated in the carboplatin- 
selected cell line but was down-regulated, when com pared to D LK P, in the other 
DLKP variants analysed. c-H a-/uvi levels were elevated in the D LK P variants, with 
the exception o f the DLKP-V P8 cell line. Elevations o f  these genes in the OAW 42 
resistant cell lines was not observed and a decrease in c -fos levels was observed in the 
adriam ycin-selected resistant variants, OAW 42A and OAW 42A1.
2. As the resistant variants o f the DLK P and OAW 42 cell lines analysed w ere a 
heterogenous population, it was decided to analyse the expression o f the same 
oncogenes in clonal sub-populations o f the  D LK P-A  cell line. Analysis was carried  out 
on the m ost sensitive clone, DLKP-A 2B, and the m ost resistant clone, DLKP-A 5F. 
Analysis revealed a greater bax:bcl-xL ratio in the least resistant clone, DLKP-A2B, 
when com pared to D LK P-A 5F, suggesting that the sensitivity o f  the form er m ay, in 
part, be due to the balance o f apoptosis-regulating genes. c-erbB -2, c -H a-ra s i and c-fos 
expression was also up-regulated in the m ore resistant D LK P-A 5F sub-population. 
These results suggest that analysis o f  gene expression in clonal populations o f  cells 
may provide greater insight into the m echanism s o f drug resistance.
3. Elevated levels o f the c-fos gene w ere found in the D LK P-A  cell line, c-fos had 
previously been reported in the literature to affect drug resistance with partial 
sensitivity restored by down-regulation o f  the c -fos gene. In this study, a c-fos 
ribozym e was used to down-regulate the expression o f the c -fos gene in  the DLKP-A 
cell line. Six clones expressing the c-fos ribozym e w ere isolated from  the heterogenous 
population. T he ribozym e is in an inducible plasm id and expression is induced by 
addition o f dexamethasone. The clones analysed had a low er resistance to adriam ycin 
than the parental DLK P-A cell line. M inim al effect of dexam ethasone induction was
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seen on toxicity levels. Unfortunately, steroids, which can substitute for 
dexamethasone, are also found at basal levels in serum . In the ribozym e-expressing 
sub-populations o f DLKP-A, ribozym e expression was seen w ithout the addition of 
supplem ented dexamethasone. It is unknown, therefore, if  the low ered resistance levels 
are due to a decrease in c-fos levels or whether m ore sensitive sub-populations had 
been cloned from  the parental DLKP-A cell line. Lower expression o f  m d rl  in the 
ribozym e-expressing clones was also seen. Unsuccessful attem pts w ere m ade to grow 
one o f the ribozym e-expressing clones in serum -free m edium  w hich would rem ove 
basal levels o f  dexamethasone. Transfection o f the ribozym e into the clonal sub­
population, D LKP-A 5F (shown to over-express c-fos m RN A ), did not affect overall 
toxicity levels o f adriam ycin. H ow ever, individual colonies w ere not isolated following 
transfection.
4. T he cell lines used in the initial part o f  this study w ere developed by continuous 
exposure to drug for prolonged periods and are resistant to drug concentrations above 
those achieved in the clinic. As patients can develop drug resistance after only a few 
courses o f  chem otherapy, a m ore clinically relevant in v itro  m odel o f drug resistance 
was developed by pulse exposure o f clonal populations o f D LK P, DLKP-SQ and 
DLKP-I, to clinically attainable levels o f  drug for a short period o f tim e. T he resulting 
resistant variants, DLKP-SQ/A25010p and D LK P-I/A 25010p, w ere developed 
following ten weekly exposures o f the sensitive parental lines to 250ng/m l adriamycin. 
The resistant variants were found to be ten  and sixteen fold resistant to adriam ycin, 
respectively. These cells exhibited a classical M D R  phenotype in that increased 
resistance to vincristine and VP-16 was also dem onstrated. No alteration in 5- 
fluorouracil toxicity level was seen. D ecreased drug accum ulation was observed in the 
resistant variants. The resistant variants displayed up-regulated m d r l  expression.
5. Characterisation o f the pulse-selected resistant variant of D LK P-SQ revealed increased 
expression (by RT-PCR) o f the bcl-xL, bax, c-erbB -2  and c-fos genes relative to the 
sensitive parental line. To determ ine the ro le expression o f  the bcl-2  fam ily o f  genes 
plays in this resistant model, bcl-xs , the apoptosis-supporting gene, was transfected into 
the resistant DLKP-SQ/A25010p cell line. Clonal populations stably expressing the b d -  
xs  gene w ere analysed and it was found that the clone expressing the m ost b d -x s 
showed the greatest increase in sensitivity to adriam ycin, V P -16 and vincristine; no 
alteration in 5-fluorouracil sensitivity was observed. This result suggests that over­
expression o f the b d -x L gene in the D LK P-SQ/A 25010p cell line plays a ro le in the
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resistance o f  that cell line to chem otherapeutic drugs. Initial toxicity w ork was 
undertaken to determ ine if  co-treatm ent o f DLK P-SQ /A 25010p with agents known to 
affect cellular signalling cascades and com m on M D R  m arkers could enhance toxicity o f 
adriam ycin in this cell line. C o-treatm ent with cyclosporin A (a P-glycoprotein 
inhibitor) enhanced the toxicity o f adriam ycin in this cell line suggesting that m d rl  
over-expression in the DLK P-SQ/A25010p has a significant role in the resistance seen 
in this cell line. Co-treatm ent with genistein (a tyrosine kinase inhibitor) also partially 
enhanced the toxicity o f adriam ycin, indicating that a kinase pathway m ay be involved 
in the resistance o f the D LKP-SQ/A25010p cell line. Co-treatm ent with another kinase 
inhibitor, em odin, previously shown to target c-erbB -2, did not enhance the toxicity of 
adriam ycin in the DLKP-SQ/A25010p cell line.
6. To determ ine the initialising events in the establishm ent o f  the M D R  phenotype in the 
pulse-selected m odel, gene induction studies following treatm ent with adriam ycin were 
carried out on the DLKP-SQ cell line. Initial results indicated an up-regulation o f bcl-xL 
and c-erbB -2  m RNA. This result could not be repeated, how ever. In an attem pt to 
m odulate resistance developm ent by m olecular m ethods, the D LK P-SQ  cell line was 
transfected w ith the bcl-xs  cD NA and the c-fos ribozym e. Pulse exposure o f five bcl-xs 
expressing clones to adriam ycin resulted in grow th o f four o f the clones but one clone, 
bcl-Xs.l, was not susceptible to resistance developm ent. This result m ay suggest that 
the up-regulation o f bcl-xL in DLK P-SQ  is an initialising event in the developm ent o f 
drug resistance in the DLKP-SQ m odel. DLKP-SQ cells transfected with the c-fos 
ribozym e did not develop resistance when exposed to adriam ycin suggesting a role for 
c-fos in  the response o f DLK P-SQ  to cellular stress caused by chem otherapeutic drugs.
7. As m d r l  levels w ere also increased in the pulse-selected resistant variants o f  DLKP, 
attempts w ere m ade to develop a resistant variant o f a clonal population o f DLKP-I 
previously transfected with the m d r l  ribozym e. A resistant line was established which 
expressed m d r l  m RNA but to a lesser extent than that expressed in DLKP-I/A 25010p. 
Resistance levels were sim ilar in the resistant variants developed from  DLKP-I and the 
m d rl ribozym e expressing clone. This finding, and subsequent adriam ycin 
accum ulation studies, suggest that factors in addition to P -glycoprotein over-expression 
may be involved in the resistant variants o f  these pulse-selected variants.
8. M olecular studies o f gene expression/alteration in the pulse-selected variant o f  DLKP- 
SQ suggested that this may be a novel system  am enable to the search for inhibitors o f 
resistance development. Initial studies have been carried out in this thesis to determ ine
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if known inhibitors/circum ventors o f the M D R  phenotype or oncogene signalling 
cascades affected the developm ent o f  resistance using the D LK P-SQ  pulse method. 
Results indicate that a P-glycoprotein inhibitor (cyclosporin A) and a tyrosine kinase 
inhibitor (genistein) affect the developm ent o f  resistance. It rem ains to be  seen if this is 
due m erely to increased toxicity effects o r due to inhibition o f  a signalling pathway. 
The potential usefulness o f DLKP-SQ pulse-selection as a m odel for the development 
o f M D R  and the assessm ent o f co-selecting agents is confirm ed by these results.
9. Attem pts w ere m ade throughout the course o f this thesis to develop resistant variants of 
a num ber o f  cell lines, including the lung cell line, A549, and the hum an breast cell 
line, BT-20. Failure to establish resistant variants o f these two cell lines prom pted 
analysis o f  gene expression in a group o f six cell lines, th ree o f  which were known to 
develop resistance w hile the other th ree did not. No consistent alteration in gene 
expression was observed for the group o f cell lines that did vs. did not develop 
resistance. One interesting finding in analysis o f the BT-20 cell line was its 
extraordinarily  high resistance levels to m ethotrexate, a surprising result as the patient 
from  whom  the BT-20 cell line was derived had not been treated with chemotherapy. 
The fact that a given tum our could be  inherently resistant to one drug m ay account, in 
som e instances, for the lack o f response to chemotherapy.
10.As this thesis and other reports have shown that expression o f  certain oncogenes can 
affect the developm ent o f resistance in hum an cancer cell lines. It is essential in the 
clinic that a broad range o f prognostic factors such as m d r l,  bcl-2  family, c-fos, c- 
erbB -2  and other genes are analysed in a given tum our to determ ine the patient’s 
response to a given chem otherapeutic regim en. As clinical m aterial is often lim iting a 
technique is required which will allow  the analysis o f  m any param eters with minimal 
tissue. R T -PC R  would be an acceptable technique; how ever, extraction o f  m RNA from  
routinely-processed archival tissue is quite difficult. A previous report in this 
laboratory described the extraction and analysis by PCR  o f m R N A  from  archival breast 
tissue. In this thesis attem pts w ere m ade to expand that study. Analysis o f RNA 
extraction from  thirty samples was unsuccessful using this protocol, although further 
optim isation o f the reverse-transcriptase step im proved R T-PCR  analysis. This finding 
implies that analysis o f  m RNA from  archival sections could not be relied on as a 
routine technique. Analysis o f  m RN A  in eight random ly selected tum ours out o f the 
thirty by in situ  hybridisation for m d r l  did, how ever, p rove successful. Analysis of 
fresh tum our samples was also carried out by RT-PCR.
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4.12 Future Work
1. Further w ork arising from  this thesis m ust include analysis o f oncogene expression in 
the DLKP and OAW 42 variants at the m RNA level, by other techniques such as 
N orthern blotting, and at the protein level using W estern blotting techniques. Further 
characterisation o f the c-fos ribozym e transfected D LK P-A  cell lines could include 
optim isation o f a serum -free m edia to support the grow th o f the clones. A 
com prehensive toxicity pro fde o f the transfected cells should also be com piled.
2. Characterisation o f the pulse-selected variants o f  DLK P-SQ  and D LK P-I should be 
com pleted. This w ould include analysis at the m RN A  and protein levels for the 
expression o f M D R-related genes and oncogenes discussed in this thesis. A com plete 
toxicity p ro fde  including analysis o f  cisplatin, taxol and other drugs should be analysed 
and m ay indicate which m echanism  o f drug resistance is involved in the resistant cell 
line. Pulse-selected variants o f these cell lines could also be established using other 
chem otherapeutic drugs to obtain a panel o f  cell lines displaying resistance to clinically 
attainable levels of drug.
3. D rug accum ulation studies in the DLKP-SQ and D LK P-I resistant variants should be 
repeated and com pared to the highly resistant cell lines such as D LK P-A . These studies 
could also include co-treatm ents w ith agents such as cyclosporin A or verapam il to 
inhibit P-glycoprotein.
4. Further characterisation o f the DLKP-SQ/A25010p-&c£ts .3 and D L K P -S Q /bcl-xs . 1 cell 
line should include com plete toxicity pro fde including drugs such as the heavy metals, 
taxol and others. Analysis o f  oncogene and M D R-related gene expression should be 
carried out at the m RNA and protein levels. D rug accum ulation studies could also be 
analysed. T he reduction in resistance levels seen in this variant suggests the DLKP- 
SQ /A25010p model may be a good system  to target by bcl-x,. anti-sense technology.
5. As the DLKP-SQIbcl-Xs. 1 cell line was not susceptible to  resistance developm ent by 
adriam ycin m ay indicate that DLK P-SQ  cells targetted by bcl-xL anti-sense technology 
and exposed to adriam ycin could also be prevented from  developing resistance. 
Selection o f the D L K P -SQ /bcl-xs . 1 cell line with clinically relevant levels o f  other 
chem otherapeutic drugs should also be undertaken to determ ine if  bcl-xs . 1 effect is 
drug-specific, a fact that is not well docum ented in the literature. D LKP-SQ cells could 
also be transfected with the bcl-xL cD N A  to determ ine if  this results in increased 
resistance to a sim ilar profile o f  drugs.
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6. Characterisation o f the c-fos ribozym e expressing D LK P cells should be completed. 
Exposure o f these cells to different drugs m ay also be interesting. Optim isation o f a 
seum -free medium for these cells w ould also be useful to  ascertain the true effect of 
ribozym e induction on chem osensitivity levels. As c-fos and c-erbB -2  levels were over­
expressed in drug resistant variants o f  the DLKP cell line, transfection o f DLKP-SQ 
w ith these cDNAs m ay determ ine if over-expression o f these genes increases 
chem oresistance in the transfected variants.
7. Further characterisation of the m d r l  ribozym e transfected resistant variant, DLKP- 
I/ndriR z2D 4/A 2501 Op, is required. Further drug accum ulation studies should be 
undertaken, including co-incubation w ith P-glycoprotein inhibitors. Selection from  the 
sensitive clone with other chem otherapeutic drugs could b e  analysed.
8. T he effect o f  tyrosine kinase inhibitors on the establishm ent o f the M D R  phenotype in 
the DLKP-SQ model should be analysed. This m odel could also be used to search for 
inhibitors o f drug resistance development.
9. Gene induction studies follow ing exposure to different chem otherapeutic drugs could 
be established and oncogene and M D R -related gene expression analysed. Further 
experim ents could be  undertaken to determ ine if  resistance developm ent is a result of 
gene induction or selection.
10.Characterisation of the BT-20 cell line and its inherent resistance to m ethotrexate 
should be addressed.
11. Clinical studies in  this thesis suggest that further optim isation o f m RN A  extraction 
from  archival sections is required before it can be used for R T-PC R  analysis. Analysis 
of gene expression in paraffin  sections by in situ  hybridisation m ay be a m ore routine 
m ethod o f analysis.
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6. Appendices
Appendix A Guidelines used in Choosing Primers for PCR Analysis
To successfully am plify cDNA by PCR, specific prim ers to the gene o f  interest m ust be 
chosen to prim e the cD N A  for PCR am plification, a num ber o f  guidelines should be 
followed, when feasible, to design the best prim er pair to g ive successful amplification o f 
a PCR product o f suitable size.
Figure A .l Hypothetical Gene Structure
intron intron
5 ' -------►— exon X —►— exon Y —►— exon Z ----------►— —3 '
(i) Complem entarity to Tem plate =  Specificity
This is the fundamental requirem ent when chosing a prim er. The prim er m ust be chosen 
to hybridise specifically to the gene o f interest and not to any other gene which may be 
present in the m RNA population. If  one prim er binds to an  extra tem plate the prim er is 
wasted through com petition with this sequence; how ever, if both prim ers bind to this extra 
tem plate another region will be amplified thereby making analysis m ore difficult.
To find the m ost hom ologous sequences to be used as prim ers, DNA data-bases (such as 
the one held by EM BL) m ust be searched. W hen the sequence o f interest is sent to the 
data-base it is com pared to all known sequences and the firs t fifty sequences to which it 
has greatest hom ology will be aligned to the sequence o f interest, their percentage 
homology will be calculated and the position on the tem plate show n and returned to the 
sender.
Care m ust be taken, how ever, to avoid areas o f secondary structure form ation or 
com plim entarity between prim ers. Long stretches o f purines o r pyrim idines m ust also be
avoided.
(ii) Primer Length and Composition and Target Length =  Efficiency
Prim ers are norm ally chosen to be 18-30 base pairs in length, shorter or longer prim ers 
could be used if absolutely necessary. A balance m ust be m et when deciding on prim er 
length, however; obviously by increasing the num ber o f base pairs included greater
specificity could be achieved but the disadvantage o f long prim ers include increasing the
possibility o f  introducing secondary strucure into your prim er and increasing the annealing 
tem perature (see below) o f the prim er. The length o f a prim er pair should be equal if 
possible.
If possible prim ers should have a balanced G/C and A /T  concentration. The distribution o f 
bases should be random  and long stetches of polypurines and polypyrim idines should be 
avoided - this is to prevent non-specific binding and avoid the possibility o f  secondary 
structure form ation. Secondary structure could also occur if a prim er possesses 
palindrom ic sequences and if such sequences are present then this area o f the gene should 
be avoided.A  prim er pair should not possess com plim entary sequences to each other, 
especially at thier 3 ’ end as this could result in the form ation o f “prim er-dim ers” i.e. both 
prim ers annealing at thier 3 ’ ends producing a tem plate that will com pete w ith the target 
of interest.
The base pair com position o f any given prim er determ ines its specificity and annealing 
tem perature to the cDNA during am plification. Increasing this tem perature reduces the 
annealing o f incorrect prim ers. Prim ers should be chosen w hose Tm  (i.e. the tem perature 
at which half of the duplex is dissociated) is between 55°C and 75°C. T he appropriate PCR 
annealing tem perature m ay be equal to the m elting tem perature or 5°C below this 
tem perature. The Tm for a given prim er can be estim ated from  the following equation:-
Tm =  2°C (no. o f A + T  residues) +  4°C (no. o f G + C  residues)
Optim um  am plification will be achieved if the difference betw een the prim er pairs is 
between 180 and 500 base pairs.
(iii) Location on Tem plate =  Analysis
The com plim entary prim ers chosen should be designed so that any contam inating DNA 
could be differentiated from  the am plified cDNA. This is m ost effectively done by picking 
prim ers which (i) flank introns i.e. prim er (a) from  exon X and prim er (b) from  exon Z  or
(ii) span introns i.e. p rim er (a) 5 ’region in exon X and 3 ’region in exon Y and prim er (b) 
in exon Z. E ither o f these methods will show if there is contam inating D N A present as 
this will present itself as a longer PCR product length than the expected cDNA band, the 
latter m ethod has the added advantage of prim er (a) not hybridising to the DNA.
The prim ers should fram e a sequence as far 3 ’ as possible on the gene - this ensures that 
cDNA produced by the oligo (dT) prim ing need not be full length, this is especially 
im portant for large genes. Areas in very close proxim ity to the 3 ’ tail should be avoided 
as it has been shown that it is from  the poly (A )+  tail that degradation o f  m RNA initially 
occurs - this is im portant to note when analysing m RNA from  biological specimens.
For further analysis o f the PCR product, the prim ers chosen should fram e a sequence with 
a diagnostic restriction site for validation purposes.
Primer design and nomenclature for bcl-2 gene fam ily members
The prim ers designed in this project to analyse bcl-2, bcl-x and bax were chosen to detect:
(a) bcl-2a  and bcl-2p
Only bcl-2a  was detected in this work and throughout the course o f this thesis the mRNA 
referred to as bcl-2 refers to the bcl-2a  transcript which is translated to the protein 
product.
(b) bcl-xL and bcl-xs
W here the text refers to bcl-x detection, analysis o f both form s o f the mRNA was sought. 
Upon analysis it was found that only the long form o f the m RNA  was expressed in most 
cell lines and the mRNA detected was term ed bcl-xL. W here bcl-xs specific detection was 
required the gene is referred to as such.
(c) b ax-a  and bcix-fi
Again two form s o f bax  m RNA are transcribed, but only the a-fo rm  is translated to 
protein. Prim ers were designed to co-amplify b ax-a  and bax-j3 and then bax~p only as a 
means o f distinguishing between both transcripts. As no band was detected in initial 
am plification steps for the bax-f3 transcript it was assum ed that the signal detected for the 
co-am plified bax-a  and bax-fi was as a result of bax-a  expression only. Therefore in
further experim ents bax m RNA expression refers to b a x-a  only.
All prim ers chosen were 100% homologous to the specific gene and m aintained minimal
or no homology to other family members.
Appendix B Use of DNA Data Bases
The most im portant criteria in the choice o f prim ers for PCR  is uniqueness to the tem plate 
to be analysed. It is essential that the prim ers do not cross-react with sequences likely to 
be present in the m RNA o f cells/tissues being studied. D N A  data bases (e.g. EM BL, 
Genbank) are used to check the hom ology o f a sequence to  all those sequences deposited 
by researchers in the data-base.
EM BL D N A  data bases w ere accessed easily via E-m ail by linking to large m ainfram e 
computers (e.g. VAX) and connecting to a UNIX system  run  through the Bioinform atics 
Centre, Trinity  College, Dublin (co-ordinator A .T .L loyd). Having accessed this system a 
wealth o f excellent research facilities was available allowing the extraction o f a deposited 
gene sequence, hom ology searching, and restriction m apping to nam e but a few, through a 
package called GCG.
The following is an exam ple o f how to access this system  via e-mail:
(Note Acer is case sensitive)
$ telnet acer.gen.tcd.ie
connected, to acer  
U sernam e:rnam hl 
Password :XXXXXX 
rnamhl@ acer : gcg
To extract a sequence fro m  the data-base the Query program m e is used. I f  the accession 
number, sequence deposited name or other identification is known the procedure is simple 
and  fast.
rnamhl@ acer : query  
find
L220121
<  Return >
<  Return >  
ex tract
lis tl
 l is tl  contains the extracted sequence which is extracted as a “sim ple extraction”;
to make the result accessible to analysis on the GCG  package the sequence is saved in 
GCG form at.
 the extracted sequence is saved as hsbclxl.seq
 to read the extracted sequence type the fo llow ing  a t the prom pt:
rnamhl@acer : cat hsbclxl.seq
The Fast A  program m e was used fo r  homology searching o f  sequences.
rnamhl@acer : fasta
FastA o f what sequence ? : hsbclxl.seq
Beginning at ? : 345 (the f ir s t  base o f  the sequence to be searched)
Ending at ? : 364 (the last base o f  the sequence to be searched)
Search what data-base ? : EMBL (a choice o f many is given)
 the sequence is then searched against all deposited sequences and the results o f  the
50 m ost homologous sequences are returned aligned to the search query. The result is 
called hsbclxl.fasta. The “c a t” command is used again to view  the result.
The map program m e is used to create a restriction digest map o f  the required sequence.
The program m e w ill search the sequence fo r  all known restriction sites or it can be
prom pted to search fo r  particu lar sites. The program m e w ill list a t the bottom those
enzymes tha t do and  d o n ’t  cut the particular sequence.
rnamhl@acer : map
map o f what sequence? hsbclxl.seq
beginning at ? 345
ending at ? 740
.....................the user is then prom pted to select the enzymes with which the search is to be
carried out and also to specify i f  protein translation is required in the result. The result is 
saved as hsbclxl. map and  again is viewed fro m  the u se r ’s directory as cat hsbclxl. map.
Appendix C PCR Primers Used for the Detection of MDR Genes
Gene Primer
length
A+T:G + 
C
Tm Amplified 
cDNA length 
(bases)
Amplified DNA 
sequence length 
(bases)
Location on template
m drl 20 10:10 60 157 1,257 2596-2615
20 12:18 56 2733-2752
tnrp 21 13:8 58 203 N.K . 1317-1337
21 11:10 62 1499-1519
T opo.IIa 21 11:10 62 139 N.K . 4052-4072
26 12:14 80 4165-4190
GST k 18 8:10 56 270 749 57-81
24 14:10 68 304-327
P-actin 29 16:13 84 383 590 660-688
22 12:10 64 1021-1042
fc - 20 11:9 58 114 1.263 222-241
inicroglobulin 20 12:8 56 316-335
for more information see O ’Driscoll e ta l., 1993
Appendix D Fold Resistance of DLKP and OAW42 Variants
Table D .l Fold Resistance of DLKP Resistant Variants
Adriamycin Cisplatin Vincristine VP-16 5-Fluorouracil
DLKP-A 254 ± 119 1.46 ± 0.42 1504 ± 707 61 ± 8 1.75 ±0 .74
DLKP-A2B 37 + 16 0.57 + 0.07 228 ± 71 18 ± 8 1.28 ±0.77
DLKP-A5F 3 3 1+ 69 1.39 + 0.03 1275 ± 625 51 ±  8 0.98 ±0.47
DLKP-VP3 9 0 + 1 3 0.32 + 0.17 1089 ± 161 58 ± 2 0.47 ±0.38
DLKP-VP8 272 + 38 0.22 ±0 .06 1737 ± 348 101 ± 7 0.90 ±0.43
DLKP-C14 1.67 12.2 1.12 1.9 0.77
This analysis was carried out by Dr.M.Heenan and Dr.I.Cleary
Table D.2 Fold resistance of OAW42 Variants
Adriamycin Cisplatin Vincristine VP-16 5-Fluorouracil
OAW42SR 8.3 0.66 20 2.1 0.52
OAW42A1 14 0.92 14 2 0.75
OAW42A 25.8 1.55 40 7.5 0.99
This analysis was carried out by Dr.I.Cleary
Appendix E P-glycoprotein/mdr/ Levels in Resistant Variants of DLKP
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(a) Western blot analysis of P-glycoprotein levels in DLKP variants and mdrl m R N A  expression in 
DLKP variants following (b) 25 cycles and (c) 20 cycles of PCR.
Appendix F Calculation of IC50 Values
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I C 50 of adriamycin from above graph =  125ng/ml
125 x 10‘g/l
Molecular Weight of adriamycin =  580
Calculation =  125 x 10'6
580
IC50 value =  2l5nM
Appendix G Resistant Variants of DLKP-SQ and DLKP-I
D L K P - I
exposure o f  DLKP-I to 
10 pulses o f  250ng/ml 
adriamycin
D L K P - I / A 2 5 0 1 0 p
transfection with the 
rndrl ribozyme
D L K P
continuous exposure to 
increasing concentrations^, 
o f  adriamycin
D L K P - S Q / A 2 5 0 C
D LK P -lm drlR z2D 4
exposure o f  DLKP-lmdrlÆ 2D4 
to 10 pulses o f  250ng/ml 
adriamycin
D L K P -lm drlR z2D 4/A 250  lOp
D L K P - S Q
exposure o f  DLKP-SQ 
to 4 pulses o f  250ng/ml 
adriamycin
D L K P - S Q / A 2 5 0 p
further exposure o f  
DLKP SQ/A250p t o  a 
total o f  10 pulses o f  
250ng/ml adriamycin
1
repeat exposure o f  DLKP-SQ 
to 10 pulses o f  250ng/ml 
adriamycin
D L K P - S Q / A 2 5 0 1 0 p 2
D L K P - S Q / A 2 5 0 1 0 p
transfection with bcl-Xj 
cDNA
D L K P - S Q /  A 2 5 0 1 O p b c l X g .  3
Selection of drug resistant cell lines from clonal populations of the parental DLKP cell line.
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Appendix I Abbreviations
1-p-D-ara 1-P-D-arabinoside
ADR Adriamycin
AIF Apoptosis Inducing Factor
AMP Ampicillin
ATCC American Tissue Culture Collection
ATF Activating Transcription Factor
BCIP 5-Bromo-4-chloro-3-indolyl-pliosphate
BHFR1 Epstein-Barr Virus Protein
BSA Bovine Serum Albumin
CAF Cyclophosphamide: Adriamycin: 5-Fluorouracil
CBP Carboplatin
cdc Cell Division Cycle
CDK Cyclin Dependent Kinase
cDNA complementary DNA
CMF Cyclophosphamide:Methotrexate: 5-Fluorouracil
CMP Cyclophosphamide (mafosphomide)
CPT Cisplatin
CsCl Caesium Chloride
Cyc A Cyclosporin A
DEPC Diethyl Pyrocarbonate
DHFR Dihydrofolate Reductase
DIG Digoxigenin
DMEM Dulbeccos Minimum Essential Medium
DMSO Dimethyl Sulfoxide
DNA Deoxyribonucleic Acid
dNDP Deoxynucleotide Diphosphate (where N =  A,C,G,T,U)
dNMP Deoxynucleotide Monophosphate (where N =  A,C,G,T,U)
dNTP Deoxynucleotide Triphosphate (where N =  A,C,G,T,U
DSP Dual Specific Phosphatases
DTT DiThiothretol
ECACC European Collection of Animal Cell Culture
ECL Enlianced Chemiluminescence
EDTA Ethylenediaminetetraacetic Acid
EGF Epidermal Growth Factor
EGFR Epidermal Growth Factor Receptor
EM/Emod Emodin
EMBL European Molecular Biology Laboratory
ER Oestrogen Receptor
ERK Extracellular Signal Regulated Protein Kinase
FCS Fetal Calf Serum
FRK Fos Regulated Kinase
5-FU 5-fluorouracil
GAP GTPase Activating Protein
GAPDH Glyceraldehyde-6-phosphate Dehydrogenase
GDI GDP Inhibition Protein
Gen Geiiistein
GIP GTPase Inhibiting Protein
GM-CSF Granulocyte Macrophage Colony Stimulating Factor.
GnSCN Guanidine Thiocyanate
Grb-2 Growth Factor Receptor Binding Protein -2
GST Glutathione-S-Transferase
HBS Hepes Buffer Saline
HIV Human Immunodeficiency Virus
HPRT Hypoxanthine-guanine phosphopribosyltransferase
IC50 Inhibitory Concentration 50 Percent
ICE Interleukin-ß-1-Converting Enzyme
IGF Insulin-like growth factor
IL-3 Interleukin -3
JNK c-Jun N-tenninal Kinase
LB broth Luria-Bertani broth
LRP Lung-resistance Related Protein
MAP Mitogen Activated Protein
MAPK Mitogen Activated Protein Kinase
MEK MAPK/ERK Kinase
MEM Minimum Essential Medium
MKP MAKP Phosphatase 1
MMLV-RT Moloney Murine Leukemia Virus-Reverse Transcriptase
111RNA Messenger RNA
MRP Multidrug Resistance-associated Protein
MTX Methotrexate
NBT 4-Nitro blue tétrazolium chloride
NCTCC National Cell and Tissue Culture Centre
NDP Nucleotide Diphosphate (where N =  A,C,G,T,U)
NF-1 Neurofibromatosis tumour suppressor gene
NISH Non-isotopic in-situ hybridisation
NMR Neuclear Magnetic Resonance
NSCLC Non-Small Cell Lung Cancer
NTP Nucleotide Triphosphate (where N =  A,C,G,T,U)
O.D. Optical Density
ORF Open Reading Frame
P-gp P-Glycoprotein
PCR Polymerase Chain Reaction
PDGF Platelet Derived Growth Factor
PKC Phosphokinase C
PMSF Phenylmethyl sulfonyl fluoride
r.p.m . Revolutions per minute
RNA Ribonucleic Acid
RNase Ribonuclease
RNasin Ribonuclease inhibitor
RT-PCR Reverse Transcriptase Polymerase Chain Reaction
RTK Receptor Tyrosine Kinase
SDS Sodium Dodecyl Sulphate
SOS Son of Sevenless Protein
SRE Serum Response Elemeut
SSC Sodium Saline Citrate
TBE Tris Boric Acid, EDTA Buffer
TBS Tris Buftere Saline
TGFß 1 Transforming Growth Factor ß 1
TLL T- lymphocyte Leukaemia
Tm Melting Temperature
TNF Tumour Necrosis Factor
TS Tliyinidylate Synthase
UV Ultra Violet
VEGF Vascular Endothelial Growth Factor
VM-26 Teniposide
VNC Vincristine
VP-16 Etoposide
Appendix J Molecular Weights of Compounds Used in Thesis
5-FluorouracU 130.1
Adriamycin 580.0
Carboplatin 371.26
Cyclosporin A 1202.6
Emodin 270.24
Genistein 270.2
Matostamide 500.5
Methotrexate 508.5
Vincristine 923.0
VP-16 588.6
Appendix K Buffers
4M Guanidium Thiocyanate:
Guanidium thiocyanate (Sigma G-6639) 
N-lauroyl sarcosine (Sima L-5125)
1M Na-citrate, pH 7
50g
0.5g
5ml
Bring to 100ml with H2O and check that pH is approximately 7.
Filter through 0.45^m filter and store at room temperature in the dark. 
Before use add:
P-mercaptoethanol (Sigma M-6250) 700|_il/100ml
Antifoam A (30%) (Sigma A-5758) 330p.1/100ml
5.7M Cesium chloride:
CsCl (Sigma C-3032) 95.8g
1M Na-citrate, pH 7 2.5ml
Bring to 100ml with H2O.
Filter sterilise, DEPC-treat and autoclave.
Store at room temperature.
1M Na-citrate:
Na-citrate (RDH 32320) 29.4g
Bring to 80ml with H2O and pH to 7 with HC1.
Bring to 100ml and filter sterilise.
Store at room temperature.
10XPBS
NaCl
K C 1
Na^HPOJFbO
KH2PO4
40g/500ml
lg/500ml
5.75g/500ml
lg/500ml
20XSSC
3M NaCl 
0.3M Na-citrate
87.66g/500ml
44.12g/500ml
20XTBS/BSA
lM T ris, pH 7.6 
3M NaCl
60.5g/500ml 
87.66g/500ml 
1.91g/ml 
10g/500ml
40mM MgCl2 
2%(w/v) BSA
100XTE
1M Tris/HCl, pH 8.0 
0.1MEDTA, pH 8.0
12. l lg /  100ml 
3.722g/ml
10XTBE
54g Tris/HCl
27.5g Boric Acid
20ml 0.5M EDTA pH 8.0
IOXMOPS
0.25M MOPS 
0.05M Na-acetate
0.01M EDTA, pH 7.0
LB Broth
5g Yeast
lOg Bactotryptone 
lOg NaCl 
in 1L H2O
Terrific Broth (TB) 
12 g Bactotryptone 
24g Bactoyeast extract 
4ml Glycerol 
100ml 0.17M H2PO4 
0.72 M KzHPO^
1XHBS
50mM Hepes, pH 7.1 
280mM NaCl 
1.5mM Na2HP04
